<?xml version="1.0" encoding="ISO-8859-1"?><COCHRANE_REVIEW DESCRIPTION="For publication" DOI="10.1002/14651858.CD001258.pub3" GROUP_ID="SCHIZ" ID="035601050218002616" MERGED_FROM="" MODIFIED="2014-04-01 11:04:49 +0100" MODIFIED_BY="Claire Irving" REVIEW_NO="0011" REVMAN_SUB_VERSION="5.2.9 " REVMAN_VERSION="5" SPLIT_FROM="" STAGE="R" STATUS="A" TYPE="INTERVENTION" VERSION_NO="10.0">
<COVER_SHEET MODIFIED="2014-04-01 11:04:49 +0100" MODIFIED_BY="Claire Irving">
<TITLE>Carbamazepine for schizophrenia</TITLE>
<CONTACT MODIFIED="2014-04-01 11:04:49 +0100" MODIFIED_BY="Claire Irving"><PERSON ID="D3501EE082E26AA20080535F42019853" ROLE="AUTHOR"><PREFIX>Prof</PREFIX><FIRST_NAME>Stefan</FIRST_NAME><LAST_NAME>Leucht</LAST_NAME><POSITION>Vice-chairman</POSITION><EMAIL_1>Stefan.Leucht@lrz.tum.de</EMAIL_1><MOBILE_PHONE>+49 151 270 42590</MOBILE_PHONE><ADDRESS><DEPARTMENT>Department of Psychiatry and Psychotherapy</DEPARTMENT><ORGANISATION>Technische Universität München</ORGANISATION><ADDRESS_1>Ismaningerstrasse 22</ADDRESS_1><CITY>München</CITY><ZIP>81675</ZIP><COUNTRY CODE="DE">Germany</COUNTRY><PHONE_1>+49-89-4140 ext: 4249</PHONE_1><FAX_1>+49-89-4140-4888</FAX_1></ADDRESS></PERSON></CONTACT>
<CREATORS MODIFIED="2014-04-01 11:04:49 +0100" MODIFIED_BY="Claire Irving"><PERSON ID="D3501EE082E26AA20080535F42019853" ROLE="AUTHOR"><PREFIX>Prof</PREFIX><FIRST_NAME>Stefan</FIRST_NAME><LAST_NAME>Leucht</LAST_NAME><POSITION>Vice-chairman</POSITION><EMAIL_1>Stefan.Leucht@lrz.tum.de</EMAIL_1><MOBILE_PHONE>+49 151 270 42590</MOBILE_PHONE><ADDRESS><DEPARTMENT>Department of Psychiatry and Psychotherapy</DEPARTMENT><ORGANISATION>Technische Universität München</ORGANISATION><ADDRESS_1>Ismaningerstrasse 22</ADDRESS_1><CITY>München</CITY><ZIP>81675</ZIP><COUNTRY CODE="DE">Germany</COUNTRY><PHONE_1>+49-89-4140 ext: 4249</PHONE_1><FAX_1>+49-89-4140-4888</FAX_1></ADDRESS></PERSON><PERSON ID="z1301311112022346974199538643931" ROLE="AUTHOR"><PREFIX>Mr</PREFIX><FIRST_NAME>Bartosz</FIRST_NAME><LAST_NAME>Helfer</LAST_NAME><POSITION>Wissenschaftlicher Mitarbeiter (Researcher)</POSITION><EMAIL_1>bartosz.helfer@gmail.com</EMAIL_1><ADDRESS><DEPARTMENT>Klinik für Psychiatrie und Psychotherapie</DEPARTMENT><ORGANISATION>Technische Universität München</ORGANISATION><ADDRESS_1>Klinikum rechts der Isar</ADDRESS_1><ADDRESS_2>Ismaningerstrasse 22</ADDRESS_2><CITY>München</CITY><ZIP>81675</ZIP><REGION>Bayern</REGION><COUNTRY CODE="DE">Germany</COUNTRY><PHONE_1>+49-89-4140 6466</PHONE_1><FAX_1>+49-89-4140-4987</FAX_1></ADDRESS></PERSON><PERSON ID="13468438652653628973110207120503" ROLE="AUTHOR"><PREFIX>Dr</PREFIX><FIRST_NAME>Markus</FIRST_NAME><LAST_NAME>Dold</LAST_NAME><POSITION>Psychiatry Resident</POSITION><EMAIL_1>markus.dold@lrz.tu-muenchen.de</EMAIL_1><EMAIL_2>markus.dold@lrz.tum.de</EMAIL_2><ADDRESS><DEPARTMENT>Klinik und Poliklinik für Psychiatrie und Psychotherapie</DEPARTMENT><ORGANISATION>Technische Universität München Klinikum rechts der Isar</ORGANISATION><ADDRESS_1>Ismaninger Straße 22</ADDRESS_1><CITY>München</CITY><ZIP>81675</ZIP><COUNTRY CODE="DE">Germany</COUNTRY><PHONE_1>+49-89-4140-6466</PHONE_1><FAX_1>+49-89-4140-6431</FAX_1></ADDRESS></PERSON><PERSON ID="11850D1F82E26AA201DC7B3E2041CA58" ROLE="AUTHOR"><PREFIX>Dr</PREFIX><FIRST_NAME>Werner</FIRST_NAME><LAST_NAME>Kissling</LAST_NAME><POSITION>Leitender Oberarzt</POSITION><ADDRESS><DEPARTMENT>Klinik und Poliklinik für Psychiatrie und Psychotherapie</DEPARTMENT><ORGANISATION>Technische Universität München Klinikum rechts der Isar</ORGANISATION><ADDRESS_1>Möhlstr. 26</ADDRESS_1><CITY>München</CITY><ZIP>81675</ZIP><COUNTRY CODE="DE">Germany</COUNTRY><PHONE_1>49-89-4140-4207</PHONE_1><FAX_1>49-89-4140-4894</FAX_1></ADDRESS></PERSON><PERSON ID="11851ACB82E26AA201DC7B3E5EEBF8BE" ROLE="AUTHOR"><PREFIX>Prof</PREFIX><FIRST_NAME>John</FIRST_NAME><LAST_NAME>McGrath</LAST_NAME><POSITION>Director</POSITION><EMAIL_1>j.mcgrath@uq.edu.au</EMAIL_1><ADDRESS><DEPARTMENT>Epidemiology and Developmental Neurobiology</DEPARTMENT><ORGANISATION>The University of Queensland</ORGANISATION><ADDRESS_1>Queensland Brain Institute</ADDRESS_1><CITY>Brisbane</CITY><ZIP>4072</ZIP><REGION>Queensland</REGION><COUNTRY CODE="AU">Australia</COUNTRY><PHONE_1>+61 7 334 66372</PHONE_1></ADDRESS></PERSON></CREATORS>
<DATES MODIFIED="2014-01-21 11:23:38 +0000" MODIFIED_BY="[Empty name]">
<UP_TO_DATE>
<DATE DAY="6" MONTH="7" YEAR="2012"/>
</UP_TO_DATE>
<LAST_SEARCH>
<DATE DAY="6" MONTH="7" YEAR="2012"/>
</LAST_SEARCH>
<NEXT_STAGE>
<DATE DAY="14" MONTH="8" YEAR="2015"/>
</NEXT_STAGE>
<PROTOCOL_PUBLISHED ISSUE="4" YEAR="1998"/>
<REVIEW_PUBLISHED ISSUE="4" YEAR="1999"/>
<LAST_CITATION_ISSUE ISSUE="4" YEAR="2014"/>
</DATES>
<WHATS_NEW MODIFIED="2014-03-03 11:55:23 +0000" MODIFIED_BY="[Empty name]">
<WHATS_NEW_ENTRY EVENT="NEW_CITATION_OLD_CONCLUSIONS" MODIFIED="2014-01-14 12:29:53 +0000" MODIFIED_BY="[Empty name]">
<DATE DAY="14" MONTH="1" YEAR="2014"/>
<DESCRIPTION>
<P>Update completed, no new studies found with no overall changes to conclusion.</P>
</DESCRIPTION>
</WHATS_NEW_ENTRY>
<WHATS_NEW_ENTRY EVENT="UPDATE" MODIFIED="2014-03-03 11:55:23 +0000" MODIFIED_BY="[Empty name]">
<DATE DAY="15" MONTH="10" YEAR="2012"/>
<DESCRIPTION>
<P>Results of 2012 update search added, the 'Risk of bias' tables and description of bias added; background information, results and discussion extended; structure of the review updated.</P>
</DESCRIPTION>
</WHATS_NEW_ENTRY>
</WHATS_NEW>
<HISTORY MODIFIED="2013-02-26 14:54:11 +0000" MODIFIED_BY="[Empty name]">
<WHATS_NEW_ENTRY EVENT="AMENDMENT" MODIFIED="2013-02-26 14:54:11 +0000" MODIFIED_BY="[Empty name]">
<DATE DAY="3" MONTH="5" YEAR="2012"/>
<DESCRIPTION>
<P>Additional table linked to text</P>
</DESCRIPTION>
</WHATS_NEW_ENTRY>
<WHATS_NEW_ENTRY EVENT="AMENDMENT" MODIFIED="2012-05-03 14:15:53 +0100" MODIFIED_BY="[Empty name]">
<DATE DAY="7" MONTH="7" YEAR="2010"/>
<DESCRIPTION>
<P>New plain language summary added</P>
</DESCRIPTION>
</WHATS_NEW_ENTRY>
<WHATS_NEW_ENTRY EVENT="AMENDMENT" MODIFIED="2010-07-07 14:05:46 +0100" MODIFIED_BY="[Empty name]">
<DATE DAY="26" MONTH="4" YEAR="2008"/>
<DESCRIPTION>
<P>Converted to new review format.</P>
</DESCRIPTION>
</WHATS_NEW_ENTRY>
<WHATS_NEW_ENTRY EVENT="NEW_CITATION_NEW_CONCLUSIONS">
<DATE DAY="21" MONTH="5" YEAR="2007"/>
<DESCRIPTION>
<P>Substantive amendment</P>
</DESCRIPTION>
</WHATS_NEW_ENTRY>
</HISTORY>
<SOURCES_OF_SUPPORT>
<INTERNAL_SOURCES>
<SOURCE>
<NAME>Queensland Health</NAME>
<COUNTRY CODE="AU">Australia</COUNTRY>
<DESCRIPTION/>
</SOURCE>
<SOURCE>
<NAME>Freistaat Bayern</NAME>
<COUNTRY CODE="DE">Germany</COUNTRY>
<DESCRIPTION/>
</SOURCE>
</INTERNAL_SOURCES>
<EXTERNAL_SOURCES/>
</SOURCES_OF_SUPPORT>
<MESH_TERMS VERIFIED="NO"/>
<KEYWORDS/>
</COVER_SHEET>
<MAIN_TEXT MODIFIED="2014-04-01 10:59:58 +0100" MODIFIED_BY="[Empty name]">
<SUMMARY MODIFIED="2014-03-03 11:55:23 +0000" MODIFIED_BY="[Empty name]">
<TITLE MODIFIED="2008-04-26 13:15:43 +0100" MODIFIED_BY="[Empty name]">Carbamazepine for schizophrenia</TITLE>
<SUMMARY_BODY MODIFIED="2014-03-03 11:55:23 +0000" MODIFIED_BY="[Empty name]">
<P>People with schizophrenia will often hear voices or see things (hallucinations) and have strange beliefs (delusions). They may also experience apathy, tiredness, lack of drive and disorganised thoughts and behaviour. These symptoms make schizophrenia a severe illness that affects many people throughout their life.</P>
<P>The main treatment for schizophrenia is antipsychotic medication. However, although this medication is successful in treating the majority of people, 5% to 15% will continue to suffer from debilitating symptoms. For these people, several treatment options are available: changing the dose of medication; switching to another antipsychotic drug; or taking additional drugs that are not antipsychotics. Carbamazepine is a drug first used to treat epilepsy in the 1950s. It is also used as a mood stabiliser when people change between &#8216;high&#8217; and &#8216;low&#8217; moods (for example bi-polar affective disorder). Side effects of carbamazepine include: poor coordination, headaches and drowsiness.</P>
<P>This review focuses on the effectiveness of carbamazepine for people with schizophrenia. A search of the Cochrane Schizophrenia Group's trials register was carried out July 2012. Ten studies were found with 283 people. Carbamazepine was compared with no active medication (&#8216;dummy&#8217; or placebo treatment), versus an antipsychotic or when taken in addition to an antipsychotic. However, all of the 10 studies were small and information in them was of a poor standard. There is therefore a lack of evidence whether carbamazepine reduces symptoms and side effects in people with schizophrenia or similar mental health problems. Larger well-designed trials are necessary to provide stronger evidence before carbamazepine can be recommended as a treatment for people with schizophrenia.</P>
<P>This plain language summary has been written by a consumer Ben Gray: Service User and Service User Expert. Rethink Mental Illness.</P>
</SUMMARY_BODY>
</SUMMARY>
<ABSTRACT MODIFIED="2014-03-03 12:09:44 +0000" MODIFIED_BY="[Empty name]">
<ABS_BACKGROUND>
<P>Many people with schizophrenia do not achieve a satisfactory treatment response with just antipsychotic drug treatment and various adjunct medications are used to promote additional response. The antiepileptic carbamazepine is one such drug.</P>
</ABS_BACKGROUND>
<ABS_OBJECTIVES MODIFIED="2013-07-25 14:25:37 +0100" MODIFIED_BY="[Empty name]">
<P>To examine whether carbamazepine or oxcarbazepine alone is an effective treatment for schizophrenia and schizoaffective psychoses and whether carbamazepine or oxcarbazepine augmentation of neuroleptic medication is an effective treatment for the same illnesses.</P>
</ABS_OBJECTIVES>
<ABS_SEARCH_STRATEGY MODIFIED="2014-03-03 11:55:23 +0000" MODIFIED_BY="[Empty name]">
<P>For the original version we searched The Cochrane Schizophrenia Group's Register of Trials (December 2001), <I>The Cochrane Library</I> (Issue 3, 2001), MEDLINE (1966-2001), EMBASE (1980-2001), Biological Abstracts (1980-2001), PsycLIT (1886-2001) and PSYNDEX (1974-2001). For the most recent update we searched the Cochrane Schizophrenia Group's Register of Trials in July 2012. We also inspected references of all identified studies for further trials and contacted relevant pharmaceutical companies and authors for additional data.</P>
</ABS_SEARCH_STRATEGY>
<ABS_SELECTION_CRITERIA MODIFIED="2014-03-03 11:55:23 +0000" MODIFIED_BY="[Empty name]">
<P>We included all randomised controlled trials (RCTs) comparing carbamazepine or compounds of the carbamazepine family with placebo or no intervention, whether as sole treatment or as an adjunct to antipsychotic medication for the treatment of schizophrenia and/or schizoaffective psychoses.</P>
</ABS_SELECTION_CRITERIA>
<ABS_DATA_COLLECTION MODIFIED="2014-03-03 11:55:23 +0000" MODIFIED_BY="[Empty name]">
<P>We extracted data independently. For homogenous dichotomous data we calculated fixed-effect, risk ratio (RR), with 95% confidence intervals (CIs) on an intention-to-treat basis. For continuous data, we calculated mean differences (MD). We assessed the risk of bias for included studies and created a 'Summary of findings' table using GRADE.</P>
</ABS_DATA_COLLECTION>
<ABS_RESULTS MODIFIED="2014-03-03 12:09:44 +0000" MODIFIED_BY="[Empty name]">
<P>The updated search did not reveal any further studies that met our inclusion criteria. The number of included studies therefore remains at 10 with the number of participants randomised still 283.</P>
<P>One study comparing carbamazepine with placebo as the sole treatment for schizophrenia was abandoned early due to high relapse rate with 26 out of 31 participants relapsing by three months. No effect of carbamazepine was evident with no difference in relapse between the two groups (1 RCT n = 31, RR 1.07 CI 0.78 to 1.45). Another study compared carbamazepine with antipsychotics as the sole treatment for schizophrenia. No differences in terms of mental state were found when comparing 50% reduction in Brief Psychiatric Rating Scale (BPRS) scores (1 RCT n = 38, RR 1.23 CI 0.78 to 1.92). A favourable effect for carbamazepine was found when more people who received the antipsychotic (perphenazine) had parkinsonism (1 RCT n = 38, RR 0.03 CI 0.00 to 0.043). Eight studies compared adjunctive carbamazepine versus adjunctive placebo, we were able use GRADE for quality of evidence for these results. Adding carbamazepine to antipsychotic treatment was as acceptable as adding placebo with no difference between the numbers leaving the study early from each group (8 RCTs n = 182, RR 0.47 CI 0.16 to 1.35, <I>very low quality evidence</I>). Carbamazepine augmentation was superior compared with antipsychotics alone in terms of overall global improvement, but participant numbers were low (2 RCTs n = 38, RR 0.57 CI 0.37 to 0.88). There were no differences for the mental state outcome of 50% reduction in BPRS scores (6 RCTs n = 147, RR 0.86 CI 0.67 to 1.12, <I>low quality evidence</I>). Less people in the carbamazepine augmentation group had movement disorders than those taking haloperidol alone (1 RCT n = 20, RR 0.38 CI 0.14 to 1.02). No data were available for the effects of carbamazepine on subgroups of people with schizophrenia and aggressive behaviour, negative symptoms or EEG abnormalities or with schizoaffective disorder.</P>
</ABS_RESULTS>
<ABS_CONCLUSIONS MODIFIED="2013-09-16 14:16:29 +0100" MODIFIED_BY="[Empty name]">
<P>Based on currently available randomised trial-derived evidence, carbamazepine cannot be recommended for routine clinical use for treatment or augmentation of antipsychotic treatment of schizophrenia. At present large, simple well-designed and reported trials are justified - especially if focusing on people with violent episodes and people with schizoaffective disorders or those with both schizophrenia and EEG abnormalities.</P>
</ABS_CONCLUSIONS>
</ABSTRACT>
<BODY MODIFIED="2014-03-03 12:09:33 +0000" MODIFIED_BY="[Empty name]">
<BACKGROUND MODIFIED="2014-03-03 12:09:33 +0000" MODIFIED_BY="[Empty name]">
<CONDITION MODIFIED="2014-03-03 11:55:23 +0000" MODIFIED_BY="[Empty name]">
<P>Schizophrenia is often a chronic and disabling psychiatric disorder. It afflicts approximately one per cent of the population world-wide with little gender differences. Its typical manifestations are 'positive' symptoms such as fixed, false beliefs (delusions) and perceptions without cause (hallucinations), 'negative' symptoms such as apathy and lack of drive, disorganisation of behaviour and thought, and catatonic symptoms such as mannerisms and bizarre posturing (<LINK REF="REF-Carpenter-1994" TYPE="REFERENCE">Carpenter 1994</LINK>). The degree of suffering and disability is considerable with 80% to 90% not working (<LINK REF="REF-Marvaha-2004" TYPE="REFERENCE">Marvaha 2004</LINK>) and up to 10% dying (<LINK REF="REF-Tsuang-1978" TYPE="REFERENCE">Tsuang 1978</LINK>).</P>
</CONDITION>
<INTERVENTION MODIFIED="2014-03-03 11:55:23 +0000" MODIFIED_BY="[Empty name]">
<P>Carbamazepine is an anticonvulsant and mood-stabiliser with a tricyclic structure. It has been employed in treatment of a variety of psychiatric disorders, including schizophrenia, where it has been used as an antipsychotic agent. Its steric structure is similar to that of chlorpromazine or imipramine. Typical adverse effects of carbamazepine include: impaired co-ordination, headaches and drowsiness (<LINK REF="REF-Pate-1986" TYPE="REFERENCE">Pate 1986</LINK>).</P>
</INTERVENTION>
<THEORY MODIFIED="2014-03-03 11:55:23 +0000" MODIFIED_BY="[Empty name]">
<P>Carbamazepine (C<SUB>15</SUB>H<SUB>12</SUB>N<SUB>2</SUB>O, <LINK REF="FIG-01" TYPE="FIGURE">Figure 1</LINK>) is a neutral lipophilic substance that can easily cross cell-membranes and efficiently get into the nervous system. Carbamazepine mainly influences sodium channels by keeping them inactive as well as by potentiation of gamma-aminobutyric acid (GABA)-receptors (<LINK REF="REF-Granger-1995" TYPE="REFERENCE">Granger 1995</LINK>; <LINK REF="REF-Pate-1986" TYPE="REFERENCE">Pate 1986</LINK>).</P>
</THEORY>
<IMPORTANCE MODIFIED="2014-03-03 12:09:33 +0000" MODIFIED_BY="[Empty name]">
<P>Despite the introduction of antipsychotic (neuroleptic) medication in the 1950s, there is still a sizeable minority of people with schizophrenia and related conditions that do not have complete remission of symptoms (<LINK REF="REF-Schooler-1993" TYPE="REFERENCE">Schooler 1993</LINK>). Over the last 40 years a variety of adjunctive treatments have been used to treat schizophrenia (<LINK REF="REF-Christison-1991" TYPE="REFERENCE">Christison 1991</LINK>). These are often used in addition to antipsychotics, in order to augment any alleviation of symptoms of schizophrenia, but can be used instead of antipsychotics. Treatments such as lithium (indicated for bipolar affective disorder), carbamazepine (or related compounds such as oxcarbazepine), benzodiazepines, beta-blockers (<LINK REF="REF-Cheine-2001" TYPE="REFERENCE">Cheine 2001</LINK>) and electroconvulsive therapy (<LINK REF="REF-Tharyan-2002" TYPE="REFERENCE">Tharyan 2002</LINK>) have all been used for people whose psychoses did not respond to traditional therapy. The situation has improved somewhat in recent years with the re-introduction of clozapine which has proven efficacy for those who have not responded to traditional medications (<LINK REF="REF-Essali-2009" TYPE="REFERENCE">Essali 2009</LINK>). However, many people with psychoses have sub-optimal responses to treatment, and clinicians are faced with the choice of changing to alternate types of medication, or augmenting existing neuroleptics with other drugs or treatments.</P>
<P>Carbamazepine is used for the treatment of epilepsy, but is also used to prevent relapse, as a 'mood stabiliser', in bipolar affective illness in a similar fashion to lithium (<LINK REF="REF-Dardennes-1995" TYPE="REFERENCE">Dardennes 1995</LINK>). Oxcarbazepine is a related compound that is said to be an improvement on the older 'parent' drug (<LINK REF="REF-Tiihonen-1995" TYPE="REFERENCE">Tiihonen 1995</LINK>). In this review we do not examine the efficacy of carbamazepine for mood disorders and the affective psychoses. However, in two companion reviews the impact of lithium and benzodiazepines as sole or adjunctive treatment for schizophrenia and schizoaffective psychoses is examined (<LINK REF="REF-Leucht-2007a" TYPE="REFERENCE">Leucht 2007a</LINK>; <LINK REF="REF-Dold-2012" TYPE="REFERENCE">Dold 2012</LINK>).</P>
</IMPORTANCE>
</BACKGROUND>
<OBJECTIVES MODIFIED="2013-05-16 08:29:17 +0100" MODIFIED_BY="[Empty name]">
<P>To examine whether carbamazepine or oxcarbazepine alone is an effective treatment for schizophrenia and schizoaffective psychoses and whether carbamazepine or oxcarbazepine augmentation of neuroleptic medication is an effective treatment for the same illnesses.</P>
</OBJECTIVES>
<METHODS MODIFIED="2014-03-03 11:55:24 +0000" MODIFIED_BY="[Empty name]">
<SELECTION_CRITERIA MODIFIED="2014-03-03 11:55:23 +0000" MODIFIED_BY="[Empty name]">
<CRIT_STUDIES MODIFIED="2014-03-03 11:55:23 +0000" MODIFIED_BY="[Empty name]">
<P>All relevant randomised controlled trials. If a trial is described as 'double blind' but implies randomisation, we included such trials in a sensitivity analysis (see <LINK TAG="SENSITIVITY_ANALYSIS" TYPE="SECTION">Sensitivity analysis</LINK>). If their inclusion did not result in a substantive difference, they remained in the analyses. If their inclusion did result in statistically significant differences, we did not add the data from these lower quality studies to the results of the better trials, but presented such data within a subcategory. We excluded quasi-randomised studies, such as those allocating by alternate days of the week. Where people were given additional treatments within carbamazepine/oxcarbazepine, we only included data if the adjunct treatment was evenly distributed between groups and it was only the carbamazepine/ oxcarbazepine that was randomised.</P>
</CRIT_STUDIES>
<CRIT_PARTICIPANTS MODIFIED="2012-09-04 07:46:59 +0100" MODIFIED_BY="[Empty name]">
<P>Adults, however defined, with schizophrenia or related disorders, including schizophreniform disorder, schizoaffective disorder and delusional disorder, again, by any means of diagnosis.</P>
<P>We are interested in making sure that information is as relevant to the current care of people with schizophrenia as possible so propose to clearly highlight the current clinical state (acute, early post-acute, partial remission, remission) as well as the stage (prodromal, first episode, early illness, persistent) and as to whether the studies primarily focused on people with particular problems (for example, negative symptoms, treatment-resistant illnesses).</P>
</CRIT_PARTICIPANTS>
<CRIT_INTERVENTIONS MODIFIED="2013-05-16 09:37:19 +0100" MODIFIED_BY="[Empty name]">
<SUBSECTION>
<HEADING LEVEL="4">1. Experimental interventions</HEADING>
<P>1.1 Carbamazepine/oxcarbazepine alone: any dose.<BR/>1.2 Carbamazepine/oxcarbazepine in combination with any antipsychotic treatment: any dose.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">2. Control interventions</HEADING>
<P>2.1 Placebo (or no intervention).<BR/>2.2 Placebo (or no intervention) in combination with any antipsychotic treatment.<BR/>2.3. Antipsychotics alone: any dose.</P>
</SUBSECTION>
</CRIT_INTERVENTIONS>
<CRIT_OUTCOMES MODIFIED="2014-03-03 11:55:23 +0000" MODIFIED_BY="[Empty name]">
<P>We grouped all outcomes by time - short term (up to 12 weeks), medium term (13 to 26 weeks) and long term (over 26 weeks).</P>
<CRIT_OUTCOMES_PRIMARY MODIFIED="2013-01-27 13:36:07 +0000" MODIFIED_BY="[Empty name]">
<P>No clinically important response to treatment (at least 50% reduction of overall symptoms or at least much improved)</P>
</CRIT_OUTCOMES_PRIMARY>
<CRIT_OUTCOMES_SECONDARY MODIFIED="2014-03-03 11:55:23 +0000" MODIFIED_BY="[Empty name]">
<SUBSECTION>
<HEADING LEVEL="5">1. Leaving the study early</HEADING>
<P>1.1 For specific reasons<BR/>1.2 Acceptability of treatment (leaving the study early for any reason)</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="5">2. Service utilisation</HEADING>
<P>2.1 Hospital admission<BR/>2.2 Days in hospital<BR/>2.3 Change in hospital status</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="5">3. Global state</HEADING>
<P>3.1 Relapse - as defined by each of the studies<BR/>3.2 Time to relapse<BR/>3.3 No change in global state<BR/>3.4 Average endpoint global state score<BR/>3.5 Average change in global state scores</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="5">4. Mental state</HEADING>
<P>4.1 General mental state</P>
<P>4.1.1 No clinically important change in general mental state - as defined by each of the studies<BR/>4.1.2 No change in general mental state<BR/>4.1.3 Average endpoint general mental state score<BR/>4.1.4 Average change in general mental state scores</P>
<P>4.2 Specific aspects of mental state</P>
<P>4.2.1 No clinically significant response in positive symptoms - as defined by each of the studies<BR/>4.2.2 No change in positive symptoms<BR/>4.2.3 Average endpoint positive symptom score<BR/>4.2.4 Average change in positive symptom scores<BR/>4.2.5 No clinically significant response in negative symptoms - as defined by each of the studies<BR/>4.2.6 No change in negative symptoms<BR/>4.2.7 Average endpoint negative symptom score<BR/>4.2.8 Average change in negative symptom scores<BR/>4.2.9 No clinically significant response in depressive symptoms - as defined by each of the studies<BR/>4.2.10 No change in depressive symptoms<BR/>4.2.11 Average endpoint depressive symptom score<BR/>4.2.12 Average change in depressive symptom scores<BR/>4.2.13 No clinically significant response in manic symptoms - as defined by each of the studies<BR/>4.2.14 No change in manic symptoms<BR/>4.2.15 Average endpoint manic symptom score<BR/>4.2.16 Average change in manic symptom scores</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="5">5. Behaviour</HEADING>
<P>5.1 General behaviour</P>
<P>5.1.1 No clinically important change in general behaviour<BR/>5.1.2 No change in general behaviour<BR/>5.1.3 Average endpoint general behaviour score<BR/>5.1.4 Average change in general behaviour scores<BR/>5.1.5 Compulsory administrations of treatment<BR/>5.1.6 Use of further doses of medication</P>
<P>5.2 Specific behaviours</P>
<P>5.2.1 Self-harm, including suicide<BR/>5.2.2 Injury to others<BR/>5.2.3 Aggression<BR/>5.2.3.1 No clinically important change in aggression<BR/>5.2.3.2 No change in aggression<BR/>5.2.3.3 Average endpoint aggression score<BR/>5.2.3.4 Average change in aggression scores<BR/>5.2.4 Self-care<BR/>5.2.4.1 No clinically important change in self-care<BR/>5.2.4.2 No change in self-care<BR/>5.2.4.3 Average endpoint self-care score<BR/>5.2.4.4 Average change in self-care scores<BR/>5.2.5 Compliance<BR/>5.2.5.1 No clinically important change in compliance<BR/>5.2.5.2 No change in compliance<BR/>5.2.5.3 Average endpoint compliance score<BR/>5.2.5.4 Average change in compliance scores</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="5">6. Social functioning</HEADING>
<P>6.1 No clinically important effects for social function<BR/>6.2 No effects for social function<BR/>6.3 Average endpoint social functioning score<BR/>6.4 Average change social functioning scores<BR/>6.5 Employment status during trial (employed / unemployed)</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="5">7. Adverse effects</HEADING>
<P>7.1 Clinically important general adverse effects<BR/>7.2 Any general adverse effects<BR/>7.3 Average endpoint general adverse effect score<BR/>7.4 Average change in general adverse effect scores<BR/>7.5 Clinically important change in specific adverse effects such as movement disorders<BR/>7.6 Any change in specific adverse effects<BR/>7.7 Average endpoint specific adverse effects<BR/>7.8 Average change in specific adverse effects<BR/>7.9 Use of antiparkinsonian treatment</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="5">8. Sudden and unexpected death</HEADING>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="5">9. Economic outcomes</HEADING>
<P>9.1 Direct costs<BR/>9.2 Indirect costs</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="5">10. Satisfaction with treatment</HEADING>
<P>10.1 Recipient of care not satisfied with treatment<BR/>10.2 Recipient of care average satisfaction score<BR/>10.3 Recipient of care average change in satisfaction scores<BR/>10.4 Carer not satisfied with treatment<BR/>10.5 Carer average satisfaction score<BR/>10.6 Carer average change in satisfaction scores</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="5">11. Quality of life</HEADING>
<P>11.1 No clinically important change in quality of life<BR/>11.2 No change in quality of life<BR/>11.3 Average endpoint quality of life score<BR/>11.4 Average change in quality of life scores<BR/>11.5 No clinically important change in specific aspects of quality of life<BR/>11.6 No change in specific aspects of quality of life<BR/>11.7 Average endpoint specific aspects of quality of life<BR/>11.8 Average change in specific aspects of quality of life</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="5">12. Pharmacokinetic interactions - change of haloperidol plasma levels.</HEADING>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="5">13. 'Summary of findings' table</HEADING>
<P>We used the GRADE approach to interpret findings (<LINK REF="REF-Sch_x00fc_nemann-2008" TYPE="REFERENCE">Schünemann 2008</LINK>) and used GRADE profiler (<LINK REF="REF-GRADE-Profiler" TYPE="REFERENCE">GRADE Profiler</LINK>) to import data from RevMan 5 (<LINK REF="REF-Review-Manager-_x0028_RevMan_x0029_" TYPE="REFERENCE">Review Manager (RevMan)</LINK>) to create 'Summary of findings' tables. These tables provide outcome-specific information concerning the overall quality of evidence from each included study in the comparison, the magnitude of effect of the interventions examined, and the sum of available data on all outcomes we rated as important to patient-care and decision making. We selected the following main outcomes for inclusion in the 'Summary of findings' table.</P>
<UL>
<LI>Acceptability of treatment - leaving the studies early for any reason</LI>
<LI>No clinically important response to treatment</LI>
<LI>General mental state</LI>
<LI>Specific mental state: positive symptoms</LI>
<LI>Specific mental state: depression</LI>
<LI>Aggressive behaviour</LI>
</UL>
</SUBSECTION>
</CRIT_OUTCOMES_SECONDARY>
</CRIT_OUTCOMES>
</SELECTION_CRITERIA>
<SEARCH_METHODS MODIFIED="2013-05-16 08:34:38 +0100" MODIFIED_BY="[Empty name]">
<P>Search methods for the 2012 update are below, for previous searches please see <LINK REF="APP-01" TYPE="APPENDIX">Appendix 1</LINK>.</P>
<P>No language restriction was applied within the limitations of the search tools.</P>
<ELECTRONIC_SEARCHES MODIFIED="2013-02-27 10:04:22 +0000" MODIFIED_BY="[Empty name]">
<SUBSECTION>
<HEADING LEVEL="3">1. Cochrane Schizophrenia Group Trials Register</HEADING>
<P>The Trials Search Co-ordinator searched the Cochrane Schizophrenia Group's Trials Register (July 2012)</P>
<SUBSECTION>
<HEADING LEVEL="4">1.1 Intervention search</HEADING>
<P>The 'Intervention' field was searched using the phrase:<BR/>(*carbama* or *amizepine* or *carbag* or *carbap* or *carbaz* or *carbymal* or *carpaz* or *cephalon* or *degranol* or *epitol* or *finlepsin* or *fokalepsin* or *hermolepsin* or *neurotol* or *neurotop* or *nordotol* or *sirtal* or *tardotol* or *tegret* or *teril* or *timonil* or *trimonil* or *trialeptal* or *trilpetal*)<BR/>
<BR/>The Cochrane Schizophrenia Group's Trials Register is compiled by systematic searches of major databases, handsearches of relevant journals and conference proceedings (see <A HREF="http://onlinelibrary.wiley.com/o/cochrane/clabout/articles/SCHIZ/frame.html">Group Module</A>). Incoming trials are assigned to existing or new review titles.</P>
</SUBSECTION>
</SUBSECTION>
</ELECTRONIC_SEARCHES>
<OTHER_SEARCHES MODIFIED="2013-02-27 10:04:56 +0000" MODIFIED_BY="[Empty name]">
<SUBSECTION>
<HEADING LEVEL="4">1. Reference searching</HEADING>
<P>We inspected references of all identified studies for further relevant studies.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">2. Personal contact</HEADING>
<P>We contacted the first author of each included study for information regarding unpublished trials.</P>
</SUBSECTION>
</OTHER_SEARCHES>
</SEARCH_METHODS>
<DATA_COLLECTION MODIFIED="2014-03-03 11:55:24 +0000" MODIFIED_BY="[Empty name]">
<P>Methods used in data collection and analysis for this 2012 update are below, for previous methods please see <LINK REF="APP-02" TYPE="APPENDIX">Appendix 2</LINK>
<BR/>
</P>
<STUDY_SELECTION MODIFIED="2014-03-03 11:55:23 +0000" MODIFIED_BY="[Empty name]">
<P>Review authors SL and MD independently inspected all citations from the searches and identified relevant abstracts. Where disputes arose, the full report was acquired for more detailed scrutiny. If citations met inclusion criteria, we obtained full reports of the papers for more detailed inspection. Again, all reports were independently inspected by SL and MD in order to ensure reliable selection. Where it was not possible to resolve disagreement by discussion, we attempted to contact the authors of the study for clarification.</P>
</STUDY_SELECTION>
<DATA_EXTRACTION MODIFIED="2014-03-03 11:55:23 +0000" MODIFIED_BY="[Empty name]">
<SUBSECTION>
<HEADING LEVEL="4">1. Extraction</HEADING>
<P>Review authors MD and BH extracted data from all included studies. Again, any disagreement was discussed, decisions documented and, if necessary, authors of studies contacted for clarification. With remaining problems SL helped clarify issues and these final decisions were documented. If data were presented only in graphs and figures, we extracted whenever possible, but only included the data if two review authors independently had the same result. We attempted to contact authors through an open-ended request in order to obtain missing information or for clarification whenever necessary.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">2. Management</HEADING>
<SUBSECTION>
<HEADING LEVEL="5">2.1 Forms</HEADING>
<P>We extracted data onto standard, simple forms.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="5">2.2 Scale-derived data</HEADING>
<P>We included continuous data from rating scales only if:<BR/>a. the psychometric properties of the measuring instrument have been described in a peer-reviewed journal (<LINK REF="REF-Marshall-2000" TYPE="REFERENCE">Marshall 2000</LINK>); and<BR/>b. the measuring instrument has not been written or modified by one of the trial lists for that particular trial.</P>
<P>Ideally, the measuring instrument should either be i. a self-report or ii. completed by an independent rater or relative (not the therapist). We realise that this is not often reported clearly.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="5">2.3 Endpoint versus change data</HEADING>
<P>There are advantages of both endpoint and change data. Change data can remove a component of between-person variability from the analysis. On the other hand, calculation of change needs two assessments (baseline and endpoint), which can be difficult in unstable and difficult to measure conditions such as schizophrenia. We decided primarily to use endpoint data, and only use change data if the former were not available. We combined endpoint and change data in the analysis as we used mean differences (MD) rather than standardised mean differences (SMD) (<LINK REF="REF-Higgins-2011" TYPE="REFERENCE">Higgins 2011</LINK>, Chapter 9.4.5.2).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="5">2.4 Skewed data (endpoint data only)</HEADING>
<P>Continuous data on clinical and social outcomes are often not normally distributed. To avoid the pitfall of applying parametric tests to non-parametric data, we aimed to apply the following standards to all endpoint data before inclusion: a) standard deviations (SDs) and means are reported in the paper or obtainable from the authors; b) when a scale starts from the finite number zero, the SD, when multiplied by two, is less than the mean (as otherwise the mean is unlikely to be an appropriate measure of the centre of the distribution), (<LINK REF="REF-Altman-1996" TYPE="REFERENCE">Altman 1996</LINK>); c) if a scale started from a positive value (such as the Positive and Negative Syndrome Scale (PANSS, <LINK REF="REF-Kay-1986" TYPE="REFERENCE">Kay 1986</LINK>), which can have values from 30 to 210), the calculation described above was modified to take the scale starting point into account. In these cases skew is present if 2 SD &gt; (S-S min), where S is the mean score and S min is the minimum score. Endpoint scores on scales often have a finite start and end point and these rules can be applied. We presented skewed endpoint data from studies of less than 200 participants in other tables within the data and analyses section rather than enter them into a statistical analysis. Skewed data pose less of a problem when looking at mean if the sample size is large; we entered endpoint data from studies with over 200 participants into syntheses.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="5">2.5 Common measure</HEADING>
<P>To facilitate comparison between trials, we intended to convert variables that can be reported in different metrics, such as days in hospital (mean days per year, per week or per month) to a common metric (e.g. mean days per month).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="5">2.6 Conversion of continuous to binary</HEADING>
<P>Where possible, we made efforts to convert outcome measures to dichotomous data. This can be done by identifying cut-off points on rating scales and dividing participants accordingly into 'clinically improved' or 'not clinically improved'. It is generally assumed that if there is a 50% reduction in a scale-derived score such as the Brief Psychiatric Rating Scale (BPRS, <LINK REF="REF-Overall-1962" TYPE="REFERENCE">Overall 1962</LINK>) or the PANSS (<LINK REF="REF-Kay-1986" TYPE="REFERENCE">Kay 1986</LINK>), this could be considered as a clinically significant response (<LINK REF="REF-Leucht-2005" TYPE="REFERENCE">Leucht 2005</LINK>; <LINK REF="REF-Leucht-2005a" TYPE="REFERENCE">Leucht 2005a</LINK>). If data based on these thresholds were not available, we used the primary cut-off presented by the original authors.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="5">2.7 Direction of graphs</HEADING>
<P>Where possible, we entered data in such a way that the area to the left of the line of no effect indicated a favourable outcome for carbamazepine.</P>
</SUBSECTION>
</SUBSECTION>
</DATA_EXTRACTION>
<QUALITY_ASSESSMENT MODIFIED="2014-03-03 11:55:23 +0000" MODIFIED_BY="[Empty name]">
<P>Review author BH assessed risk of bias by using criteria described in the <I>Cochrane Handbook for Systematic Reviews of Interventions</I> (<LINK REF="REF-Higgins-2011" TYPE="REFERENCE">Higgins 2011</LINK>) to assess trial quality. Review author SL supervised the process. This set of criteria is based on evidence of associations between overestimate of effect and high risk of bias of the article such as sequence generation, allocation concealment, blinding, incomplete outcome data and selective reporting. Where inadequate details of randomisation and other characteristics of trials were provided, we contacted the authors of the studies in order to obtain further information.</P>
<P>The level of risk of bias was noted in both the text of the review (<LINK TAG="STUDY_QUALITY" TYPE="SECTION">Risk of bias in included studies</LINK>), the <LINK TAG="CHARACTERISTICS_OF_INCLUDED_STUDIES" TYPE="SECTION">Characteristics of included studies</LINK> table and <LINK REF="SOF-01" TYPE="SOF">Summary of findings table 1</LINK>.</P>
</QUALITY_ASSESSMENT>
<EFFECT_MEASURES MODIFIED="2014-03-03 11:55:23 +0000" MODIFIED_BY="[Empty name]">
<SUBSECTION>
<HEADING LEVEL="4">1. Binary data</HEADING>
<P>For binary outcomes we calculated a standard estimation of the risk ratio (RR) and its 95% confidence interval (CI). It has been shown that RR is more intuitive (<LINK REF="REF-Boissel-1999" TYPE="REFERENCE">Boissel 1999</LINK>) than odds ratios and that odds ratios tend to be interpreted as RR by clinicians (<LINK REF="REF-Deeks-2000" TYPE="REFERENCE">Deeks 2000</LINK>). The Number Needed to Treat/Harm (NNT/H) statistic with its CIs is intuitively attractive to clinicians but is problematic both in its accurate calculation in meta-analyses and interpretation (<LINK REF="REF-Hutton-2009" TYPE="REFERENCE">Hutton 2009</LINK>). For binary data presented in the 'Summary of findings' table, where possible, we calculated illustrative comparative risks.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">2. Continuous data</HEADING>
<P>For continuous outcomes we estimated mean difference (MD) between groups. We prefer not to calculate effect size measures (standardised mean difference (SMD)). However, if scales of very considerable similarity were used, we presumed there was a small difference in measurement, and we calculated effect size and transformed the effect back to the units of one or more of the specific instruments.</P>
</SUBSECTION>
</EFFECT_MEASURES>
<UNIT_OF_ANALYSIS MODIFIED="2014-03-03 11:55:24 +0000" MODIFIED_BY="[Empty name]">
<SUBSECTION>
<HEADING LEVEL="4">1. Cluster trials</HEADING>
<P>Studies increasingly employ 'cluster randomisation' (such as randomisation by clinician or practice) but analysis and pooling of clustered data poses problems. Firstly, authors often fail to account for intra-class correlation in clustered studies, leading to a 'unit of analysis' error (<LINK REF="REF-Divine-1992" TYPE="REFERENCE">Divine 1992</LINK>) whereby P values are spuriously low, CIs unduly narrow and statistical significance overestimated. This causes type I errors (<LINK REF="REF-Bland-1997" TYPE="REFERENCE">Bland 1997</LINK>; <LINK REF="REF-Gulliford-1999" TYPE="REFERENCE">Gulliford 1999</LINK>).</P>
<P>Had we included cluster-randomised trials and clustering had not been accounted for in primary studies, we planned to present data in a table, with a (*) symbol to indicate the presence of a probable unit of analysis error. In subsequent versions of this review, if we include cluster studies, we will seek to contact the first authors of studies to obtain intra-class correlation coefficients (ICCs) for their clustered data and to adjust for this by using accepted methods (<LINK REF="REF-Gulliford-1999" TYPE="REFERENCE">Gulliford 1999</LINK>). If clustering has been incorporated into the analysis of primary studies, we will present these data as if from a non-cluster randomised study, but we will adjust for the clustering effect.</P>
<P>We have sought statistical advice and have been advised that the binary data as presented in a report should be divided by a 'design effect'. This is calculated using the mean number of participants per cluster (m) and the ICC [Design effect = 1+(m-1)*ICC] (<LINK REF="REF-Donner-2002" TYPE="REFERENCE">Donner 2002</LINK>). If the ICC is not reported, it will be assumed to be 0.1 (<LINK REF="REF-Ukoumunne-1999" TYPE="REFERENCE">Ukoumunne 1999</LINK>).</P>
<P>If cluster studies have been appropriately analysed taking into account ICCs and relevant data documented in the report, synthesis with other studies would have been possible using the generic inverse variance technique.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">2. Cross-over trials</HEADING>
<P>A major concern of cross-over trials is the carry-over effect. It occurs if an effect (e.g. pharmacological, physiological or psychological) of the treatment in the first phase is carried over to the second phase. As a consequence, on entry to the second phase the participants can differ systematically from their initial state despite a wash-out phase. For the same reason cross-over trials are not appropriate if the condition of interest is unstable (<LINK REF="REF-Elbourne-2002" TYPE="REFERENCE">Elbourne 2002</LINK>). As both effects are very likely in severe mental illness, we only used data of the first phase of cross-over studies.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">3. Studies with multiple treatment groups</HEADING>
<P>Where a study involves more than two treatment arms, if relevant, the additional treatment arms were presented in comparisons. If data were binary, these were simply added and combined within the two-by-two table. If data were continuous, we combined data following the formula in section 7.7.3.8  (Combining groups) of the <I>Cochrane Handbook for Systematic Reviews of Interventions</I>. Where the additional treatment arms were not relevant, we did not reproduce these data.</P>
</SUBSECTION>
</UNIT_OF_ANALYSIS>
<MISSING_DATA MODIFIED="2014-03-03 11:55:24 +0000" MODIFIED_BY="[Empty name]">
<SUBSECTION>
<HEADING LEVEL="4">1. Overall loss of credibility</HEADING>
<P>We share the concern that at some degree of loss of follow-up, data must lose credibility (<LINK REF="REF-Xia-2009" TYPE="REFERENCE">Xia 2009</LINK>). However, from which degree of attrition onward this is a problem, is unclear. We therefore did not exclude studies on the basis of degree of attrition, but attrition was taken into account in the 'Risk of bias' assessment.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">2. Binary</HEADING>
<P>We presented data on a 'once-randomised-always-analyse' basis (an intention-to-treat analysis). Those leaving the study early were all assumed not to have changed in the given outcome. This rule is conservative for response, because it assumes that those who left the studies early would not have responded to treatment. It is not conservative concerning side effects, however, it would often have been an overestimation of the frequency of side effects if all participants who discontinued had been assumed to have experienced rare side effects.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">3. Continuous</HEADING>
<SUBSECTION>
<HEADING LEVEL="5">3.1 Intention-to-treat analysis</HEADING>
<P>We used intention-to-treat datasets when possible, but included completer data if only these were available.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="5">3.2 Standard deviations</HEADING>
<P>If standard deviations (SDs) were not reported, we first tried to obtain the missing values from the authors. If not available, where there are missing measures of variance for continuous data, but an exact standard error (SE) and confidence intervals (CIs) available for group means, and either 'P' value or 't' values available for differences in mean, we can calculate them according to the rules described in the <I>Cochrane Handbook for Systematic Reviews of Interventions</I> (<LINK REF="REF-Higgins-2011" TYPE="REFERENCE">Higgins 2011</LINK>): When only the SE is reported, SDs are calculated by the formula SD = SE * square root (n). Chapters 7.7.3 and 16.1.3 of the <I>Cochrane Handbook for Systematic Reviews of Interventions</I> (<LINK REF="REF-Higgins-2011" TYPE="REFERENCE">Higgins 2011</LINK>) present detailed formulae for estimating SDs from P values, t or F values, CIs, ranges or other statistics. Although some of these imputation strategies can introduce error, the alternative would be to exclude a given study&#8217;s outcome and thus to lose information. We nevertheless examined the validity of the imputations in a sensitivity analysis excluding imputed values from the primary outcome.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="5">3.3 Last observation carried forward</HEADING>
<P>We anticipated that in some studies the method of last observation carried forward (LOCF) would be employed within the study report. As with all methods of imputation to deal with missing data, LOCF introduces uncertainty about the reliability of the results (<LINK REF="REF-Leucht-2007" TYPE="REFERENCE">Leucht 2007</LINK>). We reproduced these data, but readers should be aware of the problem.</P>
</SUBSECTION>
</SUBSECTION>
</MISSING_DATA>
<HETEROGENEITY_ASSESSMENT MODIFIED="2014-03-03 11:55:24 +0000" MODIFIED_BY="[Empty name]">
<SUBSECTION>
<HEADING LEVEL="4">1. Clinical heterogeneity</HEADING>
<P>We considered all included studies initially, without seeing comparison data, to judge clinical heterogeneity. We simply inspected all studies for clearly outlying people or situations which we had not predicted would arise. When such situations or participant groups arose, these were fully discussed.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">2. Methodological heterogeneity</HEADING>
<P>We considered all included studies initially, without seeing comparison data, to judge methodological heterogeneity. We simply inspected all studies for clearly outlying methods which we had not predicted would arise. When such methodological outliers arise these were fully discussed.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">3. Statistical heterogeneity</HEADING>
<SUBSECTION>
<HEADING LEVEL="5">3.1 Visual inspection</HEADING>
<P>We visually inspected graphs to investigate the possibility of statistical heterogeneity.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="5">3.2 Employing the I<SUP>2</SUP> statistic</HEADING>
<P>Heterogeneity between studies was investigated by considering the I<SUP>2 </SUP>method alongside the Chi<SUP>2</SUP> 'P' value. The I<SUP>2 </SUP>provides an estimate of the percentage of inconsistency thought to be due to chance (<LINK REF="REF-Higgins-2003" TYPE="REFERENCE">Higgins 2003</LINK>). The importance of the observed value of an I<SUP>2 </SUP>depends on i. magnitude and direction of effects and ii. strength of evidence for heterogeneity (e.g. 'P' value from Chi<SUP>2</SUP>  test, or a confidence interval for I<SUP>2</SUP>). An I<SUP>2 </SUP>estimate greater than or equal to around 50% accompanied by a statistically significant Chi<SUP>2</SUP> statistic, was interpreted as evidence of substantial levels of heterogeneity (<LINK REF="REF-Higgins-2011" TYPE="REFERENCE">Higgins 2011</LINK>). When substantial levels of heterogeneity were found in the primary outcome, we explored reasons for the heterogeneity (<LINK TAG="SUBGROUP_ANALYSIS" TYPE="SECTION">Subgroup analysis and investigation of heterogeneity</LINK>).</P>
</SUBSECTION>
</SUBSECTION>
</HETEROGENEITY_ASSESSMENT>
<BIAS_ASSESSMENT MODIFIED="2014-03-03 11:55:24 +0000" MODIFIED_BY="[Empty name]">
<P>Reporting biases arise when the dissemination of research findings is influenced by the nature and direction of results (<LINK REF="REF-Egger-1997" TYPE="REFERENCE">Egger 1997</LINK>). These are described in Section 10 of the <I>Cochrane Handbook for Systematic Reviews of Interventions</I> (<LINK REF="REF-Higgins-2011" TYPE="REFERENCE">Higgins 2011</LINK>). We are aware that funnel plots may be useful in investigating reporting biases but are of limited power to detect small-study effects. We did not use funnel plots for outcomes as there were less than 10 studies in all the analyses, and the numbers of participants were similar. In other cases, where funnel plots were possible, we sought statistical advice in their interpretation.</P>
</BIAS_ASSESSMENT>
<DATA_SYNTHESIS MODIFIED="2014-03-03 11:55:24 +0000" MODIFIED_BY="[Empty name]">
<P>We understand that there is no closed argument for preference for use of fixed-effect or random-effects models. The random-effects method incorporates an assumption that the different studies are estimating different, yet related, intervention effects. This often seems to be true to us and the random-effects model takes into account differences between studies even if there is no statistically significant heterogeneity. There is, however, a disadvantage to the random-effects model. It puts added weight onto small studies, which often are the most biased ones. Depending on the direction of effect, these studies can either inflate or deflate the effect size. In this review we therefore primarily chose the fixed-effect model (following our original method). The reader is, however, able to choose to inspect the data using the random-effects model, and we applied the random-effects model in a sensitivity analysis of the primary outcome.</P>
</DATA_SYNTHESIS>
<SUBGROUP_ANALYSIS MODIFIED="2014-03-03 11:55:24 +0000" MODIFIED_BY="[Empty name]">
<SUBSECTION>
<HEADING LEVEL="4">1. Subgroup analyses</HEADING>
<P>We proposed to undertake this review to provide an overview of the effects of carbamazepine for people with schizophrenia in general. In addition, however, we tried to report data on subgroups of people in the same clinical state, stage and with similar problems. The subgroups we planned to analyse included people with treatment-resistant schizophrenia, people with EEG abnormalities, residual patients who were suffering predominantly from negative symptoms and people with schizoaffective disorder.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">2. Investigation of heterogeneity</HEADING>
<P>If inconsistency was high, this was reported. First, we investigated whether data had been entered correctly. Second, if data were correct, we looked at whether methodological reasons of the studies accounted for the heterogeneity. Finally, the graph was visually inspected and outlying studies successively removed to see if heterogeneity was restored. When unanticipated clinical or methodological heterogeneity was obvious, we simply stated hypotheses regarding these for future reviews or versions of this review. We did not undertake analyses relating to these.</P>
</SUBSECTION>
</SUBGROUP_ANALYSIS>
<SENSITIVITY_ANALYSIS MODIFIED="2014-03-03 11:55:24 +0000" MODIFIED_BY="[Empty name]">
<P>We only applied sensitivity analyses to the primary outcome of this review.</P>
<SUBSECTION>
<HEADING LEVEL="4">1. Implication of randomisation</HEADING>
<P>We aimed to include trials in a sensitivity analysis if they were described in some way as to imply randomisation. For the primary outcome, we included these studies and if there was no substantive difference when the implied randomised studies were added to those with better description of randomisation, then all data were employed from these studies.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">2. Assumptions for lost binary data</HEADING>
<P>Where assumptions had to be made regarding missing SDs data (see <LINK TAG="MISSING_DATA" TYPE="SECTION">Dealing with missing data</LINK>), we compared the findings of the primary outcome when we used our assumption compared with complete data only.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">3. Imputed values</HEADING>
<P>Had we included any cluster-randomised trials, we would have undertaken a sensitivity analysis to assess the effects of including data from trials where we used imputed values for ICC in calculating the design effect in cluster-randomised trials.</P>
<P>If we noted substantial differences in the direction or precision of effect estimates in any of the sensitivity analyses listed above, we did not pool data from the excluded trials with the other trials contributing to the outcome, but presented them separately.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">4. Fixed and random effects</HEADING>
<P>All data were synthesised using a fixed-effect model, however, we also synthesised data for the primary outcome using a random-effects model to evaluate whether the greater weights assigned to larger trials with greater event rates, altered the significance of the results compared to the more evenly distributed weights in the random-effects model.</P>
</SUBSECTION>
</SENSITIVITY_ANALYSIS>
</DATA_COLLECTION>
</METHODS>
<RESULTS MODIFIED="2014-03-03 11:55:24 +0000" MODIFIED_BY="[Empty name]">
<STUDY_DESCRIPTION MODIFIED="2014-03-03 11:55:24 +0000" MODIFIED_BY="[Empty name]">
<P>For substantive descriptions of studies please see <LINK TAG="CHARACTERISTICS_OF_INCLUDED_STUDIES" TYPE="SECTION">Characteristics of included studies</LINK> and <LINK TAG="CHARACTERISTICS_OF_EXCLUDED_STUDIES" TYPE="SECTION">Characteristics of excluded studies</LINK> tables.<BR/>
</P>
<SEARCH_RESULTS MODIFIED="2014-03-03 11:55:24 +0000" MODIFIED_BY="[Empty name]">
<P>The original strategy identified hundreds of citations but only 10 studies met our inclusion criteria. In the update searches in 2005, 2007 and 2012 there were 24, 23 and eight new references respectively. We have not had any replies from the authors of studies that were classified as 'awaiting assessment' in previous versions of the review and we did not identify any ongoing studies (see <LINK REF="FIG-02" TYPE="FIGURE">Figure 2</LINK>).</P>
</SEARCH_RESULTS>
<INCLUDED_STUDIES_DESCR MODIFIED="2014-03-03 11:55:24 +0000" MODIFIED_BY="[Empty name]">
<P>Ten studies were included in analyses. No new studies were included in this update.</P>
<SUBSECTION>
<HEADING LEVEL="4">1. Design</HEADING>
<P>Four of the included studies had a cross-over design and six were parallel.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">2. Length of trials</HEADING>
<P>The longest study lasted for 95 days, the shortest, 18. Three out of 10 studies lasted six weeks, and four studies only five weeks. The mean duration of a study was approximately 41 days.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">3. Participants</HEADING>
<P>In the 10 included studies a total number of 283 participants were randomised. The two biggest studies involved 41 and 42 participants, the two smallest 18 and 13. On average there were about 28 participants in each study. The number of male and female participant is not indicated in two trials. In the remaining eight studies there is a proportion of about 5:2 of men and woman. Mean age of participants in not indicated in three studies. Based on the available data the mean age is around 26 years.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">4. Setting</HEADING>
<P>The majority of studies were set in hospitals with only one study involving outpatients.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">5. Interventions</HEADING>
<P>Two studies used carbamazepine as a sole treatment (one of them with a 800 to 120 mg dose range, the other with the mean dose of 1374 mg per day). The remaining eight studies used carbamazepine as an adjunctive treatment. In this case the doses were usually increasing and were at the level of 600 mg per day.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">6.Outcomes</HEADING>
<SUBSECTION>
<HEADING LEVEL="5">6.1 Leaving the study early</HEADING>
<P>The numbers of participants leaving the study early were recorded for the categories any reason, adverse events and lack of efficacy.<BR/>
</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="5">6.2 Side effects</HEADING>
<P>Side effects were reported in only two studies.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="5">6.3 Scales</HEADING>
<P>Details of scales that provided usable data are shown below.</P>
<SUBSECTION>
<HEADING LEVEL="6">6.3.1 Clinical Global Impression (CGI)</HEADING>
<P>CGI (<LINK REF="REF-Guy-1976" TYPE="REFERENCE">Guy 1976</LINK>) is a rating instrument commonly used in studies on schizophrenia that enables clinicians to quantify severity of illness and overall clinical improvement during therapy. A seven-point scoring system is usually used with low scores indicating decreased severity and/or greater recovery<BR/>
</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="6">6.3.2 Brief Psychiatric Rating Scale (BPRS)</HEADING>
<P>BPRS (<LINK REF="REF-Overall-1962" TYPE="REFERENCE">Overall 1962</LINK>) is a brief rating scale used to assess the severity of a range of psychiatric symptoms, including psychotic symptoms. The scale has 18 items, and each item can be defined on a seven-point scale varying from 'not present' (one) to 'extremely severe' (seven). Scoring ranges from 18 -126.<BR/>
</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="6">6.3.3 Scale for the Assessment of Negative Symptoms (SANS)</HEADING>
<P>SANS (<LINK REF="REF-Andreasen-1984" TYPE="REFERENCE">Andreasen 1984</LINK>) is a six-point scale that gives a global rating of the following negative symptoms: alogia, affective blunting, avolition-apathy, anhedonia-asociality and attention impairment. Higher scores indicate more symptoms.<BR/>
</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="6">6.3.4 Positive and Negative Syndrome Scale (PANSS)</HEADING>
<P>PANSS (<LINK REF="REF-Kay-1986" TYPE="REFERENCE">Kay 1986</LINK>) is a schizophrenia scale that has 30 items, each of which can be defined on a seven-point scoring system varying from one - absent to seven -extreme. It can be divided into three sub-scales for measuring the severity of general psychopathology, positive symptoms (PANSS-P), and negative symptoms (PANSS-N). A low score indicates lesser severity</P>
<P>6.3.5 Hamilton Depression Rating Scale (HAM-D)</P>
<P>The HAM-D (<LINK REF="REF-Hamilton-1960" TYPE="REFERENCE">Hamilton 1960</LINK>) is a scale developed to rate symptoms of depression. The original version contains 17 items rated on a three- or five-point scale. Higher total scores mean more symptoms.</P>
</SUBSECTION>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="5">6.4 Missing outcomes</HEADING>
<P>There were no data on aggression, service use such as 'duration of hospital stay', satisfaction with treatment or costs.</P>
</SUBSECTION>
</SUBSECTION>
</INCLUDED_STUDIES_DESCR>
<EXCLUDED_STUDIES_DESCR MODIFIED="2014-03-03 11:55:24 +0000" MODIFIED_BY="[Empty name]">
<P>In the 2012 update an additional two studies met some of the inclusion criteria closely enough to be listed as 'excluded studies' (<LINK REF="STD-Ohlmeier-2007" TYPE="STUDY">Ohlmeier 2007</LINK>; <LINK REF="STD-Ivkovi-2004" TYPE="STUDY">Ivkovi 2004</LINK>). Thus, the category 'excluded studies' currently lists 91 trials. Sixty-four trials were not randomised or the randomisation was undertaken inappropriately. Three studies were excluded due to participants not meeting the inclusion criteria, 19 studies due to type of intervention (typically there was no placebo group) and five because no usable outcomes were presented.</P>
</EXCLUDED_STUDIES_DESCR>
</STUDY_DESCRIPTION>
<STUDY_QUALITY MODIFIED="2014-03-03 11:55:24 +0000" MODIFIED_BY="[Empty name]">
<P>For graphical representations of our judgements of risk of bias please refer to <LINK REF="FIG-03" TYPE="FIGURE">Figure 3</LINK> and <LINK REF="FIG-04" TYPE="FIGURE">Figure 4</LINK>. Full details of judgements can be seen in the 'Risk of bias' tables.</P>
<ALLOCATION MODIFIED="2014-03-03 11:55:24 +0000" MODIFIED_BY="[Empty name]">
<P>Four out of 10 of all the included studies were judged as having a low risk of potential selection bias because a specific method of generating a random sequence was provided (<LINK REF="STD-Llorca-1993" TYPE="STUDY">Llorca 1993</LINK>; <LINK REF="STD-Mair-1990" TYPE="STUDY">Mair 1990</LINK>; <LINK REF="STD-Martin_x002d_Munoz-1989" TYPE="STUDY">Martin-Munoz 1989</LINK>; <LINK REF="STD-Neppe-1983" TYPE="STUDY">Neppe 1983</LINK>). These studies typically used a random number list or a coin toss method. The remaining six studies state simply that the order was randomised without giving any further details about the procedure. All these studies are rated as having an unclear risk of selection bias. No studies were rated as possessing a high risk of selection bias.<BR/>
</P>
<P>Only two studies report on allocation concealment (<LINK REF="STD-He_x00df_linger-1998" TYPE="STUDY">Heßlinger 1998</LINK>; <LINK REF="STD-Nachshoni-1994" TYPE="STUDY">Nachshoni 1994</LINK>). In one of them sealed envelopes were used, in the other only a control psychiatrist had access to the identity of the interventions. The rest of the studies do not provide any informations that could be used to assess allocation concealment, thus they are rated as unclear in this respect.<BR/>
</P>
<P>As poor reporting of randomisation has consistently been associated with an overestimate of effect (<LINK REF="REF-Schulz-1995" TYPE="REFERENCE">Schulz 1995</LINK>) all the trials rated as &#8220;unclear&#8221; could have a 30% to 40% overestimate of effect (<LINK REF="REF-Moher-2001" TYPE="REFERENCE">Moher 2001</LINK>; <LINK REF="REF-Schulz-1995" TYPE="REFERENCE">Schulz 1995</LINK>).</P>
</ALLOCATION>
<BLINDING MODIFIED="2014-03-03 11:55:24 +0000" MODIFIED_BY="[Empty name]">
<P>Objective and subjective outcomes were rated separately, because we consider blinding to be less important for objective as it is for subjective outcomes. Performance and detection bias was also rated separately resulting in four independent assessments of blinding.<BR/>
</P>
<SUBSECTION>
<HEADING LEVEL="4">1. Objective</HEADING>
<P>For both performance and detection bias, the vast majority of studies were rated as having a low risk of bias (nine out of 10 studies), because a double-blind procedure was employed. In only one study such an information was missing, thus is was rated as unclear (<LINK REF="STD-Svestka-1989" TYPE="STUDY">Svestka 1989</LINK>).<BR/>
</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">2. Subjective</HEADING>
<P>As for subjective outcomes, in terms of blinding of participants and personnel, only two studies provided enough information to be rated as having a low risk of bias (<LINK REF="STD-Llorca-1993" TYPE="STUDY">Llorca 1993</LINK>; <LINK REF="STD-Nachshoni-1994" TYPE="STUDY">Nachshoni 1994</LINK>). In both cases rhe use of identical capsules for drug and placebo was reported. The remaining eight studies did not provide any further details, hence they were rated as 'unclear'. The raters were described as blind only in three out of 10 studies (<LINK REF="STD-Carpenter-1991" TYPE="STUDY">Carpenter 1991</LINK>; <LINK REF="STD-Llorca-1993" TYPE="STUDY">Llorca 1993</LINK>; <LINK REF="STD-Nachshoni-1994" TYPE="STUDY">Nachshoni 1994</LINK>.</P>
</SUBSECTION>
</BLINDING>
<EXCLUSIONS MODIFIED="2014-03-03 11:55:24 +0000" MODIFIED_BY="[Empty name]">
<P>Eight out of 10 studies were assessed as having a low risk of attrition bias, meaning that the problem of incomplete outcome data was addressed in an appropriate way (the number of dropouts was not very high and was evenly distributed between groups). Only two studies were judged as unclear (<LINK REF="STD-Mair-1990" TYPE="STUDY">Mair 1990</LINK>; <LINK REF="STD-Neppe-1983" TYPE="STUDY">Neppe 1983</LINK>). One of them did not report on dropouts at all (<LINK REF="STD-Mair-1990" TYPE="STUDY">Mair 1990</LINK>). The other one had an uneven distribution of early discontinuations between groups (<LINK REF="STD-Neppe-1983" TYPE="STUDY">Neppe 1983</LINK>).</P>
</EXCLUSIONS>
<SELECTIVE_REPORTING MODIFIED="2014-03-03 11:55:24 +0000" MODIFIED_BY="[Empty name]">
<P>The majority of studies (six out of 10) were judged as having a high risk of reporting bias due to lack of informations about some predefined outcomes. A very typical problem comprised not reporting about standard deviations. Out of the remaining four studies, one was rated as unclear due to the fact that only an abstract with a limited number of information was available (<LINK REF="STD-Simhandl-1996" TYPE="STUDY">Simhandl 1996</LINK>). The other three did not selectively report on any outcomes and thus were judged as having a low risk of bias in that respect (<LINK REF="STD-Carpenter-1991" TYPE="STUDY">Carpenter 1991</LINK>; <LINK REF="STD-He_x00df_linger-1998" TYPE="STUDY">Heßlinger 1998</LINK>; <LINK REF="STD-Nachshoni-1994" TYPE="STUDY">Nachshoni 1994</LINK>).</P>
</SELECTIVE_REPORTING>
<OTHER_BIAS_SOURCES MODIFIED="2014-03-03 11:55:24 +0000" MODIFIED_BY="[Empty name]">
<P>Nine out of 10 studies were rated as free of other potential sources of bias. Only one study was rated as unclear in this respect, because the dosages of rescue and additional medications differed between groups (no further details were provided) (<LINK REF="STD-Dose-1987" TYPE="STUDY">Dose 1987</LINK>).</P>
</OTHER_BIAS_SOURCES>
</STUDY_QUALITY>
<INTERVENTION_EFFECTS MODIFIED="2014-03-03 11:55:24 +0000" MODIFIED_BY="[Empty name]">
<P>We used risk ratios (RR) for dichotomous data and mean differences (MD) for continuous data, with their respective 95% confidence intervals (CIs) throughout.</P>
<SUBSECTION>
<HEADING LEVEL="3">1. Comparison 1: Carbamazepine as sole treatment versus placebo as sole treatment</HEADING>
<P>Only <LINK REF="STD-Carpenter-1991" TYPE="STUDY">Carpenter 1991</LINK> compared carbamazepine as a sole agent with placebo in maintenance treatment.</P>
<SUBSECTION>
<HEADING LEVEL="4">1.1 Leaving the study early</HEADING>
<P>One person receiving carbamazepine left early due to a rash and another due to leucopenia. Two people also left early from the placebo group, due to a conduction defect on the ECG and headache, respectively. No difference between groups was found (1 RCT n = 31, RR 1.07 CI 0.17 to 6.64).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">1.2 Global state - relapse</HEADING>
<P>Data from the first 27 people included into this study showed that carbamazepine was no more effective than placebo in preventing relapse(1 RCT n = 31, RR 1.07 CI 0.78 to 1.45). As the majority of those in both groups (26 out of 31) did relapse, the study was stopped by three months.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">1.3 Mental state</HEADING>
<P>There was no significant difference in terms of mental state as measured by the number of patients with less than 20% BPRS reduction (1 RCT n = 31, RR 0.99 CI 0.75 to 1.30) or the mean BPRS at endpoint between both groups (1 RCT n = 27, MD -0.07 CI -0.46 to 0.32).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">1.4 Adverse effects</HEADING>
<P>
<LINK REF="STD-Carpenter-1991" TYPE="STUDY">Carpenter 1991</LINK> reported transient sedation and nausea in the carbamazepine group, although no figures were presented. Three people treated with carbamazepine developed a rash, this difference was not statistically significant (1 RCT n = 31, RR 7.44 CI 0.42 to 132.95), and one person developed leucopenia, again differences between treatment groups were not significant (1 RCT n = 31, RR 3.19 CI 0.14 to 72.69).</P>
</SUBSECTION>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="3">2. Comparison 2: Carbamazepine as sole treatment versus antipsychotics as sole treatment</HEADING>
<P>Again, only one trial was found that compared carbamazepine with perphenazine in acutely ill patients with schizophrenia and schizoaffective disorder (<LINK REF="STD-Svestka-1989" TYPE="STUDY">Svestka 1989</LINK>).</P>
<SUBSECTION>
<HEADING LEVEL="4">2.1 Leaving the study early</HEADING>
<P>Two patients on carbamazepine versus none on perphenazine left the study before its end, this difference is not statistically significant (1 RCT n = 38, RR 4.52 CI 0.23 to 88.38).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">2.2 Mental state</HEADING>
<P>We found no significant differences in terms of mental state. A similar number of people treated with carbamazepine and perphenazine reached less than 20% (1 RCT n = 38, RR 1.29 CI 0.62 to 2.66), 35% (1 RCT n = 38, RR 1.67 CI 0.86 to 3.24) or 50% (1 RCT n = 38, RR 1.23 CI 0.78 to 1.92) BPRS reduction. Again, no significant difference in terms of mean BPRS at endpoint was found (1 RCT n = 38, MD 2.30 CI -3.84 to 8.44). However, when those with schizoaffective disorder were excluded, a statistically significant inferiority of carbamazepine in terms of 20% BPRS reduction (1 RCT n = 28, RR 3.09 CI 1.22 to 7.84) and 35% BPRS reduction (1 RCT n = 28, RR 2.32 CI 1.15 to 4.67) was found. This effect was not as evident for 50% BPRS reduction scores and the difference between groups just failed to reach significance (1 RCT n = 28, RR 1.40 CI 0.94 to 2.09). Since only 10 participants had schizoaffective disorder, an analysis of this subgroup was not thought to be meaningful.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">2.3 Adverse effects</HEADING>
<SUBSECTION>
<HEADING LEVEL="5">2.3.1 Movement disorders</HEADING>
<P>Significantly more participants who received perphenazine needed antiparkinson medication (1 RCT n = 38, RR 0.23 CI 0.09 to 0.55, NNH 1 CI 1 to 2) or had parkinsonism (1 RCT n = 38, RR 0.03 CI 0.00 to 0.43, NNH 1 CI 0.9 to 1.4). No significant difference in terms of the number of participants with akathisia (1 RCT,n = 38, RR 0.13 CI 0.01 to 2.34) or tremor (1 RCT n = 38, RR 0.30 CI 0.01 to 6.97) was found.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="5">2.3.2 Other adverse effects</HEADING>
<P>The following other adverse effects were reported: collapse, dizziness, blurred vision, dryness of mouth, fatigue, nausea, constipation, salivation, tachycardia. Studies found no significant differences between groups.</P>
</SUBSECTION>
</SUBSECTION>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="3">3. Comparison 3: Adjunctive carbamazepine + antipsychotics versus placebo/no adjunctive treatment + antipsychotics</HEADING>
<P>Eight studies compared adding carbamazepine to antipsychotic treatment with adding a placebo to just antipsychotic treatment alone.</P>
<SUBSECTION>
<HEADING LEVEL="4">3.1 Leaving the study early</HEADING>
<P>Eight studies were able to contribute to the outcome of 'number leaving the study early', although four of these studies had no one leave early in either group. No difference was found (8 RCTs n = 182, RR 0.47 CI 0.16 to 1.35) between those allocated to the augmentation group and those taking placebo adjunctive therapy.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">3.2 Global state</HEADING>
<P>Only <LINK REF="STD-Neppe-1983" TYPE="STUDY">Neppe 1983</LINK> and <LINK REF="STD-Simhandl-1996" TYPE="STUDY">Simhandl 1996</LINK> provided data on the outcome 'no general improvement'. Carbamazepine augmentation of neuroleptics was superior compared to various antipsychotics alone, but the number of patients included was very low (2 RCTs n = 38, RR 0.57 CI 0.37 to 0.88).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">3.3 Mental state</HEADING>
<SUBSECTION>
<HEADING LEVEL="5">3.3.1 General</HEADING>
<P>The individual patient data from six studies could be used for the analysis of various degrees of BPRS reduction. No significant differences in terms of number of participants with less than 20% (6 RCTs n = 147, RR 0.69 CI 0.44 to 1.07), 35% (6 RCTs n = 147, RR 0.78 CI 0.57 to 1.05) or 50% BPRS reduction (6 RCTs n = 147, RR 0.86 CI 0.67 to 1.12) were found. The results at the 50% BPRS reduction level were significantly heterogeneous because two studies (<LINK REF="STD-Dose-1987" TYPE="STUDY">Dose 1987</LINK>; <LINK REF="STD-He_x00df_linger-1998" TYPE="STUDY">Heßlinger 1998</LINK>) showed contrary results. No obvious reasons for this heterogeneity could be derived from the publications. This was a general problem of these two studies in a number of efficacy outcomes. Removing both studies did not change statistical significance, therefore we decided to leave them in. Similar equivocal results were found when the mean BPRS (3 RCTs n = 79, MD -3.21 CI -7.82 to 1.40) was analysed. The results based on the IMPS at endpoint showed a significant superiority of the control group (2 RCTs n = 50, MD 4.61 CI 1.30 to 7.91). However, the results of the two studies were highly heterogeneous and when a random-effects model instead of the fixed-effect model was used, there was no significant difference (2 RCTs n = 50, MD 5.2 CI -11.1 to 21.4).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="5">3.3.2 Specific - positive symptoms, negative symptoms and depression</HEADING>
<P>Only very few data for specific symptoms of schizophrenia could be extracted. In the <LINK REF="STD-He_x00df_linger-1998" TYPE="STUDY">Heßlinger 1998</LINK> study, the participants in the carbamazepine group had, on average, more positive symptoms at endpoint than those in the control group (1 RCT n = 18, MD 4.22 CI 0.75 to 7.69). The <LINK REF="STD-Dose-1987" TYPE="STUDY">Dose 1987</LINK> study showed oppositional results, but the data could only be presented in the 'other data' table because they were skewed (<LINK REF="CMP-003.08" TYPE="ANALYSIS">Analysis 3.8</LINK>). No significant superiority of carbamazepine augmentation in terms of negative symptoms (2 RCTs n = 53, MD -2.75 CI -6.71 to 1.22) or depression (1 RCT n = 26, MD -0.35 CI -2.20 to 1.50) could be found.</P>
</SUBSECTION>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">3.4 Behaviour</HEADING>
<P>Two studies presented data on the average dose of additional medication needed for the treatment of agitated behaviour. In <LINK REF="STD-Dose-1987" TYPE="STUDY">Dose 1987</LINK> people receiving carbamazepine augmentation needed less additional medication, whereas in <LINK REF="STD-He_x00df_linger-1998" TYPE="STUDY">Heßlinger 1998</LINK> they needed more additional medication than in the control group. Data were skewed and could therefore only be presented in the other data table (<LINK REF="CMP-003.11" TYPE="ANALYSIS">Analysis 3.11</LINK>).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">3.5 Adverse effects</HEADING>
<P>Side effects were not well reported in the studies.</P>
<SUBSECTION>
<HEADING LEVEL="5">3.5.1 Movement disorders</HEADING>
<P>The effect of adjunctive carbamazepine on movement disorders is not clear. One small study (<LINK REF="STD-Martin_x002d_Munoz-1989" TYPE="STUDY">Martin-Munoz 1989</LINK>) reported on the binary outcome of 'movement disorder present'. Less people in the carbamazepine augmentation group had movement disorders than those taking haloperidol alone but the result just failed to reach significance (1 RCT n = 20, RR 0.38 CI 0.14 to 1.02). Skewed data from the Simpson-Angus Scale were equivocal from three studies (<LINK REF="STD-Dose-1987" TYPE="STUDY">Dose 1987</LINK>; <LINK REF="STD-Nachshoni-1994" TYPE="STUDY">Nachshoni 1994</LINK>; <LINK REF="STD-Simhandl-1996" TYPE="STUDY">Simhandl 1996</LINK>).</P>
<P>Three studies (<LINK REF="STD-Dose-1987" TYPE="STUDY">Dose 1987</LINK>; <LINK REF="STD-He_x00df_linger-1998" TYPE="STUDY">Heßlinger 1998</LINK>; <LINK REF="STD-Simhandl-1996" TYPE="STUDY">Simhandl 1996</LINK>) presented data on the mean dose of antiparkinson medication used. These data are presented in the 'other data' tables, because they are skewed (<LINK REF="CMP-003.13" TYPE="ANALYSIS">Analysis 3.13</LINK>). No consistent trend can be derived from these data.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="5">3.5.2 Other side effects</HEADING>
<P>Two studies used scales to assess side effects (<LINK REF="STD-Mair-1990" TYPE="STUDY">Mair 1990</LINK>; <LINK REF="STD-Martin_x002d_Munoz-1989" TYPE="STUDY">Martin-Munoz 1989</LINK>) but data were reported in such a way as to be unusable for this review. <LINK REF="STD-Dose-1987" TYPE="STUDY">Dose 1987</LINK> reported several carbamazepine-associated adverse effects (allergic reactions, elevation of liver enzymes, leucopenia, EEG change). Although these tended to be more prevalent in the carbamazepine augmented group, none reached the level of statistical significance.</P>
</SUBSECTION>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">3.6 Physiological effects</HEADING>
<P>
<LINK REF="STD-Dose-1987" TYPE="STUDY">Dose 1987</LINK> and <LINK REF="STD-He_x00df_linger-1998" TYPE="STUDY">Heßlinger 1998</LINK> described mean plasma haloperidol to be lower in the carbamazepine-augmented group but again these data are in the 'other data' tables.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">3.7 Missing outcomes</HEADING>
<P>Carbamazepine is said to have an effect upon aggression. <LINK REF="STD-Neppe-1983" TYPE="STUDY">Neppe 1983</LINK> reported that overt aggression was rated twice as severe with placebo compared to carbamazepine but no quantitative data were reported. <LINK REF="STD-Llorca-1993" TYPE="STUDY">Llorca 1993</LINK> did not find between-group differences in SAPS or BPRS hostility and aggressiveness items but only 'P' values were presented. No data were found for 'service' outcomes such as 'duration of hospital stay'. Nor were there data on satisfaction with treatment or costs.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">3.8 Subgroup analyses</HEADING>
<P>All subgroup analyses were only conducted on the primary outcome (less than 50% BPRS reduction).</P>
<SUBSECTION>
<HEADING LEVEL="5">3.8.1 People with treatment-resistant schizophrenia</HEADING>
<P>
<LINK REF="STD-Simhandl-1996" TYPE="STUDY">Simhandl 1996</LINK> included only those with schizophrenia who had fulfilled specific criteria of neuroleptic non-response. There was no significant difference compared to the other studies which did no have this inclusion criterion (Test for subgroup differences: Chi² = 0.28, df = 1 (P = 0.60), I² = 0%). Investigating <LINK REF="STD-Simhandl-1996" TYPE="STUDY">Simhandl 1996</LINK> alone we found that significantly more patients treated with adjunctive carbamazepine improved according to the CGI and reached at least 20% BPRS reduction. However, this result was not consistent, because there were not significantly more patients treated with carbamazepine augmentation than with placebo augmentation reaching 35% and 50% BPRS reduction (primary outcome). <LINK REF="STD-Llorca-1993" TYPE="STUDY">Llorca 1993</LINK> examined the effectiveness of adjunctive carbamazepine in those with treatment-resistant schizophrenia (<LINK REF="REF-Kane-1988" TYPE="REFERENCE">Kane 1988</LINK> criteria) using a cross-over design. No mental state data were directly reported (P values only) but carbamazepine was not stated to be better than placebo in this small study (n = 12).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="5">3.8.2 People with EEG abnormalities</HEADING>
<P>
<LINK REF="STD-Neppe-1983" TYPE="STUDY">Neppe 1983</LINK> examined a small group of 13 relatively non-responsive patients with EEG abnormalities, of which nine had schizophrenia. In this cross-over trial, more patients fared somewhat better in the carbamazepine than in the placebo phase for 'leaving the study earlier', 'no global clinical improvement' and the mental state ratings (BPRS). The patient population was quite heterogeneous and diagnostic criteria were not indicated. Overall, the effects in this study did not differ significantly from the rest of the studies (Test for subgroup differences: Chi² = 0.84, df = 1 (P = 0.36), I² = 0%).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="5">3.8.3 People with negative symptoms</HEADING>
<P>
<LINK REF="STD-Nachshoni-1994" TYPE="STUDY">Nachshoni 1994</LINK> carried out a double-blind randomised controlled trial in 28 residual patients who were suffering predominantly from negative symptoms. After five weeks no superiority of adjunctive carbamazepine compared with placebo on negative symptoms could be found. The results on the primary outcome were not different from the other studies (Test for subgroup differences: Chi² = 1.04, df = 1 (P = 0.31), I² = 3.7%).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="5">3.8.4 People with schizoaffective disorder</HEADING>
<P>Only 12 people included in this review had schizoaffective disorder so analyses of this subgroup did not appear to be meaningful.</P>
</SUBSECTION>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">3.9 Sensitivity analyses</HEADING>
<P>All sensitivity analyses were only applied to the primary outcome (less than 50% BPRS reduction). Therefore, only the use of a random-effects model instead of the fixed-effect model was relevant. There was no difference between monotherapy with antipsychotics and augmentation with carbamazepine when a random-effects model was used (6 RCTs n = 147, RR 0.93 CI 0.60 to 1.45).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">3.10 Publication bias</HEADING>
<P>Only six studies contributed to the primary outcome. Therefore, the funnel-plot method was not meaningful as described in <LINK TAG="BIAS_ASSESSMENT" TYPE="SECTION">Assessment of reporting biases</LINK>.</P>
</SUBSECTION>
</SUBSECTION>
</INTERVENTION_EFFECTS>
</RESULTS>
<DISCUSSION MODIFIED="2014-03-03 11:55:25 +0000" MODIFIED_BY="[Empty name]">
<SUMMARY_OF_RESULTS MODIFIED="2014-03-03 11:55:25 +0000" MODIFIED_BY="[Empty name]">
<SUBSECTION>
<HEADING LEVEL="4">1. General</HEADING>
<P>Although much original data were received from trial lists, a total of 258 participants is still a small base upon which to judge the effectiveness of carbamazepine. The included studies in this review, were therefore unable to provide sufficient data to clarify the role of carbamazepine for the treatment or augmentation of antipsychotic treatment of schizophrenia and schizoaffective disorder.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">2. Comparison 1: Carbamazepine as a sole treatment versus placebo as a sole treatment</HEADING>
<P>The little available data suggest that carbamazepine is no better than placebo for maintenance treatment. Considering that the single study contributing data (<LINK REF="STD-Carpenter-1991" TYPE="STUDY">Carpenter 1991</LINK>) was stopped early, because the majority of those in both groups relapsed, these data are unlikely to be supplemented.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">3. Comparison 2: Carbamazepine as a sole treatment versus antipsychotics as a sole treatment</HEADING>
<P>In the only small study available (<LINK REF="STD-Svestka-1989" TYPE="STUDY">Svestka 1989</LINK>), carbamazepine was not inferior when compared with perphenazine in terms of improvement of mental state and carbamazepine was associated with fewer extrapyramidal side effects than perphenazine. However, due to the small sample size of this trial (n = 38), carbamazepine can not be considered as a reasonable alternative to antipsychotics, and in the subgroup analysis in which those with schizoaffective disorder were excluded, perphenazine was superior to carbamazepine in some efficacy outcomes.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">4. Comparison 3: Adjunctive carbamazepine + antipsychotics versus placebo/no adjunctive treatment + antipsychotics</HEADING>
<SUBSECTION>
<HEADING LEVEL="5">4.1 Acceptability of treatment - leaving the study early for any reason</HEADING>
<P>Only 13 out of 180 people left the studies before completion with no difference between groups. This very low rate of attrition is rare within trials relevant to the care of those with schizophrenia. Adjunctive therapy of this sort seems to be very acceptable to people with schizophrenia, at least within the confines of a trial.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="5">4.2 General improvement</HEADING>
<P>Two small trials (<LINK REF="STD-Neppe-1983" TYPE="STUDY">Neppe 1983</LINK>; <LINK REF="STD-Simhandl-1996" TYPE="STUDY">Simhandl 1996</LINK>) presented data on the outcome of 'no general improvement', and found a slight, but statistically significant difference between groups favouring the carbamazepine group. Little can be concluded from two small trials including 38 schizophrenia patients. It is disappointing that more trials did not report this simple outcome.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="5">4.3 Mental state</HEADING>
<P>The interpretation of results on mental state has been improved by the analysis of individual patient data in a uniform way. The meta-analysis of the data of six out of eight trials did not show a significant superiority of carbamazepine according to several levels of reduction of the Brief Psychiatric Rating Scale (BPRS) (<LINK REF="REF-Overall-1962" TYPE="REFERENCE">Overall 1962</LINK>). Furthermore, there was a significant heterogeneity of the study results with one study (<LINK REF="STD-He_x00df_linger-1998" TYPE="STUDY">Heßlinger 1998</LINK>) showing especially bad results associated with carbamazepine augmentation. The inspection of the methods of each study did not reveal clear reasons for this heterogeneity. Therefore, current data suggest that carbamazepine augmentation of antipsychotic drugs for people with schizophrenia does not seem to have a clinically meaningful effect on mental state. However, since there was a non-significant trend in terms of 20% BPRS reduction and since the total number of patients is still low, more trials are warranted. Specific symptoms of schizophrenia (positive symptoms, negative symptoms and depression) were only reported by one or two trials so that any meaningful statement is not possible.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="5">4.4 Adverse effects</HEADING>
<P>Most data about movement disorders were too skewed to summate and individual studies reported conflicting results. As a result, no firm conclusion can be drawn. The fact that some studies found that carbamazepine augmentation leads to fewer movement disorders might be explained by a reduction in haloperidol plasma levels. This lowering of plasma levels might be the expression of an induction of liver enzymes related to carbamazepine. Two of the included studies (<LINK REF="STD-Dose-1987" TYPE="STUDY">Dose 1987</LINK>; <LINK REF="STD-He_x00df_linger-1998" TYPE="STUDY">Heßlinger 1998</LINK>), one trial excluded because it did not provide any usable data (<LINK REF="STD-Kidron-1985" TYPE="STUDY">Kidron 1985</LINK>), and several uncontrolled trials (<LINK REF="STD-Jann-1985" TYPE="STUDY">Jann 1985</LINK>; <LINK REF="STD-Kahn-1990" TYPE="STUDY">Kahn 1990</LINK>; <LINK REF="STD-Otani-1997" TYPE="STUDY">Otani 1997</LINK>) suggest that this enzyme induction occurs. This interaction must be carefully taken into account whenever carbamazepine augmentation is tried.</P>
<P>Carbamazepine augmentation may well cause more allergic reactions, elevation of liver enzymes, leucopenia, and deterioration in the EEG than placebo augmentation. Adverse effects were, however, poorly reported and the only small trial (<LINK REF="STD-Dose-1987" TYPE="STUDY">Dose 1987</LINK>, n = 41) that clearly reported these important events had limited power to investigate differences between groups.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="5">4.5 Missing outcomes</HEADING>
<P>Currently, there are no data relating to the effect of carbamazepine augmentation on aggression, 'service' outcomes such as 'duration of hospital stay', satisfaction with treatment or costs.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="5">4.6 Schizophrenia sub-types and subgroups</HEADING>
<P>Carbamazepine augmentation was not more effective when subgroups of people with schizophrenia were the focus of the studies. People with a schizophrenic illness designated as resistant to treatment were not consistently better when they received carbamazepine augmentation. Those with negative symptoms were not different in their response to antipsychotic augmentation compared with people whose illness did not have a predominance of negative symptoms. The small <LINK REF="STD-Neppe-1983" TYPE="STUDY">Neppe 1983</LINK> study (n = 9) suggested that a relatively non-responsive heterogeneous group of patients with EEG abnormalities did fare somewhat better with carbamazepine augmentation than with placebo. This should be considered as hypothesis-generating only.</P>
<P>It is not clear whether it makes sense to use carbamazepine in schizophrenia(-like) patients with 'excited states'. One randomised controlled study (<LINK REF="STD-Klein-1984" TYPE="STUDY">Klein 1984</LINK>) suggested that this could be useful, but data from this trial could not be used in this review as the treatment allocation of people who left the study early is unclear. In a letter the authors stated that they do not remember how to interpret the data sheets of the study. Furthermore, a large controlled study of adjunctive carbamazepine to antipsychotics in 'excited psychoses' (<LINK REF="STD-Okuma-1989a" TYPE="STUDY">Okuma 1989a</LINK>, n = 162) had to be excluded because of the potential for inclusion of bias at the point of randomisation. Forty-three per cent of those in the carbamazepine augmentation group showed marked and moderate improvement compared to 27% in the placebo group (not statistically significant). A post hoc analysis of individual mental state scale items suggested that this was related to an effect on disturbances of affective or emotional functions, whereas other items such as hallucinatory behaviour worsened with adjunctive carbamazepine.</P>
<P>Finally, carbamazepine augmentation for those with schizoaffective disorder has been surprisingly poorly studied, although it is frequently used in the daily routine for this condition. Only 12 participants included in this review had schizoaffective disorder so any judgment on the effects of carbamazepine for this important subgroup is impossible.</P>
</SUBSECTION>
</SUBSECTION>
</SUMMARY_OF_RESULTS>
<APPLICABILITY_OF_FINDINGS MODIFIED="2013-01-27 13:53:17 +0000" MODIFIED_BY="[Empty name]">
<P>We believe that the data we gathered covered a broad spectrum of participants and problems, but the small number of included studies (due to poor quality of all available data) is too small to conclusively judge about the potential applicability of the obtained results. Trials with small sample sizes lack sufficient power to detect a small to moderate effect, and thus results from such trials are often inconclusive, even when a real effect does exist. A review has suggested that meta-analyses based on summation of small trials should be interpreted as inconclusive, regardless of whether the combined estimate was significant (<LINK REF="REF-Davey-Smith-1998" TYPE="REFERENCE">Davey Smith 1998</LINK>).</P>
</APPLICABILITY_OF_FINDINGS>
<QUALITY_OF_EVIDENCE MODIFIED="2014-03-03 11:55:25 +0000" MODIFIED_BY="[Empty name]">
<P>The quality of all identified relevant trials has to be judged as low. As many as 64 out of 91 studies that were eventually excluded form the final analysis failed to randomise the trial sequence. Due to this low quality, only 10 studies were included in the meta-analysis and the quality of those studies is moderate at best. Almost all studies were randomised and double-blind but for most of them detailed descriptions were not presented. Therefore, it is unclear whether these studies were adequately randomised and whether treatment allocation was really concealed and blinding assured through the whole procedure. Reporting bias is especially prevalent in this study pool with high risk being a problem in a majority of reports. Without original study protocols and raw data sets one cannot really use those trials to the full extent. However, to the advantage of the 10 included studies is has to be noted that attrition bias was consistently judged as representing a low level of risk. The threat of other possible biases was also typically absent. Nevertheless, these limitations led to low or very low quality judgements in several important outcomes in the 'Summary of findings' table.</P>
</QUALITY_OF_EVIDENCE>
<POTENTIAL_BIASES MODIFIED="2014-03-03 11:55:25 +0000" MODIFIED_BY="[Empty name]">
<P>The evidence presented here is, to our best knowledge, complete. However, one can never be certain whether some additional (unpublished) material exist that was not pooled into the analysis.</P>
</POTENTIAL_BIASES>
<AGREEMENT MODIFIED="2013-05-16 09:07:15 +0100" MODIFIED_BY="[Empty name]">
<P>We are aware of only one previous unsystematic review concerning the use of carbamazepine in the treatment of schizophrenia (<LINK REF="STD-Simhandl-1992" TYPE="STUDY">Simhandl 1992</LINK>). The authors tended to a conclusion that carbamazepine could have a beneficial effect, especially when used as an adjunct treatment to other neuroleptics. We do not feel the evidence supports this stance. </P>
</AGREEMENT>
</DISCUSSION>
<CONCLUSIONS MODIFIED="2014-03-03 11:55:25 +0000" MODIFIED_BY="[Empty name]">
<IMPLICATIONS_PRACTICE MODIFIED="2014-03-03 11:55:25 +0000" MODIFIED_BY="[Empty name]">
<SUBSECTION>
<HEADING LEVEL="4">1. For clinicians</HEADING>
<P>Based on currently available randomised trial-derived evidence, carbamazepine cannot be recommended for routine clinical use for treatment or augmentation of antipsychotic treatment of schizophrenia. For patients with a past history of response to carbamazepine, a trial of the drug may be warranted. For healthcare professionals currently caring for patients who have been receiving carbamazepine as a putative treatment for schizophrenia, clinicians need to weigh up whether this treatment should be stopped. Carbamazepine is associated with a range of adverse effects. If there is no evidence that the treatment has been effective, then it should be gradually tapered off and then stopped altogether. The dose of concomitant antipsychotics may need to be revised in light of the potential pharmacokinetic interactions between carbamazepine and some antipsychotics as antipsychotic plasma levels may rise upon withdrawal.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">2. For people with schizophrenia</HEADING>
<P>People with schizophrenia should know of the lack of a strong empirical basis for the use of carbamazepine in their illness. If its recommendation is still perused, the recipient of this treatment should expect clear endpoints and duration of treatment to be agreed upon.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">3. For managers and policy makers</HEADING>
<P>Although idiosyncratic positive responses are always possible, there are no data to support the use of carbamazepine for those with schizophrenia as a routine measure.</P>
</SUBSECTION>
</IMPLICATIONS_PRACTICE>
<IMPLICATIONS_RESEARCH MODIFIED="2014-03-03 11:55:25 +0000" MODIFIED_BY="[Empty name]">
<SUBSECTION>
<HEADING LEVEL="4">1. General</HEADING>
<P>Any future studies should respect standards of measuring outcomes and of reporting data (<A HREF="http://www.consort-statement.org/">CONSORT</A>) in order to enhance the comparability of study results (<LINK REF="REF-Begg-1996" TYPE="REFERENCE">Begg 1996</LINK>). The fact that several authors (see <LINK TAG="ACKNOWLEDGEMENTS" TYPE="SECTION">Acknowledgements</LINK>) shared their data with us very much improved the quality of this review. We would like to encourage similar collaboration in the future. The Cochrane Collaboration supports the <A HREF="http://www.alltrials.net/">ALLTRIALS</A> initiative.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">2. Specific</HEADING>
<SUBSECTION>
<HEADING LEVEL="5">2.1 Reviews or additional comparisons</HEADING>
<P>
<LINK REF="TBL-01" TYPE="TABLE">Table 1</LINK>, derived from the excluded studies contains suggestions for further reviews or for further comparisons relevant to this review. Because there are so few compelling data suggesting a real effect of carbamazepine for people with schizophrenia it is difficult to know if some of the additional comparisons are warranted. However, they are added in <LINK REF="TBL-01" TYPE="TABLE">Table 1</LINK> for the sake of completeness.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="5">2.2 Trials</HEADING>
<P>There seems to be little need to undertake randomised trials investigating the effects of carbamazepine augmentation for people with uncomplicated schizophrenia. Some special indications might, however, still be of research interest.</P>
<P>Despite the reintroduction of clozapine, the only drug proven to have superior efficacy than standard drugs for those with treatment-resistant illness (<LINK REF="REF-Essali-2009" TYPE="REFERENCE">Essali 2009</LINK>), there is a need for the development of treatment strategies when clozapine does not work. The two randomised trials investigating the effects of carbamazepine augmentation for people with treatment-resistant schizophrenia (<LINK REF="STD-Llorca-1993" TYPE="STUDY">Llorca 1993</LINK>; <LINK REF="STD-Simhandl-1996" TYPE="STUDY">Simhandl 1996</LINK>) only randomised a total of 66 patients. Even the combined totals lack the power to identify anything but gross differences between groups. Even small differences in outcome may be of great importance in this subgroup and therefore a large simple trial is justified. Clarification of the role of carbamazepine for the treatment of people with both schizophrenia and EEG abnormalities may be warranted. Carbamazepine is used for those with aggressive or violent episodes and its evaluation within trials in this subgroup of people with schizophrenia would be valuable. Carbamazepine is also used for those with schizoaffective disorders but data from placebo-controlled trials do not exist. The bipolar type of schizoaffective disorder especially warrants further studies.</P>
<P>For a suggested design of study please see <LINK REF="TBL-02" TYPE="TABLE">Table 2</LINK>.</P>
</SUBSECTION>
</SUBSECTION>
</IMPLICATIONS_RESEARCH>
</CONCLUSIONS>
</BODY>
<ACKNOWLEDGEMENTS MODIFIED="2014-04-01 10:59:42 +0100" MODIFIED_BY="[Empty name]">
<P>The Cochrane Schizophrenia Group produces and maintains a template for the methods section of their reviews. We have used this and adapted it for our review.</P>
<P>We would like to thank very much Drs Carpenter, Svestka, Dose, Neppe, Martin-Munoz, Simhandl, Normann and Nachshoni for sending us their original patient data. Without their contribution this update would not have been possible.</P>
<P>We would also like to thank Paul White who helped with original protocol development and data interpretation.</P>
</ACKNOWLEDGEMENTS>
<CONFLICT_OF_INTEREST MODIFIED="2014-04-01 10:59:58 +0100" MODIFIED_BY="[Empty name]">
<P>Stefan Leucht: In the last 3 years Stefan Leucht has received consulting/advisory board honoraria from Roche, Eli Lilly, Medavante, Bristol-Myers Squibb, Alkermes, Janssen, Johnson &amp; Johnson, and Lundbeck, Lecture honoraria from Abbvie, Astra Zeneca, Bristol-Myers Squibb, ICON, Eli Lilly, Janssen, Johnson &amp; Johnson, Roche, Sanofi-Aventis, Lundbeck, and Pfizer, and Eli Lilly has provided medication for a trial with Stefan Leucht as the primary investigator.</P>
<P>Markus Dold: nothing to declare.</P>
<P>John McGrath is a member of the following advisory boards: Eli Lilly Australia, Lundbeck Australia and Pfizer Australia. In addition, JM has been a co-investigator on studies of neuroleptic medications produced by the following companies: Astra, Janssen-Cilag, Eli Lilly, Zeneca (ICI), Sandoz and Pfizer. The same companies have provided travel and accommodation expenses for John McGrath to attend relevant investigator meetings and scientific symposia. No funds have been paid directly to Dr McGrath. Payments related to participation in drug trials and board attendances have been paid to a Government-audited trust account to support schizophrenia research.</P>
<P>Werner Kissling has received honoraria and/or research support from Janssen-Cilag, SanofiAventis, Johnson &amp; Johnson, Pfizer, BMS, Astra Zeneca, Lundbeck, Novartis and Eli Lilly. Dr Kissling is an investigator on one of the excluded trials in this review (<LINK REF="STD-M_x00f6_ller-1989" TYPE="STUDY">Möller 1989</LINK>).</P>
<P>Bartosz Helfer: nothing to declare.</P>
</CONFLICT_OF_INTEREST>
<CONTRIBUTIONS MODIFIED="2014-04-01 10:59:09 +0100" MODIFIED_BY="[Empty name]">
<P>Stefan Leucht - protocol development, searching, data extraction, analysis, data interpretation and writing the final report.</P>
<P>Markus Dold - searching, data extraction, analysis, data interpretation.</P>
<P>John McGrath - protocol development, data checking, data interpretation.</P>
<P>Werner Kissling - protocol development, data interpretation.</P>
<P>Bartosz Helfer - updating, data extraction and writing parts of the report.</P>
</CONTRIBUTIONS>
<PRO_REV_DIFF/>
<PUBLIC_NOTES/>
</MAIN_TEXT>
<STUDIES_AND_REFERENCES MODIFIED="2014-03-03 12:01:39 +0000" MODIFIED_BY="[Empty name]">
<STUDIES MODIFIED="2014-03-03 12:01:39 +0000" MODIFIED_BY="[Empty name]">
<INCLUDED_STUDIES MODIFIED="2014-03-03 12:01:39 +0000" MODIFIED_BY="[Empty name]">
<STUDY DATA_SOURCE="PUB" ID="STD-Carpenter-1991" MODIFIED="2013-12-16 11:38:33 +0000" MODIFIED_BY="[Empty name]" NAME="Carpenter 1991" YEAR="1991">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Carpenter WT, Kurz R, Kirkpatrick B, Hanlon TE</AU>
<TI>Carbamazepine maintenance treatment in outpatient schizophrenics</TI>
<SO>Archives of General Psychiatry</SO>
<YR>1991</YR>
<VL>48</VL>
<NO>1</NO>
<PG>69-72</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS MODIFIED="2013-12-16 11:38:33 +0000" MODIFIED_BY="[Empty name]">
<IDENTIFIER MODIFIED="2013-12-16 11:38:33 +0000" MODIFIED_BY="[Empty name]" TYPE="OTHER" VALUE="9000100000010167"/>
</IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Dose-1987" MODIFIED="2014-03-03 12:01:39 +0000" MODIFIED_BY="[Empty name]" NAME="Dose 1987" YEAR="1987">
<REFERENCE MODIFIED="2014-01-27 09:43:00 +0000" MODIFIED_BY="Heather Maxwell" PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Dose M, Apelt S, Emrich HM</AU>
<TI>Carbamazepine as an adjunct of antipsychotic therapy</TI>
<SO>Psychiatry Research</SO>
<YR>1987</YR>
<VL>22</VL>
<NO>4</NO>
<PG>303-10</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Dose M, Emrich HM</AU>
<TI>Carbamazepine as an adjunct to antipsychotic treatment</TI>
<SO>Schizophrenia Research</SO>
<YR>1988</YR>
<VL>1</VL>
<NO>2,3</NO>
<PG>207-8</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE MODIFIED="2014-03-03 12:01:39 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Dose M, Emrich HM</AU>
<TI>Combination of neuroleptics with carbamazepine. Application in the treatment of schizophrenic psychoses</TI>
<TO>Kombination von Neuroleptika mit Carbamazepin. Einsatz in der Behandlung schizophrener Psychosen</TO>
<SO>Münchner Medizinische Wochenschrift</SO>
<YR>1990</YR>
<VL>132 (suppl 1)</VL>
<PG>87-90</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Dose M, Garcia D, Weber M, Yassouridis A, Emrich HM</AU>
<TI>Combined treatment of schizophrenic psychoses with neuroleptics and anticonvulsants</TI>
<SO>Pharmacopsychiatry</SO>
<YR>1989</YR>
<VL>22</VL>
<NO>5</NO>
<PG>195</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE PRIMARY="NO" TYPE="BOOK">
<AU>Dose M</AU>
<SO>Die Bedeutung von Antikonvulsiva und Calciumantagonisten für die Pharmakotherapie von Psychosen. Habilitationsschrift</SO>
<YR>1991</YR>
<PB>Technische Universität München</PB>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS MODIFIED="2013-12-16 11:38:56 +0000" MODIFIED_BY="[Empty name]">
<IDENTIFIER MODIFIED="2013-12-16 11:38:56 +0000" MODIFIED_BY="[Empty name]" TYPE="OTHER" VALUE="9000100000010191"/>
</IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="MIX" ID="STD-He_x00df_linger-1998" MODIFIED="2014-03-03 12:01:28 +0000" MODIFIED_BY="[Empty name]" NAME="Heßlinger 1998" YEAR="1998">
<REFERENCE MODIFIED="2014-01-27 09:44:58 +0000" MODIFIED_BY="Heather Maxwell" PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Hesslinger B, Klose P, Normann C, Langosch JM, Berger M, Walden J</AU>
<TI>Carbamazepine co-treatment in schizophrenia</TI>
<SO>Fortschritte der Neurologie Psychiatrie</SO>
<YR>1998</YR>
<VL>66</VL>
<NO>4</NO>
<PG>145-50</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE MODIFIED="2014-03-03 12:01:28 +0000" MODIFIED_BY="[Empty name]" NOTES="&lt;p&gt;Hesslinger B, Normann C, Langosch JM, Klose P, Berger M, Walden J. Effects of carbamazepine and valproate on haloperidol plasma levels and on psychopathologic outcome in schizophrenic patients. J Clin Psychopharmacol 1999;19(4):310-315.&lt;/p&gt;" NOTES_MODIFIED="2014-03-03 12:01:28 +0000" NOTES_MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Hesslinger B, Normann C, Langosch JM, Klose P, Berger M, Walden J</AU>
<TI>Effects of carbamazepine and valproate on haloperidol plasma levels and on psychopathologic outcome in schizophrenic patients</TI>
<SO>Journal of Clinical Psychopharmacology</SO>
<YR>1999</YR>
<VL>19</VL>
<NO>4</NO>
<PG>310-5</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Normann C, Klose P, Hesslinger B, Langosch JM, Berger M, Walden J</AU>
<TI>Haloperidol plasma levels and psychopathology in schizophrenic patients with antiepileptic co-medication: a clinical trial</TI>
<SO>Pharmacopsychiatry</SO>
<YR>1997</YR>
<VL>30</VL>
<PG>204</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE PRIMARY="NO" TYPE="CONFERENCE_PROC">
<AU>Walden J, Hesslinger B, Normann C, Langosch J, Berger M</AU>
<TI>Actions of carbamazepine and valproate on haloperidol plasma levels and psychopathological outcome</TI>
<SO>Proceedings of the 21st Congress of the Collegium Internationale Neuro-psychopharmacologicum, Glasgow, Scotland</SO>
<YR>1998</YR>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS MODIFIED="2013-12-16 11:39:59 +0000" MODIFIED_BY="[Empty name]">
<IDENTIFIER MODIFIED="2013-12-16 11:39:59 +0000" MODIFIED_BY="[Empty name]" TYPE="OTHER" VALUE="9000100000010494"/>
</IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Llorca-1993" MODIFIED="2014-01-27 09:47:57 +0000" MODIFIED_BY="[Empty name]" NAME="Llorca 1993" YEAR="1993">
<REFERENCE MODIFIED="2008-10-28 16:28:34 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Estorges JP, Llorca PM, Lancon C, Bougerol T, Scotto JC</AU>
<TI>Carbamazepine as adjuvant treatment to neuroleptics in schizophrenic patients</TI>
<SO>Encephale</SO>
<YR>1991</YR>
<VL>17</VL>
<NO>4</NO>
<PG>307</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE MODIFIED="2014-01-27 09:47:57 +0000" MODIFIED_BY="Heather Maxwell" NOTES="&lt;p&gt;Llorca PM, Wolf MA, Lancon C, Bougerol T. Efficacite comparee de la bromocriptine, de la carbamazepine et de la cyproheptadine en association aux neuroleptiques chez 24 patients schizophrenes chroniques resistants. / Clinical efficacy of bromocriptine, carbamazepine, and cyproheptadine as adjuvant to neuroleptics in 24 chronic resistant schizophrenics. Encephale 1993;19(5):565-71.&lt;/p&gt;" NOTES_MODIFIED="2014-01-27 09:47:57 +0000" NOTES_MODIFIED_BY="Heather Maxwell" PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Llorca PM, Wolf MA, Lancon C, Bougerol T</AU>
<TI>Clinical efficacy of bromocriptine, carbamazepine, and cyproheptadine as adjuvant to neuroleptics in 24 chronic resistant schizophrenics</TI>
<TO>Efficacite comparee de la bromocriptine, de la carbamazepine et de la cyproheptadine en association aux neuroleptiques chez 24 patients schizophrenes chroniques resistants</TO>
<SO>Encephale</SO>
<YR>1993</YR>
<VL>19</VL>
<NO>5</NO>
<PG>565-71</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS MODIFIED="2013-12-16 11:40:32 +0000" MODIFIED_BY="[Empty name]">
<IDENTIFIER MODIFIED="2013-12-16 11:40:32 +0000" MODIFIED_BY="[Empty name]" TYPE="OTHER" VALUE="9000100000010199"/>
</IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Mair-1990" MODIFIED="2014-01-27 09:48:58 +0000" MODIFIED_BY="[Empty name]" NAME="Mair 1990" YEAR="1990">
<REFERENCE MODIFIED="2014-01-27 09:48:58 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="BOOK_SECTION">
<AU>Mair M, Tschapeller I, Schubert H</AU>
<TI>Kombinationstherapie mit Neuroleptika und Carbamazepin. Eine kontrollierte Studie</TI>
<SO>Schizophrenie erkennen, verstehen, behandeln.Beiträge aus Theorie und Praxis</SO>
<YR>1990</YR>
<PG>77-92</PG>
<ED>Schonbeck G, Platz T</ED>
<PB>Springer Verlag</PB>
<CY>Wien</CY>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS MODIFIED="2013-12-16 11:40:58 +0000" MODIFIED_BY="[Empty name]">
<IDENTIFIER MODIFIED="2013-12-16 11:40:58 +0000" MODIFIED_BY="[Empty name]" TYPE="OTHER" VALUE="9000100000010214"/>
</IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Martin_x002d_Munoz-1989" MODIFIED="2014-03-03 12:01:17 +0000" MODIFIED_BY="[Empty name]" NAME="Martin-Munoz 1989" YEAR="1989">
<REFERENCE MODIFIED="2014-03-03 12:01:17 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Martin-Munoz JC, Morinigo-Dominguez AV, Mateo-Martin I, Guajardo FI</AU>
<TI>Carbamazepine: An effective adjunct treatment for schizophrenia</TI>
<TO>La carbamacepina: un tratamiento adjunto eficaz en las esquizofrenias</TO>
<SO>Actas Luso Espanolas de Neurologia, Psiquiatria y Ciencias Afines</SO>
<YR>1992</YR>
<VL>20</VL>
<NO>1</NO>
<PG>11-6</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE MODIFIED="2014-03-03 12:01:10 +0000" MODIFIED_BY="[Empty name]" PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Martin-Munoz JC, Morinigo-Dominguez AV, Mateo-Martin I, Ibarra IG</AU>
<TI>Carbamazepine: An efficacious adjuvant treatment in schizophrenia</TI>
<TO>La carbamacepina: Un tratamiento adjunto eficaz en las esquizofrenias</TO>
<SO>Actas Luso Espanolas de Neurologia, Psiquiatria y Ciencias Afines</SO>
<YR>1989</YR>
<VL>17</VL>
<NO>4</NO>
<PG>245-50</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS MODIFIED="2013-12-16 11:41:25 +0000" MODIFIED_BY="[Empty name]">
<IDENTIFIER MODIFIED="2013-12-16 11:41:25 +0000" MODIFIED_BY="[Empty name]" TYPE="OTHER" VALUE="9000100000010218"/>
</IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Nachshoni-1994" MODIFIED="2013-12-16 11:41:44 +0000" MODIFIED_BY="[Empty name]" NAME="Nachshoni 1994" YEAR="1994">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Nachshoni T, Levin Y, Levy A, Kritz A</AU>
<TI>A double-blind trial of carbamazepine in negative symptom schizophrenia</TI>
<SO>Biological Psychiatry</SO>
<YR>1994</YR>
<VL>35</VL>
<NO>1</NO>
<PG>22-6</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS MODIFIED="2013-12-16 11:41:44 +0000" MODIFIED_BY="[Empty name]">
<IDENTIFIER MODIFIED="2013-12-16 11:41:44 +0000" MODIFIED_BY="[Empty name]" TYPE="OTHER" VALUE="9000100000010219"/>
</IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="MIX" ID="STD-Neppe-1983" MODIFIED="2013-12-16 11:42:20 +0000" MODIFIED_BY="[Empty name]" NAME="Neppe 1983" YEAR="1983">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Neppe VM</AU>
<TI>Carbamazepine as adjunctive treatment in nonepileptic chronic inpatients with EEG temporal lobe abnormalities</TI>
<SO>Journal of Clinical Psychiatry</SO>
<YR>1983</YR>
<VL>44</VL>
<NO>9</NO>
<PG>326-31</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Neppe VM</AU>
<TI>Carbamazepine in the psychiatric patient</TI>
<SO>Lancet</SO>
<YR>1982</YR>
<VL>2</VL>
<NO>8293</NO>
<PG>334</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Neppe VM</AU>
<TI>Non-responsive psychosis - a biochemical difference?</TI>
<SO>South African Medical Journal</SO>
<YR>1983</YR>
<VL>63</VL>
<NO>21</NO>
<PG>797-8</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS MODIFIED="2013-12-16 11:42:20 +0000" MODIFIED_BY="[Empty name]">
<IDENTIFIER MODIFIED="2013-12-16 11:42:20 +0000" MODIFIED_BY="[Empty name]" TYPE="OTHER" VALUE="9000100000010240"/>
</IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Simhandl-1996" MODIFIED="2014-03-03 12:00:59 +0000" MODIFIED_BY="[Empty name]" NAME="Simhandl 1996" YEAR="1996">
<REFERENCE MODIFIED="2013-12-16 14:13:02 +0000" MODIFIED_BY="[Empty name]" NOTES="&lt;p&gt;Meszaros K, Simhandl C, Denk E, Liechtenstein A, Topitz A, Thau K. A carbamazepine augmentation trial in chronic nonresponsive schizophrenia. - NEEDS FIXED&lt;/p&gt;" NOTES_MODIFIED="2013-12-16 14:13:02 +0000" NOTES_MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="OTHER">
<AU>Meszaros K, Simhandl C, Denk E, Liechtenstein A, Topitz A, Thau K</AU>
<TI>A carbamazepine augmentation trial in chronic nonresponsive schizophrenia</TI>
<SO>NA</SO>
<YR>1996</YR>
<VL>NA</VL>
<PG>NA</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE MODIFIED="2014-03-03 12:00:59 +0000" MODIFIED_BY="[Empty name]" PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Simhandl C, Meszaros K, Denk E, Thau K, Topitz A</AU>
<TI>Adjunctive carbamazepine or lithium carbonate in therapyresistant chronic schizophrenia</TI>
<SO>Canadian Journal of Psychiatry/Revue Canadienne de Psychiatrie</SO>
<YR>1996</YR>
<VL>41</VL>
<NO>5</NO>
<PG>317</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS MODIFIED="2013-12-16 11:42:43 +0000" MODIFIED_BY="[Empty name]">
<IDENTIFIER MODIFIED="2013-12-16 11:42:43 +0000" MODIFIED_BY="[Empty name]" TYPE="OTHER" VALUE="9000100000010245"/>
</IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Svestka-1989" MODIFIED="2013-12-16 11:44:45 +0000" MODIFIED_BY="[Empty name]" NAME="Svestka 1989" YEAR="1989">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Svestka J, Ceskova E, Rysanek R, Nahunek K</AU>
<TI>Controlled cross-over comparison of carbamazepine with perphenazine in schizophrenic psychoses</TI>
<SO>Activitas Nervosa Superior</SO>
<YR>1989</YR>
<VL>31</VL>
<NO>4</NO>
<PG>276-7</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS MODIFIED="2013-12-16 11:44:45 +0000" MODIFIED_BY="[Empty name]">
<IDENTIFIER MODIFIED="2013-12-16 11:44:45 +0000" MODIFIED_BY="[Empty name]" TYPE="OTHER" VALUE="9000100000006581"/>
</IDENTIFIERS>
</STUDY>
</INCLUDED_STUDIES>
<EXCLUDED_STUDIES MODIFIED="2014-03-03 12:00:50 +0000" MODIFIED_BY="[Empty name]">
<STUDY DATA_SOURCE="PUB" ID="STD-Arana-1986" MODIFIED="2013-12-16 11:49:56 +0000" MODIFIED_BY="[Empty name]" NAME="Arana 1986" YEAR="1986">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Arana GW</AU>
<TI>Does carbamazepine-induced reduction of plasma haloperidol levels worsen psychotic symptoms? 138th Annual Meeting of the American Psychiatric Association (1985, Dallas, Texas)</TI>
<SO>American Journal of Psychiatry</SO>
<YR>1986</YR>
<VL>143</VL>
<NO>5</NO>
<PG>650-1</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS MODIFIED="2013-12-16 11:49:56 +0000" MODIFIED_BY="[Empty name]">
<IDENTIFIER MODIFIED="2013-12-16 11:49:56 +0000" MODIFIED_BY="[Empty name]" TYPE="OTHER" VALUE="9000100000009572"/>
</IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Azorin-1986" MODIFIED="2014-03-03 12:00:50 +0000" MODIFIED_BY="[Empty name]" NAME="Azorin 1986" YEAR="1986">
<REFERENCE MODIFIED="2014-03-03 12:00:50 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Azorin JM, Samuelian JC, Pringuey D, Donnet A</AU>
<TI>Place of carbamazepine in the treatment of endogenous psychoses: Results of an open trial</TI>
<TO>Place de la carbamazepine dans le traitement des psychoses endogenes: Resultats d'une etude ouverte</TO>
<SO>Encephale</SO>
<YR>1986</YR>
<VL>12</VL>
<NO>3</NO>
<PG>115-9</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS MODIFIED="2013-12-16 11:50:14 +0000" MODIFIED_BY="[Empty name]">
<IDENTIFIER MODIFIED="2013-12-16 11:50:14 +0000" MODIFIED_BY="[Empty name]" TYPE="OTHER" VALUE="9000100000010263"/>
</IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Ballenger-1984" MODIFIED="2014-01-27 10:16:07 +0000" MODIFIED_BY="[Empty name]" NAME="Ballenger 1984" YEAR="1984">
<REFERENCE MODIFIED="2014-01-27 10:16:07 +0000" MODIFIED_BY="Heather Maxwell" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Ballenger JC, Post RM</AU>
<TI>Carbamazepine in alcohol and withdrawal syndromes and schizophrenic psychoses</TI>
<SO>Psychopharmacology Bulletin</SO>
<YR>1984</YR>
<VL>20</VL>
<PG>572-84</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS MODIFIED="2013-12-16 11:50:30 +0000" MODIFIED_BY="[Empty name]">
<IDENTIFIER MODIFIED="2013-12-16 11:50:30 +0000" MODIFIED_BY="[Empty name]" TYPE="OTHER" VALUE="9000100000010267"/>
</IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Barnes-1996" MODIFIED="2013-12-16 11:50:47 +0000" MODIFIED_BY="[Empty name]" NAME="Barnes 1996" YEAR="1996">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Barnes TR, McEvedy CJ</AU>
<TI>Pharmacological treatment strategies in the non-responsive schizophrenic patient</TI>
<SO>International Clinical Psychopharmacology</SO>
<YR>1996</YR>
<VL>11</VL>
<NO>s2</NO>
<PG>67-71</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS MODIFIED="2013-12-16 11:50:47 +0000" MODIFIED_BY="[Empty name]">
<IDENTIFIER MODIFIED="2013-12-16 11:50:47 +0000" MODIFIED_BY="[Empty name]" TYPE="OTHER" VALUE="9000100000010269"/>
</IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Bellaire-1990" MODIFIED="2014-03-03 12:00:41 +0000" MODIFIED_BY="[Empty name]" NAME="Bellaire 1990" YEAR="1990">
<REFERENCE MODIFIED="2014-03-03 12:00:41 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Bellaire W, Demisch K, Stoll K-D</AU>
<TI>Carbamazepine vs. lithium. Application in the prophylaxis of recidivating affective and schizoaffective psychoses</TI>
<TO>Carbamazepin vs. Lithium. Einsatz in der Prophylaxe rezidivierender affektiver und schizoaffektiver Psychosen</TO>
<SO>Münchner Medizinische Wochenschrift</SO>
<YR>1990</YR>
<VL>132</VL>
<PG>82-6</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS MODIFIED="2013-12-16 11:51:11 +0000" MODIFIED_BY="[Empty name]">
<IDENTIFIER MODIFIED="2013-12-16 11:51:11 +0000" MODIFIED_BY="[Empty name]" TYPE="OTHER" VALUE="9000100000010271"/>
</IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Birkheimer-1985" MODIFIED="2013-12-16 11:51:32 +0000" MODIFIED_BY="[Empty name]" NAME="Birkheimer 1985" YEAR="1985">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Birkhimer LJ, Curtis JL, Jann MW</AU>
<TI>Use of carbamazepine in psychiatric disorders</TI>
<SO>Clinical Pharmacology</SO>
<YR>1985</YR>
<VL>4</VL>
<NO>4</NO>
<PG>425-34</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS MODIFIED="2013-12-16 11:51:32 +0000" MODIFIED_BY="[Empty name]">
<IDENTIFIER MODIFIED="2013-12-16 11:51:32 +0000" MODIFIED_BY="[Empty name]" TYPE="OTHER" VALUE="9000100000010274"/>
</IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Borison-1991" MODIFIED="2013-12-16 11:52:27 +0000" MODIFIED_BY="[Empty name]" NAME="Borison 1991" YEAR="1991">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Borison RL, Diamond BI, Dren AT</AU>
<TI>Does sigma receptor antagonism predict clinical antipsychotic efficacy?</TI>
<SO>Psychopharmacology Bulletin</SO>
<YR>1991</YR>
<VL>27</VL>
<NO>2</NO>
<PG>103-6</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="MEDLINE" VALUE="92021349"/>
<IDENTIFIER TYPE="OTHER" VALUE="PMID 1681560"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS MODIFIED="2013-12-16 11:52:27 +0000" MODIFIED_BY="[Empty name]">
<IDENTIFIER MODIFIED="2013-12-16 11:52:27 +0000" MODIFIED_BY="[Empty name]" TYPE="OTHER" VALUE="9000100000010276"/>
</IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Botte-1988" MODIFIED="2014-03-03 12:00:32 +0000" MODIFIED_BY="[Empty name]" NAME="Botte 1988" YEAR="1988">
<REFERENCE MODIFIED="2014-03-03 12:00:32 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Botte L, Charles G</AU>
<TI>Clinical use of carbamazepine: Review from the literature and personal results</TI>
<TO>Utilisations cliniques de la carbamazepine: Revue de la litterature et resultats personnels</TO>
<SO>Acta Psychiatrica Belgica</SO>
<YR>1988</YR>
<VL>88</VL>
<NO>3</NO>
<PG>181-94</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS MODIFIED="2013-12-16 11:52:45 +0000" MODIFIED_BY="[Empty name]">
<IDENTIFIER MODIFIED="2013-12-16 11:52:45 +0000" MODIFIED_BY="[Empty name]" TYPE="OTHER" VALUE="9000100000010279"/>
</IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Cabrera-1987" MODIFIED="2013-12-16 11:53:33 +0000" MODIFIED_BY="[Empty name]" NAME="Cabrera 1987" YEAR="1986">
<REFERENCE NOTES="&lt;p&gt;&amp;lt;Empty&amp;gt;&lt;/p&gt;" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Cabrera J, Albrecht J, Muller-Oerlinghausen B</AU>
<TI>Combined preventive treatment of recurrent manic-depressive disease with lithium and carbamazepine or oxcarbazepine</TI>
<SO>Nervenarzt</SO>
<YR>1987</YR>
<VL>58</VL>
<NO>4</NO>
<PG>245-9</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS MODIFIED="2013-12-16 11:53:33 +0000" MODIFIED_BY="[Empty name]">
<IDENTIFIER MODIFIED="2013-12-16 11:53:33 +0000" MODIFIED_BY="[Empty name]" TYPE="OTHER" VALUE="9000100000010281"/>
</IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Cegalis-1984" MODIFIED="2013-12-16 11:53:54 +0000" MODIFIED_BY="[Empty name]" NAME="Cegalis 1984" YEAR="1984">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Cegalis JA, Possick SG</AU>
<TI>Carbamazepine and psychotherapy in the treatment of schizoaffective psychosis</TI>
<SO>Yale Journal of Biology and Medicine</SO>
<YR>1985</YR>
<VL>58</VL>
<NO>4</NO>
<PG>327-36</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS MODIFIED="2013-12-16 11:53:54 +0000" MODIFIED_BY="[Empty name]">
<IDENTIFIER MODIFIED="2013-12-16 11:53:54 +0000" MODIFIED_BY="[Empty name]" TYPE="OTHER" VALUE="9000100000010284"/>
</IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Chouinard-1990" MODIFIED="2013-12-16 11:54:11 +0000" MODIFIED_BY="[Empty name]" NAME="Chouinard 1990" YEAR="1990">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Chouinard G, Sultan S</AU>
<TI>Treatment of supersensitivity psychosis with antiepileptic drugs: Report of a series of 43 cases</TI>
<SO>Psychopharmacology Bulletin</SO>
<YR>1990</YR>
<VL>26</VL>
<NO>3</NO>
<PG>337</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS MODIFIED="2013-12-16 11:54:11 +0000" MODIFIED_BY="[Empty name]">
<IDENTIFIER MODIFIED="2013-12-16 11:54:11 +0000" MODIFIED_BY="[Empty name]" TYPE="OTHER" VALUE="9000100000010311"/>
</IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Costa-1986" MODIFIED="2013-12-16 11:54:30 +0000" MODIFIED_BY="[Empty name]" NAME="Costa 1986" YEAR="1986">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Costa JF, Sramek J, Herrera JM</AU>
<TI>Hepatic reaction to carbamazepine</TI>
<SO>Journal of Clinical Psychopharmacology</SO>
<YR>1986</YR>
<VL>6</VL>
<NO>4</NO>
<PG>251-2</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS MODIFIED="2013-12-16 11:54:30 +0000" MODIFIED_BY="[Empty name]">
<IDENTIFIER MODIFIED="2013-12-16 11:54:30 +0000" MODIFIED_BY="[Empty name]" TYPE="OTHER" VALUE="9000100000010315"/>
</IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Covell-2004" MODIFIED="2013-12-16 11:54:47 +0000" MODIFIED_BY="[Empty name]" NAME="Covell 2004" YEAR="2004">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Covell NH, Weissman EM, Essock SM</AU>
<TI>Weight gain with clozapine compared to first generation antipsychotic medications</TI>
<SO>Schizophrenia Bulletin</SO>
<YR>2004</YR>
<VL>30</VL>
<NO>2</NO>
<PG>229-40</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="MEDLINE" VALUE="15279042"/>
<IDENTIFIER TYPE="OTHER" VALUE="EMBASE 2004274059"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS MODIFIED="2013-12-16 11:54:47 +0000" MODIFIED_BY="[Empty name]">
<IDENTIFIER MODIFIED="2013-12-16 11:54:47 +0000" MODIFIED_BY="[Empty name]" TYPE="OTHER" VALUE="9000100000010324"/>
</IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Dalby-1971" MODIFIED="2013-12-16 11:55:06 +0000" MODIFIED_BY="[Empty name]" NAME="Dalby 1971" YEAR="1971">
<REFERENCE NOTES="&lt;p&gt;Dalby MA. Antiepileptic and psychotropic effect of carbamazepine (Tegretol) in the treatment of psychomotor epilepsy. Epilepsia 1971:12:12;335-40.&lt;/p&gt;" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Dalby MA</AU>
<TI>Antiepileptic and psychotropic effect of carbamazepine (Tegretol) in the treatment of psychomotor epilepsy</TI>
<SO>Epilepsia</SO>
<YR>1971</YR>
<VL>12</VL>
<NO>12</NO>
<PG>335-40</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS MODIFIED="2013-12-16 11:55:06 +0000" MODIFIED_BY="[Empty name]">
<IDENTIFIER MODIFIED="2013-12-16 11:55:06 +0000" MODIFIED_BY="[Empty name]" TYPE="OTHER" VALUE="9000100000010326"/>
</IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Dehing-1968" MODIFIED="2013-12-16 11:55:28 +0000" MODIFIED_BY="[Empty name]" NAME="Dehing 1968" YEAR="1968">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Dehing J</AU>
<TI>Studies on the psychotropic action of tegretol</TI>
<SO>Acta Neurologica Belgica</SO>
<YR>1968</YR>
<VL>68</VL>
<PG>895-905</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS MODIFIED="2013-12-16 11:55:28 +0000" MODIFIED_BY="[Empty name]">
<IDENTIFIER MODIFIED="2013-12-16 11:55:28 +0000" MODIFIED_BY="[Empty name]" TYPE="OTHER" VALUE="9000100000010328"/>
</IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Denicoff-1994" MODIFIED="2013-12-16 11:55:47 +0000" MODIFIED_BY="[Empty name]" NAME="Denicoff 1994" YEAR="1994">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Denicoff KD, Meglathery SB, Post RM, Tandeciarz SI</AU>
<TI>Efficacy of carbamazepine compared with other agents: A clinical practice survey</TI>
<SO>Journal of Clinical Psychiatry</SO>
<YR>1994</YR>
<VL>55</VL>
<NO>2</NO>
<PG>70</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS MODIFIED="2013-12-16 11:55:47 +0000" MODIFIED_BY="[Empty name]">
<IDENTIFIER MODIFIED="2013-12-16 11:55:47 +0000" MODIFIED_BY="[Empty name]" TYPE="OTHER" VALUE="9000100000010331"/>
</IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-de-Vogelaer-1981" MODIFIED="2014-03-03 12:00:20 +0000" MODIFIED_BY="[Empty name]" NAME="de Vogelaer 1981" YEAR="1981">
<REFERENCE MODIFIED="2014-03-03 12:00:20 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>de Vogelaer J</AU>
<TI>Carbamazepine in the treatment of psychotic and behavioral disorders. A pilot study</TI>
<SO>Acta Psychiatrica Belgica</SO>
<YR>1981</YR>
<VL>81</VL>
<PG>532-41</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS MODIFIED="2013-12-16 11:56:08 +0000" MODIFIED_BY="[Empty name]">
<IDENTIFIER MODIFIED="2013-12-16 11:56:08 +0000" MODIFIED_BY="[Empty name]" TYPE="OTHER" VALUE="9000100000010332"/>
</IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Elphick-1985" MODIFIED="2013-12-16 11:56:36 +0000" MODIFIED_BY="[Empty name]" NAME="Elphick 1985" YEAR="1985">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Elphick M</AU>
<TI>An open clinical trial of carbamazepine in treatment-resistant bipolar and schizo-affective psychotics</TI>
<SO>British Journal of Psychiatry</SO>
<YR>1985</YR>
<VL>147</VL>
<PG>198-200</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS MODIFIED="2013-12-16 11:56:36 +0000" MODIFIED_BY="[Empty name]">
<IDENTIFIER MODIFIED="2013-12-16 11:56:36 +0000" MODIFIED_BY="[Empty name]" TYPE="OTHER" VALUE="9000100000010334"/>
</IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Frankenburg-1988" MODIFIED="2013-12-16 11:56:53 +0000" MODIFIED_BY="[Empty name]" NAME="Frankenburg 1988" YEAR="1988">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Frankenburg FR, Tohen M, Cohen BM, Lipinski JF</AU>
<TI>Long-term response to carbamazepine: A retrospective study</TI>
<SO>Journal of Clinical Psychopharmacology</SO>
<YR>1988</YR>
<VL>8</VL>
<NO>2</NO>
<PG>130-2</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS MODIFIED="2013-12-16 11:56:53 +0000" MODIFIED_BY="[Empty name]">
<IDENTIFIER MODIFIED="2013-12-16 11:56:53 +0000" MODIFIED_BY="[Empty name]" TYPE="OTHER" VALUE="9000100000010336"/>
</IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Gadow-1992" MODIFIED="2013-12-16 11:57:09 +0000" MODIFIED_BY="[Empty name]" NAME="Gadow 1992" YEAR="1992">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Gadow KD</AU>
<TI>Pediatric psychopharmacotherapy: A review of recent research</TI>
<SO>Journal of Child Psychology and Psychiatry and Allied Disciplines</SO>
<YR>1992</YR>
<VL>33</VL>
<NO>1</NO>
<PG>153-95</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS MODIFIED="2013-12-16 11:57:09 +0000" MODIFIED_BY="[Empty name]">
<IDENTIFIER MODIFIED="2013-12-16 11:57:09 +0000" MODIFIED_BY="[Empty name]" TYPE="OTHER" VALUE="9000100000010338"/>
</IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Galletly-1997" MODIFIED="2013-12-16 11:57:25 +0000" MODIFIED_BY="[Empty name]" NAME="Galletly 1997" YEAR="1997">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Galletly CA, Tsourtos G</AU>
<TI>Antipsychotic drug doses and adjunctive drugs in the outpatient treatment of schizophrenia</TI>
<SO>Annals of Clinical Psychiatry</SO>
<YR>1997</YR>
<VL>9</VL>
<NO>2</NO>
<PG>77-80</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS MODIFIED="2013-12-16 11:57:25 +0000" MODIFIED_BY="[Empty name]">
<IDENTIFIER MODIFIED="2013-12-16 11:57:25 +0000" MODIFIED_BY="[Empty name]" TYPE="OTHER" VALUE="9000100000010340"/>
</IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Ginestet-1996" MODIFIED="2013-12-16 11:57:41 +0000" MODIFIED_BY="[Empty name]" NAME="Ginestet 1996" YEAR="1996">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Ginestet D, Ghanem T, Slama M</AU>
<TI>The variety of indications for carbamazepine</TI>
<SO>Revue du Praticien Medecine Generale</SO>
<YR>1996</YR>
<VL>10</VL>
<NO>336</NO>
<PG>11</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS MODIFIED="2013-12-16 11:57:41 +0000" MODIFIED_BY="[Empty name]">
<IDENTIFIER MODIFIED="2013-12-16 11:57:41 +0000" MODIFIED_BY="[Empty name]" TYPE="OTHER" VALUE="9000100000010342"/>
</IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Goncalves-1985" MODIFIED="2013-12-16 11:57:59 +0000" MODIFIED_BY="[Empty name]" NAME="Goncalves 1985" YEAR="1985">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Goncalves N, Stoll KD</AU>
<TI>A controlled double-blind trial of carbamazepine in manic illness</TI>
<TO>Carbamazepin bei manischen Syndromen. Eine kontrollierte Doppelblind-Studie</TO>
<SO>Nervenarzt</SO>
<YR>1985</YR>
<VL>56</VL>
<NO>1</NO>
<PG>43-7</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS MODIFIED="2013-12-16 11:57:59 +0000" MODIFIED_BY="[Empty name]">
<IDENTIFIER MODIFIED="2013-12-16 11:57:59 +0000" MODIFIED_BY="[Empty name]" TYPE="OTHER" VALUE="9000100000010344"/>
</IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Greil-1997" MODIFIED="2013-12-16 11:58:17 +0000" MODIFIED_BY="[Empty name]" NAME="Greil 1997" YEAR="1997">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Greil W, Ludwig-Mayerhofer W, Erazo N, Engel RR</AU>
<TI>Lithium vs cambamazepine in the maintenance treatment of schizoaffective disorder: A randomised study</TI>
<SO>European Archives of Psychiatry and Clinical Neuroscience</SO>
<YR>1997</YR>
<VL>247</VL>
<NO>1</NO>
<PG>42-50</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS MODIFIED="2013-12-16 11:58:17 +0000" MODIFIED_BY="[Empty name]">
<IDENTIFIER MODIFIED="2013-12-16 11:58:17 +0000" MODIFIED_BY="[Empty name]" TYPE="OTHER" VALUE="9000100000010346"/>
</IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Hakola-1982" MODIFIED="2013-12-16 11:58:42 +0000" MODIFIED_BY="[Empty name]" NAME="Hakola 1982" YEAR="1982">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Hakola HA, Laulumaa VA</AU>
<TI>Carbamazepine in treatment of violent schizophrenics</TI>
<SO>Lancet</SO>
<YR>1982</YR>
<VL>1</VL>
<NO>8285</NO>
<PG>1358</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS MODIFIED="2013-12-16 11:58:42 +0000" MODIFIED_BY="[Empty name]">
<IDENTIFIER MODIFIED="2013-12-16 11:58:42 +0000" MODIFIED_BY="[Empty name]" TYPE="OTHER" VALUE="9000100000010349"/>
</IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Hermle-1993" MODIFIED="2013-12-16 11:59:00 +0000" MODIFIED_BY="[Empty name]" NAME="Hermle 1993" YEAR="1993">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Hermle L, Spitzer M</AU>
<TI>Succesful desensitization of a patient with schizoaffective psychosis and carbamazepin allergy</TI>
<SO>Nervenarzt</SO>
<YR>1993</YR>
<VL>64</VL>
<NO>3</NO>
<PG>208</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS MODIFIED="2013-12-16 11:59:00 +0000" MODIFIED_BY="[Empty name]">
<IDENTIFIER MODIFIED="2013-12-16 11:59:00 +0000" MODIFIED_BY="[Empty name]" TYPE="OTHER" VALUE="9000100000010353"/>
</IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Herrera-1987" MODIFIED="2014-03-03 12:00:06 +0000" MODIFIED_BY="[Empty name]" NAME="Herrera 1987" YEAR="1987">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Heh CW, Sramek J, Herrera J, Costa J</AU>
<TI>Exacerbation of psychosis after discontinuation of carbamazepine treatment</TI>
<SO>American Journal of Psychiatry</SO>
<YR>1988</YR>
<VL>145</VL>
<NO>7</NO>
<PG>878-9</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE MODIFIED="2014-03-03 12:00:06 +0000" MODIFIED_BY="[Empty name]" PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Herrera JM, Sramek JJ, Costa JF</AU>
<TI>Efficacy of adjunctive carbamazepine in the treatment of chronic schizophrenia</TI>
<SO>Drug Intelligence &amp; Clinical Pharmacy</SO>
<YR>1987</YR>
<VL>21</VL>
<NO>4</NO>
<PG>355-8</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS MODIFIED="2013-12-16 11:59:17 +0000" MODIFIED_BY="[Empty name]">
<IDENTIFIER MODIFIED="2013-12-16 11:59:17 +0000" MODIFIED_BY="[Empty name]" TYPE="OTHER" VALUE="9000100000010357"/>
</IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Ivkovi-2004" MODIFIED="2013-12-16 12:00:47 +0000" MODIFIED_BY="[Empty name]" NAME="Ivkovi 2004" YEAR="2004">
<REFERENCE MODIFIED="2013-02-27 16:38:50 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Ivkovi M, Damjanovi A, Marinkovi D, Paunovi RV</AU>
<TI>Carbamazepine for acute psychosis with EEG abnormalities</TI>
<SO>Military-Medical and Pharmaceutical Review</SO>
<YR>2004</YR>
<VL>61</VL>
<NO>4</NO>
<PG>399-403</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS MODIFIED="2013-12-16 12:00:47 +0000" MODIFIED_BY="[Empty name]">
<IDENTIFIER MODIFIED="2013-12-16 12:00:47 +0000" MODIFIED_BY="[Empty name]" TYPE="OTHER" VALUE="9000100000046906"/>
</IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Iwahashi-1995" MODIFIED="2013-12-16 12:01:38 +0000" MODIFIED_BY="[Empty name]" NAME="Iwahashi 1995" YEAR="1995">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Iwahashi K, Miyatake R, Suwaki H, Hosokawa K</AU>
<TI>The drug-drug interaction effects of haloperidol on plasma carbamazepine levels</TI>
<SO>Clinical Neuropharmacology</SO>
<YR>1995</YR>
<VL>18</VL>
<NO>3</NO>
<PG>233-6</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS MODIFIED="2013-12-16 12:01:38 +0000" MODIFIED_BY="[Empty name]">
<IDENTIFIER MODIFIED="2013-12-16 12:01:38 +0000" MODIFIED_BY="[Empty name]" TYPE="OTHER" VALUE="9000100000010359"/>
</IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Iwahashi-1996" MODIFIED="2013-12-16 12:01:55 +0000" MODIFIED_BY="[Empty name]" NAME="Iwahashi 1996" YEAR="1996">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Iwahashi K</AU>
<TI>Significantly higher plasma haloperidol level during cotreatment with carbamazepine may herald cardiac change [see comments]</TI>
<SO>Clinical Neuropharmacology</SO>
<YR>1996</YR>
<VL>19</VL>
<NO>3</NO>
<PG>267-70</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS MODIFIED="2013-12-16 12:01:55 +0000" MODIFIED_BY="[Empty name]">
<IDENTIFIER MODIFIED="2013-12-16 12:01:55 +0000" MODIFIED_BY="[Empty name]" TYPE="OTHER" VALUE="9000100000010363"/>
</IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Jann-1985" MODIFIED="2014-03-03 11:59:57 +0000" MODIFIED_BY="[Empty name]" NAME="Jann 1985" YEAR="1985">
<REFERENCE MODIFIED="2014-03-03 11:59:57 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Jann MW, Ereshefsky L, Saklad SR, Seidel DR, Davis CM, Burch NR, et al</AU>
<TI>Effects of carbamazepine on plasma haloperidol levels</TI>
<SO>Journal of Clinical Psychopharmacology</SO>
<YR>1985</YR>
<VL>5</VL>
<NO>2</NO>
<PG>106-9</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS MODIFIED="2013-12-16 12:02:12 +0000" MODIFIED_BY="[Empty name]">
<IDENTIFIER MODIFIED="2013-12-16 12:02:12 +0000" MODIFIED_BY="[Empty name]" TYPE="OTHER" VALUE="9000100000010367"/>
</IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Johns-1995" MODIFIED="2013-12-16 12:02:31 +0000" MODIFIED_BY="[Empty name]" NAME="Johns 1995" YEAR="1995">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Johns CA, Thompson JW</AU>
<TI>Adjunctive treatments in schizophrenia: Pharmacotherapies and electroconvulsive therapy</TI>
<SO>Schizophrenia Bulletin</SO>
<YR>1995</YR>
<VL>21</VL>
<NO>4</NO>
<PG>607-19</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS MODIFIED="2013-12-16 12:02:31 +0000" MODIFIED_BY="[Empty name]">
<IDENTIFIER MODIFIED="2013-12-16 12:02:31 +0000" MODIFIED_BY="[Empty name]" TYPE="OTHER" VALUE="9000100000010370"/>
</IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Kahn-1990" MODIFIED="2013-12-16 12:03:45 +0000" MODIFIED_BY="[Empty name]" NAME="Kahn 1990" YEAR="1990">
<REFERENCE PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Kahn EM, Schulz SC, Perel JM, Alexander JE</AU>
<TI>Change in haloperidol level due to carbamazepine: A complicating factor in combined medication for schizophrenia</TI>
<SO>Journal of Clinical Psychopharmacology</SO>
<YR>1990</YR>
<VL>10</VL>
<NO>1</NO>
<PG>54-7</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS MODIFIED="2013-12-16 12:03:45 +0000" MODIFIED_BY="[Empty name]">
<IDENTIFIER MODIFIED="2013-12-16 12:03:45 +0000" MODIFIED_BY="[Empty name]" TYPE="OTHER" VALUE="9000100000010371"/>
</IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Karper-1992" MODIFIED="2013-12-16 12:04:13 +0000" MODIFIED_BY="[Empty name]" NAME="Karper 1992" YEAR="1992">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Karper LP, Seibyl JP, Krystal JH</AU>
<TI>Valproate management of psychosis in a patient with carbamazepine-induced hyponatremia</TI>
<SO>Journal of Clinical Psychopharmacology</SO>
<YR>1992</YR>
<VL>12</VL>
<NO>2</NO>
<PG>137-9</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS MODIFIED="2013-12-16 12:04:13 +0000" MODIFIED_BY="[Empty name]">
<IDENTIFIER MODIFIED="2013-12-16 12:04:13 +0000" MODIFIED_BY="[Empty name]" TYPE="OTHER" VALUE="9000100000010373"/>
</IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Keck-1996" MODIFIED="2013-12-16 12:04:29 +0000" MODIFIED_BY="[Empty name]" NAME="Keck 1996" YEAR="1996">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Keck PE, McElroy SL, Strakowski SM</AU>
<TI>New developments in the pharmacologic treatment of schizoaffective disorder</TI>
<SO>Journal of Clinical Psychiatry</SO>
<YR>1996</YR>
<VL>57</VL>
<NO>s9</NO>
<PG>41-8</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS MODIFIED="2013-12-16 12:04:29 +0000" MODIFIED_BY="[Empty name]">
<IDENTIFIER MODIFIED="2013-12-16 12:04:29 +0000" MODIFIED_BY="[Empty name]" TYPE="OTHER" VALUE="9000100000010394"/>
</IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Kessler-1989" MODIFIED="2013-12-16 12:05:55 +0000" MODIFIED_BY="[Empty name]" NAME="Kessler 1989" YEAR="1989">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Kessler AJ, Barklage NE, Jefferson JW</AU>
<TI>Mood disorders in the psychoneurologic borderland: Three cases of responsiveness to carbamazepine. 29th Annual Meeting of the International Psychiatric Research Society (1987, Madison, Wisconsin)</TI>
<SO>American Journal of Psychiatry</SO>
<YR>1989</YR>
<VL>146</VL>
<NO>1</NO>
<PG>81-3</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS MODIFIED="2013-12-16 12:05:55 +0000" MODIFIED_BY="[Empty name]">
<IDENTIFIER MODIFIED="2013-12-16 12:05:55 +0000" MODIFIED_BY="[Empty name]" TYPE="OTHER" VALUE="9000100000010396"/>
</IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Kidron-1985" MODIFIED="2013-12-16 12:05:39 +0000" MODIFIED_BY="[Empty name]" NAME="Kidron 1985" YEAR="1985">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Kidron R, Averbuch I, Klein E, Belmaker RH</AU>
<TI>Carbamazepine-induced reduction of blood levels of haloperidol in chronic schizophrenia</TI>
<SO>Biological Psychiatry</SO>
<YR>1985</YR>
<VL>20</VL>
<NO>2</NO>
<PG>219-22</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS MODIFIED="2013-12-16 12:05:39 +0000" MODIFIED_BY="[Empty name]">
<IDENTIFIER MODIFIED="2013-12-16 12:05:39 +0000" MODIFIED_BY="[Empty name]" TYPE="OTHER" VALUE="9000100000010397"/>
</IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Klein-1984" MODIFIED="2013-12-16 12:06:30 +0000" MODIFIED_BY="[Empty name]" NAME="Klein 1984" YEAR="1984">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Klein E, Bental E, Lerer B, Belmaker RH</AU>
<TI>Carbamazepine and haloperidol v placebo and haloperidol in excited psychoses. A controlled study</TI>
<SO>Archives of General Psychiatry</SO>
<YR>1984</YR>
<VL>41</VL>
<NO>2</NO>
<PG>165-70</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS MODIFIED="2013-12-16 12:06:30 +0000" MODIFIED_BY="[Empty name]">
<IDENTIFIER MODIFIED="2013-12-16 12:06:30 +0000" MODIFIED_BY="[Empty name]" TYPE="OTHER" VALUE="9000100000010400"/>
</IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Kraft-1984" MODIFIED="2013-12-16 12:06:44 +0000" MODIFIED_BY="[Empty name]" NAME="Kraft 1984" YEAR="1984">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Kraft AM, Hassenfeld IN, Zarr M</AU>
<TI>Response to functional hallucinations to carbamazepine</TI>
<SO>American Journal of Psychiatry</SO>
<YR>1984</YR>
<VL>141</VL>
<NO>8</NO>
<PG>1018</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS MODIFIED="2013-12-16 12:06:44 +0000" MODIFIED_BY="[Empty name]">
<IDENTIFIER MODIFIED="2013-12-16 12:06:44 +0000" MODIFIED_BY="[Empty name]" TYPE="OTHER" VALUE="9000100000010403"/>
</IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Lambert-1987" MODIFIED="2014-01-27 10:32:26 +0000" MODIFIED_BY="[Empty name]" NAME="Lambert 1987" YEAR="1987">
<REFERENCE MODIFIED="2014-01-27 10:32:26 +0000" MODIFIED_BY="Heather Maxwell" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Lambert PA, Venaud G</AU>
<TI>Use of valpromide in psychiatric therapeutics</TI>
<SO>Encephale</SO>
<YR>1987</YR>
<VL>13</VL>
<NO>6</NO>
<PG>367-73</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="OTHER" VALUE="CN-00477270"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS MODIFIED="2013-12-16 12:06:58 +0000" MODIFIED_BY="[Empty name]">
<IDENTIFIER MODIFIED="2013-12-16 12:06:58 +0000" MODIFIED_BY="[Empty name]" TYPE="OTHER" VALUE="9000100000010405"/>
</IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Lapensee-1992" MODIFIED="2013-12-16 12:07:17 +0000" MODIFIED_BY="[Empty name]" NAME="Lapensee 1992" YEAR="1992">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Lapensee MA</AU>
<TI>A review of schizoaffective disorder: II. Somatic treatment</TI>
<SO>Canadian Journal of Psychiatry Revue Canadienne de Psychiatrie</SO>
<YR>1992</YR>
<VL>37</VL>
<NO>5</NO>
<PG>347</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS MODIFIED="2013-12-16 12:07:17 +0000" MODIFIED_BY="[Empty name]">
<IDENTIFIER MODIFIED="2013-12-16 12:07:17 +0000" MODIFIED_BY="[Empty name]" TYPE="OTHER" VALUE="9000100000010407"/>
</IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Lenzi-1986" MODIFIED="2014-03-03 11:59:45 +0000" MODIFIED_BY="[Empty name]" NAME="Lenzi 1986" YEAR="1986">
<REFERENCE MODIFIED="2014-03-03 11:59:45 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Lenzi A, Lazzerini F, Grossi E, Massimetti G, Placidi GF</AU>
<TI>Use of carbamazepine in acute psychosis: A controlled study</TI>
<SO>Journal of International Medical Research</SO>
<YR>1986</YR>
<VL>14</VL>
<NO>2</NO>
<PG>78-84</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS MODIFIED="2013-12-16 12:07:49 +0000" MODIFIED_BY="[Empty name]">
<IDENTIFIER MODIFIED="2013-12-16 12:07:49 +0000" MODIFIED_BY="[Empty name]" TYPE="OTHER" VALUE="9000100000010409"/>
</IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Llorca-1992" MODIFIED="2013-12-16 12:08:15 +0000" MODIFIED_BY="[Empty name]" NAME="Llorca 1992" YEAR="1992">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Llorca PM, Wolf MA, Lancon C, Bougerol T</AU>
<TI>Adjuvant drugs for use in patients under neuroleptics</TI>
<SO>Annales de Psychiatrie</SO>
<YR>1992</YR>
<VL>7</VL>
<NO>4</NO>
<PG>195</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS MODIFIED="2013-12-16 12:08:15 +0000" MODIFIED_BY="[Empty name]">
<IDENTIFIER MODIFIED="2013-12-16 12:08:15 +0000" MODIFIED_BY="[Empty name]" TYPE="OTHER" VALUE="9000100000010411"/>
</IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Luchins-1983" MODIFIED="2014-01-27 10:35:10 +0000" MODIFIED_BY="[Empty name]" NAME="Luchins 1983" YEAR="1983">
<REFERENCE MODIFIED="2014-01-27 10:35:10 +0000" MODIFIED_BY="Heather Maxwell" PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Luchins DJ</AU>
<TI>Carbamazepine for the violent psychiatric patient</TI>
<SO>Lancet</SO>
<YR>1983</YR>
<VL>1</VL>
<NO>8327</NO>
<PG>766</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE NOTES="&lt;p&gt;Luchins DJ. Carbamazepine in violent nonepileptic schizophrenics. Psychopharmacology Bulletin 1984;20(3).&lt;/p&gt;" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Luchins DJ</AU>
<TI>Carbamazepine in violent nonepileptic schizophrenics</TI>
<SO>Psychopharmacology Bulletin</SO>
<YR>1984</YR>
<VL>20</VL>
<NO>3</NO>
<PG>569-571</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS MODIFIED="2013-12-16 12:09:05 +0000" MODIFIED_BY="[Empty name]">
<IDENTIFIER MODIFIED="2013-12-16 12:09:05 +0000" MODIFIED_BY="[Empty name]" TYPE="OTHER" VALUE="9000100000010414"/>
</IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Luchins-1984" MODIFIED="2013-12-16 12:09:36 +0000" MODIFIED_BY="[Empty name]" NAME="Luchins 1984" YEAR="1984">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Luchins DJ</AU>
<TI>Fatal agranulocytosis in a chronic schizophrenic patient treated with carbamazepine</TI>
<SO>American Journal of Psychiatry</SO>
<YR>1984</YR>
<VL>141</VL>
<NO>5</NO>
<PG>687-8</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS MODIFIED="2013-12-16 12:09:36 +0000" MODIFIED_BY="[Empty name]">
<IDENTIFIER MODIFIED="2013-12-16 12:09:36 +0000" MODIFIED_BY="[Empty name]" TYPE="OTHER" VALUE="9000100000010418"/>
</IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Makaric-2000" MODIFIED="2013-12-16 12:09:55 +0000" MODIFIED_BY="[Empty name]" NAME="Makaric 2000" YEAR="2000">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Makaric G, Folnegovic-Smalc V, Folnegovic Z, Imica N</AU>
<TI>Agitation in acute episode of schizophrenia: carbamazepine treatment in combination with haloperidol versus combined neuroleptics</TI>
<SO>Schizophrenia Research</SO>
<YR>2000</YR>
<VL>41</VL>
<NO>1</NO>
<PG>210</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="MEDLINE" VALUE="1999367069"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS MODIFIED="2013-12-16 12:09:55 +0000" MODIFIED_BY="[Empty name]">
<IDENTIFIER MODIFIED="2013-12-16 12:09:55 +0000" MODIFIED_BY="[Empty name]" TYPE="OTHER" VALUE="9000100000010441"/>
</IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-McAllister-1985" MODIFIED="2013-12-16 12:10:13 +0000" MODIFIED_BY="[Empty name]" NAME="McAllister 1985" YEAR="1985">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>McAllister TW</AU>
<TI>Carbamazepine in mixed frontal lobe and psychiatric disorders</TI>
<SO>Journal of Clinical Psychiatry</SO>
<YR>1985</YR>
<VL>46</VL>
<NO>9</NO>
<PG>393-4</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS MODIFIED="2013-12-16 12:10:13 +0000" MODIFIED_BY="[Empty name]">
<IDENTIFIER MODIFIED="2013-12-16 12:10:13 +0000" MODIFIED_BY="[Empty name]" TYPE="OTHER" VALUE="9000100000010443"/>
</IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-McKee-1989" MODIFIED="2013-12-16 12:10:29 +0000" MODIFIED_BY="[Empty name]" NAME="McKee 1989" YEAR="1989">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>McKee RW, Larkin JG, Brodie MJ</AU>
<TI>Acute psychosis with carbamazepine and sodium valproate</TI>
<SO>Lancet</SO>
<YR>1989</YR>
<VL>1</VL>
<NO>8630</NO>
<PG>167</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS MODIFIED="2013-12-16 12:10:29 +0000" MODIFIED_BY="[Empty name]">
<IDENTIFIER MODIFIED="2013-12-16 12:10:29 +0000" MODIFIED_BY="[Empty name]" TYPE="OTHER" VALUE="9000100000010446"/>
</IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Meltzer-1992" MODIFIED="2014-01-27 10:36:27 +0000" MODIFIED_BY="[Empty name]" NAME="Meltzer 1992" YEAR="1992">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Meltzer HY</AU>
<TI>Novel approaches to the pharmacotherapy of schizophrenia</TI>
<SO>Drug Development Research</SO>
<YR>1986</YR>
<VL>9</VL>
<NO>1</NO>
<PG>23-40</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE MODIFIED="2014-01-27 10:36:27 +0000" MODIFIED_BY="Heather Maxwell" PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Meltzer HY</AU>
<TI>Treatment of the neuroleptic-nonresponsive schizophrenic patient</TI>
<SO>Schizophrenia Bulletin</SO>
<YR>1992</YR>
<VL>18</VL>
<NO>3</NO>
<PG>515-42</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS MODIFIED="2013-12-16 12:10:44 +0000" MODIFIED_BY="[Empty name]">
<IDENTIFIER MODIFIED="2013-12-16 12:10:44 +0000" MODIFIED_BY="[Empty name]" TYPE="OTHER" VALUE="9000100000010449"/>
</IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Meshel-1967" MODIFIED="2013-12-16 12:11:10 +0000" MODIFIED_BY="[Empty name]" NAME="Meshel 1967" YEAR="1967">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Meshel E, Denber HC</AU>
<TI>Double-blind study of tybamate in psychotic patients</TI>
<SO>Diseases of the Nervous System</SO>
<YR>1967</YR>
<VL>28</VL>
<NO>5</NO>
<PG>311-3</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="MEDLINE" VALUE="67165839"/>
<IDENTIFIER TYPE="OTHER" VALUE="PMID 5338174"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS MODIFIED="2013-12-16 12:11:10 +0000" MODIFIED_BY="[Empty name]">
<IDENTIFIER MODIFIED="2013-12-16 12:11:10 +0000" MODIFIED_BY="[Empty name]" TYPE="OTHER" VALUE="9000100000010461"/>
</IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Meshel-1968" MODIFIED="2013-12-16 12:11:36 +0000" MODIFIED_BY="[Empty name]" NAME="Meshel 1968" YEAR="1968">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Meshel E, Denber HC</AU>
<TI>The use of tybamate in psychotic patients. (A further double blind study)</TI>
<SO>Diseases of the Nervous System</SO>
<YR>1968</YR>
<VL>29</VL>
<NO>4</NO>
<PG>243-5</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="MEDLINE" VALUE="68271597"/>
<IDENTIFIER TYPE="OTHER" VALUE="PMID 4870945"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS MODIFIED="2013-12-16 12:11:36 +0000" MODIFIED_BY="[Empty name]">
<IDENTIFIER MODIFIED="2013-12-16 12:11:36 +0000" MODIFIED_BY="[Empty name]" TYPE="OTHER" VALUE="9000100000010462"/>
</IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Miceli-2000" MODIFIED="2014-01-27 10:36:54 +0000" MODIFIED_BY="[Empty name]" NAME="Miceli 2000" YEAR="2000">
<REFERENCE MODIFIED="2014-01-27 10:36:54 +0000" MODIFIED_BY="Heather Maxwell" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Miceli JJ, Anziano RJ, Robarge L, Hansen RA, Laurent A</AU>
<TI>The effect of carbamazepine on the steady-state pharmacokinetics of ziprasidone in healthy volunteers</TI>
<SO>British Journal of Clinical Pharmacology</SO>
<YR>2000</YR>
<VL>49 (suppl I)</VL>
<PG>65S-70S</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS MODIFIED="2013-12-16 12:12:09 +0000" MODIFIED_BY="[Empty name]">
<IDENTIFIER MODIFIED="2013-12-16 12:12:09 +0000" MODIFIED_BY="[Empty name]" TYPE="OTHER" VALUE="9000100000010464"/>
</IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Miller-1965" MODIFIED="2013-12-16 12:12:32 +0000" MODIFIED_BY="[Empty name]" NAME="Miller 1965" YEAR="1965">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Miller MJ, Shettel R, Fiedler HT</AU>
<TI>Chronic toxicologic evaluation of hydroxyphenamate and possible synergism with phenothiazines</TI>
<SO>Psychosomatics</SO>
<YR>1965</YR>
<VL>6</VL>
<NO>5</NO>
<PG>340-2</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="MEDLINE" VALUE="66013834"/>
<IDENTIFIER TYPE="OTHER" VALUE="PMID 5319246"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS MODIFIED="2013-12-16 12:12:32 +0000" MODIFIED_BY="[Empty name]">
<IDENTIFIER MODIFIED="2013-12-16 12:12:32 +0000" MODIFIED_BY="[Empty name]" TYPE="OTHER" VALUE="9000100000010465"/>
</IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Miodownik-2003" MODIFIED="2013-12-16 12:14:27 +0000" MODIFIED_BY="[Empty name]" NAME="Miodownik 2003" YEAR="2003">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Miodownik C, Cohen H, Kotler M, Lerner V</AU>
<TI>Vitamin B6 add-on therapy in treatment of schizophrenic patients with psychotic symptoms and movement disorders</TI>
<SO>Harefuah</SO>
<YR>2003</YR>
<VL>142</VL>
<NO>8-9</NO>
<PG>592-6, 647</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="MEDLINE" VALUE="14518160"/>
<IDENTIFIER TYPE="OTHER" VALUE="EMBASE 2003374828;  CN-00440574."/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS MODIFIED="2013-12-16 12:14:27 +0000" MODIFIED_BY="[Empty name]">
<IDENTIFIER MODIFIED="2013-12-16 12:14:27 +0000" MODIFIED_BY="[Empty name]" TYPE="OTHER" VALUE="9000100000010466"/>
</IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Mokrusch-1987" MODIFIED="2013-12-16 12:22:52 +0000" MODIFIED_BY="[Empty name]" NAME="Mokrusch 1987" YEAR="1987">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Mokrusch T, Negele J, Kaschka WP</AU>
<TI>New aspects in the prophylaxis of affective and schizoaffective psychoses</TI>
<SO>Fortschritte der Medizin</SO>
<YR>1987</YR>
<VL>105</VL>
<NO>1</NO>
<PG>30-4</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS MODIFIED="2013-12-16 12:22:52 +0000" MODIFIED_BY="[Empty name]">
<IDENTIFIER MODIFIED="2013-12-16 12:22:52 +0000" MODIFIED_BY="[Empty name]" TYPE="OTHER" VALUE="9000100000010469"/>
</IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-M_x00f6_ller-1989" MODIFIED="2013-12-16 12:17:34 +0000" MODIFIED_BY="[Empty name]" NAME="Möller 1989" YEAR="1989">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Moller HJ, Kissling W, Riehl T, Bauml J</AU>
<TI>Double-blind evaluation of the antimanic properties of carbamazepine as a comedication to haloperidol</TI>
<SO>Progress in Neuropsychopharmacology and Biological Psychiatry</SO>
<YR>1989</YR>
<VL>13</VL>
<NO>1-2</NO>
<PG>127-36</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS MODIFIED="2013-12-16 12:17:34 +0000" MODIFIED_BY="[Empty name]">
<IDENTIFIER MODIFIED="2013-12-16 12:17:34 +0000" MODIFIED_BY="[Empty name]" TYPE="OTHER" VALUE="9000100000038126"/>
</IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-M_x00f6_ller-1996" MODIFIED="2014-01-27 10:37:51 +0000" MODIFIED_BY="[Empty name]" NAME="Möller 1996" YEAR="1996">
<REFERENCE MODIFIED="2014-01-27 10:37:51 +0000" MODIFIED_BY="Heather Maxwell" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Möller H</AU>
<TI>Treatment of schizophrenia. State of the art</TI>
<SO>European Archives of Psychiatry and Clinical Neuroscience</SO>
<YR>1996</YR>
<VL>246</VL>
<NO>5</NO>
<PG>229</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS MODIFIED="2013-12-16 12:17:51 +0000" MODIFIED_BY="[Empty name]">
<IDENTIFIER MODIFIED="2013-12-16 12:17:51 +0000" MODIFIED_BY="[Empty name]" TYPE="OTHER" VALUE="9000100000010476"/>
</IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Morinigo-1992" MODIFIED="2013-12-16 12:24:03 +0000" MODIFIED_BY="[Empty name]" NAME="Morinigo 1992" YEAR="1992">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Morinigo A, Mateo I, Martin J, Noval D, Gonzalez S</AU>
<TI>Efectos terapeuticos del valproato sodico y la carbamacepina en la mania</TI>
<SO>Psiquis</SO>
<YR>1992</YR>
<VL>13</VL>
<NO>8</NO>
<PG>335-8</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS MODIFIED="2013-12-16 12:24:03 +0000" MODIFIED_BY="[Empty name]">
<IDENTIFIER MODIFIED="2013-12-16 12:24:03 +0000" MODIFIED_BY="[Empty name]" TYPE="OTHER" VALUE="9000100000010479"/>
</IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Mosca-1998" MODIFIED="2013-12-16 12:24:39 +0000" MODIFIED_BY="[Empty name]" NAME="Mosca 1998" YEAR="1998">
<REFERENCE PRIMARY="NO" TYPE="CONFERENCE_PROC">
<AU>Mosca LD//Licciardo JP//Coppola JL</AU>
<TI>A double-blind carbamazepine-controlled efficacy and safety study of valproate in impulsivity and violence</TI>
<SO>11th Congress of The European College of Neuropsychopharmacology; Oct 31 - Nov 4, Paris, France</SO>
<YR>1998</YR>
<IDENTIFIERS>
<IDENTIFIER TYPE="MEDLINE" VALUE="CONFERENCE ABSTRACT"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS MODIFIED="2013-12-16 12:24:39 +0000" MODIFIED_BY="[Empty name]">
<IDENTIFIER MODIFIED="2013-12-16 12:24:39 +0000" MODIFIED_BY="[Empty name]" TYPE="OTHER" VALUE="9000100000010481"/>
</IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Munetz-1989" MODIFIED="2013-12-16 12:24:56 +0000" MODIFIED_BY="[Empty name]" NAME="Munetz 1989" YEAR="1989">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Munetz MR, Schulz SC, Bellin M, Harty I</AU>
<TI>Rimcazole (BW234U) in the maintenance treatment of outpatients with schizophrenia</TI>
<SO>Drug Development Research</SO>
<YR>1989</YR>
<VL>16</VL>
<NO>1</NO>
<PG>79-83</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="MEDLINE" VALUE="83197879"/>
<IDENTIFIER TYPE="OTHER" VALUE="PMID 6342171"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS MODIFIED="2013-12-16 12:24:56 +0000" MODIFIED_BY="[Empty name]">
<IDENTIFIER MODIFIED="2013-12-16 12:24:56 +0000" MODIFIED_BY="[Empty name]" TYPE="OTHER" VALUE="9000100000010483"/>
</IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Nasser-1990" MODIFIED="2013-12-16 12:26:45 +0000" MODIFIED_BY="[Empty name]" NAME="Nasser 1990" YEAR="1990">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Nasser D, Thomas B</AU>
<TI>Anticonvulsant treatment of psychoses</TI>
<SO>Australian and New Zealand Journal of Psychiatry</SO>
<YR>1990</YR>
<VL>24</VL>
<NO>2</NO>
<PG>164</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS MODIFIED="2013-12-16 12:26:45 +0000" MODIFIED_BY="[Empty name]">
<IDENTIFIER MODIFIED="2013-12-16 12:26:45 +0000" MODIFIED_BY="[Empty name]" TYPE="OTHER" VALUE="9000100000010485"/>
</IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Nelson-1993" MODIFIED="2013-12-16 12:27:05 +0000" MODIFIED_BY="[Empty name]" NAME="Nelson 1993" YEAR="1993">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Nelson JC</AU>
<TI>Combined treatment strategies in psychiatry</TI>
<SO>Journal of Clinical Psychiatry</SO>
<YR>1993</YR>
<VL>54</VL>
<NO>s9</NO>
<PG>42</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS MODIFIED="2013-12-16 12:27:05 +0000" MODIFIED_BY="[Empty name]">
<IDENTIFIER MODIFIED="2013-12-16 12:27:05 +0000" MODIFIED_BY="[Empty name]" TYPE="OTHER" VALUE="9000100000010487"/>
</IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Neppe-1988a" MODIFIED="2013-12-16 12:27:37 +0000" MODIFIED_BY="[Empty name]" NAME="Neppe 1988a" YEAR="1988">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Neppe VM</AU>
<TI>Carbamazepine in nonresponsive psychosis</TI>
<SO>Journal of Clinical Psychiatry</SO>
<YR>1988</YR>
<VL>49</VL>
<NO>s</NO>
<PG>22-8</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS MODIFIED="2013-12-16 12:27:37 +0000" MODIFIED_BY="[Empty name]">
<IDENTIFIER MODIFIED="2013-12-16 12:27:37 +0000" MODIFIED_BY="[Empty name]" TYPE="OTHER" VALUE="9000100000010490"/>
</IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Neppe-1988b" MODIFIED="2013-12-16 12:43:00 +0000" MODIFIED_BY="[Empty name]" NAME="Neppe 1988b" YEAR="1988">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Neppe VM, Tucker GJ, Wilensky AJ</AU>
<TI>Fundamentals of carbamazepine use in neuropsychiatry</TI>
<SO>Journal of Clinical Psychiatry</SO>
<YR>1988</YR>
<VL>49</VL>
<NO>s</NO>
<PG>4-6</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS MODIFIED="2013-12-16 12:43:00 +0000" MODIFIED_BY="[Empty name]">
<IDENTIFIER MODIFIED="2013-12-16 12:43:00 +0000" MODIFIED_BY="[Empty name]" TYPE="OTHER" VALUE="9000100000010495"/>
</IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Neppe-1988c" MODIFIED="2013-12-16 12:43:22 +0000" MODIFIED_BY="[Empty name]" NAME="Neppe 1988c" YEAR="1988">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Neppe VM</AU>
<TI>Carbamazepine for withdrawal pseudohallucinations</TI>
<SO>American Journal of Psychiatry</SO>
<YR>1988</YR>
<VL>145</VL>
<NO>12</NO>
<PG>1605</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS MODIFIED="2013-12-16 12:43:22 +0000" MODIFIED_BY="[Empty name]">
<IDENTIFIER MODIFIED="2013-12-16 12:43:22 +0000" MODIFIED_BY="[Empty name]" TYPE="OTHER" VALUE="9000100000010502"/>
</IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Neppe-1991" MODIFIED="2013-12-16 12:43:39 +0000" MODIFIED_BY="[Empty name]" NAME="Neppe 1991" YEAR="1991">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Neppe VM, Bowman BR, Sawchuk KS</AU>
<TI>Carbamazepine for atypical psychosis with episodic hostility</TI>
<SO>Journal of Nervous and Mental Disease</SO>
<YR>1991</YR>
<VL>179</VL>
<NO>7</NO>
<PG>439-41</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS MODIFIED="2013-12-16 12:43:39 +0000" MODIFIED_BY="[Empty name]">
<IDENTIFIER MODIFIED="2013-12-16 12:43:39 +0000" MODIFIED_BY="[Empty name]" TYPE="OTHER" VALUE="9000100000010522"/>
</IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Nijdam-1992" MODIFIED="2013-12-16 12:43:54 +0000" MODIFIED_BY="[Empty name]" NAME="Nijdam 1992" YEAR="1992">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Nijdam JR, Doorschot CH, van Bavel LP, Loonen AJ</AU>
<TI>A comparison of carbamazepine Divitabs and a normal carbamazepine preparation in psychiatric and oligophrenic patients</TI>
<SO>Pharmacopsychiatry</SO>
<YR>1992</YR>
<VL>25</VL>
<NO>3</NO>
<PG>145-9</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="MEDLINE" VALUE="92342659"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS MODIFIED="2013-12-16 12:43:54 +0000" MODIFIED_BY="[Empty name]">
<IDENTIFIER MODIFIED="2013-12-16 12:43:54 +0000" MODIFIED_BY="[Empty name]" TYPE="OTHER" VALUE="9000100000010526"/>
</IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Ohlmeier-2007" MODIFIED="2014-01-27 10:42:12 +0000" MODIFIED_BY="[Empty name]" NAME="Ohlmeier 2007" YEAR="2007">
<REFERENCE MODIFIED="2014-01-27 10:42:12 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Ohlmeier MD, Jahn K, Wilhelm-Gossling C, Godecke-Koch T, Hoffmann J, Seifert J, et al</AU>
<TI>Perazine and carbamazepine in comparison to olanzapine in schizophrenia</TI>
<SO>Neuropsychobiology</SO>
<YR>2007</YR>
<VL>55</VL>
<NO>2</NO>
<PG>81-8</PG>
<CY>Switzerland</CY>
<IDENTIFIERS>
<IDENTIFIER TYPE="MEDLINE" VALUE="17570951"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS MODIFIED="2013-12-16 12:44:11 +0000" MODIFIED_BY="[Empty name]">
<IDENTIFIER MODIFIED="2013-12-16 12:44:11 +0000" MODIFIED_BY="[Empty name]" TYPE="OTHER" VALUE="9000100000020599"/>
</IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="MIX" ID="STD-Okuma-1989a" MODIFIED="2014-03-03 11:59:23 +0000" MODIFIED_BY="[Empty name]" NAME="Okuma 1989a" YEAR="1989">
<REFERENCE MODIFIED="2014-03-03 11:59:23 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Okuma T, Yamashita I, Takahashi R, Itoh H, Otsuki S, Watanabe S, et al</AU>
<TI>Comparison of the therapeutic effect of carbamazepine and placebo in schizophrenia and atypical psychosis by double blind controlled study</TI>
<SO>Rinsho Hyoka</SO>
<YR>1988</YR>
<VL>16</VL>
<NO>2</NO>
<PG>327-73</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE MODIFIED="2014-01-27 10:43:15 +0000" MODIFIED_BY="Heather Maxwell" PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Okuma T, Yamashita I, Takahashi R, Itoh H</AU>
<TI>A double-blind study of adjunctive carbamazepine versus placebo on excited states of schizophrenic and schizoaffective disorders</TI>
<SO>Acta Psychiatrica Scandinavica</SO>
<YR>1989</YR>
<VL>80</VL>
<NO>3</NO>
<PG>250-9</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS MODIFIED="2013-12-16 12:44:35 +0000" MODIFIED_BY="[Empty name]">
<IDENTIFIER MODIFIED="2013-12-16 12:44:35 +0000" MODIFIED_BY="[Empty name]" TYPE="OTHER" VALUE="9000100000010530"/>
</IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Okuma-1989b" MODIFIED="2013-12-16 12:44:52 +0000" MODIFIED_BY="[Empty name]" NAME="Okuma 1989b" YEAR="1989">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Okuma T, Yamashita I, Takahashi R, Itoh H</AU>
<TI>Clinical efficacy of carbamazepine in affective, schizoaffective, and schizophrenic disorders</TI>
<SO>Pharmacopsychiatry</SO>
<YR>1989</YR>
<VL>22</VL>
<NO>2</NO>
<PG>47-53</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS MODIFIED="2013-12-16 12:44:52 +0000" MODIFIED_BY="[Empty name]">
<IDENTIFIER MODIFIED="2013-12-16 12:44:52 +0000" MODIFIED_BY="[Empty name]" TYPE="OTHER" VALUE="9000100000010534"/>
</IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Ortega-1991" MODIFIED="2014-03-03 11:59:13 +0000" MODIFIED_BY="[Empty name]" NAME="Ortega 1991" YEAR="1991">
<REFERENCE MODIFIED="2014-03-03 11:59:13 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Hernandez-Avila CA, Ortega-Soto HA, Jasso A, Hasfura-Buenaga CA, Kranzler HR</AU>
<TI>Treatment of inhalant-induced psychotic disorder with carbamazepine versus haloperidol</TI>
<SO>Psychiatric Services</SO>
<YR>1998</YR>
<VL>49</VL>
<PG>812-5</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE MODIFIED="2014-01-27 10:44:06 +0000" MODIFIED_BY="Heather Maxwell" PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Ortega SHA, Jasso A, Cecena G, Hernandez ACA</AU>
<TI>Validity and reproductivity of a scale for measuring neuroleptic-induced extrapyramidal symptoms</TI>
<TO>La validez y la reproducibilidad de dos escalas para evaluar los sintomas extrapiramidales inducidos por neurolepticos</TO>
<SO>Salud Mental</SO>
<YR>1991</YR>
<VL>14</VL>
<NO>3</NO>
<PG>1-5</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS MODIFIED="2013-12-16 12:45:07 +0000" MODIFIED_BY="[Empty name]">
<IDENTIFIER MODIFIED="2013-12-16 12:45:07 +0000" MODIFIED_BY="[Empty name]" TYPE="OTHER" VALUE="9000100000010539"/>
</IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Otani-1997" MODIFIED="2014-03-03 11:59:06 +0000" MODIFIED_BY="[Empty name]" NAME="Otani 1997" YEAR="1997">
<REFERENCE MODIFIED="2014-03-03 11:59:06 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Otani K, Ishida M, Yasui N, Kondo T, Mihara K, Suzuki A, et al</AU>
<TI>Interaction between carbamazepine and bromperidol</TI>
<SO>European Journal of Clinical Pharmacology</SO>
<YR>1997</YR>
<VL>52</VL>
<NO>3</NO>
<PG>219</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS MODIFIED="2013-12-16 12:45:27 +0000" MODIFIED_BY="[Empty name]">
<IDENTIFIER MODIFIED="2013-12-16 12:45:27 +0000" MODIFIED_BY="[Empty name]" TYPE="OTHER" VALUE="9000100000010031"/>
</IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Pantelis-1996" MODIFIED="2013-12-16 12:45:55 +0000" MODIFIED_BY="[Empty name]" NAME="Pantelis 1996" YEAR="1996">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Pantelis C, Barnes TR</AU>
<TI>Drug strategies and treatment-resistant schizophrenia</TI>
<SO>Australian and New Zealand Journal of Psychiatry</SO>
<YR>1996</YR>
<VL>30</VL>
<NO>1</NO>
<PG>20-37</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS MODIFIED="2013-12-16 12:45:55 +0000" MODIFIED_BY="[Empty name]">
<IDENTIFIER MODIFIED="2013-12-16 12:45:55 +0000" MODIFIED_BY="[Empty name]" TYPE="OTHER" VALUE="9000100000010550"/>
</IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Panu-1984" MODIFIED="2014-03-03 11:58:56 +0000" MODIFIED_BY="[Empty name]" NAME="Panu 1984" YEAR="1984">
<REFERENCE MODIFIED="2014-03-03 11:58:56 +0000" MODIFIED_BY="[Empty name]" NOTES="&lt;p&gt;Panu H, Hakola A, Laulumaa VA. Carbamazepine in violent schizophrenics. In: Emrich HM, Okuma T (editors). Anticonvulsants in affective disorders. Elsevier, Amsterdam: 1984. :1984. pp 204-7.&lt;/p&gt;" NOTES_MODIFIED="2014-03-03 11:58:56 +0000" NOTES_MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="BOOK_SECTION">
<AU>Panu H, Hakola A, Laulumaa VA</AU>
<TI>Carbamazepine in violent schizophrenics</TI>
<SO>Anticonvulsants in Affective Disorders</SO>
<YR>1984</YR>
<PG>204-7</PG>
<ED>Emrich HM, Okuma T</ED>
<PB>Elsevier</PB>
<CY>Amsterdam</CY>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS MODIFIED="2013-12-16 12:46:13 +0000" MODIFIED_BY="[Empty name]">
<IDENTIFIER MODIFIED="2013-12-16 12:46:13 +0000" MODIFIED_BY="[Empty name]" TYPE="OTHER" VALUE="9000100000010554"/>
</IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Placidi-1986" MODIFIED="2014-03-03 11:58:45 +0000" MODIFIED_BY="[Empty name]" NAME="Placidi 1986" YEAR="1986">
<REFERENCE MODIFIED="2014-01-27 10:45:40 +0000" MODIFIED_BY="Heather Maxwell" PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Placidi GF, Lenzi A, Lazzerini F, Cassano GB</AU>
<TI>The comparative efficacy and safety of carbamazepine versus lithium: A randomized, double-blind 3-year trial in 83 patients</TI>
<SO>Journal of Clinical Psychiatry</SO>
<YR>1986</YR>
<VL>47</VL>
<NO>10</NO>
<PG>490-4</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE MODIFIED="2014-03-03 11:58:45 +0000" MODIFIED_BY="[Empty name]" NOTES="&lt;p&gt;Placidi GF, Lenzi A, Rampello E, Andreani MF, Cassano GB, Grossi E. Long term-double blind prospective study on carbamazepine versus lithium in bipolar and schizoaffective disorders. Preliminary results. In: Emrich HM, Okuma T (eds.) Anticonvulsants in affective disorders. :188-197.&lt;/p&gt;" NOTES_MODIFIED="2014-03-03 11:58:45 +0000" NOTES_MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="BOOK_SECTION">
<AU>Placidi GF, Lenzi A, Rampello E, Andreani MF, Cassano GB, Grossi E</AU>
<TI>Long term-double blind prospective study on carbamazepine versus lithium in bipolar and schizoaffective disorders. Preliminary results</TI>
<SO>Anticonvulsants in Affective Disorders</SO>
<YR>1984</YR>
<PG>188-97</PG>
<ED>Emrich HM, Okuma T</ED>
<PB>Elsevier</PB>
<CY>Amsterdam</CY>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS MODIFIED="2013-12-16 12:46:30 +0000" MODIFIED_BY="[Empty name]">
<IDENTIFIER MODIFIED="2013-12-16 12:46:30 +0000" MODIFIED_BY="[Empty name]" TYPE="OTHER" VALUE="9000100000010556"/>
</IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Raitasuo-1994" MODIFIED="2013-12-16 12:46:50 +0000" MODIFIED_BY="[Empty name]" NAME="Raitasuo 1994" YEAR="1994">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Raitasuo V, Lehtovaara R, Huttunen MO</AU>
<TI>Effect of switching carbamazepine to oxcarbazepine on the plasma levels of neuroleptics: A case report</TI>
<SO>Psychopharmacology</SO>
<YR>1994</YR>
<VL>116</VL>
<NO>1</NO>
<PG>115-6</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS MODIFIED="2013-12-16 12:46:50 +0000" MODIFIED_BY="[Empty name]">
<IDENTIFIER MODIFIED="2013-12-16 12:46:50 +0000" MODIFIED_BY="[Empty name]" TYPE="OTHER" VALUE="9000100000010559"/>
</IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Rankel-1988" MODIFIED="2013-12-16 14:01:13 +0000" MODIFIED_BY="[Empty name]" NAME="Rankel 1988" YEAR="1988">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Rankel HW, Rankel LE</AU>
<TI>Carbamazepine in the treatment of catatonia</TI>
<SO>American Journal of Psychiatry</SO>
<YR>1988</YR>
<VL>145</VL>
<NO>3</NO>
<PG>361-2</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS MODIFIED="2013-12-16 14:01:13 +0000" MODIFIED_BY="[Empty name]">
<IDENTIFIER MODIFIED="2013-12-16 14:01:13 +0000" MODIFIED_BY="[Empty name]" TYPE="OTHER" VALUE="9000100000010561"/>
</IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Rittmannsberger-1990" MODIFIED="2013-12-16 14:01:38 +0000" MODIFIED_BY="[Empty name]" NAME="Rittmannsberger 1990" YEAR="1990">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Rittmannsberger H</AU>
<TI>Carbamazepine in the treatment of psychiatric illness: Effects and side effects</TI>
<SO>Wiener Medizinische Wochenschrift</SO>
<YR>1990</YR>
<VL>140</VL>
<NO>15</NO>
<PG>398</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS MODIFIED="2013-12-16 14:01:38 +0000" MODIFIED_BY="[Empty name]">
<IDENTIFIER MODIFIED="2013-12-16 14:01:38 +0000" MODIFIED_BY="[Empty name]" TYPE="OTHER" VALUE="9000100000010575"/>
</IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Scher-1983" MODIFIED="2013-12-16 14:01:54 +0000" MODIFIED_BY="[Empty name]" NAME="Scher 1983" YEAR="1983">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Scher M, Neppe V</AU>
<TI>Carbamazepine adjunct for nonresponsive psychosis with prior hallucinogenic abuse</TI>
<SO>Journal of Nervous and Mental Disease</SO>
<YR>1989</YR>
<VL>177</VL>
<NO>12</NO>
<PG>755</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS MODIFIED="2013-12-16 14:01:54 +0000" MODIFIED_BY="[Empty name]">
<IDENTIFIER MODIFIED="2013-12-16 14:01:54 +0000" MODIFIED_BY="[Empty name]" TYPE="OTHER" VALUE="9000100000010595"/>
</IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Schulz-1990" MODIFIED="2014-03-03 11:58:36 +0000" MODIFIED_BY="[Empty name]" NAME="Schulz 1990" YEAR="1990">
<REFERENCE PRIMARY="NO" TYPE="BOOK_SECTION">
<AU>Schulz SC, Conley RR, Kahn EM, et al.</AU>
<TI>Nonresponders to neuroleptics: a distinct subtype</TI>
<SO>Schizophrenia: scientific progress</SO>
<YR>Date of publication and page numbers not indicated</YR>
<PB>Oxford University Press</PB>
<CY>New York</CY>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE MODIFIED="2014-03-03 11:58:36 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="BOOK_SECTION">
<AU>Schulz SC, Kahn EM, Baker RW, et al</AU>
<TI>Lithium and carbamazepine augmentation in treatment-refractory schizophrenia</TI>
<SO>The Neuroleptic-Nonresponsive Patient: Characterization and Treatment</SO>
<YR>1990</YR>
<PG>111-36</PG>
<PB>American Psychiatric Press</PB>
<CY>Washington DC</CY>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS MODIFIED="2013-12-16 14:02:12 +0000" MODIFIED_BY="[Empty name]">
<IDENTIFIER MODIFIED="2013-12-16 14:02:12 +0000" MODIFIED_BY="[Empty name]" TYPE="OTHER" VALUE="9000100000010603"/>
</IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Simhandl-1992" MODIFIED="2013-12-16 14:02:32 +0000" MODIFIED_BY="[Empty name]" NAME="Simhandl 1992" YEAR="1992">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Simhandl C, Meszaros K</AU>
<TI>The use of carbamazepine in the treatment of schizophrenic and schizoaffective psychoses: A review</TI>
<SO>Journal of Psychiatry and Neuroscience</SO>
<YR>1992</YR>
<VL>17</VL>
<NO>1</NO>
<PG>1-14</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS MODIFIED="2013-12-16 14:02:32 +0000" MODIFIED_BY="[Empty name]">
<IDENTIFIER MODIFIED="2013-12-16 14:02:32 +0000" MODIFIED_BY="[Empty name]" TYPE="OTHER" VALUE="9000100000010627"/>
</IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Siris-1993" MODIFIED="2013-12-16 14:02:48 +0000" MODIFIED_BY="[Empty name]" NAME="Siris 1993" YEAR="1993">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Siris SG</AU>
<TI>Adjunctive medication in the maintenance treatment of schizophrenia and its conceptual implications</TI>
<SO>British Journal of Psychiatry</SO>
<YR>1993</YR>
<VL>163</VL>
<NO>s22</NO>
<PG>22-78</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS MODIFIED="2013-12-16 14:02:48 +0000" MODIFIED_BY="[Empty name]">
<IDENTIFIER MODIFIED="2013-12-16 14:02:48 +0000" MODIFIED_BY="[Empty name]" TYPE="OTHER" VALUE="9000100000005396"/>
</IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Sramek-1988" MODIFIED="2014-03-03 11:58:29 +0000" MODIFIED_BY="[Empty name]" NAME="Sramek 1988" YEAR="1988">
<REFERENCE MODIFIED="2014-03-03 11:58:29 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Heh CW, Potkin SG, Pickar D, Costa J, Herrera J, Sramek J, et al</AU>
<TI>Serum homovanillic acid concentrations in carbamazepine-treated chronic schizophrenics</TI>
<SO>Biological Psychiatry</SO>
<YR>1989</YR>
<VL>25</VL>
<NO>5</NO>
<PG>639-41</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE NOTES="&lt;p&gt;Herrera J, Sramek J, Costa C, Heh C, Wernberg C. An evaluation of carbamazepine (Tegretol) in chronic treatment-refractory schizophrenia. Proceedings of the 95th Annual Conference of the American Psychiatric Association, 1987;588-9.&lt;/p&gt;" PRIMARY="NO" TYPE="CONFERENCE_PROC">
<AU>Herrera J, Sramek J, Costa C, Heh C, Wernberg C</AU>
<TI>An evaluation of carbamazepine (Tegretol) in chronic treatment-refractory schizophrenia</TI>
<SO>Proceedings of the 95th Annual Conference of the American Psychiatric Association</SO>
<YR>1987</YR>
<PG>588-9</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE MODIFIED="2014-01-27 10:51:53 +0000" MODIFIED_BY="Heather Maxwell" PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Sramek J, Herrera J, Costa J, Heh C, Tran Johnson T, Simpson G</AU>
<TI>A carbamazepine trial in chronic, treatment-refractory schizophrenia</TI>
<SO>American Journal of Psychiatry</SO>
<YR>1988</YR>
<VL>145</VL>
<NO>6</NO>
<PG>748-50</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Tran-Johnson T, Sramek JJ, Walker NR, Heh CD, Costa JF, Herrera JM</AU>
<TI>Effects of carbamazepine on serum calcium in schizophrenia</TI>
<SO>DICP</SO>
<YR>1989</YR>
<VL>23</VL>
<NO>12</NO>
<PG>1034</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS MODIFIED="2013-12-16 14:03:05 +0000" MODIFIED_BY="[Empty name]">
<IDENTIFIER MODIFIED="2013-12-16 14:03:05 +0000" MODIFIED_BY="[Empty name]" TYPE="OTHER" VALUE="9000100000010639"/>
</IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Sugerman-1970" MODIFIED="2013-12-16 14:03:26 +0000" MODIFIED_BY="[Empty name]" NAME="Sugerman 1970" YEAR="1970">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Sugerman AA, Hyams L</AU>
<TI>Electroencephalographic effects of adrenochrome semicarbazone in schizophrenia: quantitative amplitude analysis</TI>
<SO>Research Communications in Chemical Pathology and Pharmacology</SO>
<YR>1970</YR>
<VL>1</VL>
<NO>1</NO>
<PG>86-98</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="MEDLINE" VALUE="72091267"/>
<IDENTIFIER TYPE="OTHER" VALUE="PMID 4944698"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS MODIFIED="2013-12-16 14:03:26 +0000" MODIFIED_BY="[Empty name]">
<IDENTIFIER MODIFIED="2013-12-16 14:03:26 +0000" MODIFIED_BY="[Empty name]" TYPE="OTHER" VALUE="9000100000010640"/>
</IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Svestka-1985" MODIFIED="2013-12-16 14:03:43 +0000" MODIFIED_BY="[Empty name]" NAME="Svestka 1985" YEAR="1985">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Svestka J, Nahunek K, Ceskova E, Korbicka J</AU>
<TI>Carbamazepine prophylaxis of affective psychoses: Intraindividual comparison with lithium carbonate. 27th Annual Psychopharmacology Meeting (1985, Jesenik, Czechoslovakia)</TI>
<SO>Activitas Nervosa Superior</SO>
<YR>1985</YR>
<VL>27</VL>
<NO>4</NO>
<PG>261-2</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS MODIFIED="2013-12-16 14:03:43 +0000" MODIFIED_BY="[Empty name]">
<IDENTIFIER MODIFIED="2013-12-16 14:03:43 +0000" MODIFIED_BY="[Empty name]" TYPE="OTHER" VALUE="9000100000010642"/>
</IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Svestka-1988" MODIFIED="2014-03-03 11:58:18 +0000" MODIFIED_BY="[Empty name]" NAME="Svestka 1988" YEAR="1988">
<REFERENCE MODIFIED="2014-03-03 11:58:18 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Svestka J, Nahunek K, Ceskova E</AU>
<TI>Carbamazepine in the treatment and prophylaxis of affective psychoses</TI>
<TO>Pouziti carbamazepinu v lecbe a profylaxi afektivnich psychoz</TO>
<SO>Ceskoslovenska Psychiatrie</SO>
<YR>1988</YR>
<VL>84</VL>
<NO>3</NO>
<PG>145-55</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS MODIFIED="2013-12-16 14:04:00 +0000" MODIFIED_BY="[Empty name]">
<IDENTIFIER MODIFIED="2013-12-16 14:04:00 +0000" MODIFIED_BY="[Empty name]" TYPE="OTHER" VALUE="9000100000010644"/>
</IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Tohen-1994" MODIFIED="2013-12-16 14:04:19 +0000" MODIFIED_BY="[Empty name]" NAME="Tohen 1994" YEAR="1994">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Tohen M, Castillo J, Pope HG, Herbstein J</AU>
<TI>Concomitant use of valproate and carbamazepine in bipolar and schizoaffective disorders</TI>
<SO>Journal of Clinical Psychopharmacology</SO>
<YR>1994</YR>
<VL>14</VL>
<NO>1</NO>
<PG>67</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS MODIFIED="2013-12-16 14:04:19 +0000" MODIFIED_BY="[Empty name]">
<IDENTIFIER MODIFIED="2013-12-16 14:04:19 +0000" MODIFIED_BY="[Empty name]" TYPE="OTHER" VALUE="9000100000010647"/>
</IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Walden-1996" MODIFIED="2013-12-16 14:04:49 +0000" MODIFIED_BY="[Empty name]" NAME="Walden 1996" YEAR="1996">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Walden J, Von WJ, Berger M, Grunze H</AU>
<TI>Efficacy of antiepileptic drugs in the treatment of psychiatric diseases</TI>
<SO>EEG Labor</SO>
<YR>1996</YR>
<VL>18</VL>
<NO>1</NO>
<PG>32</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS MODIFIED="2013-12-16 14:04:49 +0000" MODIFIED_BY="[Empty name]">
<IDENTIFIER MODIFIED="2013-12-16 14:04:49 +0000" MODIFIED_BY="[Empty name]" TYPE="OTHER" VALUE="9000100000010650"/>
</IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Wetterling-1987" MODIFIED="2013-12-16 14:05:30 +0000" MODIFIED_BY="[Empty name]" NAME="Wetterling 1987" YEAR="1987">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Wetterling T</AU>
<TI>Open clinical trial of carbamazepine in chronic schizophrenic inpatients</TI>
<SO>Pharmacopsychiatry</SO>
<YR>1987</YR>
<VL>20</VL>
<NO>3</NO>
<PG>127-30</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS MODIFIED="2013-12-16 14:05:30 +0000" MODIFIED_BY="[Empty name]">
<IDENTIFIER MODIFIED="2013-12-16 14:05:30 +0000" MODIFIED_BY="[Empty name]" TYPE="OTHER" VALUE="9000100000010656"/>
</IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Wunderlich-1983" MODIFIED="2013-12-16 14:05:46 +0000" MODIFIED_BY="[Empty name]" NAME="Wunderlich 1983" YEAR="1983">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Wunderlich HP, Grunes JU, Neumann J, Zahlten W</AU>
<TI>Carbamazepine (Finlepsin(TM)) for manicdepressive and schizophrenic diseases</TI>
<SO>Deutsche Gesundheitswesen</SO>
<YR>1983</YR>
<VL>38</VL>
<NO>35</NO>
<PG>1352-6</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS MODIFIED="2013-12-16 14:05:46 +0000" MODIFIED_BY="[Empty name]">
<IDENTIFIER MODIFIED="2013-12-16 14:05:46 +0000" MODIFIED_BY="[Empty name]" TYPE="OTHER" VALUE="9000100000010660"/>
</IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Yassa-1983" MODIFIED="2013-12-16 14:06:06 +0000" MODIFIED_BY="[Empty name]" NAME="Yassa 1983" YEAR="1983">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Yassa R, Dupont D</AU>
<TI>Carbamazepine in the treatment of aggressive behavior in schizophrenic patients: A case report</TI>
<SO>Canadian Journal of Psychiatry</SO>
<YR>1983</YR>
<VL>28</VL>
<NO>7</NO>
<PG>566-8</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS MODIFIED="2013-12-16 14:06:06 +0000" MODIFIED_BY="[Empty name]">
<IDENTIFIER MODIFIED="2013-12-16 14:06:06 +0000" MODIFIED_BY="[Empty name]" TYPE="OTHER" VALUE="9000100000010662"/>
</IDENTIFIERS>
</STUDY>
</EXCLUDED_STUDIES>
<AWAITING_STUDIES MODIFIED="2014-03-03 11:58:01 +0000" MODIFIED_BY="[Empty name]">
<STUDY DATA_SOURCE="PUB" ID="STD-Kamisada-1988" MODIFIED="2014-03-03 11:58:01 +0000" MODIFIED_BY="[Empty name]" NAME="Kamisada 1988" YEAR="1988">
<REFERENCE MODIFIED="2014-03-03 11:58:01 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Kamisada M, Tateyama M, Nakano Y, Kawachi Y, Fujii Y, Tanoue A, et al</AU>
<TI>Comparison of the clinical effects of lithium carbonate and carbamazepine on excited schizophrenics</TI>
<SO>Psychopharmacology</SO>
<YR>1988</YR>
<VL>96</VL>
<NO>Suppl</NO>
<PG>348</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="MEDLINE" VALUE="72091267"/>
<IDENTIFIER TYPE="OTHER" VALUE="PMID 4944698"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS MODIFIED="2013-12-16 14:06:32 +0000" MODIFIED_BY="[Empty name]">
<IDENTIFIER MODIFIED="2013-12-16 14:06:32 +0000" MODIFIED_BY="[Empty name]" TYPE="OTHER" VALUE="9000100000010665"/>
</IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Lee-1996" MODIFIED="2013-12-16 14:07:11 +0000" MODIFIED_BY="[Empty name]" NAME="Lee 1996" YEAR="1996">
<REFERENCE NOTES="&lt;p&gt;We contacted the authors 29th january 2002, but have not received an answer yet&lt;/p&gt;" PRIMARY="NO" TYPE="CONFERENCE_PROC">
<AU>Lee MS, Choi BH, Kim SH</AU>
<TI>Combined use of carbamazepine and valproic acid in negative symptom schizophrenia</TI>
<SO>9th Congress of the European College of Neuropsychopharmacology; September 21-25, Amsterdam, The Netherlands</SO>
<YR>1996</YR>
<IDENTIFIERS>
<IDENTIFIER TYPE="MEDLINE" VALUE="98249354"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS MODIFIED="2013-12-16 14:07:11 +0000" MODIFIED_BY="[Empty name]">
<IDENTIFIER MODIFIED="2013-12-16 14:07:11 +0000" MODIFIED_BY="[Empty name]" TYPE="OTHER" VALUE="9000100000010669"/>
</IDENTIFIERS>
</STUDY>
</AWAITING_STUDIES>
<ONGOING_STUDIES/>
</STUDIES>
<OTHER_REFERENCES MODIFIED="2014-03-03 11:57:33 +0000" MODIFIED_BY="[Empty name]">
<ADDITIONAL_REFERENCES MODIFIED="2014-03-03 11:57:13 +0000" MODIFIED_BY="[Empty name]">
<REFERENCE ID="REF-Altman-1996" NAME="Altman 1996" TYPE="JOURNAL_ARTICLE">
<AU>Altman DG, Bland JM</AU>
<TI>Detecting skewness from summary information</TI>
<SO>BMJ</SO>
<YR>1996</YR>
<VL>313</VL>
<PG>1200</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Andreasen-1982" NAME="Andreasen 1982" TYPE="JOURNAL_ARTICLE">
<AU>Andreasen NC</AU>
<TI>Negative symptoms in schizophrenia: definition and reliability</TI>
<SO>Archives of General Psychiatry</SO>
<YR>1982</YR>
<VL>39</VL>
<PG>784-8</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Andreasen-1984" MODIFIED="2013-05-23 18:17:31 +0100" MODIFIED_BY="[Empty name]" NAME="Andreasen 1984" TYPE="CORRESPONDENCE">
<AU>Andreasen NC</AU>
<TI>The scale for assessment of positive symptoms</TI>
<SO>University of Iowa</SO>
<YR>1984</YR>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Begg-1996" MODIFIED="2014-03-03 11:56:04 +0000" MODIFIED_BY="[Empty name]" NAME="Begg 1996" TYPE="JOURNAL_ARTICLE">
<AU>Beg C, Cho M, Eastwood S, Horton R, Moher D, Olkin I, et al</AU>
<TI>Improving the quality of reporting of randomized controlled trials: the CONSORT statement</TI>
<SO>JAMA</SO>
<YR>1996</YR>
<VL>276</VL>
<PG>637-9</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Bland-1997" NAME="Bland 1997" TYPE="JOURNAL_ARTICLE">
<AU>Bland JM, Kerry SM</AU>
<TI>Statistics notes. Trials randomised in clusters</TI>
<SO>BMJ</SO>
<YR>1997</YR>
<VL>315</VL>
<PG>600</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Boissel-1999" MODIFIED="2014-03-03 11:56:14 +0000" MODIFIED_BY="[Empty name]" NAME="Boissel 1999" TYPE="JOURNAL_ARTICLE">
<AU>Boissel JP, Cucherat M, Li W, Chatellier G, Gueyffier F, Buyse M, et al</AU>
<TI>The problem of therapeutic efficacy indices. 3. Comparison of the indices and their use</TI>
<SO>Therapie</SO>
<YR>1999</YR>
<VL>54</VL>
<NO>4</NO>
<PG>405-11</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Carpenter-1994" MODIFIED="2012-07-20 17:19:20 +0100" MODIFIED_BY="[Empty name]" NAME="Carpenter 1994" TYPE="JOURNAL_ARTICLE">
<AU>Carpenter WT, Buchanan RW</AU>
<TI>Schizophrenia</TI>
<SO>New England Journal of Medicine</SO>
<YR>1994</YR>
<VL>330</VL>
<PG>681-90</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Cheine-2001" MODIFIED="2013-12-16 14:18:51 +0000" MODIFIED_BY="[Empty name]" NAME="Cheine 2001" TYPE="COCHRANE_REVIEW">
<AU>Cheine M, Ahonen J, Wahlbeck K</AU>
<TI>Beta-blocker supplementation of standard drug treatment for schizophrenia</TI>
<SO>Cochrane Database of Systematic Reviews</SO>
<YR>2001</YR>
<NO>Issue 3</NO>
<PB>Update Software</PB>
<CY>Oxford</CY>
<IDENTIFIERS MODIFIED="2013-12-16 14:18:51 +0000" MODIFIED_BY="[Empty name]">
<IDENTIFIER MODIFIED="2013-12-16 14:18:51 +0000" MODIFIED_BY="[Empty name]" TYPE="DOI" VALUE="10.1002/14651858.CD000234"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Christison-1991" NAME="Christison 1991" TYPE="JOURNAL_ARTICLE">
<AU>Christison GW, Kirch DG, Wyatt RJ</AU>
<TI>When symptoms persist: choosing among alternative somatic treatments for schizophrenia</TI>
<SO>Schizophrenia Bulletin</SO>
<YR>1991</YR>
<VL>17</VL>
<PG>217-45</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Dardennes-1995" NAME="Dardennes 1995" TYPE="JOURNAL_ARTICLE">
<AU>Dardennes R, Even C, Bange F, Heim A</AU>
<TI>Comparison of carbamazepine and lithium in the prophylaxis of bipolar disorder: a meta-analysis</TI>
<SO>British Journal of Psychiatry</SO>
<YR>1995</YR>
<VL>166</VL>
<PG>378-81</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Davey-Smith-1998" NAME="Davey Smith 1998" TYPE="JOURNAL_ARTICLE">
<AU>Davey Smith G, Egger M</AU>
<TI>Meta-analysis: Unresolved issues and future developments</TI>
<SO>BMJ</SO>
<YR>1998</YR>
<VL>16</VL>
<PG>221-5</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Deeks-2000" NAME="Deeks 2000" TYPE="CONFERENCE_PROC">
<AU>Deeks J</AU>
<TI>Issues in the selection for meta-analyses of binary data</TI>
<SO>Abstracts of 8th International Cochrane Colloquium; 2000 Oct 25-28th; Cape Town, South Africa</SO>
<YR>2000</YR>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Divine-1992" NAME="Divine 1992" TYPE="JOURNAL_ARTICLE">
<AU>Divine GW, Brown JT, Frazer LM</AU>
<TI>The unit of analysis error in studies about physicians' patient care behavior</TI>
<SO>Journal of General Internal Medicine</SO>
<YR>1992</YR>
<VL>7</VL>
<PG>623-9</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Dold-2012" MODIFIED="2014-03-03 11:45:36 +0000" MODIFIED_BY="[Empty name]" NAME="Dold 2012" TYPE="COCHRANE_REVIEW">
<AU>Dold M, Li C, Tardy M, Khorsand V, Gillies D, Leucht S</AU>
<TI>Benzodiazepines for schizophrenia</TI>
<SO>Cochrane Database of Systematic Reviews</SO>
<YR>2012</YR>
<NO>11</NO>
<IDENTIFIERS MODIFIED="2014-03-03 11:45:36 +0000" MODIFIED_BY="[Empty name]">
<IDENTIFIER MODIFIED="2014-03-03 11:45:36 +0000" MODIFIED_BY="[Empty name]" TYPE="DOI" VALUE="10.1002/14651858.CD006391.pub2"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Donner-2002" NAME="Donner 2002" TYPE="JOURNAL_ARTICLE">
<AU>Donner A, Klar N</AU>
<TI>Issues in the meta-analysis of cluster randomized trials</TI>
<SO>Statistics in Medicine</SO>
<YR>2002</YR>
<VL>21</VL>
<PG>2971-80</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Egger-1997" MODIFIED="2013-05-23 16:46:13 +0100" MODIFIED_BY="[Empty name]" NAME="Egger 1997" TYPE="JOURNAL_ARTICLE">
<AU>Egger M, Davey Smith G, Schneider M, Minder C</AU>
<TI>Bias in meta-analysis detected by a simple, graphical test</TI>
<SO>BMJ</SO>
<YR>1997</YR>
<VL>315</VL>
<PG>629-34</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Elbourne-2002" MODIFIED="2011-02-10 11:04:06 +0000" MODIFIED_BY="[Empty name]" NAME="Elbourne 2002" TYPE="JOURNAL_ARTICLE">
<AU>Elbourne D, Altman DG, Higgins JPT, Curtina F, Worthingtond HV, Vaile A</AU>
<TI>Meta-analyses involving cross-over trials: methodological issues</TI>
<SO>International Journal of Epidemiology</SO>
<YR>2002</YR>
<VL>31</VL>
<NO>1</NO>
<PG>140-9</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Essali-2009" MODIFIED="2013-05-16 10:55:16 +0100" MODIFIED_BY="[Empty name]" NAME="Essali 2009" TYPE="COCHRANE_REVIEW">
<AU>Essali A, Al-Haj Haasan N, Li C, Rathbone J</AU>
<TI>Clozapine versus typical neuroleptic medication for schizophrenia</TI>
<SO>Cochrane Database of Systematic Reviews</SO>
<YR>2009</YR>
<NO>1</NO>
<PG>CD000059</PG>
<IDENTIFIERS MODIFIED="2013-05-16 10:55:16 +0100" MODIFIED_BY="[Empty name]">
<IDENTIFIER MODIFIED="2013-05-16 10:55:16 +0100" MODIFIED_BY="[Empty name]" TYPE="DOI" VALUE="10.1002/14651858.CD000059.pub2"/>
<IDENTIFIER TYPE="PUBMED" VALUE="19160174"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-GRADE-Profiler" MODIFIED="2011-02-10 11:04:06 +0000" MODIFIED_BY="[Empty name]" NAME="GRADE Profiler" TYPE="COMPUTER_PROGRAM">
<TI>GRADE Profiler</TI>
<YR>2004</YR>
<EN>3.2</EN>
<PB>GRADE Working Group</PB>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Granger-1995" MODIFIED="2014-03-03 11:56:26 +0000" MODIFIED_BY="[Empty name]" NAME="Granger 1995" TYPE="JOURNAL_ARTICLE">
<AU>Granger P, Biton B, Faure C, Vige X, Depoortere H, Graham D, et al</AU>
<TI>Modulation of the gamma-aminobutyric acid type A receptor by the antiepileptic drugs carbamazepine and phenytoin</TI>
<SO>Molecular Pharmacology</SO>
<YR>1995</YR>
<VL>47</VL>
<PG>1189&#8211;96</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Gulliford-1999" NAME="Gulliford 1999" TYPE="JOURNAL_ARTICLE">
<AU>Gulliford MC, Ukoumunne OC, Chinn S</AU>
<TI>Components of variance and intraclass correlations for the design of community-based surveys and intervention studies: data from the Health Survey for England 1994</TI>
<SO>American Journal of Epidemiology</SO>
<YR>1999</YR>
<VL>149</VL>
<PG>876-83</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Guy-1976" MODIFIED="2013-12-16 14:17:40 +0000" MODIFIED_BY="[Empty name]" NAME="Guy 1976" TYPE="OTHER">
<AU>Guy W</AU>
<TI>ECDEU assessment manual for psychopharmacology-revised</TI>
<SO>Washington, D.C: DHEW. National Institute of Mental Health</SO>
<YR>1976</YR>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Hamilton-1960" NAME="Hamilton 1960" TYPE="JOURNAL_ARTICLE">
<AU>Hamilton M</AU>
<TI>A rating scale of depression</TI>
<SO>Journal of Neurology, Neurosurgery and Psychiatry</SO>
<YR>1960</YR>
<VL>23</VL>
<PG>56-62</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Higgins-2003" MODIFIED="2011-02-10 11:04:06 +0000" MODIFIED_BY="[Empty name]" NAME="Higgins 2003" TYPE="JOURNAL_ARTICLE">
<AU>Higgins JPT, Thompson SG, Deeks JJ, Altman DG</AU>
<TI>Measuring inconsistency in meta-analyses</TI>
<SO>BMJ</SO>
<YR>2003</YR>
<VL>327</VL>
<PG>557-60</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Higgins-2011" MODIFIED="2013-02-27 10:08:38 +0000" MODIFIED_BY="[Empty name]" NAME="Higgins 2011" TYPE="OTHER">
<AU>Higgins JPT, Green S (editors)</AU>
<TI>Cochrane Handbook for Systematic Reviews of Interventions Version 5.0.2 [updated September 2011]. The Cochrane Collaboration, 2011</TI>
<SO>Available from www.cochrane-handbook.org.</SO>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Hutton-2009" MODIFIED="2014-03-03 11:56:40 +0000" MODIFIED_BY="[Empty name]" NAME="Hutton 2009" TYPE="JOURNAL_ARTICLE">
<AU>Hutton JL</AU>
<TI>Number needed to treat and number needed to harm are not the best way to report and assess the results of randomised clinical trials</TI>
<SO>British Journal of Haematology</SO>
<YR>2009</YR>
<VL>146</VL>
<NO>1</NO>
<PG>27-30</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Jadad-1996" MODIFIED="2014-03-03 11:56:48 +0000" MODIFIED_BY="[Empty name]" NAME="Jadad 1996" TYPE="JOURNAL_ARTICLE">
<AU>Jadad A, Moore A, Carroll D, Jenkinson C, Reynolds DJM, Gavanagh DJ, et al</AU>
<TI>Assessing the quality of reports of randomized clinical trials: Is blinding necessary?</TI>
<SO>Controlled Clinical Trials</SO>
<YR>1996</YR>
<VL>17</VL>
<PG>1-12</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Kane-1988" NAME="Kane 1988" TYPE="JOURNAL_ARTICLE">
<AU>Kane JM, Honigfeld G, Singer J, Meltzer H, and the Clozaril Collaborative study group</AU>
<TI>Clozapine for the treatment-resistant schizophrenic. A double-blind comparison with chlorpromazine</TI>
<SO>Archives of General Psychiatry</SO>
<YR>1988</YR>
<VL>45</VL>
<PG>789-96</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Kay-1986" MODIFIED="2014-03-03 11:56:54 +0000" MODIFIED_BY="[Empty name]" NAME="Kay 1986" TYPE="BOOK">
<AU>Kay SR, Opler LA, Fiszbein A</AU>
<TI>Positive and negative syndrome scale (PANSS) manual</TI>
<SO>Positive and Negative Syndrome Scale (PANSS) Manual</SO>
<YR>1986</YR>
<PB>North Tonawanda, NY: Multi-Health Systems</PB>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Kay-1987" NAME="Kay 1987" TYPE="JOURNAL_ARTICLE">
<AU>Kay SR, Fiszbein A</AU>
<TI>The positive and negative symptome scale (PANSS) for schizophrenia</TI>
<SO>Schizophrenia Bulletin</SO>
<YR>1987</YR>
<VL>13</VL>
<NO>2</NO>
<PG>261-75</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Leucht-2005" MODIFIED="2011-02-10 11:04:06 +0000" MODIFIED_BY="[Empty name]" NAME="Leucht 2005" TYPE="JOURNAL_ARTICLE">
<AU>Leucht S, Kane JM, Kissling W, Hamann J, Etschel E, Engel R</AU>
<TI>Clinical implications of Brief Psychiatric Rating Scale scores</TI>
<SO>British Journal of Psychiatry</SO>
<YR>2005</YR>
<VL>187</VL>
<PG>366-71</PG>
<IDENTIFIERS MODIFIED="2011-02-10 11:04:04 +0000" MODIFIED_BY="[Empty name]">
<IDENTIFIER TYPE="PUBMED" VALUE="16199797"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Leucht-2005a" MODIFIED="2011-02-10 11:04:06 +0000" MODIFIED_BY="[Empty name]" NAME="Leucht 2005a" TYPE="JOURNAL_ARTICLE">
<AU>Leucht S, Kane JM, Kissling W, Hamann J, Etschel E, Engel RR</AU>
<TI>What does the PANSS mean?</TI>
<SO>Schizophrenia Research</SO>
<YR>2005</YR>
<VL>79</VL>
<NO>2-3</NO>
<PG>231-8</PG>
<IDENTIFIERS MODIFIED="2011-02-10 11:04:04 +0000" MODIFIED_BY="[Empty name]">
<IDENTIFIER TYPE="PUBMED" VALUE="15982856"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Leucht-2007" MODIFIED="2011-02-10 11:04:06 +0000" MODIFIED_BY="[Empty name]" NAME="Leucht 2007" TYPE="JOURNAL_ARTICLE">
<AU>Leucht S, Engel RR, Bauml J, Davis JM</AU>
<TI>Is the superior efficacy of new generation antipsychotics an artifact of LOCF?</TI>
<SO>Schizophrenia Bulletin</SO>
<YR>2007</YR>
<VL>33</VL>
<NO>1</NO>
<PG>183-91</PG>
<IDENTIFIERS MODIFIED="2011-02-10 11:04:04 +0000" MODIFIED_BY="[Empty name]">
<IDENTIFIER TYPE="PUBMED" VALUE="16905632"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Leucht-2007a" MODIFIED="2014-03-03 11:42:45 +0000" MODIFIED_BY="[Empty name]" NAME="Leucht 2007a" TYPE="COCHRANE_REVIEW">
<AU>Leucht S, Kissling W, McGrath J</AU>
<TI>Lithium for schizophrenia</TI>
<SO>Cochrane Database of Systematic Reviews</SO>
<YR>2007</YR>
<NO>3</NO>
<IDENTIFIERS MODIFIED="2014-03-03 11:42:45 +0000" MODIFIED_BY="[Empty name]">
<IDENTIFIER MODIFIED="2014-03-03 11:42:45 +0000" MODIFIED_BY="[Empty name]" TYPE="DOI" VALUE="10.1002/14651858.CD003834.pub2"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Lorr-1962" NAME="Lorr 1962" TYPE="JOURNAL_ARTICLE">
<AU>Lorr M, McNair DM, Klett CJ, Lasky JJ</AU>
<TI>Evidence of ten psychotic symptoms</TI>
<SO>Journal of Consulting Psychology</SO>
<YR>1962</YR>
<VL>26</VL>
<PG>185</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Marshall-2000" MODIFIED="2011-02-10 11:04:06 +0000" MODIFIED_BY="[Empty name]" NAME="Marshall 2000" TYPE="JOURNAL_ARTICLE">
<AU>Marshall M, Lockwood A, Bradley C, Adams CE, Joy C, Fenton M</AU>
<TI>Unpublished rating scales: a major source of bias in randomised controlled trials of treatments for schizophrenia</TI>
<SO>British Journal of Psychiatry</SO>
<YR>2000</YR>
<VL>176</VL>
<PG>249-52</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Marvaha-2004" MODIFIED="2012-07-20 17:15:14 +0100" MODIFIED_BY="[Empty name]" NAME="Marvaha 2004" TYPE="JOURNAL_ARTICLE">
<AU>Marwaha S, Johnson S</AU>
<TI>Schizophrenia and employment ? A review</TI>
<SO>Social Psychiatry and Psychiatric Epidemiology</SO>
<YR>2004</YR>
<VL>39</VL>
<PG>337-49</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Moher-2001" MODIFIED="2012-09-02 20:18:37 +0100" MODIFIED_BY="[Empty name]" NAME="Moher 2001" TYPE="JOURNAL_ARTICLE">
<AU>Moher D, Schulz KF, Altman D, CONSORT Group (Consolidated Standards of Reporting Trials)</AU>
<TI>The CONSORT statement: revised recommendations for improving the quality of reports of parallel-group randomized trials</TI>
<SO>JAMA</SO>
<YR>2001</YR>
<VL>258</VL>
<PG>1987-91</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Overall-1962" NAME="Overall 1962" TYPE="JOURNAL_ARTICLE">
<AU>Overall JE, Gorham DR</AU>
<TI>The brief psychiatric rating scale</TI>
<SO>Psychological Reports</SO>
<YR>1962</YR>
<VL>10</VL>
<PG>790-812</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Pate-1986" MODIFIED="2013-12-16 14:15:57 +0000" MODIFIED_BY="[Empty name]" NAME="Pate 1986" TYPE="JOURNAL_ARTICLE">
<AU>Pate LA</AU>
<TI>Carbamazepine in treatment of the violent psychotic patients</TI>
<SO>Jefferson Journal of Psychiatry</SO>
<YR>1986</YR>
<VL>4</VL>
<NO>1</NO>
<PG>28-36</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Review-Manager-_x0028_RevMan_x0029_" MODIFIED="2011-02-10 11:04:06 +0000" MODIFIED_BY="[Empty name]" NAME="Review Manager (RevMan)" TYPE="COMPUTER_PROGRAM">
<TI>Review Manager (RevMan)</TI>
<YR>2008</YR>
<EN>5.0</EN>
<PB>The Nordic Cochrane Centre, The Cochrane Collaboration</PB>
<CY>Copenhagen</CY>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Schooler-1993" NAME="Schooler 1993" TYPE="JOURNAL_ARTICLE">
<AU>Schooler NR, Keith SJ</AU>
<TI>Clinical research for the treatment of schizophrenia</TI>
<SO>Psychopharmacology Bulletin</SO>
<YR>1993</YR>
<VL>29</VL>
<PG>431-46</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Schulz-1995" NAME="Schulz 1995" TYPE="JOURNAL_ARTICLE">
<AU>Schulz KF, Chalmers I, Hayes RJ, Altman DG</AU>
<TI>Empirical evidence of bias: dimensions of methodological quality associated with estimates of treatment effects in controlled trials</TI>
<SO>JAMA</SO>
<YR>1995</YR>
<VL>273</VL>
<PG>408-12</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Sch_x00fc_nemann-2008" MODIFIED="2011-02-10 11:04:06 +0000" MODIFIED_BY="[Empty name]" NAME="Schünemann 2008" TYPE="BOOK_SECTION">
<AU>Schünemann HJ, Oxman AD, Vist GE, Higgins JPT, Deeks JJ, Glasziou P, et al</AU>
<TI>Chapter 12: Interpreting results and drawing conclusions</TI>
<SO>Cochrane Handbook for Systematic Reviews of Interventions</SO>
<YR>2008</YR>
<PG>359-83</PG>
<ED>Higgins JPT, Green S</ED>
<PB>The Cochrane Collaboration</PB>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Tharyan-2002" MODIFIED="2013-12-16 14:14:40 +0000" MODIFIED_BY="[Empty name]" NAME="Tharyan 2002" TYPE="COCHRANE_REVIEW">
<AU>Tharyan P, Adams CE</AU>
<TI>Electroconvulsive therapy for schizophrenia</TI>
<SO>Cochrane Database of Systematic Reviews</SO>
<YR>2005</YR>
<NO>2</NO>
<PB>Update Software</PB>
<CY>Oxford</CY>
<IDENTIFIERS MODIFIED="2013-12-16 14:14:40 +0000" MODIFIED_BY="[Empty name]">
<IDENTIFIER MODIFIED="2013-12-16 14:14:40 +0000" MODIFIED_BY="[Empty name]" TYPE="DOI" VALUE="10.1002/14651858.CD000076.pub2"/>
<IDENTIFIER MODIFIED="2013-05-16 11:00:39 +0100" MODIFIED_BY="[Empty name]" TYPE="OTHER" VALUE="CD000076"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Tiihonen-1995" NAME="Tiihonen 1995" TYPE="JOURNAL_ARTICLE">
<AU>Tiihonen J, Vartiainen H, Hakola P</AU>
<TI>Carbamazepine-induced changes in plasma levels of neuroleptics</TI>
<SO>Pharmacopsychiatry</SO>
<YR>1995</YR>
<VL>28</VL>
<PG>26-8</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Tsuang-1978" MODIFIED="2014-03-03 11:57:13 +0000" MODIFIED_BY="[Empty name]" NAME="Tsuang 1978" TYPE="JOURNAL_ARTICLE">
<AU>Tsuang MT</AU>
<TI>Suicide in schizophrenics, manics, depressives, and surgical controls: a comparison with general population suicide mortality</TI>
<SO>Archives of General Psychiatry</SO>
<YR>1978</YR>
<VL>35</VL>
<PG>153-5</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Ukoumunne-1999" NAME="Ukoumunne 1999" TYPE="JOURNAL_ARTICLE">
<AU>Ukoumunne OC, Gulliford MC, Chinn S, Sterne JAC, Burney PGJ</AU>
<TI>Methods for evaluating area-wide and organisation-based interventions in health and health care: a systematic review</TI>
<SO>Health Technology Assessment</SO>
<YR>1999</YR>
<VL>3</VL>
<NO>5</NO>
<PG>iii-92</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="MEDLINE" VALUE="10982317"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Xia-2009" MODIFIED="2011-02-10 11:04:06 +0000" MODIFIED_BY="[Empty name]" NAME="Xia 2009" TYPE="JOURNAL_ARTICLE">
<AU>Xia J, Adams CE, Bhagat N, Bhagat V, Bhoopathi P, El-Sayeh H, et al</AU>
<TI>Loss to outcomes stakeholder survey: the LOSS study</TI>
<SO>Psychiatric Bulletin</SO>
<YR>2009</YR>
<VL>33</VL>
<NO>7</NO>
<PG>254-7</PG>
<CY>Sao Paulo</CY>
<IDENTIFIERS/>
</REFERENCE>
</ADDITIONAL_REFERENCES>
<OTHER_VERSIONS_REFERENCES MODIFIED="2014-03-03 11:57:33 +0000" MODIFIED_BY="[Empty name]">
<REFERENCE ID="REF-Leucht-2002" NAME="Leucht 2002" TYPE="JOURNAL_ARTICLE">
<AU>Leucht S, McGrath J, White P, Kissling W</AU>
<TI>Carbamazepine augmentation for schizophrenia: how good is the evidence?</TI>
<SO>Journal of Clinical Psychiatry</SO>
<YR>2002</YR>
<VL>63</VL>
<NO>3</NO>
<PG>218-24</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Leucht-2002b" MODIFIED="2014-03-03 11:57:28 +0000" MODIFIED_BY="[Empty name]" NAME="Leucht 2002b" TYPE="COCHRANE_REVIEW">
<AU>Leucht S, McGrath J, White P, Kissling W</AU>
<TI>Carbamazepine for schizophrenia and schizoaffective psychoses</TI>
<SO>Cochrane Database of Systematic Reviews</SO>
<YR>2002</YR>
<NO>3</NO>
<IDENTIFIERS MODIFIED="2014-01-27 11:17:14 +0000" MODIFIED_BY="Heather Maxwell">
<IDENTIFIER MODIFIED="2014-01-27 11:17:14 +0000" MODIFIED_BY="Heather Maxwell" TYPE="DOI" VALUE="10.1002/14651858.CD001258"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Leucht-2007b" MODIFIED="2014-03-03 11:57:33 +0000" MODIFIED_BY="[Empty name]" NAME="Leucht 2007b" TYPE="COCHRANE_REVIEW">
<AU>Leucht S, Kissling W, McGrath J, White P</AU>
<TI>Carbamazepine for schizophrenia</TI>
<SO>Cochrane Database of Systematic Reviews</SO>
<YR>2007</YR>
<NO>3</NO>
<IDENTIFIERS MODIFIED="2014-01-27 11:16:12 +0000" MODIFIED_BY="Heather Maxwell">
<IDENTIFIER MODIFIED="2014-01-27 11:16:12 +0000" MODIFIED_BY="Heather Maxwell" TYPE="DOI" VALUE="10.1002/14651858.CD001258.pub2"/>
</IDENTIFIERS>
</REFERENCE>
</OTHER_VERSIONS_REFERENCES>
<PENDING_REFERENCES MODIFIED="2013-01-30 12:10:48 +0000" MODIFIED_BY="[Empty name]"/>
</OTHER_REFERENCES>
</STUDIES_AND_REFERENCES>
<CHARACTERISTICS_OF_STUDIES MODIFIED="2014-03-03 11:55:25 +0000" MODIFIED_BY="[Empty name]">
<CHARACTERISTICS_OF_INCLUDED_STUDIES MODIFIED="2014-03-03 11:55:25 +0000" MODIFIED_BY="[Empty name]" SORT_BY="STUDY" USER_DEF_1_ENABLED="NO" USER_DEF_2_ENABLED="NO" USER_DEF_3_ENABLED="NO">
<INCLUDED_CHAR MODIFIED="2014-01-21 11:28:10 +0000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Carpenter-1991">
<CHAR_METHODS>
<P>Allocation: randomised - no further details.<BR/>Blinding: double - no further information.<BR/>Design: cross-over.<BR/>Duration: 95 days each phase.<BR/>Setting: outpatient department.</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2014-01-21 11:28:10 +0000" MODIFIED_BY="[Empty name]">
<P>Diagnosis: schizophrenia (DSM-III &amp; RDC).<BR/>N = 34.*<BR/>Sex: 18 M, 9 F.*<BR/>Age: mean ~ 33 years.<BR/>History: stabilised on neuroleptic maintenance, hospitalised ~3 times, ill ~10 years.</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS>
<P>1. Carbamazepine: dose 800-1200 mg/day. N~15.*<BR/>2. Placebo (neuroleptics withdrawn over 1-5 days when study medication dose was reached). N~16.*</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES>
<P>1. Leaving the study early.<BR/>2. Relapse.*<BR/>3. Mental state: BPRS (mean and number with 20% reduction).*<BR/>4. Side effects - allergic reactions, blood dyscrasia.*</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2012-07-20 17:30:57 +0100" MODIFIED_BY="[Empty name]">
<P>Data analysed on 31 patients, no information about treatment status of 3 people.<BR/>Interim analyses showed high relapse rates in both arms of study - study stopped.</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2014-03-03 11:55:25 +0000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Dose-1987">
<CHAR_METHODS>
<P>Allocation: randomised - no further details.<BR/>Blinding: double - no further information.<BR/>Design: parallel.<BR/>Duration: 5 weeks (at week 4 interventions withdrawn).<BR/>Setting: in hospital.</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2014-01-21 11:28:10 +0000" MODIFIED_BY="[Empty name]">
<P>Diagnosis: acute schizophrenia (ICD-9 &amp; DSM-III).<BR/>N = 41.<BR/>Sex: not reported.<BR/>Age: not reported.<BR/>History: hospitalised ~1.2 times, ill ~6 years.</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2014-01-27 11:46:26 +0000" MODIFIED_BY="[Empty name]">
<P>1. Adjunctive carbamazepine: dose 200 mg, increased to 600-1200 mg/day (target plasma level 8-12 micrograms/dL) + haloperidol 6 mg/day then titrated to clinical judgement. N = 18.<BR/>2. Placebo additional treatment + haloperidol 6 mg/day then titrated to clinical judgement. N = 23.</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2014-03-03 11:55:25 +0000" MODIFIED_BY="[Empty name]">
<P>1. Leaving the study early.<BR/>2. Mental state: (BPRS 20%, 35%, 50% reduction, mean at endpoint; mean IMPS at endpoint).<BR/>3. Side effects: allergic reactions, substantial white blood cell decline, increase of liver enzymes, worsening of EEG.</P>
<P>Unable to use:.<BR/>Medication use (mean haloperidol dose - no SD, biperiden, chlorprothixene - data skewed).<BR/>Movement disorder (SAS - data skewed).<BR/>Haloperidol plasma-levels - data skewed.</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2012-07-20 17:31:20 +0100" MODIFIED_BY="[Empty name]">
<P>** Two people taking carbamazepine had falls in white cell counts, but not below usual reference range.</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2014-03-03 11:55:25 +0000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-He_x00df_linger-1998">
<CHAR_METHODS>
<P>Allocation: randomised - sealed envelopes.<BR/>Blinding: single.<BR/>Design: parallel.<BR/>Duration: 4 weeks.<BR/>Setting: in hospital.</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2014-01-21 11:28:10 +0000" MODIFIED_BY="[Empty name]">
<P>Diagnosis: schizophrenia (n = 16) or schizoaffective (n = 2) psychosis (ICD-10).<BR/>N = 18.<BR/>Sex: 12 M, 6F.</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2014-03-03 11:55:25 +0000" MODIFIED_BY="[Empty name]">
<P>1. Adjunctive carbamazepine: dose mean 567mg/day, titrated in week 1 to plasma-level of 6-12 mg/mL + constant haloperidol dose: dose mean ~ 15 mg/day, higher in this group to maintain effective plasma levels. N = 9.<BR/>2. No additional treatment + constant haloperidol dose. N = 9.</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2014-01-28 13:44:02 +0000" MODIFIED_BY="Heather Maxwell">
<P>1. Leaving the study early.<BR/>2. Mental state (BPRS 20%, 35%, 50% reduction and mean at endpoint, PANSS positive score at endpoint).</P>
<P>Unable to use:.<BR/>Haloperidol plasma levels - data skewed.<BR/>Mean biperiden and chlorprothixen dose - data skewed.</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2012-07-20 17:31:27 +0100" MODIFIED_BY="[Empty name]"/>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2014-03-03 11:55:25 +0000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Llorca-1993">
<CHAR_METHODS MODIFIED="2014-03-03 11:55:25 +0000" MODIFIED_BY="[Empty name]">
<P>Allocation: randomised - Latin square procedure.<BR/>Blindness: double - identical capsules.<BR/>Design: cross-over, no wash-out.<BR/>Duration: 4 X 5 week cross-over (preceded by 5 weeks no adjunctive treatment).<BR/>Setting: in hospital.</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2014-01-27 11:50:14 +0000" MODIFIED_BY="[Empty name]">
<P>Diagnosis: treatment-resistant schizophrenia patients (DSM-III-R, Kane criteria).<BR/>N = 24.<BR/>Sex: 18 M, 6 F.<BR/>Age: mean ~44 years.</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2014-01-27 11:50:53 +0000" MODIFIED_BY="[Empty name]">
<P>1. Adjunctive carbamazepine: dose 2 weeks 200 mg/day, 3 weeks 400 mg/day + constant haloperidol (15-65 mg/day). N = 6.<BR/>2. Adjunctive bromocriptine: dose 2.5 mg/day + constant haloperidol (15-65 mg/day). N = 6.*<BR/>3. Adjunctive cyproheptadine: 12-24 mg/day + constant haloperidol (15-65 mg/day). N = 6.*<BR/>4. Placebo additional treatment + constant haloperidol (15-65 mg/day). N = 6.</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2014-03-03 11:55:25 +0000" MODIFIED_BY="[Empty name]">
<P>1. Leaving the study early.</P>
<P>Unable to use: .<BR/>Mental state (BPRS, SAPS, SANS - P values only).<BR/>Movement disorder (SAS, AIMS - P values only).</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2012-07-20 17:31:39 +0100" MODIFIED_BY="[Empty name]">
<P>* Data from groups 2 &amp; 3 not used in this review.</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2014-03-03 11:55:25 +0000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Mair-1990">
<CHAR_METHODS>
<P>Allocation: randomised - no further details.<BR/>Blinding: open.<BR/>Design: parallel.<BR/>Duration: 5 weeks.<BR/>Setting: in hospital.</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2014-01-21 11:28:10 +0000" MODIFIED_BY="[Empty name]">
<P>Diagnosis: schizophrenia &amp; schizophrenia-like psychoses (ICD-9).<BR/>N = 23.<BR/>Age: range 31-44 years.<BR/>History: "acutely ill", unresponsive to 5 days clozapine or haloperidol, admitted 4-9 times.</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2014-01-27 11:51:49 +0000" MODIFIED_BY="[Empty name]">
<P>1. Adjunctive carbamazepine: dose 600 mg/day + titrated dose of haloperidol or clozapine. N = 13.<BR/>2. No additional treatment + titrated dose of haloperidol or clozapine. N = 10.</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2014-03-03 11:55:25 +0000" MODIFIED_BY="[Empty name]">
<P>1. Leaving the study early.</P>
<P>Unable to use:.<BR/>General functioning (CGI - no SD).<BR/>Mental state (BPRS - no SD).<BR/>Extrapyramidal side effects (Webster scale - no data).<BR/>Other side effects (FSUCL - no data).<BR/>Mean haloperidol/clozapine dose - no SD.</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2012-07-20 17:31:44 +0100" MODIFIED_BY="[Empty name]"/>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2014-03-03 11:55:25 +0000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Martin_x002d_Munoz-1989">
<CHAR_METHODS>
<P>Allocation: randomised - no further information.<BR/>Blinding: not stated.<BR/>Design: parallel.<BR/>Duration: 18 days.<BR/>Setting: in hospital.</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2014-01-21 11:28:10 +0000" MODIFIED_BY="[Empty name]">
<P>Diagnosis: paranoid schizophrenia (RDC).<BR/>N = 20.<BR/>Age: mean ~29 years.<BR/>Sex: 18 M, 2 F.</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2014-03-03 11:55:25 +0000" MODIFIED_BY="[Empty name]">
<P>1. Adjunctive carbamazepine: dose initially 600 mg/day, adjusted to plasma levels of 8-12 ng/mL + haloperidol, 30 mg/day, fixed dose. N = 10.<BR/>2. No additional treatment + haloperidol, 30 mg/day, fixed dose. N = 10.</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES>
<P>1. Leaving the study early.<BR/>2. Mental state (20%, 35%, 50% BPRS reduction).<BR/>3. Movement disorder.</P>
<P>Unable to use:.<BR/>Side effects (UKU-scale - no data).</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2012-07-20 17:31:50 +0100" MODIFIED_BY="[Empty name]"/>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2014-03-03 11:55:25 +0000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Nachshoni-1994">
<CHAR_METHODS MODIFIED="2012-07-21 13:32:18 +0100" MODIFIED_BY="[Empty name]">
<P>Allocation: randomised - random allocation list.<BR/>Blinding: double - identical capsules.<BR/>Design: parallel.<BR/>Duration: 5 weeks.<BR/>Setting: in hospital.</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2014-01-21 11:28:10 +0000" MODIFIED_BY="[Empty name]">
<P>Diagnosis: residual schizophrenia (DSM-III-R).<BR/>N = 30.*<BR/>Age: mean ~46 years.<BR/>Sex: 15 M, 13 F.<BR/>History: predominant negative symptoms, ill mean ~19 years.</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2014-03-03 11:55:25 +0000" MODIFIED_BY="[Empty name]">
<P>1. Adjunctive carbamazepine: dose increased to 600 mg/day during week 1, then adjustment to plasma levels of 4-12 ng/mL + 300-800 chlorpromazine equivalent antipsychotic treatment. N = 15.<BR/>2. Placebo adjunctive treatment + 300-800 chlorpromazine equivalent antipsychotic treatment. N = 15.<BR/>
</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES>
<P>1. Leaving the study early.<BR/>2. Mental state (20%, 35%, 50% BPRS reduction, HRSD, SANS at endpoint).</P>
<P>Unable to use:.<BR/>EPS (SAS - no data).</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2012-07-20 17:31:55 +0100" MODIFIED_BY="[Empty name]">
<P>
<BR/>
</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2014-03-03 11:55:25 +0000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Neppe-1983">
<CHAR_METHODS MODIFIED="2014-03-03 11:55:25 +0000" MODIFIED_BY="[Empty name]">
<P>Allocation: randomised - no further information.<BR/>Blinding: double - no further information.<BR/>Design: cross-over.<BR/>Duration: 2 X 6 weeks (preceded by 3-week baseline).<BR/>Setting: in hospital.</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2014-01-21 11:28:10 +0000" MODIFIED_BY="[Empty name]">
<P>Diagnosis: schizophrenia (10), non-progressive dementia (2), rapid cycling (1) (diagnostic criteria unclear).<BR/>N = 13.*<BR/>Age: mean ~34 years.<BR/>Sex: 8 M, 5 F.<BR/>History: chronic, "poor-responders", EEG abnormalities.</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2014-01-27 11:55:08 +0000" MODIFIED_BY="[Empty name]">
<P>1. Adjunctive carbamazepine: dose 600 mg/day + various antipsychotics (constant dose). N = 3.<BR/>2. Placebo adjunctive treatment + various antipsychotics (constant dose). N = 6.</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES>
<P>1. Leaving the study early.<BR/>2. Global impression (CGI).<BR/>3. Mental state (20%, 35%, 50% BPRS reduction).</P>
<P>Unable to use: .<BR/>General improvement (Global Assessment, OCR unpublished scales).</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2014-03-03 11:55:25 +0000" MODIFIED_BY="[Empty name]">
<P>*Data extracted for 9 participants with schizophrenia from published data.<BR/>
</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2014-03-03 11:55:25 +0000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Simhandl-1996">
<CHAR_METHODS MODIFIED="2013-05-23 17:12:21 +0100" MODIFIED_BY="[Empty name]">
<P>Allocation: randomised - no further details.<BR/>Blindness: double.<BR/>Design: parallel.<BR/>Duration: 8 weeks (intervention withdrawn at week 6).<BR/>Setting: no information available.</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2014-01-21 11:28:10 +0000" MODIFIED_BY="[Empty name]">
<P>Diagnosis: schizophrenia (DSM-III-R).<BR/>N = 42.<BR/>Age: mean ~35 years.<BR/>Sex: 30 M, 12 F.<BR/>History: "chronic", non-response to &gt; 3 neuroleptics (2 different chemical classes) in last 2 years, duration ill ~ 10 years.</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2014-03-03 11:55:25 +0000" MODIFIED_BY="[Empty name]">
<P>1. Adjunctive carbamazepine: dose increased week 1-2 until plasma levels = 15-42 micromol/L + constant dose of antipsychotics. N = 15.<BR/>2. Lithium*: dose increased week 1-2 until plasma level = 0.6-1.2 mml/L) + constant dose of antipsychotics. N = 13.<BR/>3. Placebo + constant dose of antipsychotics. N = 14.</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2014-01-27 11:56:33 +0000" MODIFIED_BY="Heather Maxwell">
<P>1. Leaving the study early.<BR/>2. Global impression (CGI).<BR/>3. Mental state (20%, 35%, 50% BPRS reduction, SANS at endpoint).</P>
<P>Unable to use: .<BR/>Plasma levels of antipsychotics - skewed data.</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2014-01-21 11:28:10 +0000" MODIFIED_BY="[Empty name]">
<P>Jadad = 4.<BR/>*This group was not used in the analysis.</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2014-03-03 11:55:25 +0000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Svestka-1989">
<CHAR_METHODS MODIFIED="2014-03-03 11:55:25 +0000" MODIFIED_BY="[Empty name]">
<P>Allocation: randomised - no further details.<BR/>Blindness: single (raters).<BR/>Design: cross-over.<BR/>Duration: 6 weeks (2 weeks placebo - 3 weeks carbamazepine/perphenazine - 1 week placebo - 3 weeks carbamazepine/perphenazine).<BR/>Setting: hospital.</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2014-01-21 11:28:10 +0000" MODIFIED_BY="[Empty name]">
<P>Diagnosis: ICD-9 schizophrenia (n = 28) or schizoaffective disorder (n = 10).<BR/>History: "acutely ill", duration ill ~9 years.<BR/>N = 38.<BR/>Age: mean ~38 years.<BR/>Sex: 30 M, 8 F (the gender of 2 people who left early is unknown).</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2014-01-27 11:57:38 +0000" MODIFIED_BY="[Empty name]">
<P>1. Carbamazepine, flexible dose, mean = 1374 SD = 334, N = 22.<BR/>2. Perphenazine, flexible dose, mean = 53, SD = 12. N = 18.<BR/>Then 1 week placebo and 3 weeks cross-over to other treatment.</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2014-03-03 11:55:25 +0000" MODIFIED_BY="[Empty name]">
<P>1. Leaving the study early.<BR/>2. Mental state (20%, 35%, 50% BPRS reduction and BPRS at endpoint).<BR/>3. Various side effects.</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2014-01-21 11:28:10 +0000" MODIFIED_BY="[Empty name]">
<P>Jadad = 4.</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<FOOTNOTES>
<P>
<I>General abbreviations</I>
<BR/>CBZ - carbamazepine<BR/>
<BR/>EPS - Extrapyramidal side effects.<BR/>EEG - electroencephalogram<BR/>M - males<BR/>F - females<BR/>ITT - intention-to-treat<BR/>N = number<BR/>Mg = milligram<BR/>SD - standard deviation<BR/>
</P>
<P>
<I>Diagnostic tools<BR/>
</I>DSM-III-R - Diagnostic and Statistical Manual of Mental disorders, third edition, revised.<BR/>ICD-9/10 - International Classification of Diseases, ninth/tenth revision.<BR/>RDC - Research Diagnostic Criteria</P>
<P>
<I>Global effect scales</I>
<BR/>CGI - Clinical Global Impression (<LINK REF="REF-Guy-1976" TYPE="REFERENCE">Guy 1976</LINK>)<BR/>OCR - Overall Clinical Rating</P>
<P>
<I>Mental state scales</I>
<BR/>BPRS - Brief Psychiatric Rating Scale (<LINK REF="REF-Overall-1962" TYPE="REFERENCE">Overall 1962</LINK>)<BR/>HRSD - Hamilton Rating Scale for Depression<BR/>IMPS - Inpatient Multidimensional Rating Scale (<LINK REF="REF-Lorr-1962" TYPE="REFERENCE">Lorr 1962</LINK>)<BR/>PANSS - Positive and Negative Symptoms Scale (<LINK REF="REF-Kay-1987" TYPE="REFERENCE">Kay 1987</LINK>)<BR/>
<BR/>
<BR/>SANS - Scale for Assessment of Negative Symptoms (<LINK REF="REF-Andreasen-1982" TYPE="REFERENCE">Andreasen 1982</LINK>)<BR/>SAPS - Scale for Assessment of Positive Symptoms (<LINK REF="REF-Andreasen-1984" TYPE="REFERENCE">Andreasen 1984</LINK>)</P>
<P>
<I>Side effect scales</I>
<BR/>CGI - Clinical Global Impression, side effects (<LINK REF="REF-Guy-1976" TYPE="REFERENCE">Guy 1976</LINK>)<BR/>UKU - UKU Side effect Scale (Lingjaerde et al. 1987)<BR/>AIMS - Abnormal Involuntary Movement Scale (<LINK REF="REF-Guy-1976" TYPE="REFERENCE">Guy 1976</LINK>)<BR/>SAS - Simpson and Angus Scale (Simpson and Angus 1970)<BR/>FSUCL - Fischers Somatische Symptome oder Unerwünschte Effekte Check List (Fischer-Cornellson 1986)</P>
</FOOTNOTES>
</CHARACTERISTICS_OF_INCLUDED_STUDIES>
<CHARACTERISTICS_OF_EXCLUDED_STUDIES MODIFIED="2014-01-27 11:34:03 +0000" MODIFIED_BY="[Empty name]" SORT_BY="STUDY">
<EXCLUDED_CHAR STUDY_ID="STD-Arana-1986">
<CHAR_REASON_FOR_EXCLUSION>
<P>Allocation: not randomised, A-B design.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Azorin-1986">
<CHAR_REASON_FOR_EXCLUSION>
<P>Allocation: not randomised, A-B design.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Ballenger-1984">
<CHAR_REASON_FOR_EXCLUSION>
<P>Allocation: not randomised, case series.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Barnes-1996">
<CHAR_REASON_FOR_EXCLUSION>
<P>Allocation: not randomised, review.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Bellaire-1990">
<CHAR_REASON_FOR_EXCLUSION>
<P>Allocation: randomised.<BR/>Participants: people with schizoaffective disorders or bipolar illness.<BR/>Interventions: lithium versus carbamazepine, no placebo group.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Birkheimer-1985">
<CHAR_REASON_FOR_EXCLUSION>
<P>Allocation: not randomised, review.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2014-01-27 11:28:44 +0000" MODIFIED_BY="Heather Maxwell" STUDY_ID="STD-Borison-1991">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2014-01-27 11:28:44 +0000" MODIFIED_BY="Heather Maxwell">
<P>Allocation: randomised.<BR/>Participants: people with schizophrenia.<BR/>Interventions: rimcazole, no carbamazepine.<BR/>
</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Botte-1988">
<CHAR_REASON_FOR_EXCLUSION>
<P>Allocation: not randomised, A-B design.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Cabrera-1987">
<CHAR_REASON_FOR_EXCLUSION>
<P>Allocation: randomised.<BR/>Participants: people with schizoaffective disorders and bipolar illness.<BR/>Interventions: oxcarbazepine versus lithium, no placebo group.<BR/>
</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Cegalis-1984">
<CHAR_REASON_FOR_EXCLUSION>
<P>Allocation: not randomised, case report.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Chouinard-1990">
<CHAR_REASON_FOR_EXCLUSION>
<P>Allocation: not randomised, case series.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Costa-1986">
<CHAR_REASON_FOR_EXCLUSION>
<P>Allocation: not randomised, case report.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Covell-2004">
<CHAR_REASON_FOR_EXCLUSION>
<P>Allocation: randomised.<BR/>Participants: people with schizophrenia.<BR/>Interventions: clozapine versus typical antipsychotics, no carbamazepine group.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Dalby-1971">
<CHAR_REASON_FOR_EXCLUSION>
<P>Allocation: not randomised, A-B design.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-de-Vogelaer-1981">
<CHAR_REASON_FOR_EXCLUSION>
<P>Allocation: randomised.<BR/>Participants: very heterogeneous group of patients, some with "behavioral disorders", some with "psychotic" disorders. No clear diagnoses, study focuses on character disorders.<BR/>Interventions: not entirely clear, but probably carbamazepine or placebo were added to antipsychotic drugs .<BR/>Outcomes: impossible to extract data just for people with serious mental illness. As yet, no response from the author to a letter.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Dehing-1968">
<CHAR_REASON_FOR_EXCLUSION>
<P>Allocation: randomised (random number list).<BR/>Participants: mixed group, no data on people with schizophrenia, the focus of the study was on 'character disorders'.<BR/>Interventions: Carbamazepine or placebo added to ongoing treatment.<BR/>Outcomes: according to the authors no original data are available and therefore no single outcome parameter can be used for this review.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Denicoff-1994">
<CHAR_REASON_FOR_EXCLUSION>
<P>Allocation: not randomised, clinical practice survey/audit.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Elphick-1985">
<CHAR_REASON_FOR_EXCLUSION>
<P>Allocation: not randomised, A-B-A design.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Frankenburg-1988">
<CHAR_REASON_FOR_EXCLUSION>
<P>Allocation: not randomised, case series.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Gadow-1992">
<CHAR_REASON_FOR_EXCLUSION>
<P>Allocation: not randomised, review.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Galletly-1997">
<CHAR_REASON_FOR_EXCLUSION>
<P>Allocation: not randomised, case series.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Ginestet-1996">
<CHAR_REASON_FOR_EXCLUSION>
<P>Allocation: not randomised, review.<BR/>
</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Goncalves-1985">
<CHAR_REASON_FOR_EXCLUSION>
<P>Allocation: randomised.<BR/>Participants: manic people, seven with bipolar disorder, five with schizoaffective disorder.<BR/>Interventions: carbamazepine versus placebo, but most participants also received haloperidol. The trial could therefore not be classified according to the three comparisons analysed in this review and no data could be extracted.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Greil-1997">
<CHAR_REASON_FOR_EXCLUSION>
<P>Allocation: randomised.<BR/>Participants: people with schizoaffective disorder.<BR/>Interventions: carbamazepine versus lithium, no placebo group.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Hakola-1982">
<CHAR_REASON_FOR_EXCLUSION>
<P>Allocation: not randomised, A-B design.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Hermle-1993">
<CHAR_REASON_FOR_EXCLUSION>
<P>Allocation: not randomised, case report.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Herrera-1987">
<CHAR_REASON_FOR_EXCLUSION>
<P>Allocation: not randomised, A-B-A design.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2013-01-30 12:11:07 +0000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Ivkovi-2004">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2013-01-30 12:11:07 +0000" MODIFIED_BY="[Empty name]">
<P>Allocation: not randomised, controlled clinical trial.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Iwahashi-1995">
<CHAR_REASON_FOR_EXCLUSION>
<P>Allocation: not randomised, case-control study.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Iwahashi-1996">
<CHAR_REASON_FOR_EXCLUSION>
<P>Allocation: not randomised, case series.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Jann-1985">
<CHAR_REASON_FOR_EXCLUSION>
<P>Allocation: not randomised, A-B design.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Johns-1995">
<CHAR_REASON_FOR_EXCLUSION>
<P>Allocation: not randomised, review.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Kahn-1990">
<CHAR_REASON_FOR_EXCLUSION>
<P>Allocation: randomised.<BR/>Participants: people with schizophrenia.<BR/>Intervention: carbamazepine plus neuroleptics versus lithium plus neuroleptics, no placebo group.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Karper-1992">
<CHAR_REASON_FOR_EXCLUSION>
<P>Allocation: not randomised, case report.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Keck-1996">
<CHAR_REASON_FOR_EXCLUSION>
<P>Allocation: not randomised, review.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Kessler-1989">
<CHAR_REASON_FOR_EXCLUSION>
<P>Allocation: not randomised, case series.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Kidron-1985">
<CHAR_REASON_FOR_EXCLUSION>
<P>Allocation: randomised, cross-over.<BR/>Participants: people with schizophrenia or schizoaffective disorders and excited states.<BR/>Interventions: haloperidol + carbamazepine versus haloperidol + placebo.<BR/>Outcomes: no usable data.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Klein-1984">
<CHAR_REASON_FOR_EXCLUSION>
<P>Allocation: randomised, parallel (participants with poor response were crossed-over at the end).<BR/>Participants: those with schizophrenia or schizoaffective disorders and excited states.<BR/>Interventions: haloperidol + carbamazepine versus haloperidol + placebo.<BR/>Outcomes: no usable data.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Kraft-1984">
<CHAR_REASON_FOR_EXCLUSION>
<P>Allocation: not randomised, case report.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Lambert-1987">
<CHAR_REASON_FOR_EXCLUSION>
<P>Allocation: review.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Lapensee-1992">
<CHAR_REASON_FOR_EXCLUSION>
<P>Allocation: not randomised, review.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Lenzi-1986">
<CHAR_REASON_FOR_EXCLUSION>
<P>Allocation: randomised.<BR/>Participants: mixed affective and nonaffective psychoses.<BR/>Interventions: carbamazepine + chlorpromazine versus lithium + chlorpromazine, no placebo group.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Llorca-1992">
<CHAR_REASON_FOR_EXCLUSION>
<P>Allocation: not randomised, review.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Luchins-1983">
<CHAR_REASON_FOR_EXCLUSION>
<P>Allocation: not randomised, case series.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Luchins-1984">
<CHAR_REASON_FOR_EXCLUSION>
<P>Allocation: not randomised, case report.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Makaric-2000">
<CHAR_REASON_FOR_EXCLUSION>
<P>Allocation: controlled clinical trial, but not randomised.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-McAllister-1985">
<CHAR_REASON_FOR_EXCLUSION>
<P>Allocation: not randomised, case series.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-McKee-1989">
<CHAR_REASON_FOR_EXCLUSION>
<P>Allocation: not randomised, case report.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Meltzer-1992">
<CHAR_REASON_FOR_EXCLUSION>
<P>Allocation: not randomised, review.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Meshel-1967">
<CHAR_REASON_FOR_EXCLUSION>
<P>Allocation: randomised.<BR/>Participants: people with psychosis.<BR/>Interventions: tybamate versus placebo, no carbamazepine group.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Meshel-1968">
<CHAR_REASON_FOR_EXCLUSION>
<P>Allocation: randomised.<BR/>Participants: people with schizophrenia.<BR/>Interventions: tybamate versus placebo, no carbamazepine group.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Miceli-2000">
<CHAR_REASON_FOR_EXCLUSION>
<P>Allocation: randomised.<BR/>Participants: healthy volunteers.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Miller-1965">
<CHAR_REASON_FOR_EXCLUSION>
<P>Allocation: unclear.<BR/>Participants: people with schizophrenia.<BR/>Interventions: hydroxyphenamate, no carbamazepine group.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Miodownik-2003">
<CHAR_REASON_FOR_EXCLUSION>
<P>Allocation: unclear, but probably randomised.<BR/>Participants: people with schizophrenia.<BR/>Interventions: vitamin B6, no carbamazepine group.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Mokrusch-1987">
<CHAR_REASON_FOR_EXCLUSION>
<P>Allocation: not randomised, review.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Morinigo-1992">
<CHAR_REASON_FOR_EXCLUSION>
<P>Allocation: randomised.<BR/>Participants: people with mania.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Mosca-1998">
<CHAR_REASON_FOR_EXCLUSION>
<P>Allocation: randomised.<BR/>Participants: people with violent behaviour or impulsivity.<BR/>Interventions: carbamazepine versus valproate, no placebo.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Munetz-1989">
<CHAR_REASON_FOR_EXCLUSION>
<P>Allocation: randomised.<BR/>Participants: people with schizophrenia.<BR/>Interventions: rimcazole, no carbamazepine group.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-M_x00f6_ller-1989">
<CHAR_REASON_FOR_EXCLUSION>
<P>Allocation: randomised, cross-over.<BR/>Participants: people with schizophrenia or schizoaffective disorders and excited states.<BR/>Interventions: haloperidol + carbamazepine versus haloperidol + placebo.<BR/>Outcomes: no usable data.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-M_x00f6_ller-1996">
<CHAR_REASON_FOR_EXCLUSION>
<P>Allocation: not randomised, review.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Nasser-1990">
<CHAR_REASON_FOR_EXCLUSION>
<P>Allocation: not randomised, case series.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Nelson-1993">
<CHAR_REASON_FOR_EXCLUSION>
<P>Allocation: not randomised, review.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Neppe-1988a">
<CHAR_REASON_FOR_EXCLUSION>
<P>Allocation: not randomised, review.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Neppe-1988b">
<CHAR_REASON_FOR_EXCLUSION>
<P>Allocation: not randomised, review.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Neppe-1988c">
<CHAR_REASON_FOR_EXCLUSION>
<P>Allocation: not randomised, case report.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Neppe-1991">
<CHAR_REASON_FOR_EXCLUSION>
<P>Allocation: not randomised, case series.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Nijdam-1992">
<CHAR_REASON_FOR_EXCLUSION>
<P>Allocation: unclear.<BR/>Participants: people with mental retardation and psychoses.<BR/>Interventions: comparison of two different formulations of carbamazepine, no placebo.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2013-01-30 12:13:05 +0000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Ohlmeier-2007">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2013-01-30 12:13:05 +0000" MODIFIED_BY="[Empty name]">
<P>Allocation: randomised.</P>
<P>Participants: people with schizophrenia.</P>
<P>Interventions: carbamazepine plus perazine versus olanzapine, i.e. not the same antipsychotic in both groups.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Okuma-1989a">
<CHAR_REASON_FOR_EXCLUSION>
<P>Allocation: alternate allocation, category C, inadequate randomisation.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Okuma-1989b">
<CHAR_REASON_FOR_EXCLUSION>
<P>Allocation: not randomised, A-B design.<BR/>
</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2014-01-27 11:33:20 +0000" MODIFIED_BY="Heather Maxwell" STUDY_ID="STD-Ortega-1991">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2014-01-27 11:33:20 +0000" MODIFIED_BY="Heather Maxwell">
<P>Allocation: randomised (aleatory numbers list generated with a computer program).<BR/>Participants: inhalant-induced psychotic disorders, not schizophrenia.<BR/>Interventions: carbamazepine as a sole treatment versus haloperidol as a sole treatment.<BR/>
</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Otani-1997">
<CHAR_REASON_FOR_EXCLUSION>
<P>Allocation: not randomised, A-B design.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Pantelis-1996">
<CHAR_REASON_FOR_EXCLUSION>
<P>Allocation: not randomised, review.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Panu-1984">
<CHAR_REASON_FOR_EXCLUSION>
<P>Allocation: not randomised, case series.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2014-01-27 11:34:03 +0000" MODIFIED_BY="Heather Maxwell" STUDY_ID="STD-Placidi-1986">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2014-01-27 11:34:03 +0000" MODIFIED_BY="Heather Maxwell">
<P>Allocation: randomised.<BR/>Participants: mixed affective and nonaffective psychoses.<BR/>Intervention: carbamazepine versus lithium, no placebo.<BR/>
</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Raitasuo-1994">
<CHAR_REASON_FOR_EXCLUSION>
<P>Allocation: not randomised, case report.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Rankel-1988">
<CHAR_REASON_FOR_EXCLUSION>
<P>Allocation: not randomised, case series.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Rittmannsberger-1990">
<CHAR_REASON_FOR_EXCLUSION>
<P>Allocation: not randomised, review.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Scher-1983">
<CHAR_REASON_FOR_EXCLUSION>
<P>Allocation: not randomised, case series.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Schulz-1990">
<CHAR_REASON_FOR_EXCLUSION>
<P>Allocation: randomised.<BR/>Participants: people with schizophrenia.<BR/>Interventions: antipsychotics + carbamazepine versus antipsychotics versus lithium, no placebo.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Simhandl-1992">
<CHAR_REASON_FOR_EXCLUSION>
<P>Allocation: not randomised, review.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Siris-1993">
<CHAR_REASON_FOR_EXCLUSION>
<P>Allocation: not randomised, review.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Sramek-1988">
<CHAR_REASON_FOR_EXCLUSION>
<P>Allocation: not randomised, A-B design.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Sugerman-1970">
<CHAR_REASON_FOR_EXCLUSION>
<P>Allocation: unclear, probably randomised.<BR/>Participants: people with schizophrenia.<BR/>Interventions: adrenochrome semicarbazone, no carbamazepine group.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Svestka-1985">
<CHAR_REASON_FOR_EXCLUSION>
<P>Allocation: not randomised, A-B design.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Svestka-1988">
<CHAR_REASON_FOR_EXCLUSION>
<P>Allocation: not randomised, A-B design.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Tohen-1994">
<CHAR_REASON_FOR_EXCLUSION>
<P>Allocation: not randomised, case series.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Walden-1996">
<CHAR_REASON_FOR_EXCLUSION>
<P>Allocation: not randomised, review.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Wetterling-1987">
<CHAR_REASON_FOR_EXCLUSION>
<P>Allocation: not randomised, A-B-A design.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Wunderlich-1983">
<CHAR_REASON_FOR_EXCLUSION>
<P>Allocation: not randomised, A-B design.<BR/>
</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Yassa-1983">
<CHAR_REASON_FOR_EXCLUSION>
<P>Allocation: not randomised, case report.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<FOOTNOTES/>
</CHARACTERISTICS_OF_EXCLUDED_STUDIES>
<CHARACTERISTICS_OF_AWAITING_STUDIES MODIFIED="2014-03-03 11:55:25 +0000" MODIFIED_BY="[Empty name]" SORT_BY="STUDY" USER_DEF_1_ENABLED="NO" USER_DEF_2_ENABLED="NO" USER_DEF_3_ENABLED="NO">
<AWAITING_CHAR MODIFIED="2014-03-03 11:55:25 +0000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Kamisada-1988">
<CHAR_METHODS MODIFIED="2013-01-30 12:19:02 +0000" MODIFIED_BY="[Empty name]">
<P>Unclear whether study was randomised.</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2013-01-30 12:19:41 +0000" MODIFIED_BY="[Empty name]">
<P>Schizophrenia.</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2013-01-30 12:20:07 +0000" MODIFIED_BY="[Empty name]">
<P>Probably either lithium or carbamazepine added to antipsychotic drugs.</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2014-03-03 11:55:25 +0000" MODIFIED_BY="[Empty name]">
<P>Symptoms, side effects.</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2013-01-30 12:24:59 +0000" MODIFIED_BY="[Empty name]">
<P>We wrote a letter but have not received an answer, we can not be sure whether the address was still correct.</P>
</CHAR_NOTES>
</AWAITING_CHAR>
<AWAITING_CHAR MODIFIED="2014-03-03 11:55:25 +0000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Lee-1996">
<CHAR_METHODS MODIFIED="2013-01-30 12:24:16 +0000" MODIFIED_BY="[Empty name]">
<P>Unclear whether study was randomised.</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2013-01-30 12:24:24 +0000" MODIFIED_BY="[Empty name]">
<P>People with schizophrenia and negative symptoms.</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2013-01-30 12:24:38 +0000" MODIFIED_BY="[Empty name]">
<P>Probably carbamazepine and valproate added to antipsychotic drugs.</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2014-03-03 11:55:25 +0000" MODIFIED_BY="[Empty name]">
<P>Probably symptoms, side effects.</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2013-01-30 12:25:07 +0000" MODIFIED_BY="[Empty name]">
<P>We wrote a letter but have not received an answer, we can not be sure whether the address was still correct.</P>
</CHAR_NOTES>
</AWAITING_CHAR>
<FOOTNOTES/>
</CHARACTERISTICS_OF_AWAITING_STUDIES>
<CHARACTERISTICS_OF_ONGOING_STUDIES SORT_BY="STUDY" USER_DEF_1_ENABLED="NO" USER_DEF_2_ENABLED="NO" USER_DEF_3_ENABLED="NO">
<FOOTNOTES/>
</CHARACTERISTICS_OF_ONGOING_STUDIES>
</CHARACTERISTICS_OF_STUDIES>
<QUALITY_ITEMS MODIFIED="2013-05-23 18:16:56 +0100" MODIFIED_BY="[Empty name]">
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-01" LEVEL="STUDY" MODIFIED="2013-05-23 18:16:56 +0100" MODIFIED_BY="[Empty name]" NO="1">
<NAME>Random sequence generation (selection bias)</NAME>
<DESCRIPTION>
<P>Selection bias (biased allocation to interventions) due to inadequate generation of a randomised sequence</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-05-23 17:10:27 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Carpenter-1991">
<DESCRIPTION>
<P>"Patients were randomly assigned, within prognostic strata", no further details (p.69).</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-05-23 17:14:27 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Dose-1987">
<DESCRIPTION>
<P>"Randomized", "randomly assigned" (p.304) - no further details.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-05-23 17:15:24 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-He_x00df_linger-1998">
<DESCRIPTION>
<P>"Randomly assigned" (p.311).</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-05-23 17:16:17 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Llorca-1993">
<DESCRIPTION>
<P>"Randomized succession using a latin square procedure" (p.565).</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-05-23 17:16:50 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Mair-1990">
<DESCRIPTION>
<P>"random number list" (p.79).</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-05-23 17:17:32 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Martin_x002d_Munoz-1989">
<DESCRIPTION>
<P>"Allocated (...) randomly using a coin toss method" (letter).</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-05-23 17:18:27 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Nachshoni-1994">
<DESCRIPTION>
<P>"Random allocation list" (p.24).</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-05-23 17:19:10 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Neppe-1983">
<DESCRIPTION>
<P>"Randomized" (p.326), "random number list" (letter).</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-05-23 18:16:56 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Simhandl-1996">
<DESCRIPTION>
<P>"Random", no further details.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-05-23 18:16:49 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Svestka-1989">
<DESCRIPTION>
<P>"Randomised" - no further details ("intraindividual comparison", p.276).</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
</QUALITY_ITEM_DATA>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-02" LEVEL="STUDY" MODIFIED="2013-05-23 17:19:41 +0100" MODIFIED_BY="[Empty name]" NO="2">
<NAME>Allocation concealment (selection bias)</NAME>
<DESCRIPTION>
<P>Selection bias (biased allocation to interventions) due to inadequate concealment of allocations prior to assignment</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-05-23 17:13:24 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Carpenter-1991">
<DESCRIPTION>
<P>No information available.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-05-23 17:11:12 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Dose-1987">
<DESCRIPTION>
<P>No information available.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-05-23 17:15:26 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-He_x00df_linger-1998">
<DESCRIPTION>
<P>"Sealed envelopes".</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-05-23 17:11:13 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Llorca-1993">
<DESCRIPTION>
<P>No information available.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-05-23 17:11:13 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Mair-1990">
<DESCRIPTION>
<P>No information available.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-05-23 17:12:06 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Martin_x002d_Munoz-1989">
<DESCRIPTION>
<P>No information available.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-05-23 17:18:17 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Nachshoni-1994">
<DESCRIPTION>
<P>"Dr. Joseph Levin was the control psychiatrist who knew what the patients were receiving, according to a random allocation list" (letter from the authors). It appears that other members of the team were blind to allocation.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-05-23 17:12:07 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Neppe-1983">
<DESCRIPTION>
<P>No information available.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-05-23 17:19:41 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Simhandl-1996">
<DESCRIPTION>
<P>No information available.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-05-23 17:12:26 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Svestka-1989">
<DESCRIPTION>
<P>No information available.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
</QUALITY_ITEM_DATA>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-03" LEVEL="GROUP" MODIFIED="2012-07-05 13:18:35 +0100" MODIFIED_BY="[Empty name]" NO="3">
<NAME>Blinding (performance bias and detection bias)</NAME>
<DESCRIPTION>
<P>Performance bias or detection bias due to knowledge of the allocated interventions after assignment</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA_ENTRY_GROUP ID="QIG-03.03" NO="3">
<NAME>All outcomes</NAME>
</QUALITY_ITEM_DATA_ENTRY_GROUP>
<QUALITY_ITEM_DATA_ENTRY_GROUP ID="QIG-03.02" NO="2">
<NAME>Objective outcomes</NAME>
</QUALITY_ITEM_DATA_ENTRY_GROUP>
<QUALITY_ITEM_DATA_ENTRY_GROUP ID="QIG-03.01" NO="1">
<NAME>Subjective outcomes</NAME>
</QUALITY_ITEM_DATA_ENTRY_GROUP>
<QUALITY_ITEM_DATA/>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="NO" ID="QIT-07" LEVEL="GROUP" MODIFIED="2013-05-23 17:19:56 +0100" MODIFIED_BY="[Empty name]" NO="7">
<NAME>Blinding of participants and personnel (performance bias)</NAME>
<DESCRIPTION>
<P>Performance bias due to knowledge of the allocated interventions by participants and personnel during the study</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA_ENTRY_GROUP ID="QIG-07.01" NO="1">
<NAME>Objective outcomes</NAME>
</QUALITY_ITEM_DATA_ENTRY_GROUP>
<QUALITY_ITEM_DATA_ENTRY_GROUP ID="QIG-07.02" NO="2">
<NAME>Subjective outcomes</NAME>
</QUALITY_ITEM_DATA_ENTRY_GROUP>
<QUALITY_ITEM_DATA>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-07.01" MODIFIED="2013-05-23 17:14:01 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Carpenter-1991">
<DESCRIPTION>
<P>"Double-blind", "identical placebo tablets" (p.69), "number of carbamazepine tablets was adjusted by a nonblind psychiatrist" (p.70).</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-07.02" MODIFIED="2013-05-23 17:14:03 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Carpenter-1991">
<DESCRIPTION>
<P>"Double-blind", "identical placebo tablets" (p.69), "number of carbamazepine tablets was adjusted by a nonblind psychiatrist" (p.70).</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-07.01" MODIFIED="2013-05-23 17:14:47 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Dose-1987">
<DESCRIPTION>
<P>"Double-blind" - no further details (p.304).</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-07.02" MODIFIED="2013-05-23 17:14:49 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Dose-1987">
<DESCRIPTION>
<P>"Double-blind" - no further details (p.304).</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-07.01" MODIFIED="2013-05-23 17:15:30 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-He_x00df_linger-1998">
<DESCRIPTION>
<P>"Psychiatrist (...) was blind to medication and drug levels. However, he had access to the nursing charts" (p.311). Patients were not aware of the treatment (information received by letter).</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-07.02" MODIFIED="2013-05-23 17:15:34 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-He_x00df_linger-1998">
<DESCRIPTION>
<P>"Psychiatrist (...) was blind to medication and drug levels. However, he had access to the nursing charts" (p.311) Patients were not aware of the treatment (information received by letter).</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-07.01" MODIFIED="2013-05-23 17:16:25 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Llorca-1993">
<DESCRIPTION>
<P>"Tout au long de l'étude, les patients sont à l'insu du traitement recu. Durant les 4 phase de l'expérimentation, patients et investigateurs sont à l'insu de la médication adjuvante recue". "Afin de maintenir les conditions de double aveugle, les résultats des dosages pratiqués sont collectés au fur et à mesure de l'étude par un médecin différent du cotateur (M.A.W.)". "capsules identiques".</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-07.02" MODIFIED="2013-05-23 17:16:29 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Llorca-1993">
<DESCRIPTION>
<P>"Tout au long de l'étude, les patients sont à l'insu du traitement recu. Durant les 4 phase de l'expérimentation, patients et investigateurs sont à l'insu de la médication adjuvante recue". "Afin de maintenir les conditions de double aveugle, les résultats des dosages pratiqués sont collectés au fur et à mesure de l'étude par un médecin différent du cotateur (M.A.W.)" "capsules identiques".</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-07.01" MODIFIED="2013-05-23 17:16:59 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Mair-1990">
<DESCRIPTION>
<P>Blinding not described (an open study) (p.79).</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-07.02" MODIFIED="2013-05-23 17:17:05 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Mair-1990">
<DESCRIPTION>
<P>Blinding not described (an open study) (p.79).</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-07.01" MODIFIED="2013-05-23 17:17:43 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Martin_x002d_Munoz-1989">
<DESCRIPTION>
<P>"Doble ciego", no further details.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-07.02" MODIFIED="2013-05-23 17:17:47 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Martin_x002d_Munoz-1989">
<DESCRIPTION>
<P>"Doble ciego", no further details.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-07.01" MODIFIED="2013-05-23 17:18:32 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Nachshoni-1994">
<DESCRIPTION>
<P>"Double-blind design" (p.24), patients and personal were blind, tablets were identical (letter).</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-07.02" MODIFIED="2013-05-23 17:18:39 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Nachshoni-1994">
<DESCRIPTION>
<P>"Double-blind design" (p.24), patients and personal were blind, tablets were identical (letter).</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-07.01" MODIFIED="2013-05-23 17:19:14 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Neppe-1983">
<DESCRIPTION>
<P>"Double blind" (p.326).</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-07.02" MODIFIED="2013-05-23 17:19:19 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Neppe-1983">
<DESCRIPTION>
<P>"Double blind" (p.326).</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-07.01" MODIFIED="2013-05-23 17:19:52 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Simhandl-1996">
<DESCRIPTION>
<P>"Double-blind", no further details.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-07.02" MODIFIED="2013-05-23 17:19:56 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Simhandl-1996">
<DESCRIPTION>
<P>"Double-blind", no further details.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-07.01" MODIFIED="2013-05-23 17:12:27 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Svestka-1989">
<DESCRIPTION>
<P>No information available.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-07.02" MODIFIED="2013-05-23 17:12:28 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Svestka-1989">
<DESCRIPTION>
<P>No information available.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
</QUALITY_ITEM_DATA>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="NO" ID="QIT-08" LEVEL="GROUP" MODIFIED="2013-05-23 17:20:02 +0100" MODIFIED_BY="[Empty name]" NO="8">
<NAME>Blinding of outcome assessment (detection bias)</NAME>
<DESCRIPTION>
<P>Detection bias due to knowledge of the allocated interventions by outcome assessors</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA_ENTRY_GROUP ID="QIG-08.01" NO="1">
<NAME>Objective outcomes</NAME>
</QUALITY_ITEM_DATA_ENTRY_GROUP>
<QUALITY_ITEM_DATA_ENTRY_GROUP ID="QIG-08.02" NO="2">
<NAME>Subjective outcomes</NAME>
</QUALITY_ITEM_DATA_ENTRY_GROUP>
<QUALITY_ITEM_DATA>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-08.01" MODIFIED="2013-05-23 17:14:05 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Carpenter-1991">
<DESCRIPTION>
<P>"Double-blind", "identical placebo tablets" (p.69).</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-08.02" MODIFIED="2013-05-23 17:14:08 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Carpenter-1991">
<DESCRIPTION>
<P>"Blind rater" (p.69).</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-08.01" MODIFIED="2013-05-23 17:14:50 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Dose-1987">
<DESCRIPTION>
<P>"Double-blind" - no further details (p.304).</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-08.02" MODIFIED="2013-05-23 17:14:50 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Dose-1987">
<DESCRIPTION>
<P>"Double-blind" - no further details (p.304).</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-08.01" MODIFIED="2013-05-23 17:15:37 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-He_x00df_linger-1998">
<DESCRIPTION>
<P>"Psychiatrist (...) was blind to medication and drug levels. However, he had access to the nursing charts" (p.311). Patients were not aware of the treatment (information received by letter).</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-08.02" MODIFIED="2013-05-23 17:15:41 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-He_x00df_linger-1998">
<DESCRIPTION>
<P>"Psychiatrist (...) was blind to medication and drug levels. However, he had access to the nursing charts" (p.311). Patients were not aware of the treatment (information received by letter).</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-08.01" MODIFIED="2013-05-23 17:16:32 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Llorca-1993">
<DESCRIPTION>
<P>"Tout au long de l'étude, les patients sont à l'insu du traitement recu. Durant les 4 phase de l'expérimentation, patients et investigateurs sont à l'insu de la médication adjuvante recue". "Afin de maintenir les conditions de double aveugle, les résultats des dosages pratiqués sont collectés au fur et à mesure de l'étude par un médecin différent du cotateur (M.A.W.)". "capsules identiques".</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-08.02" MODIFIED="2013-05-23 17:16:35 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Llorca-1993">
<DESCRIPTION>
<P>"Tout au long de l'étude, les patients sont à l'insu du traitement recu. Durant les 4 phase de l'expérimentation, patients et investigateurs sont à l'insu de la médication adjuvante recue". "Afin de maintenir les conditions de double aveugle, les résultats des dosages pratiqués sont collectés au fur et à mesure de l'étude par un médecin différent du cotateur (M.A.W.)". "capsules identiques".</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-08.01" MODIFIED="2013-05-23 17:17:09 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Mair-1990">
<DESCRIPTION>
<P>Blinding not described (an open study) (p.79).</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-08.02" MODIFIED="2013-05-23 17:17:11 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Mair-1990">
<DESCRIPTION>
<P>Blinding not described (an open study) (p.79).</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-08.01" MODIFIED="2013-05-23 17:17:50 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Martin_x002d_Munoz-1989">
<DESCRIPTION>
<P>"Doble ciego", no further details.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-08.02" MODIFIED="2013-05-23 17:17:53 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Martin_x002d_Munoz-1989">
<DESCRIPTION>
<P>"Doble ciego", no further details.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-08.01" MODIFIED="2013-05-23 17:18:42 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Nachshoni-1994">
<DESCRIPTION>
<P>"Double-blind design" (p.24), patients and personal were blind, tablets were identical (letter).</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-08.02" MODIFIED="2013-05-23 17:18:20 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Nachshoni-1994">
<DESCRIPTION>
<P>"Ratings were done by psychiatrist, who was blind to whether the patients were receiving placebo or carbamazepine" (p.23).</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-08.01" MODIFIED="2013-05-23 17:19:21 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Neppe-1983">
<DESCRIPTION>
<P>"Double blind" (p.326).</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-08.02" MODIFIED="2013-05-23 17:19:24 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Neppe-1983">
<DESCRIPTION>
<P>"Double blind" (p.326).</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-08.01" MODIFIED="2013-05-23 17:19:59 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Simhandl-1996">
<DESCRIPTION>
<P>"Double-blind", no further details.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-08.02" MODIFIED="2013-05-23 17:20:02 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Simhandl-1996">
<DESCRIPTION>
<P>"Double-blind", no further details.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-08.01" MODIFIED="2013-05-23 17:12:28 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Svestka-1989">
<DESCRIPTION>
<P>No information available.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-08.02" MODIFIED="2013-05-23 17:12:29 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Svestka-1989">
<DESCRIPTION>
<P>No information available.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
</QUALITY_ITEM_DATA>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-04" LEVEL="GROUP" MODIFIED="2013-05-23 17:20:24 +0100" MODIFIED_BY="[Empty name]" NO="4">
<NAME>Incomplete outcome data (attrition bias)</NAME>
<DESCRIPTION>
<P>Attrition bias due to amount, nature or handling of incomplete outcome data</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA_ENTRY_GROUP ID="QIG-04.01" NO="1">
<NAME>All outcomes</NAME>
</QUALITY_ITEM_DATA_ENTRY_GROUP>
<QUALITY_ITEM_DATA>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2013-05-23 17:14:10 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Carpenter-1991">
<DESCRIPTION>
<P>Same dropout rate in each group.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2013-05-23 17:14:59 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Dose-1987">
<DESCRIPTION>
<P>"[All patients] survived for the end-of-treatment-analysis without any dropouts" (p.304).</P>
<P>"No patients dropped out because of side effects or adverse reactions" (p.306).</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2013-05-23 17:15:51 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-He_x00df_linger-1998">
<DESCRIPTION>
<P>"25 out of 27 patients completed the study protocol", 2 CBZ dropouts, ITT analysis (p.311).</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2013-05-23 17:16:38 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Llorca-1993">
<DESCRIPTION>
<P>No participant left the study early.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2013-05-23 17:17:15 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Mair-1990">
<DESCRIPTION>
<P>It was not mentioned whether there were dropouts or not.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2013-05-23 17:17:56 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Martin_x002d_Munoz-1989">
<DESCRIPTION>
<P>No dropouts (according to the letter).</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2013-05-23 17:18:46 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Nachshoni-1994">
<DESCRIPTION>
<P>"Two patients were withdrawn, one from each group" (p.24).</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2013-05-23 17:19:05 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Neppe-1983">
<DESCRIPTION>
<P>"Two out of six patients in the control group compared to zero out of three in the intervention group dropped out [out of 13]" (p.327).</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2013-05-23 17:19:45 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Simhandl-1996">
<DESCRIPTION>
<P>Two patients in each group dropped out, both because of non-compliance.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2013-05-23 17:20:24 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Svestka-1989">
<DESCRIPTION>
<P>Two out of 20 participants in the intervention group dropped out compared to zero out of 18 in the control group.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
</QUALITY_ITEM_DATA>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-05" LEVEL="STUDY" MODIFIED="2013-05-23 17:20:27 +0100" MODIFIED_BY="[Empty name]" NO="5">
<NAME>Selective reporting (reporting bias)</NAME>
<DESCRIPTION>
<P>Reporting bias due to selective outcome reporting</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-05-23 17:14:13 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Carpenter-1991">
<DESCRIPTION>
<P>No selective reporting.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-05-23 17:15:06 +0100" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Dose-1987">
<DESCRIPTION>
<P>CGI results not reported.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-05-23 17:15:49 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-He_x00df_linger-1998">
<DESCRIPTION>
<P>No selective outcome reporting.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-05-23 17:16:41 +0100" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Llorca-1993">
<DESCRIPTION>
<P>No SDs reported.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-05-23 17:17:17 +0100" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Mair-1990">
<DESCRIPTION>
<P>No SDs reported for CGI and BPRS, no data reported for FSUCL and Webster Scale.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-05-23 17:17:59 +0100" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Martin_x002d_Munoz-1989">
<DESCRIPTION>
<P>No SD's in BPRS, UKU-scale results not reported.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-05-23 17:18:49 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Nachshoni-1994">
<DESCRIPTION>
<P>No selective reporting.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-05-23 17:19:30 +0100" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Neppe-1983">
<DESCRIPTION>
<P>No SDs for BPRS.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-05-23 17:20:05 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Simhandl-1996">
<DESCRIPTION>
<P>The study is only available as an abstract.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-05-23 17:20:27 +0100" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Svestka-1989">
<DESCRIPTION>
<P>No SDs and global scores reported for BPRS.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
</QUALITY_ITEM_DATA>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-06" LEVEL="STUDY" MODIFIED="2013-05-23 17:20:29 +0100" MODIFIED_BY="[Empty name]" NO="6">
<NAME>Other bias</NAME>
<DESCRIPTION>
<P>Bias due to problems not covered elsewhere in the table</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-05-23 17:14:15 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Carpenter-1991">
<DESCRIPTION>
<P>No other bias.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-05-23 17:15:07 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Dose-1987">
<DESCRIPTION>
<P>"Dosages of haloperidol, chlorprothixene and biperiden, as well as the occurrence of side effects, differed significantly (...) between the carbamazepine and placebo group" (p.307-8).</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-05-23 17:15:57 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-He_x00df_linger-1998">
<DESCRIPTION>
<P>No other bias.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-05-23 17:16:43 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Llorca-1993">
<DESCRIPTION>
<P>No clear evidence for other bias.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-05-23 17:17:20 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Mair-1990">
<DESCRIPTION>
<P>No other bias.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-05-23 17:18:02 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Martin_x002d_Munoz-1989">
<DESCRIPTION>
<P>No clear evidence for other bias.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-05-23 17:18:52 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Nachshoni-1994">
<DESCRIPTION>
<P>No other bias.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-05-23 17:19:33 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Neppe-1983">
<DESCRIPTION>
<P>No other bias ("one [subject had] a history of contaminating cannabis use", p.327).</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-05-23 17:20:08 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Simhandl-1996">
<DESCRIPTION>
<P>No clear other bias.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-05-23 17:20:29 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Svestka-1989">
<DESCRIPTION>
<P>No other bias.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
</QUALITY_ITEM_DATA>
</QUALITY_ITEM>
</QUALITY_ITEMS>
<SOF_TABLES MODIFIED="2014-03-03 12:02:24 +0000" MODIFIED_BY="[Empty name]">
<SOF_TABLE ID="SOF-01" MODIFIED="2014-03-03 12:02:24 +0000" MODIFIED_BY="[Empty name]" NO="1" READONLY="YES">
<TITLE MODIFIED="2014-03-03 12:02:24 +0000" MODIFIED_BY="[Empty name]">Adjunctive carbamazepine + antipsychotics compared with placebo/no adjunctive treatment + antipsychotics for schizophrenia</TITLE>
<TABLE COLS="7" ROWS="8">
<TR>
<TD COLSPAN="7">
<P>
<B>adjunctive Carbamazepine + antipsychotics compared to placebo/no adjunctive treatment + antipsychotics for schizophrenia</B>
</P>
</TD>
</TR>
<TR>
<TD COLSPAN="7">
<P>
<B>Patient or population:</B> People with schizophrenia<BR/>
<B>Settings:</B> Outpatients/ inpatients<BR/>
<B>Intervention:</B> Adjunctive Carbamazepine + antipsychotics<BR/>
<B>Comparison: </B>Placebo/no adjunctive treatment + antipsychotics</P>
</TD>
</TR>
<TR>
<TH ALIGN="LEFT" ROWSPAN="3" VALIGN="TOP">
<P>Outcomes</P>
</TH>
<TH ALIGN="LEFT" COLSPAN="2" VALIGN="TOP">
<P>Illustrative comparative risks* (95% CI)</P>
</TH>
<TH ALIGN="LEFT" ROWSPAN="3" VALIGN="TOP">
<P>Relative effect<BR/>(95% CI)</P>
</TH>
<TH ALIGN="LEFT" ROWSPAN="3" VALIGN="TOP">
<P>No of Participants<BR/>(studies)</P>
</TH>
<TH ALIGN="LEFT" ROWSPAN="3" VALIGN="TOP">
<P>Quality of the evidence<BR/>(GRADE)</P>
</TH>
<TH ALIGN="LEFT" ROWSPAN="3" VALIGN="TOP">
<P>Comments</P>
</TH>
</TR>
<TR>
<TH ALIGN="LEFT" VALIGN="TOP">
<P>Assumed risk</P>
</TH>
<TH ALIGN="LEFT" VALIGN="TOP">
<P>Corresponding risk</P>
</TH>
</TR>
<TR>
<TH ALIGN="LEFT" VALIGN="TOP">
<P>
<B>Placebo/no adjunctive treatment + antipsychotics</B>
</P>
</TH>
<TH ALIGN="LEFT" VALIGN="TOP">
<P>
<B>Adjunctive Carbamazepine + antipsychotics</B>
</P>
</TH>
</TR>
<TR>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>
<B>Acceptability of treatment</B>
<BR/>Leaving the study early due to any reason<BR/>Follow-up: mean 7.7 weeks</P>
</TD>
<TD ROWSPAN="1" VALIGN="TOP">
<P>
<B>108 per 1000</B>
</P>
</TD>
<TD ROWSPAN="1" VALIGN="TOP">
<P>
<B>51 per 1000</B>
<BR/>(17 to 145)</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>
<B>RR 0.47 </B>
<BR/>(0.16 to 1.35)</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>182<BR/>(8 studies)</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>&#8853;&#8861;&#8861;&#8861;<BR/>
<B>very low</B>
<SUP>1,2,3</SUP>
</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P/>
</TD>
</TR>
<TR>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>
<B>No clinically important change in general mental state</B>
<BR/>Scale used: less than 50% BPRS reduction<BR/>Follow-up: mean 6.1 weeks</P>
</TD>
<TD ROWSPAN="1" VALIGN="TOP">
<P>
<B>623 per 1000</B>
</P>
</TD>
<TD ROWSPAN="1" VALIGN="TOP">
<P>
<B>536 per 1000</B>
<BR/>(418 to 698)</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>
<B>RR 0.86 </B>
<BR/>(0.67 to 1.12)</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>147<BR/>(6 studies)</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>&#8853;&#8853;&#8861;&#8861;<BR/>
<B>low</B>
<SUP>1,4</SUP>
</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P/>
</TD>
</TR>
<TR>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>
<B>Average endpoint general mental state score</B>
<BR/>Scale used: Average BPRS endpoint score. Scale from: 0 to 108.<BR/>Follow-up: mean 5.7 weeks</P>
</TD>
<TD ROWSPAN="1" VALIGN="TOP">
<P>The mean global mental state in the control groups was<BR/>
<B>BPRS total score points</B>
</P>
</TD>
<TD ROWSPAN="1" VALIGN="TOP">
<P>The mean global mental state in the intervention groups was<BR/>
<B>0.3 higher</B>
<BR/>(12.49 lower to 13.09 higher)</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P/>
</TD>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>79<BR/>(3 studies)</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>&#8853;&#8853;&#8861;&#8861;<BR/>
<B>low</B>
<SUP>5,6</SUP>
</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P/>
</TD>
</TR>
<TR>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>
<B>Average endpoint positive symptom score</B>
</P>
<P>Scale used: Mean PANSS positive subscore at endpoint. Scale from: 7 to 49.<BR/>Follow-up: mean 4 weeks</P>
</TD>
<TD ROWSPAN="1" VALIGN="TOP">
<P>The mean positive symptoms in the control groups was<BR/>
<B>PANSS positive subscore</B>
</P>
</TD>
<TD ROWSPAN="1" VALIGN="TOP">
<P>The mean positive symptoms in the intervention groups was<BR/>
<B>4.22 higher</B>
<BR/>(0.75 to 7.69 higher)</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P/>
</TD>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>18<BR/>(1 study)</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>&#8853;&#8853;&#8853;&#8861;<BR/>
<B>moderate</B>
<SUP>6</SUP>
</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P/>
</TD>
</TR>
<TR>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>
<B>Average endpoint depressive symptom score</B>
<BR/>Scale used: Hamilton scale at endpoint. Scale from: 0 to 54.<BR/>Follow-up: mean 5 weeks</P>
</TD>
<TD ROWSPAN="1" VALIGN="TOP">
<P>The mean depression in the control groups was<BR/>
<B>Hamilton scale at endpoint</B>
</P>
</TD>
<TD ROWSPAN="1" VALIGN="TOP">
<P>The mean depression in the intervention groups was<BR/>
<B>0.35 lower</B>
<BR/>(2.2 lower to 1.5 higher)</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P/>
</TD>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>26<BR/>(1 study)</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>&#8853;&#8853;&#8861;&#8861;<BR/>
<B>low</B>
<SUP>6</SUP>
</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P/>
</TD>
</TR>
<TR>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>
<B>Aggression</B>
</P>
</TD>
<TD ROWSPAN="1" VALIGN="TOP">
<P>See comment</P>
</TD>
<TD ROWSPAN="1" VALIGN="TOP">
<P>See comment</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>Not estimable</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>0<BR/>(0)</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>See comment</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P/>
</TD>
</TR>
<TR>
<TD COLSPAN="7">
<P>*The basis for the <B>assumed risk</B> (e.g. the median control group risk across studies) is provided in footnotes. The <B>corresponding risk</B> (and its 95% confidence interval) is based on the assumed risk in the comparison group and the <B>relative effect</B> of the intervention (and its 95% CI).<BR/>
<B>CI:</B> Confidence interval; <B>RR:</B> Risk ratio;</P>
</TD>
</TR>
<TR>
<TD COLSPAN="7">
<P>GRADE Working Group grades of evidence<BR/>
<B>High quality:</B> Further research is very unlikely to change our confidence in the estimate of effect.<BR/>
<B>Moderate quality:</B> Further research is likely to have an important impact on our confidence in the estimate of effect and may change the estimate.<BR/>
<B>Low quality:</B> Further research is very likely to have an important impact on our confidence in the estimate of effect and is likely to change the estimate.<BR/>
<B>Very low quality:</B> We are very uncertain about the estimate.<BR/>
</P>
</TD>
</TR>
</TABLE>
<FOOTNOTES>
<P>
<SUP>1</SUP> Risk of bias: reporting bias is especially prevalent in this study pool with high risk being a problem in a majority of reports.<BR/>
<SUP>2</SUP> Inconsistency: differences between studies (number of events, effects size sometimes in favour of carbamazepine sometimes in favour of no treatment).<BR/>
<SUP>3</SUP> Indirectness: acceptability was measured by the number of participants leaving the studies for any reason which is an indirect measure of acceptability.<BR/>
<SUP>4</SUP> Imprecision: 95% confidence interval includes both benefit and harm. Moreover, the number of events was small.<BR/>
<SUP>5</SUP> Inconsistency: high heterogeneity of trial results<BR/>
<SUP>6</SUP> Imprecision: very small population size.</P>
</FOOTNOTES>
</SOF_TABLE>
</SOF_TABLES>
<ADDITIONAL_TABLES MODIFIED="2014-01-21 11:28:10 +0000" MODIFIED_BY="[Empty name]">
<ADDITIONAL_TABLE ID="TBL-01" MODIFIED="2013-09-16 17:10:06 +0100" MODIFIED_BY="[Empty name]" NO="1">
<TITLE MODIFIED="2013-05-16 10:36:34 +0100" MODIFIED_BY="[Empty name]">Reviews or additional comparisons</TITLE>
<TABLE COLS="3" ROWS="12">
<TR>
<TH>
<P>Category</P>
</TH>
<TH>
<P>Title</P>
</TH>
<TH>
<P>Excluded study</P>
</TH>
</TR>
<TR>
<TD ROWSPAN="5">
<P>
<B>Additional comparison</B>
</P>
</TD>
<TD>
<P>Carbamazepine (+/- antipsychotics) versus lithium (+/- antipsychotics)<B> </B>
</P>
</TD>
<TD>
<P>
<LINK REF="STD-Bellaire-1990" TYPE="STUDY">Bellaire 1990</LINK>, <LINK REF="STD-Greil-1997" TYPE="STUDY">Greil 1997</LINK>, <LINK REF="STD-Kahn-1990" TYPE="STUDY">Kahn 1990</LINK>, <LINK REF="STD-Lenzi-1986" TYPE="STUDY">Lenzi 1986</LINK>, <LINK REF="STD-Placidi-1986" TYPE="STUDY">Placidi 1986</LINK>, <LINK REF="STD-Schulz-1990" TYPE="STUDY">Schulz 1990</LINK>
</P>
</TD>
</TR>
<TR>
<TD>
<P>Carbamazepine plus one antipsychotic versus another antipsychotic</P>
</TD>
<TD>
<P>
<LINK REF="STD-Ohlmeier-2007" TYPE="STUDY">Ohlmeier 2007</LINK>
</P>
</TD>
</TR>
<TR>
<TD>
<P>Carbamazepine versus valproate</P>
</TD>
<TD>
<P>
<LINK REF="STD-Mosca-1998" TYPE="STUDY">Mosca 1998</LINK>
</P>
</TD>
</TR>
<TR>
<TD>
<P>Different formulations of carbamazepine</P>
</TD>
<TD>
<P>
<LINK REF="STD-Nijdam-1992" TYPE="STUDY">Nijdam 1992</LINK>
</P>
</TD>
</TR>
<TR>
<TD>
<P>Oxcarbazepine versus lithium</P>
</TD>
<TD>
<P>
<LINK REF="STD-Cabrera-1987" TYPE="STUDY">Cabrera 1987</LINK>
</P>
</TD>
</TR>
<TR>
<TD>
<P>
<B>Existing review*</B>
</P>
</TD>
<TD>
<P>Clozapine versus typical antipsychotics</P>
</TD>
<TD>
<P>
<LINK REF="STD-Covell-2004" TYPE="STUDY">Covell 2004</LINK>
</P>
</TD>
</TR>
<TR>
<TD ROWSPAN="5">
<P>
<B>New review</B>
</P>
</TD>
<TD>
<P>Adrenochrome semicarbazone for schizophrenia</P>
</TD>
<TD>
<P>
<LINK REF="STD-Sugerman-1970" TYPE="STUDY">Sugerman 1970</LINK>
</P>
</TD>
</TR>
<TR>
<TD>
<P>Hydroxyphenamate for schizophrenia</P>
</TD>
<TD>
<P>
<LINK REF="STD-Miller-1965" TYPE="STUDY">Miller 1965</LINK>
</P>
</TD>
</TR>
<TR>
<TD>
<P>Rimcazole for schizophrenia</P>
</TD>
<TD>
<P>
<LINK REF="STD-Borison-1991" TYPE="STUDY">Borison 1991</LINK>, <LINK REF="STD-Munetz-1989" TYPE="STUDY">Munetz 1989</LINK>
</P>
</TD>
</TR>
<TR>
<TD>
<P>Tybamate for schizophrenia</P>
</TD>
<TD>
<P>
<LINK REF="STD-Meshel-1967" TYPE="STUDY">Meshel 1967</LINK>, <LINK REF="STD-Meshel-1968" TYPE="STUDY">Meshel 1968</LINK>
</P>
</TD>
</TR>
<TR>
<TD>
<P>Vitamin B6 for schizophrenia</P>
</TD>
<TD>
<P>
<LINK REF="STD-Miodownik-2003" TYPE="STUDY">Miodownik 2003</LINK>
</P>
</TD>
</TR>
</TABLE>
<FOOTNOTES>
<P>* <LINK REF="REF-Essali-2009" TYPE="REFERENCE">Essali 2009</LINK>
</P>
</FOOTNOTES>
</ADDITIONAL_TABLE>
<ADDITIONAL_TABLE ID="TBL-02" MODIFIED="2014-01-21 11:28:10 +0000" MODIFIED_BY="[Empty name]" NO="2">
<TITLE MODIFIED="2013-05-15 21:15:40 +0100" MODIFIED_BY="[Empty name]">Suggested design for future study</TITLE>
<TABLE COLS="2" ROWS="5">
<TR>
<TH>
<P>Methods</P>
</TH>
<TD>
<P>Allocation: random.<BR/>Blinding: blind or independent raters.<BR/>Duration: minimum one year follow-up.</P>
</TD>
</TR>
<TR>
<TH>
<P>Participants</P>
</TH>
<TD>
<P>Diagnosis: people with schizophrenia whose illness is resistant to treatment; people with psychoses and EEG abnormalities; people with psychoses and aggressive behaviour; and people with schizoaffective disorders.<BR/>Age: Sex: male and female.<BR/>N = 750.</P>
</TD>
</TR>
<TR>
<TH>
<P>Interventions</P>
</TH>
<TD>
<P>1. Carbamazepine/oxcarbazepine alone: any dose.<BR/>2. Placebo (or no intervention).<BR/>3. Carbamazepine/oxcarbazepine in combination with any antipsychotic treatment: any dose.<BR/>4. Placebo (or no intervention) in combination with any antipsychotic treatment.<BR/>5. Antipsychotics alone: any dose.</P>
</TD>
</TR>
<TR>
<TH>
<P>Outcomes</P>
</TH>
<TD>
<P>Leaving the study early.</P>
<P>Service utilisation.</P>
<P>Global state - no clinically important change.*</P>
<P>Relapse.</P>
<P>Mental state - no clinically important change.</P>
<P>Behaviour - no clinically important change.</P>
<P>Social functioning - no clinically important change.<BR/>Adverse effects - clinically important general adverse effects*; sudden and unexpected death.</P>
<P>Economic outcomes.</P>
<P>Satisfaction with treatment.</P>
<P>Quality of life.</P>
<P>Pharmacokinetic interactions.<BR/>
<BR/>All outcomes by time - short term (up to 12 weeks), medium term (13 to 26 weeks) and long term (over 26 weeks).</P>
</TD>
</TR>
<TR>
<TH>
<P>Notes</P>
</TH>
<TD>
<P>*Primary outcomes of interest.<BR/>
</P>
</TD>
</TR>
</TABLE>
<FOOTNOTES/>
</ADDITIONAL_TABLE>
</ADDITIONAL_TABLES>
<ANALYSES_AND_DATA CALCULATED_DATA="YES" MODIFIED="2014-01-28 11:16:32 +0000" MODIFIED_BY="[Empty name]">
<COMPARISON ID="CMP-001" NO="1">
<NAME>CARBAMAZEPINE AS SOLE TREATMENT vs PLACEBO AS SOLE TREATMENT</NAME>
<DICH_OUTCOME CHI2="0.0" CI_END="6.642886317962055" CI_START="0.1712776229063682" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="RR" EFFECT_SIZE="1.0666666666666667" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="2" I2="0.0" I2_Q="0.0" ID="CMP-001.01" LOG_CI_END="0.8223568202717129" LOG_CI_START="-0.766299373071226" LOG_EFFECT_SIZE="0.028028723600243534" METHOD="MH" NO="1" P_CHI2="1.0" P_Q="1.0" P_Z="0.9448627055072608" Q="0.0" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="15" TOTAL_2="16" WEIGHT="100.0" Z="0.06915944308064198">
<NAME>Leaving the study early</NAME>
<GROUP_LABEL_1>Treatment</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours Treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours Control</GRAPH_LABEL_2>
<DICH_DATA CI_END="6.642886317962055" CI_START="0.1712776229063682" EFFECT_SIZE="1.0666666666666667" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="2" LOG_CI_END="0.8223568202717129" LOG_CI_START="-0.766299373071226" LOG_EFFECT_SIZE="0.028028723600243534" ORDER="734" O_E="0.0" SE="0.9331845119446279" STUDY_ID="STD-Carpenter-1991" TOTAL_1="15" TOTAL_2="16" VAR="0.8708333333333333" WEIGHT="100.0"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="1.4512759086958997" CI_START="0.7839844725322921" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="RR" EFFECT_SIZE="1.0666666666666667" ESTIMABLE="YES" EVENTS_1="13" EVENTS_2="13" I2="0.0" I2_Q="0.0" ID="CMP-001.02" LOG_CI_END="0.16174998599605286" LOG_CI_START="-0.10569253879556577" LOG_EFFECT_SIZE="0.028028723600243534" METHOD="MH" NO="2" P_CHI2="1.0" P_Q="1.0" P_Z="0.6812049678060865" Q="0.0" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="15" TOTAL_2="16" WEIGHT="100.0" Z="0.41081940003302564">
<NAME>Relapse (by 3 months)</NAME>
<GROUP_LABEL_1>Treatment</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours Treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours Control</GRAPH_LABEL_2>
<DICH_DATA CI_END="1.4512759086958997" CI_START="0.783984472532292" EFFECT_SIZE="1.0666666666666667" ESTIMABLE="YES" EVENTS_1="13" EVENTS_2="13" LOG_CI_END="0.16174998599605286" LOG_CI_START="-0.10569253879556582" LOG_EFFECT_SIZE="0.028028723600243534" ORDER="735" O_E="0.0" SE="0.1570970629244455" STUDY_ID="STD-Carpenter-1991" TOTAL_1="15" TOTAL_2="16" VAR="0.02467948717948719" WEIGHT="100.0"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="1.2994029486346006" CI_START="0.7549952729683251" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="RR" EFFECT_SIZE="0.9904761904761905" ESTIMABLE="YES" EVENTS_1="13" EVENTS_2="14" I2="0.0" I2_Q="0.0" ID="CMP-001.03" LOG_CI_END="0.11374384794134251" LOG_CI_START="-0.12205576748365791" LOG_EFFECT_SIZE="-0.0041559597711577035" METHOD="MH" NO="3" P_CHI2="1.0" P_Q="1.0" P_Z="0.9449191032109446" Q="0.0" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="15" TOTAL_2="16" WEIGHT="100.0" Z="0.06908858997064166">
<NAME>Mental state: 1. Less than 20% BPRS reduction</NAME>
<GROUP_LABEL_1>Treatment</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours Treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours Control</GRAPH_LABEL_2>
<DICH_DATA CI_END="1.2994029486346006" CI_START="0.7549952729683251" EFFECT_SIZE="0.9904761904761905" ESTIMABLE="YES" EVENTS_1="13" EVENTS_2="14" LOG_CI_END="0.11374384794134251" LOG_CI_START="-0.12205576748365791" LOG_EFFECT_SIZE="-0.0041559597711577035" ORDER="736" O_E="0.0" SE="0.13850986132756643" STUDY_ID="STD-Carpenter-1991" TOTAL_1="15" TOTAL_2="16" VAR="0.019184981684981686" WEIGHT="100.0"/>
</DICH_OUTCOME>
<CONT_OUTCOME CHI2="0.0" CI_END="0.3181835892601288" CI_START="-0.4581835892601289" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="MD" EFFECT_SIZE="-0.07000000000000006" ESTIMABLE="YES" I2="0.0" I2_Q="0.0" ID="CMP-001.04" NO="4" P_CHI2="1.0" P_Q="1.0" P_Z="0.7237627141558094" Q="0.0" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="YES" TAU2="0.0" TOTALS="YES" TOTAL_1="13" TOTAL_2="14" UNITS="" WEIGHT="100.0" Z="0.3534345158158281">
<NAME>Mental state: 2. Average endpoint score of the BPRS at 3 months</NAME>
<GROUP_LABEL_1>Treatment</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours Treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours Control</GRAPH_LABEL_2>
<CONT_DATA CI_END="0.3181835892601288" CI_START="-0.4581835892601289" EFFECT_SIZE="-0.07000000000000006" ESTIMABLE="YES" MEAN_1="1.93" MEAN_2="2.0" ORDER="737" SD_1="0.36" SD_2="0.64" SE="0.1980564909978303" STUDY_ID="STD-Carpenter-1991" TOTAL_1="13" TOTAL_2="14" WEIGHT="100.0"/>
</CONT_OUTCOME>
<DICH_OUTCOME CHI2="0.1548250966238217" CI_END="43.039742679663156" CI_START="0.6557347812243215" CI_STUDY="95" CI_TOTAL="95" DF="1" EFFECT_MEASURE="RR" EFFECT_SIZE="5.3125" ESTIMABLE="YES" EVENTS_1="4" EVENTS_2="0" I2="0.0" I2_Q="0.0" ID="CMP-001.05" LOG_CI_END="1.633869666163527" LOG_CI_START="-0.18327178004679093" LOG_EFFECT_SIZE="0.725298943058368" METHOD="MH" NO="5" P_CHI2="0.6939664987091898" P_Q="0.696222268318897" P_Z="0.11767413289526939" Q="0.15243189539833385" RANDOM="NO" SCALE="1000.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="YES" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="SUB" TOTAL_1="30" TOTAL_2="32" WEIGHT="200.0" Z="1.5646110646852045">
<NAME>Adverse effects</NAME>
<GROUP_LABEL_1>Treatment</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours Treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours Control</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="0.0" CI_END="132.95463996948232" CI_START="0.41605472560188184" DF="0" EFFECT_SIZE="7.4375" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="0" I2="0.0" ID="CMP-001.05.01" LOG_CI_END="2.123703498327829" LOG_CI_START="-0.3808495408546176" LOG_EFFECT_SIZE="0.871426978736606" NO="1" P_CHI2="1.0" P_Z="0.17260267343899235" STUDIES="1" TAU2="0.0" TOTAL_1="15" TOTAL_2="16" WEIGHT="100.0" Z="1.3638884597451566">
<NAME>allergic reactions</NAME>
<DICH_DATA CI_END="132.95463996948232" CI_START="0.41605472560188184" EFFECT_SIZE="7.4375" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="0" LOG_CI_END="2.123703498327829" LOG_CI_START="-0.3808495408546176" LOG_EFFECT_SIZE="0.871426978736606" ORDER="738" O_E="0.0" SE="1.4711868529532615" STUDY_ID="STD-Carpenter-1991" TOTAL_1="15" TOTAL_2="16" VAR="2.164390756302521" WEIGHT="100.0"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="72.6889396455693" CI_START="0.1397758214597825" DF="0" EFFECT_SIZE="3.1875" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="0" I2="0.0" ID="CMP-001.05.02" LOG_CI_END="1.8614683336055944" LOG_CI_START="-0.8545679467215712" LOG_EFFECT_SIZE="0.5034501934420116" NO="2" P_CHI2="1.0" P_Z="0.4674673036900284" STUDIES="1" TAU2="0.0" TOTAL_1="15" TOTAL_2="16" WEIGHT="100.0" Z="0.72660608718909">
<NAME>blood dyscrasia</NAME>
<DICH_DATA CI_END="72.6889396455693" CI_START="0.1397758214597825" EFFECT_SIZE="3.1875" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="0" LOG_CI_END="1.8614683336055944" LOG_CI_START="-0.8545679467215712" LOG_EFFECT_SIZE="0.5034501934420116" ORDER="739" O_E="0.0" SE="1.5954131556605964" STUDY_ID="STD-Carpenter-1991" TOTAL_1="15" TOTAL_2="16" VAR="2.545343137254902" WEIGHT="100.0"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
</COMPARISON>
<COMPARISON ID="CMP-002" NO="2">
<NAME>CARBAMAZEPINE AS SOLE TREATMENT vs ANTIPSYCHOTICS AS SOLE TREATMENT</NAME>
<DICH_OUTCOME CHI2="0.0" CI_END="88.37817528633498" CI_START="0.23156002645908913" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="RR" EFFECT_SIZE="4.523809523809524" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="0" I2="0.0" I2_Q="0.0" ID="CMP-002.01" LOG_CI_END="1.9463450305906491" LOG_CI_START="-0.6353364094807923" LOG_EFFECT_SIZE="0.6555043105549285" METHOD="MH" NO="1" P_CHI2="1.0" P_Q="1.0" P_Z="0.31959375399625456" Q="0.0" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="20" TOTAL_2="18" WEIGHT="100.0" Z="0.9952930833812448">
<NAME>Leaving the study early</NAME>
<GROUP_LABEL_1>Treatment</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours Treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours Control</GRAPH_LABEL_2>
<DICH_DATA CI_END="88.37817528633498" CI_START="0.23156002645908913" EFFECT_SIZE="4.523809523809524" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="0" LOG_CI_END="1.9463450305906491" LOG_CI_START="-0.6353364094807923" LOG_EFFECT_SIZE="0.6555043105549285" ORDER="740" O_E="0.0" SE="1.5164924574271987" STUDY_ID="STD-Svestka-1989" TOTAL_1="20" TOTAL_2="18" VAR="2.299749373433584" WEIGHT="100.0"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.6059011095677028" CI_END="1.9219773466096137" CI_START="0.9736972203658952" CI_STUDY="95" CI_TOTAL="95" DF="2" EFFECT_MEASURE="RR" EFFECT_SIZE="1.3679999999999999" ESTIMABLE="YES" EVENTS_1="38" EVENTS_2="25" I2="0.0" I2_Q="0.0" ID="CMP-002.02" LOG_CI_END="0.28374826454978974" LOG_CI_START="-0.011576069781594972" LOG_EFFECT_SIZE="0.13608609738409738" METHOD="MH" NO="2" P_CHI2="0.7386356531345997" P_Q="0.7451147619266539" P_Z="0.07086971872885248" Q="0.5884341378328991" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="YES" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="SUB" TOTAL_1="60" TOTAL_2="54" WEIGHT="300.0" Z="1.8063113578046663">
<NAME>Mental state: 1. Categories of reduction on BPRS scores</NAME>
<GROUP_LABEL_1>Treatment</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="0.0" CI_END="2.657973440060904" CI_START="0.6219254111327458" DF="0" EFFECT_SIZE="1.2857142857142858" ESTIMABLE="YES" EVENTS_1="10" EVENTS_2="7" I2="0.0" ID="CMP-002.02.01" LOG_CI_END="0.4245506369179923" LOG_CI_START="-0.2062616980678561" LOG_EFFECT_SIZE="0.10914446942506807" NO="1" P_CHI2="1.0" P_Z="0.4976232570790735" STUDIES="1" TAU2="0.0" TOTAL_1="20" TOTAL_2="18" WEIGHT="100.0" Z="0.6782341350051934">
<NAME>less than 20% reduction</NAME>
<DICH_DATA CI_END="2.657973440060904" CI_START="0.6219254111327458" EFFECT_SIZE="1.2857142857142858" ESTIMABLE="YES" EVENTS_1="10" EVENTS_2="7" LOG_CI_END="0.4245506369179923" LOG_CI_START="-0.2062616980678561" LOG_EFFECT_SIZE="0.10914446942506807" ORDER="741" O_E="0.0" SE="0.3705422881421057" STUDY_ID="STD-Svestka-1989" TOTAL_1="20" TOTAL_2="18" VAR="0.13730158730158729" WEIGHT="100.0"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="3.241675921758853" CI_START="0.8617991239148844" DF="0" EFFECT_SIZE="1.6714285714285715" ESTIMABLE="YES" EVENTS_1="13" EVENTS_2="7" I2="0.0" ID="CMP-002.02.02" LOG_CI_END="0.5107695952049913" LOG_CI_START="-0.06459395174118174" LOG_EFFECT_SIZE="0.22308782173190483" NO="2" P_CHI2="1.0" P_Z="0.1285391088527622" STUDIES="1" TAU2="0.0" TOTAL_1="20" TOTAL_2="18" WEIGHT="100.0" Z="1.519888071827849">
<NAME>less than 35% reduction</NAME>
<DICH_DATA CI_END="3.241675921758853" CI_START="0.8617991239148844" EFFECT_SIZE="1.6714285714285715" ESTIMABLE="YES" EVENTS_1="13" EVENTS_2="7" LOG_CI_END="0.5107695952049913" LOG_CI_START="-0.06459395174118174" LOG_EFFECT_SIZE="0.22308782173190483" ORDER="742" O_E="0.0" SE="0.33797139557167294" STUDY_ID="STD-Svestka-1989" TOTAL_1="20" TOTAL_2="18" VAR="0.11422466422466424" WEIGHT="100.0"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="1.9190336966494392" CI_START="0.7848733191799622" DF="0" EFFECT_SIZE="1.2272727272727273" ESTIMABLE="YES" EVENTS_1="15" EVENTS_2="11" I2="0.0" ID="CMP-002.02.03" LOG_CI_END="0.28308260065544366" LOG_CI_START="-0.1052004339818815" LOG_EFFECT_SIZE="0.08894108333678108" NO="3" P_CHI2="1.0" P_Z="0.3692343385937885" STUDIES="1" TAU2="0.0" TOTAL_1="20" TOTAL_2="18" WEIGHT="100.00000000000001" Z="0.8979085076374294">
<NAME>less than 50% reduction</NAME>
<DICH_DATA CI_END="1.9190336966494397" CI_START="0.7848733191799621" EFFECT_SIZE="1.2272727272727273" ESTIMABLE="YES" EVENTS_1="15" EVENTS_2="11" LOG_CI_END="0.2830826006554438" LOG_CI_START="-0.10520043398188156" LOG_EFFECT_SIZE="0.08894108333678108" ORDER="743" O_E="0.0" SE="0.22807937657798444" STUDY_ID="STD-Svestka-1989" TOTAL_1="20" TOTAL_2="18" VAR="0.052020202020202036" WEIGHT="100.00000000000001"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<CONT_OUTCOME CHI2="0.0" CI_END="8.436509899557723" CI_START="-3.836509899557714" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="MD" EFFECT_SIZE="2.3000000000000043" ESTIMABLE="YES" I2="0.0" I2_Q="0.0" ID="CMP-002.03" NO="3" P_CHI2="1.0" P_Q="1.0" P_Z="0.4625794712905863" Q="0.0" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="YES" TAU2="0.0" TOTALS="YES" TOTAL_1="20" TOTAL_2="18" UNITS="" WEIGHT="100.0" Z="0.7346060282192385">
<NAME>Mental state: 2. Mean BPRS at endpoint</NAME>
<GROUP_LABEL_1>Treatment</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours Treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours Control</GRAPH_LABEL_2>
<CONT_DATA CI_END="8.436509899557723" CI_START="-3.836509899557714" EFFECT_SIZE="2.3000000000000043" ESTIMABLE="YES" MEAN_1="36.7" MEAN_2="34.4" ORDER="744" SD_1="10.1" SD_2="9.2" SE="3.130929929305704" STUDY_ID="STD-Svestka-1989" TOTAL_1="20" TOTAL_2="18" WEIGHT="100.0"/>
</CONT_OUTCOME>
<DICH_OUTCOME CHI2="2.8914107521654353" CI_END="0.29727281083296925" CI_START="0.05887030912190453" CI_STUDY="95" CI_TOTAL="95" DF="3" EFFECT_MEASURE="RR" EFFECT_SIZE="0.13228961511499815" ESTIMABLE="YES" EVENTS_1="4" EVENTS_2="36" I2="0.0" I2_Q="0.0" ID="CMP-002.04" LOG_CI_END="-0.5268448104223378" LOG_CI_START="-1.2301036837464363" LOG_EFFECT_SIZE="-0.878474247084387" METHOD="MH" NO="4" P_CHI2="0.4086724195195718" P_Q="0.5326554557714347" P_Z="9.752429219796819E-7" Q="2.1964123452519493" RANDOM="NO" SCALE="1000.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="YES" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="SUB" TOTAL_1="80" TOTAL_2="72" WEIGHT="400.0" Z="4.896569246237877">
<NAME>Adverse effects: 1. Movement disorders</NAME>
<GROUP_LABEL_1>Treatment</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="0.0" CI_END="2.343118297038127" CI_START="0.007129815916618582" DF="0" EFFECT_SIZE="0.1292517006802721" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="3" I2="0.0" ID="CMP-002.04.01" LOG_CI_END="0.3697942153805557" LOG_CI_START="-2.1469216829712496" LOG_EFFECT_SIZE="-0.8885637337953471" NO="1" P_CHI2="1.0" P_Z="0.16636197955140905" STUDIES="1" TAU2="0.0" TOTAL_1="20" TOTAL_2="18" WEIGHT="100.0" Z="1.3839884886076">
<NAME>akathisia</NAME>
<DICH_DATA CI_END="2.343118297038126" CI_START="0.007129815916618582" EFFECT_SIZE="0.1292517006802721" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="3" LOG_CI_END="0.3697942153805555" LOG_CI_START="-2.1469216829712496" LOG_EFFECT_SIZE="-0.8885637337953471" ORDER="745" O_E="0.0" SE="1.4783313766364663" STUDY_ID="STD-Svestka-1989" TOTAL_1="20" TOTAL_2="18" VAR="2.1854636591478696" WEIGHT="100.0"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="0.426393498490197" CI_START="0.001762910070270019" DF="0" EFFECT_SIZE="0.027417027417027416" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="16" I2="0.0" ID="CMP-002.04.02" LOG_CI_END="-0.37018942591243587" LOG_CI_START="-2.75376984140552" LOG_EFFECT_SIZE="-1.5619796336589777" NO="2" P_CHI2="1.0" P_Z="0.010206291533009528" STUDIES="1" TAU2="0.0" TOTAL_1="20" TOTAL_2="18" WEIGHT="100.0" Z="2.5687606817522513">
<NAME>parkinsonism</NAME>
<DICH_DATA CI_END="0.426393498490197" CI_START="0.001762910070270019" EFFECT_SIZE="0.027417027417027416" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="16" LOG_CI_END="-0.37018942591243587" LOG_CI_START="-2.75376984140552" LOG_EFFECT_SIZE="-1.5619796336589777" ORDER="746" O_E="0.0" SE="1.4001269349739847" STUDY_ID="STD-Svestka-1989" TOTAL_1="20" TOTAL_2="18" VAR="1.9603554340396447" WEIGHT="100.0"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="6.966924792831061" CI_START="0.013055243623743749" DF="0" EFFECT_SIZE="0.30158730158730157" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="1" I2="0.0" ID="CMP-002.04.03" LOG_CI_END="0.8430411223998254" LOG_CI_START="-1.8842150194013312" LOG_EFFECT_SIZE="-0.5205869485007528" NO="3" P_CHI2="1.0" P_Z="0.45431072503614434" STUDIES="1" TAU2="0.0" TOTAL_1="20" TOTAL_2="18" WEIGHT="100.0" Z="0.7482477749297343">
<NAME>tremor</NAME>
<DICH_DATA CI_END="6.966924792831061" CI_START="0.013055243623743749" EFFECT_SIZE="0.30158730158730157" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="1" LOG_CI_END="0.8430411223998254" LOG_CI_START="-1.8842150194013312" LOG_EFFECT_SIZE="-0.5205869485007528" ORDER="747" O_E="0.0" SE="1.6020037578296284" STUDY_ID="STD-Svestka-1989" TOTAL_1="20" TOTAL_2="18" VAR="2.5664160401002505" WEIGHT="100.0"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="0.5487870598832632" CI_START="0.09224889524685376" DF="0" EFFECT_SIZE="0.225" ESTIMABLE="YES" EVENTS_1="4" EVENTS_2="16" I2="0.0" ID="CMP-002.04.04" LOG_CI_END="-0.26059613762118394" LOG_CI_START="-1.035038826156091" LOG_EFFECT_SIZE="-0.6478174818886375" NO="4" P_CHI2="1.0" P_Z="0.0010417549748041532" STUDIES="1" TAU2="0.0" TOTAL_1="20" TOTAL_2="18" WEIGHT="100.0" Z="3.2790003749901198">
<NAME>use of anticholinergic drugs</NAME>
<DICH_DATA CI_END="0.5487870598832632" CI_START="0.09224889524685376" EFFECT_SIZE="0.225" ESTIMABLE="YES" EVENTS_1="4" EVENTS_2="16" LOG_CI_END="-0.26059613762118394" LOG_CI_START="-1.035038826156091" LOG_EFFECT_SIZE="-0.6478174818886375" ORDER="748" O_E="0.0" SE="0.4549114687985394" STUDY_ID="STD-Svestka-1989" TOTAL_1="20" TOTAL_2="18" VAR="0.20694444444444446" WEIGHT="100.0"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="7.426639229214545" CI_END="1.9115063527776093" CI_START="0.5826048898384644" CI_STUDY="95" CI_TOTAL="95" DF="8" EFFECT_MEASURE="RR" EFFECT_SIZE="1.0552975637636637" ESTIMABLE="YES" EVENTS_1="19" EVENTS_2="16" I2="0.0" I2_Q="0.0" ID="CMP-002.05" LOG_CI_END="0.281375745709311" LOG_CI_START="-0.23462587463291285" LOG_EFFECT_SIZE="0.02337493553819908" METHOD="MH" NO="5" P_CHI2="0.49137677533989266" P_Q="0.509941449954554" P_Z="0.8590581662934355" Q="7.249755798137575" RANDOM="NO" SCALE="1000.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="YES" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="SUB" TOTAL_1="180" TOTAL_2="162" WEIGHT="900.0" Z="0.17757320903539292">
<NAME>Adverse effects: 2. Others</NAME>
<GROUP_LABEL_1>Treatment</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="0.0" CI_END="4.5537318334993575" CI_START="0.04446902176151794" DF="0" EFFECT_SIZE="0.45" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="2" I2="0.0" ID="CMP-002.05.01" LOG_CI_END="0.6583674516940081" LOG_CI_START="-1.3519424241433209" LOG_EFFECT_SIZE="-0.3467874862246563" NO="1" P_CHI2="1.0" P_Z="0.4989103839008485" STUDIES="1" TAU2="0.0" TOTAL_1="20" TOTAL_2="18" WEIGHT="100.0" Z="0.6762051875275232">
<NAME>blurred vision</NAME>
<DICH_DATA CI_END="4.5537318334993575" CI_START="0.04446902176151794" EFFECT_SIZE="0.45" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="2" LOG_CI_END="0.6583674516940081" LOG_CI_START="-1.3519424241433209" LOG_EFFECT_SIZE="-0.3467874862246563" ORDER="749" O_E="0.0" SE="1.1808659722612234" STUDY_ID="STD-Svestka-1989" TOTAL_1="20" TOTAL_2="18" VAR="1.3944444444444444" WEIGHT="100.0"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="2.6320629231214827" CI_START="0.034193711407653156" DF="0" EFFECT_SIZE="0.3" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="3" I2="0.0" ID="CMP-002.05.02" LOG_CI_END="0.42029626747907384" LOG_CI_START="-1.4660537580397492" LOG_EFFECT_SIZE="-0.5228787452803376" NO="2" P_CHI2="1.0" P_Z="0.2772279208167625" STUDIES="1" TAU2="0.0" TOTAL_1="20" TOTAL_2="18" WEIGHT="100.0" Z="1.0865677050038332">
<NAME>collapse</NAME>
<DICH_DATA CI_END="2.6320629231214827" CI_START="0.034193711407653156" EFFECT_SIZE="0.3" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="3" LOG_CI_END="0.42029626747907384" LOG_CI_START="-1.4660537580397492" LOG_EFFECT_SIZE="-0.5228787452803376" ORDER="750" O_E="0.0" SE="1.1080513425729774" STUDY_ID="STD-Svestka-1989" TOTAL_1="20" TOTAL_2="18" VAR="1.2277777777777776" WEIGHT="100.0"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="4.5537318334993575" CI_START="0.04446902176151794" DF="0" EFFECT_SIZE="0.45" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="2" I2="0.0" ID="CMP-002.05.03" LOG_CI_END="0.6583674516940081" LOG_CI_START="-1.3519424241433209" LOG_EFFECT_SIZE="-0.3467874862246563" NO="3" P_CHI2="1.0" P_Z="0.4989103839008485" STUDIES="1" TAU2="0.0" TOTAL_1="20" TOTAL_2="18" WEIGHT="100.0" Z="0.6762051875275232">
<NAME>constipation</NAME>
<DICH_DATA CI_END="4.5537318334993575" CI_START="0.04446902176151794" EFFECT_SIZE="0.45" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="2" LOG_CI_END="0.6583674516940081" LOG_CI_START="-1.3519424241433209" LOG_EFFECT_SIZE="-0.3467874862246563" ORDER="751" O_E="0.0" SE="1.1808659722612234" STUDY_ID="STD-Svestka-1989" TOTAL_1="20" TOTAL_2="18" VAR="1.3944444444444444" WEIGHT="100.0"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="88.37817528633498" CI_START="0.23156002645908913" DF="0" EFFECT_SIZE="4.523809523809524" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="0" I2="0.0" ID="CMP-002.05.04" LOG_CI_END="1.9463450305906491" LOG_CI_START="-0.6353364094807923" LOG_EFFECT_SIZE="0.6555043105549285" NO="4" P_CHI2="1.0" P_Z="0.31959375399625456" STUDIES="1" TAU2="0.0" TOTAL_1="20" TOTAL_2="18" WEIGHT="100.0" Z="0.9952930833812448">
<NAME>dizziness</NAME>
<DICH_DATA CI_END="88.37817528633498" CI_START="0.23156002645908913" EFFECT_SIZE="4.523809523809524" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="0" LOG_CI_END="1.9463450305906491" LOG_CI_START="-0.6353364094807923" LOG_EFFECT_SIZE="0.6555043105549285" ORDER="752" O_E="0.0" SE="1.5164924574271987" STUDY_ID="STD-Svestka-1989" TOTAL_1="20" TOTAL_2="18" VAR="2.299749373433584" WEIGHT="100.0"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="4.5537318334993575" CI_START="0.04446902176151794" DF="0" EFFECT_SIZE="0.45" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="2" I2="0.0" ID="CMP-002.05.05" LOG_CI_END="0.6583674516940081" LOG_CI_START="-1.3519424241433209" LOG_EFFECT_SIZE="-0.3467874862246563" NO="5" P_CHI2="1.0" P_Z="0.4989103839008485" STUDIES="1" TAU2="0.0" TOTAL_1="20" TOTAL_2="18" WEIGHT="100.0" Z="0.6762051875275232">
<NAME>dry mouth</NAME>
<DICH_DATA CI_END="4.5537318334993575" CI_START="0.04446902176151794" EFFECT_SIZE="0.45" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="2" LOG_CI_END="0.6583674516940081" LOG_CI_START="-1.3519424241433209" LOG_EFFECT_SIZE="-0.3467874862246563" ORDER="753" O_E="0.0" SE="1.1808659722612234" STUDY_ID="STD-Svestka-1989" TOTAL_1="20" TOTAL_2="18" VAR="1.3944444444444444" WEIGHT="100.0"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="40.664794046300926" CI_START="0.7170822005590006" DF="0" EFFECT_SIZE="5.4" ESTIMABLE="YES" EVENTS_1="6" EVENTS_2="1" I2="0.0" ID="CMP-002.05.06" LOG_CI_END="1.60921857708418" LOG_CI_START="-0.14443105743824286" LOG_EFFECT_SIZE="0.7323937598229685" NO="6" P_CHI2="1.0" P_Z="0.1016058875684214" STUDIES="1" TAU2="0.0" TOTAL_1="20" TOTAL_2="18" WEIGHT="100.0" Z="1.6371176585063092">
<NAME>fatigue</NAME>
<DICH_DATA CI_END="40.664794046300926" CI_START="0.7170822005590006" EFFECT_SIZE="5.4" ESTIMABLE="YES" EVENTS_1="6" EVENTS_2="1" LOG_CI_END="1.60921857708418" LOG_CI_START="-0.14443105743824286" LOG_EFFECT_SIZE="0.7323937598229685" ORDER="754" O_E="0.0" SE="1.0301024760241628" STUDY_ID="STD-Svestka-1989" TOTAL_1="20" TOTAL_2="18" VAR="1.0611111111111111" WEIGHT="100.0"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="62.70232313547956" CI_START="0.11749719261369382" DF="0" EFFECT_SIZE="2.7142857142857144" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="0" I2="0.0" ID="CMP-002.05.07" LOG_CI_END="1.7972836318391503" LOG_CI_START="-0.929972509962006" LOG_EFFECT_SIZE="0.43365556093857216" NO="7" P_CHI2="1.0" P_Z="0.5330874473283729" STUDIES="1" TAU2="0.0" TOTAL_1="20" TOTAL_2="18" WEIGHT="100.0" Z="0.6232999299976173">
<NAME>nausia</NAME>
<DICH_DATA CI_END="62.70232313547956" CI_START="0.11749719261369382" EFFECT_SIZE="2.7142857142857144" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="0" LOG_CI_END="1.7972836318391503" LOG_CI_START="-0.929972509962006" LOG_EFFECT_SIZE="0.43365556093857216" ORDER="755" O_E="0.0" SE="1.6020037578296284" STUDY_ID="STD-Svestka-1989" TOTAL_1="20" TOTAL_2="18" VAR="2.5664160401002505" WEIGHT="100.0"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="62.70232313547956" CI_START="0.11749719261369382" DF="0" EFFECT_SIZE="2.7142857142857144" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="0" I2="0.0" ID="CMP-002.05.08" LOG_CI_END="1.7972836318391503" LOG_CI_START="-0.929972509962006" LOG_EFFECT_SIZE="0.43365556093857216" NO="8" P_CHI2="1.0" P_Z="0.5330874473283729" STUDIES="1" TAU2="0.0" TOTAL_1="20" TOTAL_2="18" WEIGHT="100.0" Z="0.6232999299976173">
<NAME>salivation</NAME>
<DICH_DATA CI_END="62.70232313547956" CI_START="0.11749719261369382" EFFECT_SIZE="2.7142857142857144" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="0" LOG_CI_END="1.7972836318391503" LOG_CI_START="-0.929972509962006" LOG_EFFECT_SIZE="0.43365556093857216" ORDER="756" O_E="0.0" SE="1.6020037578296284" STUDY_ID="STD-Svestka-1989" TOTAL_1="20" TOTAL_2="18" VAR="2.5664160401002505" WEIGHT="100.0"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="1.0621298757131307E-31" CI_END="2.041817941522334" CI_START="0.27548979199419343" DF="0" EFFECT_SIZE="0.7499999999999999" ESTIMABLE="YES" EVENTS_1="5" EVENTS_2="6" I2="100.0" ID="CMP-002.05.09" LOG_CI_END="0.31001701565631296" LOG_CI_START="-0.5598944888729129" LOG_EFFECT_SIZE="-0.12493873660830002" NO="9" P_CHI2="0.0" P_Z="0.5734421890848476" STUDIES="1" TAU2="0.0" TOTAL_1="20" TOTAL_2="18" WEIGHT="100.0" Z="0.5629892759234733">
<NAME>tachycardia</NAME>
<DICH_DATA CI_END="2.0418179415223343" CI_START="0.2754897919941933" EFFECT_SIZE="0.75" ESTIMABLE="YES" EVENTS_1="5" EVENTS_2="6" LOG_CI_END="0.31001701565631307" LOG_CI_START="-0.559894488872913" LOG_EFFECT_SIZE="-0.12493873660829995" ORDER="757" O_E="0.0" SE="0.5109903238918632" STUDY_ID="STD-Svestka-1989" TOTAL_1="20" TOTAL_2="18" VAR="0.2611111111111112" WEIGHT="100.0"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="3.970071207296972" CI_END="2.835220531455806" CI_START="1.392562083532519" CI_STUDY="95" CI_TOTAL="95" DF="2" EFFECT_MEASURE="RR" EFFECT_SIZE="1.987012987012987" ESTIMABLE="YES" EVENTS_1="27" EVENTS_2="21" I2="49.623069824943954" I2_Q="37.78872314712924" ID="CMP-002.06" LOG_CI_END="0.45258684519343967" LOG_CI_START="0.1438145660967942" LOG_EFFECT_SIZE="0.2982007056451169" METHOD="MH" NO="6" P_CHI2="0.13737591361592683" P_Q="0.20040300640995412" P_Z="1.5326438326978463E-4" Q="3.2148512314415054" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="YES" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="SUB" TOTAL_1="33" TOTAL_2="51" WEIGHT="300.0" Z="3.785719656821414">
<NAME>Subgroup analysis - schizoaffective disorder excluded - Mental state: Categories of reduction on BPRS score</NAME>
<GROUP_LABEL_1>Treatment</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="0.0" CI_END="7.835855334412469" CI_START="1.2192311624625978" DF="0" EFFECT_SIZE="3.090909090909091" ESTIMABLE="YES" EVENTS_1="8" EVENTS_2="4" I2="0.0" ID="CMP-002.06.01" LOG_CI_END="0.8940864094505263" LOG_CI_START="0.08608605431753379" LOG_EFFECT_SIZE="0.49008623188403005" NO="1" P_CHI2="1.0" P_Z="0.017425653971159364" STUDIES="1" TAU2="0.0" TOTAL_1="11" TOTAL_2="17" WEIGHT="100.0" Z="2.3776013406665966">
<NAME>less than 20% reduction</NAME>
<DICH_DATA CI_END="7.835855334412469" CI_START="1.2192311624625982" EFFECT_SIZE="3.090909090909091" ESTIMABLE="YES" EVENTS_1="8" EVENTS_2="4" LOG_CI_END="0.8940864094505263" LOG_CI_START="0.08608605431753395" LOG_EFFECT_SIZE="0.49008623188403005" ORDER="758" O_E="0.0" SE="0.47462340827138344" STUDY_ID="STD-Svestka-1989" TOTAL_1="11" TOTAL_2="17" VAR="0.22526737967914434" WEIGHT="100.0"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="4.6745125652984125" CI_START="1.1496315106825898" DF="0" EFFECT_SIZE="2.3181818181818183" ESTIMABLE="YES" EVENTS_1="9" EVENTS_2="6" I2="0.0" ID="CMP-002.06.02" LOG_CI_END="0.6697363315213067" LOG_CI_START="0.06055865903015373" LOG_EFFECT_SIZE="0.36514749527573015" NO="2" P_CHI2="1.0" P_Z="0.018791273153631275" STUDIES="1" TAU2="0.0" TOTAL_1="11" TOTAL_2="17" WEIGHT="100.0" Z="2.3496459969019448">
<NAME>less than 35% reduction</NAME>
<DICH_DATA CI_END="4.6745125652984125" CI_START="1.1496315106825896" EFFECT_SIZE="2.3181818181818183" ESTIMABLE="YES" EVENTS_1="9" EVENTS_2="6" LOG_CI_END="0.6697363315213067" LOG_CI_START="0.06055865903015364" LOG_EFFECT_SIZE="0.36514749527573015" ORDER="759" O_E="0.0" SE="0.3578339802994151" STUDY_ID="STD-Svestka-1989" TOTAL_1="11" TOTAL_2="17" VAR="0.1280451574569222" WEIGHT="100.0"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="2.091169572782688" CI_START="0.9439257876052604" DF="0" EFFECT_SIZE="1.4049586776859504" ESTIMABLE="YES" EVENTS_1="10" EVENTS_2="11" I2="0.0" ID="CMP-002.06.03" LOG_CI_END="0.3203892511523477" LOG_CI_START="-0.025062149028699965" LOG_EFFECT_SIZE="0.14766355106182386" NO="3" P_CHI2="1.0" P_Z="0.09382104126328515" STUDIES="1" TAU2="0.0" TOTAL_1="11" TOTAL_2="17" WEIGHT="100.0" Z="1.6755771825431098">
<NAME>less than 50% reduction</NAME>
<DICH_DATA CI_END="2.091169572782688" CI_START="0.9439257876052604" EFFECT_SIZE="1.4049586776859504" ESTIMABLE="YES" EVENTS_1="10" EVENTS_2="11" LOG_CI_END="0.3203892511523477" LOG_CI_START="-0.025062149028699965" LOG_EFFECT_SIZE="0.14766355106182386" ORDER="760" O_E="0.0" SE="0.20291986247835697" STUDY_ID="STD-Svestka-1989" TOTAL_1="11" TOTAL_2="17" VAR="0.0411764705882353" WEIGHT="100.0"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
</COMPARISON>
<COMPARISON ID="CMP-003" MODIFIED="2014-01-28 11:16:32 +0000" MODIFIED_BY="[Empty name]" NO="3">
<NAME>ADJUNCTIVE CARBAMAZEPINE + ANTIPSYCHOTICS vs PLACEBO/NO ADJUNCTIVE TREATMENT + ANTIPSYCHOTICS</NAME>
<DICH_OUTCOME CHI2="3.5401508991119135" CI_END="1.3521449860100514" CI_START="0.1608933164157872" CI_STUDY="95" CI_TOTAL="95" DF="3" EFFECT_MEASURE="RR" EFFECT_SIZE="0.46642372481911265" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="10" I2="15.257849580576252" I2_Q="0.0" ID="CMP-003.01" LOG_CI_END="0.13102326205542997" LOG_CI_START="-0.7934619963237841" LOG_EFFECT_SIZE="-0.3312193671341771" METHOD="MH" NO="1" P_CHI2="0.31559204253013495" P_Q="1.0" P_Z="0.16019688511553218" Q="0.0" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="8" SUBGROUPS="NO" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="89" TOTAL_2="93" WEIGHT="99.99999999999999" Z="1.4044096964904784">
<NAME>Leaving the study early</NAME>
<GROUP_LABEL_1>Treatment</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours Treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours Control</GRAPH_LABEL_2>
<DICH_DATA CI_END="1.6136870543922073" CI_START="0.02810534017145384" EFFECT_SIZE="0.21296296296296297" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="6" LOG_CI_END="0.20781931494091346" LOG_CI_START="-1.5512111538796272" LOG_EFFECT_SIZE="-0.6716959194693568" ORDER="761" O_E="0.0" SE="1.0332632047264365" STUDY_ID="STD-Dose-1987" TOTAL_1="18" TOTAL_2="23" VAR="1.067632850241546" WEIGHT="51.81696348485541"/>
<DICH_DATA CI_END="91.51787421498676" CI_START="0.2731706807488985" EFFECT_SIZE="5.0" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="0" LOG_CI_END="1.9615059237367205" LOG_CI_START="-0.5635659150646829" LOG_EFFECT_SIZE="0.6989700043360189" ORDER="762" O_E="0.0" SE="1.4832396974191324" STUDY_ID="STD-He_x00df_linger-1998" TOTAL_1="9" TOTAL_2="9" VAR="2.1999999999999997" WEIGHT="4.917813664071925"/>
<DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="763" O_E="0.0" SE="0.0" STUDY_ID="STD-Llorca-1993" TOTAL_1="6" TOTAL_2="6" VAR="0.0" WEIGHT="0.0"/>
<DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="764" O_E="0.0" SE="0.0" STUDY_ID="STD-Mair-1990" TOTAL_1="13" TOTAL_2="10" VAR="0.0" WEIGHT="0.0"/>
<DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="765" O_E="0.0" SE="0.0" STUDY_ID="STD-Martin_x002d_Munoz-1989" TOTAL_1="10" TOTAL_2="10" VAR="0.0" WEIGHT="0.0"/>
<DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="766" O_E="0.0" SE="0.0" STUDY_ID="STD-Nachshoni-1994" TOTAL_1="15" TOTAL_2="15" VAR="0.0" WEIGHT="0.0"/>
<DICH_DATA CI_END="5.623367980845718" CI_START="0.021784098144965562" EFFECT_SIZE="0.35" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="2" LOG_CI_END="0.7499965037160101" LOG_CI_START="-1.661860415015459" LOG_EFFECT_SIZE="-0.4559319556497244" ORDER="767" O_E="0.0" SE="1.4167366929471605" STUDY_ID="STD-Neppe-1983" TOTAL_1="3" TOTAL_2="6" VAR="2.007142857142857" WEIGHT="17.882958778443363"/>
<DICH_DATA CI_END="3.595018160086855" CI_START="0.009779157833002613" EFFECT_SIZE="0.1875" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="2" LOG_CI_END="0.5557010885452135" LOG_CI_START="-2.009698544417738" LOG_EFFECT_SIZE="-0.7269987279362623" ORDER="768" O_E="0.0" SE="1.5069284433354269" STUDY_ID="STD-Simhandl-1996" TOTAL_1="15" TOTAL_2="14" VAR="2.270833333333333" WEIGHT="25.38226407262929"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="1.793600234429641" CI_END="0.8755750552194921" CI_START="0.37011285168905383" CI_STUDY="95" CI_TOTAL="95" DF="1" EFFECT_MEASURE="RR" EFFECT_SIZE="0.5692640692640693" ESTIMABLE="YES" EVENTS_1="10" EVENTS_2="19" I2="44.2462160294043" I2_Q="0.0" ID="CMP-003.02" LOG_CI_END="-0.05770661980264947" LOG_CI_START="-0.4316658343300859" LOG_EFFECT_SIZE="-0.24468622706636764" METHOD="MH" NO="2" P_CHI2="0.18048826464123613" P_Q="1.0" P_Z="0.01032179563336673" Q="0.0" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="2" SUBGROUPS="NO" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="18" TOTAL_2="20" WEIGHT="99.99999999999999" Z="2.5648582729488276">
<NAME>Global state: No improvement</NAME>
<GROUP_LABEL_1>Treatment</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours Treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours Control</GRAPH_LABEL_2>
<DICH_DATA CI_END="2.1884914871904293" CI_START="0.011565006079993763" EFFECT_SIZE="0.1590909090909091" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="5" LOG_CI_END="0.34014486163068985" LOG_CI_START="-1.936854134574551" LOG_EFFECT_SIZE="-0.7983546364719306" ORDER="769" O_E="0.0" SE="1.3375204816977715" STUDY_ID="STD-Neppe-1983" TOTAL_1="3" TOTAL_2="6" VAR="1.7889610389610389" WEIGHT="21.088435374149658"/>
<DICH_DATA CI_END="0.9797647883905795" CI_START="0.4703956740181827" EFFECT_SIZE="0.6788793103448276" ESTIMABLE="YES" EVENTS_1="10" EVENTS_2="14" LOG_CI_END="-0.00887817263888302" LOG_CI_START="-0.32753668089167765" LOG_EFFECT_SIZE="-0.16820742676528033" ORDER="770" O_E="0.0" SE="0.18718158513274716" STUDY_ID="STD-Simhandl-1996" TOTAL_1="15" TOTAL_2="14" VAR="0.035036945812807876" WEIGHT="78.91156462585033"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="31.05436003842115" CI_END="0.947705692361251" CI_START="0.6559068802151738" CI_STUDY="95" CI_TOTAL="95" DF="16" EFFECT_MEASURE="RR" EFFECT_SIZE="0.788420372668559" ESTIMABLE="YES" EVENTS_1="86" EVENTS_2="120" I2="48.47744413279024" I2_Q="0.0" ID="CMP-003.03" LOG_CI_END="-0.023326510792666896" LOG_CI_START="-0.18315781348916393" LOG_EFFECT_SIZE="-0.10324216214091542" METHOD="MH" NO="3" P_CHI2="0.01324279754273816" P_Q="0.6605252079320609" P_Z="0.011339581879824366" Q="0.8294400271410698" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="6" SUBGROUPS="YES" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="SUB" TOTAL_1="210" TOTAL_2="231" WEIGHT="300.0" Z="2.5320561875977723">
<NAME>Mental state: 1a. General - categories of reduction on BPRS scores</NAME>
<GROUP_LABEL_1>Treatment</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="6.6288675858590835" CI_END="1.0688345524989176" CI_START="0.440793410699487" DF="4" EFFECT_SIZE="0.686392910707459" ESTIMABLE="YES" EVENTS_1="19" EVENTS_2="31" I2="39.65786843392482" ID="CMP-003.03.01" LOG_CI_END="0.02891048491165611" LOG_CI_START="-0.35576490625754553" LOG_EFFECT_SIZE="-0.16342721067294472" NO="1" P_CHI2="0.15684971909492473" P_Z="0.09584101449378515" STUDIES="6" TAU2="0.0" TOTAL_1="70" TOTAL_2="77" WEIGHT="100.00000000000003" Z="1.6653596999758213">
<NAME>less than 20% reduction</NAME>
<DICH_DATA CI_END="1.5513521993480555" CI_START="0.14800036673872796" EFFECT_SIZE="0.4791666666666667" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="8" LOG_CI_END="0.19071040572413145" LOG_CI_START="-0.8297372084401202" LOG_EFFECT_SIZE="-0.31951340135799433" ORDER="771" O_E="0.0" SE="0.5994159798572378" STUDY_ID="STD-Dose-1987" TOTAL_1="18" TOTAL_2="23" VAR="0.3592995169082126" WEIGHT="24.561575485477345"/>
<DICH_DATA CI_END="23.679169312297123" CI_START="0.38008090069807043" EFFECT_SIZE="3.0" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="1" LOG_CI_END="1.3743664628560583" LOG_CI_START="-0.4201239534167336" LOG_EFFECT_SIZE="0.47712125471966244" ORDER="772" O_E="0.0" SE="1.0540925533894596" STUDY_ID="STD-He_x00df_linger-1998" TOTAL_1="9" TOTAL_2="9" VAR="1.111111111111111" WEIGHT="3.4966131767519832"/>
<DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="773" O_E="0.0" SE="0.0" STUDY_ID="STD-Martin_x002d_Munoz-1989" TOTAL_1="10" TOTAL_2="10" VAR="0.0" WEIGHT="0.0"/>
<DICH_DATA CI_END="1.6587437267659693" CI_START="0.6028658820911936" EFFECT_SIZE="1.0" ESTIMABLE="YES" EVENTS_1="10" EVENTS_2="10" LOG_CI_END="0.219779293409146" LOG_CI_START="-0.21977929340914606" LOG_EFFECT_SIZE="0.0" ORDER="774" O_E="0.0" SE="0.25819888974716115" STUDY_ID="STD-Nachshoni-1994" TOTAL_1="15" TOTAL_2="15" VAR="0.0666666666666667" WEIGHT="34.96613176751983"/>
<DICH_DATA CI_END="2.061703921857245" CI_START="0.07760571161734377" EFFECT_SIZE="0.4" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="5" LOG_CI_END="0.31422629705994987" LOG_CI_START="-1.110106314404025" LOG_EFFECT_SIZE="-0.3979400086720376" ORDER="775" O_E="0.0" SE="0.8366600265340756" STUDY_ID="STD-Neppe-1983" TOTAL_1="3" TOTAL_2="6" VAR="0.7000000000000001" WEIGHT="11.655377255839944"/>
<DICH_DATA CI_END="1.0732934239859022" CI_START="0.06625505152824374" EFFECT_SIZE="0.26666666666666666" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="7" LOG_CI_END="0.030718468468461112" LOG_CI_START="-1.1787810039238988" LOG_EFFECT_SIZE="-0.5740312677277188" ORDER="776" O_E="0.0" SE="0.7104659772022196" STUDY_ID="STD-Simhandl-1996" TOTAL_1="15" TOTAL_2="14" VAR="0.5047619047619047" WEIGHT="25.320302314410913"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="6.812090864843231" CI_END="1.053550832032494" CI_START="0.5708677831809227" DF="5" EFFECT_SIZE="0.7755244857197008" ESTIMABLE="YES" EVENTS_1="29" EVENTS_2="41" I2="26.60109650320898" ID="CMP-003.03.02" LOG_CI_END="0.02265549441838676" LOG_CI_START="-0.24346446563151758" LOG_EFFECT_SIZE="-0.11040448560656545" NO="2" P_CHI2="0.23499470075105644" P_Z="0.10389644678574018" STUDIES="6" TAU2="0.0" TOTAL_1="70" TOTAL_2="77" WEIGHT="100.0" Z="1.6262501728916583">
<NAME>less than 35% reduction</NAME>
<DICH_DATA CI_END="1.1905009446520833" CI_START="0.12343076677472783" EFFECT_SIZE="0.38333333333333336" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="10" LOG_CI_END="0.07572974434990694" LOG_CI_START="-0.9085765730820083" LOG_EFFECT_SIZE="-0.41642341436605074" ORDER="777" O_E="0.0" SE="0.5781864032543593" STUDY_ID="STD-Dose-1987" TOTAL_1="18" TOTAL_2="23" VAR="0.3342995169082126" WEIGHT="22.830983656747968"/>
<DICH_DATA CI_END="23.679169312297123" CI_START="0.38008090069807043" EFFECT_SIZE="3.0" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="1" LOG_CI_END="1.3743664628560583" LOG_CI_START="-0.4201239534167336" LOG_EFFECT_SIZE="0.47712125471966244" ORDER="778" O_E="0.0" SE="1.0540925533894596" STUDY_ID="STD-He_x00df_linger-1998" TOTAL_1="9" TOTAL_2="9" VAR="1.111111111111111" WEIGHT="2.6001953609074073"/>
<DICH_DATA CI_END="18.687408406451837" CI_START="0.21404787186108687" EFFECT_SIZE="2.0" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="1" LOG_CI_END="1.2715490770440216" LOG_CI_START="-0.6694890857160593" LOG_EFFECT_SIZE="0.3010299956639812" ORDER="779" O_E="0.0" SE="1.1401754250991378" STUDY_ID="STD-Martin_x002d_Munoz-1989" TOTAL_1="10" TOTAL_2="10" VAR="1.2999999999999998" WEIGHT="2.6001953609074073"/>
<DICH_DATA CI_END="1.1806724097271986" CI_START="0.7302998620577663" EFFECT_SIZE="0.9285714285714286" ESTIMABLE="YES" EVENTS_1="13" EVENTS_2="14" LOG_CI_END="0.07212941464718184" LOG_CI_START="-0.13649878138998436" LOG_EFFECT_SIZE="-0.03218468337140124" ORDER="780" O_E="0.0" SE="0.12254923507845743" STUDY_ID="STD-Nachshoni-1994" TOTAL_1="15" TOTAL_2="15" VAR="0.01501831501831502" WEIGHT="36.402735052703704"/>
<DICH_DATA CI_END="1.9220243686433105" CI_START="0.33298225061098136" EFFECT_SIZE="0.8" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="5" LOG_CI_END="0.2837588896281722" LOG_CI_START="-0.477578915644285" LOG_EFFECT_SIZE="-0.09691001300805639" ORDER="781" O_E="0.0" SE="0.4472135954999579" STUDY_ID="STD-Neppe-1983" TOTAL_1="3" TOTAL_2="6" VAR="0.19999999999999998" WEIGHT="8.667317869691358"/>
<DICH_DATA CI_END="1.1308425937252407" CI_START="0.2773153414454736" EFFECT_SIZE="0.56" ESTIMABLE="YES" EVENTS_1="6" EVENTS_2="10" LOG_CI_END="0.0534021580341951" LOG_CI_START="-0.5570261040217942" LOG_EFFECT_SIZE="-0.25181197299379954" ORDER="782" O_E="0.0" SE="0.3585685828003181" STUDY_ID="STD-Simhandl-1996" TOTAL_1="15" TOTAL_2="14" VAR="0.1285714285714286" WEIGHT="26.898572699042145"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="14.309321890535195" CI_END="1.1192653033476905" CI_START="0.6658884428774787" DF="5" EFFECT_SIZE="0.863310969473331" ESTIMABLE="YES" EVENTS_1="38" EVENTS_2="48" I2="65.0577432092906" ID="CMP-003.03.03" LOG_CI_END="0.0489330410622024" LOG_CI_START="-0.17659852263275028" LOG_EFFECT_SIZE="-0.06383274078527391" NO="3" P_CHI2="0.01375949305490265" P_Z="0.2672289462444084" STUDIES="6" TAU2="0.0" TOTAL_1="70" TOTAL_2="77" WEIGHT="100.0" Z="1.1094666389387322">
<NAME>less than 50% reduction</NAME>
<DICH_DATA CI_END="0.6508442277923566" CI_START="0.04459755784973722" EFFECT_SIZE="0.17037037037037037" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="15" LOG_CI_END="-0.1865229424691657" LOG_CI_START="-1.3506889224856609" LOG_EFFECT_SIZE="-0.7686059324774133" ORDER="783" O_E="0.0" SE="0.6838368593762301" STUDY_ID="STD-Dose-1987" TOTAL_1="18" TOTAL_2="23" VAR="0.4676328502415459" WEIGHT="28.892988929889295"/>
<DICH_DATA CI_END="45.90114898403462" CI_START="1.0675114040618723" EFFECT_SIZE="7.0" ESTIMABLE="YES" EVENTS_1="7" EVENTS_2="1" LOG_CI_END="1.6618235568048125" LOG_CI_START="0.02837252322370104" LOG_EFFECT_SIZE="0.8450980400142568" ORDER="784" O_E="0.0" SE="0.9594972228385659" STUDY_ID="STD-He_x00df_linger-1998" TOTAL_1="9" TOTAL_2="9" VAR="0.9206349206349205" WEIGHT="2.1937269372693726"/>
<DICH_DATA CI_END="18.687408406451837" CI_START="0.21404787186108687" EFFECT_SIZE="2.0" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="1" LOG_CI_END="1.2715490770440216" LOG_CI_START="-0.6694890857160593" LOG_EFFECT_SIZE="0.3010299956639812" ORDER="785" O_E="0.0" SE="1.1401754250991378" STUDY_ID="STD-Martin_x002d_Munoz-1989" TOTAL_1="10" TOTAL_2="10" VAR="1.2999999999999998" WEIGHT="2.1937269372693726"/>
<DICH_DATA CI_END="1.2107898309978289" CI_START="0.8259071677005132" EFFECT_SIZE="1.0" ESTIMABLE="YES" EVENTS_1="14" EVENTS_2="14" LOG_CI_END="0.08306876481172813" LOG_CI_START="-0.08306876481172817" LOG_EFFECT_SIZE="0.0" ORDER="786" O_E="0.0" SE="0.09759000729485329" STUDY_ID="STD-Nachshoni-1994" TOTAL_1="15" TOTAL_2="15" VAR="0.009523809523809518" WEIGHT="30.712177121771216"/>
<DICH_DATA CI_END="1.9026084875830005" CI_START="0.6518345516206052" EFFECT_SIZE="1.1136363636363635" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="5" LOG_CI_END="0.27934942981336025" LOG_CI_START="-0.18586262272870785" LOG_EFFECT_SIZE="0.046743403542326194" ORDER="787" O_E="0.0" SE="0.27326786250001056" STUDY_ID="STD-Neppe-1983" TOTAL_1="3" TOTAL_2="6" VAR="0.07467532467532467" WEIGHT="8.77490774907749"/>
<DICH_DATA CI_END="1.1800480896702055" CI_START="0.5126386601532517" EFFECT_SIZE="0.7777777777777778" ESTIMABLE="YES" EVENTS_1="10" EVENTS_2="12" LOG_CI_END="0.07189970616446736" LOG_CI_START="-0.29018864501460345" LOG_EFFECT_SIZE="-0.10914446942506803" ORDER="788" O_E="0.0" SE="0.21269248984883143" STUDY_ID="STD-Simhandl-1996" TOTAL_1="15" TOTAL_2="14" VAR="0.04523809523809526" WEIGHT="27.232472324723247"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<CONT_OUTCOME CHI2="12.894296713865355" CI_END="1.4008489043706724" CI_START="-7.824837198160399" CI_STUDY="95" CI_TOTAL="95" DF="2" EFFECT_MEASURE="MD" EFFECT_SIZE="-3.211994146894863" ESTIMABLE="YES" I2="84.4892664998985" I2_Q="0.0" ID="CMP-003.04" MODIFIED="2014-01-21 11:28:10 +0000" MODIFIED_BY="[Empty name]" NO="4" P_CHI2="0.0015850413749922687" P_Q="1.0" P_Z="0.17233059639943876" Q="0.0" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="3" SUBGROUPS="NO" SUBGROUP_TEST="YES" TAU2="0.0" TOTALS="YES" TOTAL_1="41" TOTAL_2="38" UNITS="" WEIGHT="100.0" Z="1.3647533151469882">
<NAME>Mental state: 1b. General - average BPRS endpoint score (high = poor)</NAME>
<GROUP_LABEL_1>Treatment</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours Treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours Control</GRAPH_LABEL_2>
<CONT_DATA CI_END="-3.016300818847216" CI_START="-14.983699181152783" EFFECT_SIZE="-9.0" ESTIMABLE="YES" MEAN_1="27.5" MEAN_2="36.5" ORDER="789" SD_1="7.9" SD_2="9.8" SE="3.0529638444131826" STUDY_ID="STD-Dose-1987" TOTAL_1="17" TOTAL_2="17" WEIGHT="59.42892198340482"/>
<CONT_DATA CI_END="23.83475873776183" CI_START="2.6052412622381755" EFFECT_SIZE="13.220000000000002" ESTIMABLE="YES" MEAN_1="41.78" MEAN_2="28.56" ORDER="790" SD_1="14.13" SD_2="8.02" SE="5.415792750014638" STUDY_ID="STD-He_x00df_linger-1998" TOTAL_1="9" TOTAL_2="9" WEIGHT="18.88500488364952"/>
<CONT_DATA CI_END="8.245541441925221" CI_START="-11.565541441925214" EFFECT_SIZE="-1.6599999999999966" ESTIMABLE="YES" MEAN_1="37.67" MEAN_2="39.33" ORDER="791" SD_1="6.94" SD_2="16.37" SE="5.053940541795086" STUDY_ID="STD-Simhandl-1996" TOTAL_1="15" TOTAL_2="12" WEIGHT="21.68607313294566"/>
</CONT_OUTCOME>
<OTHER_OUTCOME COLS="1" ID="CMP-003.05" MODIFIED="2014-01-21 11:28:10 +0000" MODIFIED_BY="[Empty name]" NO="5" ROWS_PER_STUDY="1" SORT_BY="STUDY" STUDIES="3" SUBGROUPS="NO">
<NAME>Mental state: 1c. General - average BPRS endpoint score (high = poor, skewed data)</NAME>
<TR>
<TH>
<P>Data</P>
</TH>
</TR>
<OTHER_DATA MODIFIED="2014-01-21 11:28:10 +0000" MODIFIED_BY="[Empty name]" ORDER="167" STUDY_ID="STD-Martin_x002d_Munoz-1989">
<TR>
<TD>
<P>1. Carbamazepine + antipsychotics: mean 8.6, SD 9.6, N = 10.<BR/>2. Placebo + antipsychotics: mean 7.4, SD 4.7, N = 10.</P>
</TD>
</TR>
</OTHER_DATA>
<OTHER_DATA MODIFIED="2014-01-21 11:28:10 +0000" MODIFIED_BY="[Empty name]" ORDER="168" STUDY_ID="STD-Nachshoni-1994">
<TR>
<TD>
<P>1. Carbamazepine + antipsychotics: mean 5.0, SD 2.70, N = 15.<BR/>2. Placebo + antipsychotics: mean 5.1, SD 1.6, N = 15.</P>
</TD>
</TR>
</OTHER_DATA>
<OTHER_DATA MODIFIED="2014-01-21 11:28:10 +0000" MODIFIED_BY="[Empty name]" ORDER="169" STUDY_ID="STD-Neppe-1983">
<TR>
<TD>
<P>1. Carbamazepine + antipsychotics: mean 14.7, SD 5.8, N = 3.<BR/>2. Placebo + antipsychotics: mean 22.0, SD 13.4, N = 4.</P>
</TD>
</TR>
</OTHER_DATA>
</OTHER_OUTCOME>
<CONT_OUTCOME CHI2="24.08214987983395" CI_END="7.913504284350587" CI_START="1.3005223706636144" CI_STUDY="95" CI_TOTAL="95" DF="1" EFFECT_MEASURE="MD" EFFECT_SIZE="4.607013327507101" ESTIMABLE="YES" I2="95.84754681376107" I2_Q="0.0" ID="CMP-003.06" MODIFIED="2014-01-21 11:28:10 +0000" MODIFIED_BY="[Empty name]" NO="6" NOTES="&lt;p&gt;These data do not look right&lt;/p&gt;" NOTES_MODIFIED="2014-01-21 11:28:10 +0000" NOTES_MODIFIED_BY="[Empty name]" P_CHI2="9.231472176685074E-7" P_Q="1.0" P_Z="0.006316835459436603" Q="0.0" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="2" SUBGROUPS="NO" SUBGROUP_TEST="YES" TAU2="0.0" TOTALS="YES" TOTAL_1="25" TOTAL_2="25" UNITS="" WEIGHT="100.0" Z="2.730864930848008">
<NAME>Mental state: 1d. General - average IMPS endpoint score (high = poor)</NAME>
<GROUP_LABEL_1>Treatment</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<CONT_DATA CI_END="1.4174937725399852" CI_START="-7.6174937725399845" EFFECT_SIZE="-3.0999999999999996" ESTIMABLE="YES" MEAN_1="8.9" MEAN_2="12.0" ORDER="795" SD_1="7.0" SD_2="6.0" SE="2.3048861143232218" STUDY_ID="STD-Dose-1987" TOTAL_1="16" TOTAL_2="16" WEIGHT="53.572208870439155"/>
<CONT_DATA CI_END="18.35264284394133" CI_START="8.647357156058671" EFFECT_SIZE="13.5" ESTIMABLE="YES" MEAN_1="42.0" MEAN_2="28.5" ORDER="796" SD_1="5.1" SD_2="5.4" SE="2.4758836806279896" STUDY_ID="STD-He_x00df_linger-1998" TOTAL_1="9" TOTAL_2="9" WEIGHT="46.42779112956085"/>
</CONT_OUTCOME>
<CONT_OUTCOME CHI2="0.0" CI_END="7.686058987013908" CI_START="0.7539410129860902" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="MD" EFFECT_SIZE="4.219999999999999" ESTIMABLE="YES" I2="0.0" I2_Q="0.0" ID="CMP-003.07" MODIFIED="2014-01-21 11:28:10 +0000" MODIFIED_BY="[Empty name]" NO="7" P_CHI2="1.0" P_Q="1.0" P_Z="0.017018975645497446" Q="0.0" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="YES" TAU2="0.0" TOTALS="YES" TOTAL_1="9" TOTAL_2="9" UNITS="" WEIGHT="99.99999999999999" Z="2.3862975343892603">
<NAME>Mental state: 2a. Specific - positive symptoms (PANSS subscale at endpoint, high = poor)</NAME>
<GROUP_LABEL_1>Treatment</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours Treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours Control</GRAPH_LABEL_2>
<CONT_DATA CI_END="7.686058987013908" CI_START="0.7539410129860902" EFFECT_SIZE="4.219999999999999" ESTIMABLE="YES" MEAN_1="14.44" MEAN_2="10.22" ORDER="797" SD_1="4.5" SD_2="2.81" SE="1.7684299376691304" STUDY_ID="STD-He_x00df_linger-1998" TOTAL_1="9" TOTAL_2="9" WEIGHT="99.99999999999999"/>
</CONT_OUTCOME>
<OTHER_OUTCOME COLS="1" ID="CMP-003.08" MODIFIED="2014-01-21 11:28:10 +0000" MODIFIED_BY="[Empty name]" NO="8" ROWS_PER_STUDY="1" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO">
<NAME>Mental state: 2b. Specific - positive symptoms (IMPS score at endpoint, high = poor)</NAME>
<TR>
<TH>
<P>Data</P>
</TH>
</TR>
<OTHER_DATA MODIFIED="2014-01-21 11:28:10 +0000" MODIFIED_BY="[Empty name]" ORDER="173" STUDY_ID="STD-Dose-1987">
<TR>
<TD>
<P>1. Carbamazepine + antipsychotics: mean 4.9, SD 6.4, N = 16.<BR/>2. Placebo + antipsychotics: mean 7.5, SD 8.1, N = 16.</P>
</TD>
</TR>
</OTHER_DATA>
</OTHER_OUTCOME>
<CONT_OUTCOME CHI2="0.16562667575201714" CI_END="1.2162076338741938" CI_START="-6.710794569788663" CI_STUDY="95" CI_TOTAL="95" DF="1" EFFECT_MEASURE="MD" EFFECT_SIZE="-2.7472934679572347" ESTIMABLE="YES" I2="0.0" I2_Q="0.0" ID="CMP-003.09" MODIFIED="2014-01-21 11:28:10 +0000" MODIFIED_BY="[Empty name]" NO="9" P_CHI2="0.6840283735572412" P_Q="1.0" P_Z="0.1742906819123698" Q="0.0" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="2" SUBGROUPS="NO" SUBGROUP_TEST="YES" TAU2="0.0" TOTALS="YES" TOTAL_1="28" TOTAL_2="25" UNITS="" WEIGHT="100.0" Z="1.358545415736165">
<NAME>Mental state: 2c. Specific - negative symptoms (SANS at endpoint, high = poor)</NAME>
<GROUP_LABEL_1>Treatment</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours Treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours Control</GRAPH_LABEL_2>
<CONT_DATA CI_END="8.677658072869447" CI_START="-10.53765807286946" EFFECT_SIZE="-0.9300000000000068" ESTIMABLE="YES" MEAN_1="67.0" MEAN_2="67.93" ORDER="799" SD_1="13.77" SD_2="11.08" SE="4.901956438308782" STUDY_ID="STD-Nachshoni-1994" TOTAL_1="13" TOTAL_2="13" WEIGHT="17.01856310697562"/>
<CONT_DATA CI_END="1.2309942353610452" CI_START="-7.470994235361044" EFFECT_SIZE="-3.119999999999999" ESTIMABLE="YES" MEAN_1="13.13" MEAN_2="16.25" ORDER="800" SD_1="4.16" SD_2="6.73" SE="2.2199358098827995" STUDY_ID="STD-Simhandl-1996" TOTAL_1="15" TOTAL_2="12" WEIGHT="82.98143689302438"/>
</CONT_OUTCOME>
<CONT_OUTCOME CHI2="0.0" CI_END="1.499194120087378" CI_START="-2.1991941200873772" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="MD" EFFECT_SIZE="-0.34999999999999964" ESTIMABLE="YES" I2="0.0" I2_Q="0.0" ID="CMP-003.10" MODIFIED="2014-01-21 11:28:10 +0000" MODIFIED_BY="[Empty name]" NO="10" P_CHI2="1.0" P_Q="1.0" P_Z="0.7106631591875232" Q="0.0" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="YES" TAU2="0.0" TOTALS="YES" TOTAL_1="13" TOTAL_2="13" UNITS="" WEIGHT="100.0" Z="0.37096559368067006">
<NAME>Mental state: 2d. Specific - depression (Hamilton scale at endpoint, high = poor)</NAME>
<GROUP_LABEL_1>Treatment</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours Treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours Control</GRAPH_LABEL_2>
<CONT_DATA CI_END="1.499194120087378" CI_START="-2.1991941200873772" EFFECT_SIZE="-0.34999999999999964" ESTIMABLE="YES" MEAN_1="4.79" MEAN_2="5.14" ORDER="801" SD_1="2.36" SD_2="2.45" SE="0.9434837245345244" STUDY_ID="STD-Nachshoni-1994" TOTAL_1="13" TOTAL_2="13" WEIGHT="100.0"/>
</CONT_OUTCOME>
<OTHER_OUTCOME COLS="1" ID="CMP-003.11" MODIFIED="2014-01-27 17:55:04 +0000" MODIFIED_BY="[Empty name]" NO="11" ROWS_PER_STUDY="1" SORT_BY="STUDY" STUDIES="2" SUBGROUPS="NO">
<NAME>Behaviour: Average dose of medication used for agitation (chlorprothixene, skewed data)</NAME>
<TR>
<TH>
<P>Data</P>
</TH>
</TR>
<OTHER_DATA MODIFIED="2014-01-27 17:54:58 +0000" MODIFIED_BY="[Empty name]" ORDER="177" STUDY_ID="STD-Dose-1987">
<TR>
<TD>
<P>1. Carbamazepine + antipsychotics: mean dose 40 mg/day, SD 36. N = 17.<BR/>2. Placebo + antipsychotics: mean dose 63 mg/day, SD 49. N = 17.</P>
</TD>
</TR>
</OTHER_DATA>
<OTHER_DATA MODIFIED="2014-01-27 17:55:04 +0000" MODIFIED_BY="[Empty name]" ORDER="178" STUDY_ID="STD-He_x00df_linger-1998">
<TR>
<TD>
<P>1. Carbamazepine + haloperidol: mean chlorprothixene dose 182 mg/day, SD 30.1. N = 9.<BR/>2. Placebo + haloperidol: mean dose 21.6 mg/day, SD 5.8. N = 9.</P>
</TD>
</TR>
</OTHER_DATA>
</OTHER_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="1.0154703316942852" CI_START="0.1384826278138239" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="RR" EFFECT_SIZE="0.375" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="8" I2="0.0" I2_Q="0.0" ID="CMP-003.12" LOG_CI_END="0.0066672394398108355" LOG_CI_START="-0.8586047039843732" LOG_EFFECT_SIZE="-0.42596873227228116" METHOD="MH" NO="12" P_CHI2="1.0" P_Q="1.0" P_Z="0.05363664455095179" Q="0.0" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="10" TOTAL_2="10" WEIGHT="100.0" Z="1.9297594938532967">
<NAME>Adverse effects: 1a Movement disorders - at least one movement disorder</NAME>
<GROUP_LABEL_1>Treatment</GROUP_LABEL_1>
<GROUP_LABEL_2>control</GROUP_LABEL_2>
<GRAPH_LABEL_1>favours treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>favours control</GRAPH_LABEL_2>
<DICH_DATA CI_END="1.015470331694285" CI_START="0.13848262781382395" EFFECT_SIZE="0.375" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="8" LOG_CI_END="0.006667239439810741" LOG_CI_START="-0.8586047039843729" LOG_EFFECT_SIZE="-0.42596873227228116" ORDER="804" O_E="0.0" SE="0.5082650227325635" STUDY_ID="STD-Martin_x002d_Munoz-1989" TOTAL_1="10" TOTAL_2="10" VAR="0.2583333333333333" WEIGHT="100.0"/>
</DICH_OUTCOME>
<OTHER_OUTCOME COLS="1" ID="CMP-003.13" MODIFIED="2014-01-27 17:56:16 +0000" MODIFIED_BY="[Empty name]" NO="13" ROWS_PER_STUDY="1" SORT_BY="STUDY" STUDIES="3" SUBGROUPS="NO">
<NAME>Adverse effects: 1b. Movement disorders - average dose of antiparkinsonism drugs (biperiden, skewed data)</NAME>
<TR>
<TH>
<P>Data</P>
</TH>
</TR>
<OTHER_DATA MODIFIED="2014-01-27 17:56:08 +0000" MODIFIED_BY="[Empty name]" ORDER="180" STUDY_ID="STD-Dose-1987">
<TR>
<TD>
<P>1. Carbamazepine + antipsychotics: mean dose 1.3 mg/day, SD 1.6. N = 17.<BR/>2. Placebo + antipsychotics: mean dose 3.8 mg/day, SD 2.3. N = 17.</P>
</TD>
</TR>
</OTHER_DATA>
<OTHER_DATA MODIFIED="2014-01-27 17:56:13 +0000" MODIFIED_BY="[Empty name]" ORDER="181" STUDY_ID="STD-He_x00df_linger-1998">
<TR>
<TD>
<P>1. Carbamazepine + haloperidol: mean dose 3.9 mg/day, SD 0.8. N = 9.<BR/>2. Placebo + haloperidol: mean dose 2.9 mg/day, SD 1.0 N = 9.</P>
</TD>
</TR>
</OTHER_DATA>
<OTHER_DATA MODIFIED="2014-01-27 17:56:16 +0000" MODIFIED_BY="[Empty name]" ORDER="182" STUDY_ID="STD-Simhandl-1996">
<TR>
<TD>
<P>1. Carbamazepine + antipsychotics: mean dose 2.67 mg/day, SD 2.89. N = 15.<BR/>2. Placebo + antipsychotics: mean dose 2.67 mg/day, SD 4.62. N = 12.</P>
</TD>
</TR>
</OTHER_DATA>
</OTHER_OUTCOME>
<OTHER_OUTCOME COLS="1" ID="CMP-003.14" MODIFIED="2014-01-21 11:28:10 +0000" MODIFIED_BY="[Empty name]" NO="14" ROWS_PER_STUDY="1" SORT_BY="STUDY" STUDIES="3" SUBGROUPS="NO">
<NAME>Adverse effects: 1c. Movement disorders - average endpoint score (SAS, high = poor, skewed data)</NAME>
<TR>
<TH>
<P>Data</P>
</TH>
</TR>
<OTHER_DATA MODIFIED="2014-01-21 11:28:10 +0000" MODIFIED_BY="[Empty name]" ORDER="183" STUDY_ID="STD-Dose-1987">
<TR>
<TD>
<P>1. Carbamazepine + antipsychotics: mean 1.03, SD 0.86. N = 17.<BR/>2. Placebo + antipsychotics: mean 2.84, SD 2.18. N = 17.</P>
</TD>
</TR>
</OTHER_DATA>
<OTHER_DATA MODIFIED="2014-01-21 11:28:10 +0000" MODIFIED_BY="[Empty name]" ORDER="184" STUDY_ID="STD-Nachshoni-1994">
<TR>
<TD>
<P>1. Carbamazepine + antipsychotics: mean 0.9, SD 0.9. N = 13.<BR/>2. Placebo + antipsychotics: mean 0.4, SD 0.5. N = 13.</P>
</TD>
</TR>
</OTHER_DATA>
<OTHER_DATA MODIFIED="2014-01-21 11:28:10 +0000" MODIFIED_BY="[Empty name]" ORDER="185" STUDY_ID="STD-Simhandl-1996">
<TR>
<TD>
<P>1. Carbamazepine + antipsychotics: mean 0.27, SD 0.19. N = 15.<BR/>2. Placebo + antipsychotics: mean 0.31, SD 0.35. N = 12.</P>
</TD>
</TR>
</OTHER_DATA>
</OTHER_OUTCOME>
<OTHER_OUTCOME COLS="1" ID="CMP-003.15" MODIFIED="2014-01-21 11:28:10 +0000" MODIFIED_BY="[Empty name]" NO="15" ROWS_PER_STUDY="1" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO">
<NAME>Adverse effects: 1d. Movement disorders - average endpoint TD rating (high = poor, skewed data)</NAME>
<TR>
<TH>
<P>Data</P>
</TH>
</TR>
<OTHER_DATA MODIFIED="2014-01-21 11:28:10 +0000" MODIFIED_BY="[Empty name]" ORDER="186" STUDY_ID="STD-Simhandl-1996">
<TR>
<TD>
<P>1. Carbamazepine + antipsychotics: mean 7.1, SD 0.2. N = 15.<BR/>2. Placebo + antipsychotics: mean 13.1, SD 14.2. N = 12.</P>
</TD>
</TR>
</OTHER_DATA>
</OTHER_OUTCOME>
<DICH_OUTCOME CHI2="0.30616769331563376" CI_END="5.52160830440624" CI_START="0.9234418706186465" CI_STUDY="95" CI_TOTAL="95" DF="3" EFFECT_MEASURE="RR" EFFECT_SIZE="2.258070924803814" ESTIMABLE="YES" EVENTS_1="11" EVENTS_2="6" I2="0.0" I2_Q="0.0" ID="CMP-003.16" LOG_CI_END="0.7420655951195164" LOG_CI_START="-0.034590437596905915" LOG_EFFECT_SIZE="0.35373757876130524" METHOD="MH" NO="16" P_CHI2="0.9588643631383369" P_Q="0.9589380024841517" P_Z="0.07419976704679022" Q="0.30577882774693693" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="YES" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="SUB" TOTAL_1="72" TOTAL_2="92" WEIGHT="400.0" Z="1.7853795892774738">
<NAME>Adverse effects: 2. Others</NAME>
<GROUP_LABEL_1>Treatment</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours Treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours Control</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="0.0" CI_END="87.85923273744554" CI_START="0.16344452775085336" DF="0" EFFECT_SIZE="3.789473684210526" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="0" I2="0.0" ID="CMP-003.16.01" LOG_CI_END="1.9437874063120861" LOG_CI_START="-0.7866296153552073" LOG_EFFECT_SIZE="0.5785788954784394" NO="1" P_CHI2="1.0" P_Z="0.4061782806537195" STUDIES="1" TAU2="0.0" TOTAL_1="18" TOTAL_2="23" WEIGHT="100.0" Z="0.8306378024703696">
<NAME>allergic reaction</NAME>
<DICH_DATA CI_END="87.85923273744554" CI_START="0.16344452775085336" EFFECT_SIZE="3.789473684210526" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="0" LOG_CI_END="1.9437874063120861" LOG_CI_START="-0.7866296153552073" LOG_EFFECT_SIZE="0.5785788954784394" ORDER="812" O_E="0.0" SE="1.603860474309605" STUDY_ID="STD-Dose-1987" TOTAL_1="18" TOTAL_2="23" VAR="2.5723684210526314" WEIGHT="100.0"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="7.749217599273241" CI_START="0.5852619701660952" DF="0" EFFECT_SIZE="2.1296296296296298" ESTIMABLE="YES" EVENTS_1="5" EVENTS_2="3" I2="0.0" ID="CMP-003.16.02" LOG_CI_END="0.8892578561229195" LOG_CI_START="-0.23264969506163302" LOG_EFFECT_SIZE="0.3283040805306432" NO="2" P_CHI2="1.0" P_Z="0.25134466133077926" STUDIES="1" TAU2="0.0" TOTAL_1="18" TOTAL_2="23" WEIGHT="100.0" Z="1.1470894783410708">
<NAME>EEG deterioration</NAME>
<DICH_DATA CI_END="7.749217599273241" CI_START="0.5852619701660952" EFFECT_SIZE="2.1296296296296298" ESTIMABLE="YES" EVENTS_1="5" EVENTS_2="3" LOG_CI_END="0.8892578561229195" LOG_CI_START="-0.23264969506163302" LOG_EFFECT_SIZE="0.3283040805306432" ORDER="813" O_E="0.0" SE="0.6590140490977507" STUDY_ID="STD-Dose-1987" TOTAL_1="18" TOTAL_2="23" VAR="0.43429951690821256" WEIGHT="100.0"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="12.423838641985377" CI_START="0.5256720073182797" DF="0" EFFECT_SIZE="2.5555555555555554" ESTIMABLE="YES" EVENTS_1="4" EVENTS_2="2" I2="0.0" ID="CMP-003.16.03" LOG_CI_END="1.094255802238336" LOG_CI_START="-0.27928514908180013" LOG_EFFECT_SIZE="0.40748532657826797" NO="3" P_CHI2="1.0" P_Z="0.24486349304524746" STUDIES="1" TAU2="0.0" TOTAL_1="18" TOTAL_2="23" WEIGHT="100.0" Z="1.1629162764376897">
<NAME>liver enzyme elevation</NAME>
<DICH_DATA CI_END="12.423838641985377" CI_START="0.5256720073182797" EFFECT_SIZE="2.5555555555555554" ESTIMABLE="YES" EVENTS_1="4" EVENTS_2="2" LOG_CI_END="1.094255802238336" LOG_CI_START="-0.27928514908180013" LOG_EFFECT_SIZE="0.40748532657826797" ORDER="814" O_E="0.0" SE="0.8068247539428121" STUDY_ID="STD-Dose-1987" TOTAL_1="18" TOTAL_2="23" VAR="0.6509661835748792" WEIGHT="100.0"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="19.056975337514732" CI_START="0.08567550833571272" DF="0" EFFECT_SIZE="1.2777777777777777" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="1" I2="0.0" ID="CMP-003.16.04" LOG_CI_END="1.2800539719336714" LOG_CI_START="-1.067143310105098" LOG_EFFECT_SIZE="0.10645533091428677" NO="4" P_CHI2="1.0" P_Z="0.8588915736196783" STUDIES="1" TAU2="0.0" TOTAL_1="18" TOTAL_2="23" WEIGHT="100.0" Z="0.1777853239273214">
<NAME>white blood cell decline (substantial)</NAME>
<DICH_DATA CI_END="19.056975337514732" CI_START="0.08567550833571272" EFFECT_SIZE="1.2777777777777777" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="1" LOG_CI_END="1.2800539719336714" LOG_CI_START="-1.067143310105098" LOG_EFFECT_SIZE="0.10645533091428677" ORDER="815" O_E="0.0" SE="1.378755302283505" STUDY_ID="STD-Dose-1987" TOTAL_1="18" TOTAL_2="23" VAR="1.9009661835748792" WEIGHT="100.0"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<OTHER_OUTCOME COLS="1" ID="CMP-003.17" MODIFIED="2014-01-27 17:57:23 +0000" MODIFIED_BY="[Empty name]" NO="17" ROWS_PER_STUDY="1" SORT_BY="STUDY" STUDIES="2" SUBGROUPS="NO">
<NAME>Physiological effect: Haloperidol plasma levels</NAME>
<TR>
<TH>
<P>Data</P>
</TH>
</TR>
<OTHER_DATA MODIFIED="2014-01-21 11:28:10 +0000" MODIFIED_BY="[Empty name]" ORDER="191" STUDY_ID="STD-Dose-1987">
<TR>
<TD>
<P>1. Carbamazepine + antipsychotics: mean level 5.8 (mg haloperidol/d)/(microgms/L haloperidol), SEM 3.3. N = 17.<BR/>2. Placebo + antipsychotics: mean level 3.1 (mg haloperidol/d)/(microgms/L haloperidol), SEM 1.65. N = 17.</P>
</TD>
</TR>
</OTHER_DATA>
<OTHER_DATA MODIFIED="2014-01-27 17:57:23 +0000" MODIFIED_BY="[Empty name]" ORDER="192" STUDY_ID="STD-He_x00df_linger-1998">
<TR>
<TD>
<P>1. Carbamazepine + haloperidol: mean haloperidol level change -3.8 ng/mL, SD 3.0. N = 9 (~45% decrease).<BR/>2. Placebo + haloperidol: mean haloperidol level change 1.9 ng/mL, SD 2.3. N = 9 (~51% increase).</P>
</TD>
</TR>
</OTHER_DATA>
</OTHER_OUTCOME>
<DICH_OUTCOME CHI2="14.309321890535191" CI_END="1.1192653033476905" CI_START="0.6658884428774787" CI_STUDY="95" CI_TOTAL="95" DF="5" EFFECT_MEASURE="RR" EFFECT_SIZE="0.863310969473331" ESTIMABLE="YES" EVENTS_1="38" EVENTS_2="48" I2="65.05774320929059" I2_Q="0.0" ID="CMP-003.18" LOG_CI_END="0.0489330410622024" LOG_CI_START="-0.17659852263275028" LOG_EFFECT_SIZE="-0.06383274078527391" METHOD="MH" MODIFIED="2014-01-28 11:16:32 +0000" MODIFIED_BY="[Empty name]" NO="18" P_CHI2="0.013759493054903205" P_Q="0.5991448744434347" P_Z="0.2672289462444084" Q="0.2762876409074666" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="6" SUBGROUPS="YES" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="SUB" TOTAL_1="70" TOTAL_2="77" WEIGHT="200.0" Z="1.1094666389387322">
<NAME>Subgroup analysis - treatment-resistant participants</NAME>
<GROUP_LABEL_1>Treatment</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="0.0" CI_END="1.1800480896702052" CI_START="0.5126386601532517" DF="0" EFFECT_SIZE="0.7777777777777778" ESTIMABLE="YES" EVENTS_1="10" EVENTS_2="12" I2="0.0" ID="CMP-003.18.01" LOG_CI_END="0.0718997061644673" LOG_CI_START="-0.29018864501460345" LOG_EFFECT_SIZE="-0.10914446942506803" MODIFIED="2014-01-28 11:16:32 +0000" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="1.0" P_Z="0.2373701069222207" STUDIES="1" TAU2="0.0" TOTAL_1="15" TOTAL_2="14" WEIGHT="100.0" Z="1.181585811795822">
<NAME>treatment-resistant</NAME>
<DICH_DATA CI_END="1.1800480896702055" CI_START="0.5126386601532517" EFFECT_SIZE="0.7777777777777778" ESTIMABLE="YES" EVENTS_1="10" EVENTS_2="12" LOG_CI_END="0.07189970616446736" LOG_CI_START="-0.29018864501460345" LOG_EFFECT_SIZE="-0.10914446942506803" MODIFIED="2013-01-26 21:27:04 +0000" MODIFIED_BY="[Empty name]" ORDER="788" O_E="0.0" SE="0.21269248984883143" STUDY_ID="STD-Simhandl-1996" TOTAL_1="15" TOTAL_2="14" VAR="0.04523809523809526" WEIGHT="100.0"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="12.899004226626346" CI_END="1.2314830701183643" CI_START="0.6509220093639465" DF="4" EFFECT_SIZE="0.8953208556149731" ESTIMABLE="YES" EVENTS_1="28" EVENTS_2="36" I2="68.98985433508788" ID="CMP-003.18.02" LOG_CI_END="0.09042844572874505" LOG_CI_START="-0.1864710435853089" LOG_EFFECT_SIZE="-0.048021298928281934" MODIFIED="2013-01-26 21:30:14 +0000" MODIFIED_BY="[Empty name]" NO="2" P_CHI2="0.011779990236229665" P_Z="0.4966225122243392" STUDIES="5" TAU2="0.0" TOTAL_1="55" TOTAL_2="63" WEIGHT="100.0" Z="0.6798135787351737">
<NAME>not treatment-resistant</NAME>
<DICH_DATA CI_END="0.6508442277923566" CI_START="0.04459755784973722" EFFECT_SIZE="0.17037037037037037" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="15" LOG_CI_END="-0.1865229424691657" LOG_CI_START="-1.3506889224856609" LOG_EFFECT_SIZE="-0.7686059324774133" MODIFIED="2013-01-26 21:30:14 +0000" MODIFIED_BY="[Empty name]" ORDER="783" O_E="0.0" SE="0.6838368593762301" STUDY_ID="STD-Dose-1987" TOTAL_1="18" TOTAL_2="23" VAR="0.4676328502415459" WEIGHT="39.705882352941174"/>
<DICH_DATA CI_END="45.90114898403462" CI_START="1.0675114040618723" EFFECT_SIZE="7.0" ESTIMABLE="YES" EVENTS_1="7" EVENTS_2="1" LOG_CI_END="1.6618235568048125" LOG_CI_START="0.02837252322370104" LOG_EFFECT_SIZE="0.8450980400142568" MODIFIED="2013-01-26 21:30:14 +0000" MODIFIED_BY="[Empty name]" ORDER="784" O_E="0.0" SE="0.9594972228385659" STUDY_ID="STD-He_x00df_linger-1998" TOTAL_1="9" TOTAL_2="9" VAR="0.9206349206349205" WEIGHT="3.014705882352941"/>
<DICH_DATA CI_END="18.687408406451837" CI_START="0.21404787186108687" EFFECT_SIZE="2.0" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="1" LOG_CI_END="1.2715490770440216" LOG_CI_START="-0.6694890857160593" LOG_EFFECT_SIZE="0.3010299956639812" MODIFIED="2013-01-26 21:30:14 +0000" MODIFIED_BY="[Empty name]" ORDER="785" O_E="0.0" SE="1.1401754250991378" STUDY_ID="STD-Martin_x002d_Munoz-1989" TOTAL_1="10" TOTAL_2="10" VAR="1.2999999999999998" WEIGHT="3.014705882352941"/>
<DICH_DATA CI_END="1.2107898309978289" CI_START="0.8259071677005132" EFFECT_SIZE="1.0" ESTIMABLE="YES" EVENTS_1="14" EVENTS_2="14" LOG_CI_END="0.08306876481172813" LOG_CI_START="-0.08306876481172817" LOG_EFFECT_SIZE="0.0" MODIFIED="2013-01-26 21:30:14 +0000" MODIFIED_BY="[Empty name]" ORDER="786" O_E="0.0" SE="0.09759000729485329" STUDY_ID="STD-Nachshoni-1994" TOTAL_1="15" TOTAL_2="15" VAR="0.009523809523809518" WEIGHT="42.205882352941174"/>
<DICH_DATA CI_END="1.9026084875830005" CI_START="0.6518345516206052" EFFECT_SIZE="1.1136363636363635" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="5" LOG_CI_END="0.27934942981336025" LOG_CI_START="-0.18586262272870785" LOG_EFFECT_SIZE="0.046743403542326194" MODIFIED="2013-01-26 21:30:14 +0000" MODIFIED_BY="[Empty name]" ORDER="787" O_E="0.0" SE="0.27326786250001056" STUDY_ID="STD-Neppe-1983" TOTAL_1="3" TOTAL_2="6" VAR="0.07467532467532467" WEIGHT="12.058823529411764"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="14.309321890535186" CI_END="1.1192653033476907" CI_START="0.6658884428774788" CI_STUDY="95" CI_TOTAL="95" DF="5" EFFECT_MEASURE="RR" EFFECT_SIZE="0.8633109694733311" ESTIMABLE="YES" EVENTS_1="38" EVENTS_2="48" I2="65.05774320929058" I2_Q="0.0" ID="CMP-003.19" LOG_CI_END="0.04893304106220248" LOG_CI_START="-0.1765985226327502" LOG_EFFECT_SIZE="-0.06383274078527386" METHOD="MH" MODIFIED="2013-01-27 12:23:00 +0000" MODIFIED_BY="[Empty name]" NO="19" P_CHI2="0.01375949305490276" P_Q="0.35984317799225696" P_Z="0.26722894624440885" Q="0.8384407247861909" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="6" SUBGROUPS="YES" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="SUB" TOTAL_1="70" TOTAL_2="77" WEIGHT="200.0" Z="1.1094666389387313">
<NAME>Subgroup analysis - EEG abnormalities</NAME>
<GROUP_LABEL_1>Treatment</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="0.0" CI_END="1.9026084875830005" CI_START="0.6518345516206052" DF="0" EFFECT_SIZE="1.1136363636363635" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="5" I2="0.0" ID="CMP-003.19.01" LOG_CI_END="0.27934942981336025" LOG_CI_START="-0.18586262272870785" LOG_EFFECT_SIZE="0.046743403542326194" MODIFIED="2013-01-27 12:20:33 +0000" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="1.0" P_Z="0.6936806655219192" STUDIES="1" TAU2="0.0" TOTAL_1="3" TOTAL_2="6" WEIGHT="100.0" Z="0.39386506414511585">
<NAME>with EEG abnormalities</NAME>
<DICH_DATA CI_END="1.9026084875830005" CI_START="0.6518345516206052" EFFECT_SIZE="1.1136363636363635" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="5" LOG_CI_END="0.27934942981336025" LOG_CI_START="-0.18586262272870785" LOG_EFFECT_SIZE="0.046743403542326194" MODIFIED="2013-01-26 21:27:24 +0000" MODIFIED_BY="[Empty name]" ORDER="787" O_E="0.0" SE="0.27326786250001056" STUDY_ID="STD-Neppe-1983" TOTAL_1="3" TOTAL_2="6" VAR="0.07467532467532467" WEIGHT="100.0"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="14.257591766786364" CI_END="1.1132117033479354" CI_START="0.6326836025369621" DF="4" EFFECT_SIZE="0.8392322627619125" ESTIMABLE="YES" EVENTS_1="35" EVENTS_2="43" I2="71.94477114067635" ID="CMP-003.19.02" LOG_CI_END="0.0465777634837" LOG_CI_START="-0.19881342114381725" LOG_EFFECT_SIZE="-0.07611782883005859" MODIFIED="2013-01-27 12:20:33 +0000" MODIFIED_BY="[Empty name]" NO="2" P_CHI2="0.006516737215310098" P_Z="0.22401486690709083" STUDIES="5" TAU2="0.0" TOTAL_1="67" TOTAL_2="71" WEIGHT="100.00000000000001" Z="1.215921454674538">
<NAME>without EEG abnormalities</NAME>
<DICH_DATA CI_END="0.6508442277923566" CI_START="0.04459755784973722" EFFECT_SIZE="0.17037037037037037" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="15" LOG_CI_END="-0.1865229424691657" LOG_CI_START="-1.3506889224856609" LOG_EFFECT_SIZE="-0.7686059324774133" MODIFIED="2013-01-27 12:20:33 +0000" MODIFIED_BY="[Empty name]" ORDER="783" O_E="0.0" SE="0.6838368593762301" STUDY_ID="STD-Dose-1987" TOTAL_1="18" TOTAL_2="23" VAR="0.4676328502415459" WEIGHT="31.672194806245454"/>
<DICH_DATA CI_END="45.90114898403462" CI_START="1.0675114040618723" EFFECT_SIZE="7.0" ESTIMABLE="YES" EVENTS_1="7" EVENTS_2="1" LOG_CI_END="1.6618235568048125" LOG_CI_START="0.02837252322370104" LOG_EFFECT_SIZE="0.8450980400142568" MODIFIED="2013-01-27 12:20:33 +0000" MODIFIED_BY="[Empty name]" ORDER="784" O_E="0.0" SE="0.9594972228385659" STUDY_ID="STD-He_x00df_linger-1998" TOTAL_1="9" TOTAL_2="9" VAR="0.9206349206349205" WEIGHT="2.404740716770488"/>
<DICH_DATA CI_END="18.687408406451837" CI_START="0.21404787186108687" EFFECT_SIZE="2.0" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="1" LOG_CI_END="1.2715490770440216" LOG_CI_START="-0.6694890857160593" LOG_EFFECT_SIZE="0.3010299956639812" MODIFIED="2013-01-27 12:20:33 +0000" MODIFIED_BY="[Empty name]" ORDER="785" O_E="0.0" SE="1.1401754250991378" STUDY_ID="STD-Martin_x002d_Munoz-1989" TOTAL_1="10" TOTAL_2="10" VAR="1.2999999999999998" WEIGHT="2.404740716770488"/>
<DICH_DATA CI_END="1.2107898309978289" CI_START="0.8259071677005132" EFFECT_SIZE="1.0" ESTIMABLE="YES" EVENTS_1="14" EVENTS_2="14" LOG_CI_END="0.08306876481172813" LOG_CI_START="-0.08306876481172817" LOG_EFFECT_SIZE="0.0" MODIFIED="2013-01-27 12:20:33 +0000" MODIFIED_BY="[Empty name]" ORDER="786" O_E="0.0" SE="0.09759000729485329" STUDY_ID="STD-Nachshoni-1994" TOTAL_1="15" TOTAL_2="15" VAR="0.009523809523809518" WEIGHT="33.66637003478684"/>
<DICH_DATA CI_END="1.1800480896702055" CI_START="0.5126386601532517" EFFECT_SIZE="0.7777777777777778" ESTIMABLE="YES" EVENTS_1="10" EVENTS_2="12" LOG_CI_END="0.07189970616446736" LOG_CI_START="-0.29018864501460345" LOG_EFFECT_SIZE="-0.10914446942506803" MODIFIED="2013-01-27 12:20:33 +0000" MODIFIED_BY="[Empty name]" ORDER="788" O_E="0.0" SE="0.21269248984883143" STUDY_ID="STD-Simhandl-1996" TOTAL_1="15" TOTAL_2="14" VAR="0.04523809523809526" WEIGHT="29.85195372542675"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="14.309321890535188" CI_END="1.1192653033476907" CI_START="0.6658884428774788" CI_STUDY="95" CI_TOTAL="95" DF="5" EFFECT_MEASURE="RR" EFFECT_SIZE="0.8633109694733311" ESTIMABLE="YES" EVENTS_1="38" EVENTS_2="48" I2="65.05774320929059" I2_Q="3.683475658018451" ID="CMP-003.20" LOG_CI_END="0.04893304106220248" LOG_CI_START="-0.1765985226327502" LOG_EFFECT_SIZE="-0.06383274078527386" METHOD="MH" MODIFIED="2013-01-27 12:23:38 +0000" MODIFIED_BY="[Empty name]" NO="20" P_CHI2="0.01375949305490276" P_Q="0.30823068280283494" P_Z="0.26722894624440885" Q="1.0382434445510087" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="6" SUBGROUPS="YES" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="SUB" TOTAL_1="70" TOTAL_2="77" WEIGHT="200.0" Z="1.1094666389387313">
<NAME>Subgroup analysis - negative symptoms</NAME>
<GROUP_LABEL_1>Treatment</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="0.0" CI_END="1.210789830997829" CI_START="0.8259071677005132" DF="0" EFFECT_SIZE="1.0" ESTIMABLE="YES" EVENTS_1="14" EVENTS_2="14" I2="0.0" ID="CMP-003.20.01" LOG_CI_END="0.08306876481172822" LOG_CI_START="-0.08306876481172817" LOG_EFFECT_SIZE="0.0" MODIFIED="2013-01-27 12:21:43 +0000" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="1.0" P_Z="1.0" STUDIES="1" TAU2="0.0" TOTAL_1="15" TOTAL_2="15" WEIGHT="100.0" Z="0.0">
<NAME>predominant negative symptoms</NAME>
<DICH_DATA CI_END="1.2107898309978289" CI_START="0.8259071677005132" EFFECT_SIZE="1.0" ESTIMABLE="YES" EVENTS_1="14" EVENTS_2="14" LOG_CI_END="0.08306876481172813" LOG_CI_START="-0.08306876481172817" LOG_EFFECT_SIZE="0.0" MODIFIED="2013-01-26 21:27:26 +0000" MODIFIED_BY="[Empty name]" ORDER="786" O_E="0.0" SE="0.09759000729485329" STUDY_ID="STD-Nachshoni-1994" TOTAL_1="15" TOTAL_2="15" VAR="0.009523809523809518" WEIGHT="100.0"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="12.33049321671776" CI_END="1.1702155835792585" CI_START="0.550637002418105" DF="4" EFFECT_SIZE="0.8027228669503793" ESTIMABLE="YES" EVENTS_1="24" EVENTS_2="34" I2="67.56009731567936" ID="CMP-003.20.02" LOG_CI_END="0.06826587724540258" LOG_CI_START="-0.25913460767926055" LOG_EFFECT_SIZE="-0.09543436521692895" MODIFIED="2013-01-27 12:21:43 +0000" MODIFIED_BY="[Empty name]" NO="2" P_CHI2="0.01505565780947804" P_Z="0.25319452007882837" STUDIES="5" TAU2="0.0" TOTAL_1="55" TOTAL_2="62" WEIGHT="99.99999999999999" Z="1.1426245673134154">
<NAME>no predominant negative symptoms</NAME>
<DICH_DATA CI_END="0.6508442277923566" CI_START="0.04459755784973722" EFFECT_SIZE="0.17037037037037037" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="15" LOG_CI_END="-0.1865229424691657" LOG_CI_START="-1.3506889224856609" LOG_EFFECT_SIZE="-0.7686059324774133" MODIFIED="2013-01-27 12:21:43 +0000" MODIFIED_BY="[Empty name]" ORDER="783" O_E="0.0" SE="0.6838368593762301" STUDY_ID="STD-Dose-1987" TOTAL_1="18" TOTAL_2="23" VAR="0.4676328502415459" WEIGHT="41.699952069020604"/>
<DICH_DATA CI_END="45.90114898403462" CI_START="1.0675114040618723" EFFECT_SIZE="7.0" ESTIMABLE="YES" EVENTS_1="7" EVENTS_2="1" LOG_CI_END="1.6618235568048125" LOG_CI_START="0.02837252322370104" LOG_EFFECT_SIZE="0.8450980400142568" MODIFIED="2013-01-27 12:21:43 +0000" MODIFIED_BY="[Empty name]" ORDER="784" O_E="0.0" SE="0.9594972228385659" STUDY_ID="STD-He_x00df_linger-1998" TOTAL_1="9" TOTAL_2="9" VAR="0.9206349206349205" WEIGHT="3.1661074719071203"/>
<DICH_DATA CI_END="18.687408406451837" CI_START="0.21404787186108687" EFFECT_SIZE="2.0" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="1" LOG_CI_END="1.2715490770440216" LOG_CI_START="-0.6694890857160593" LOG_EFFECT_SIZE="0.3010299956639812" MODIFIED="2013-01-27 12:21:43 +0000" MODIFIED_BY="[Empty name]" ORDER="785" O_E="0.0" SE="1.1401754250991378" STUDY_ID="STD-Martin_x002d_Munoz-1989" TOTAL_1="10" TOTAL_2="10" VAR="1.2999999999999998" WEIGHT="3.1661074719071203"/>
<DICH_DATA CI_END="1.9026084875830005" CI_START="0.6518345516206052" EFFECT_SIZE="1.1136363636363635" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="5" LOG_CI_END="0.27934942981336025" LOG_CI_START="-0.18586262272870785" LOG_EFFECT_SIZE="0.046743403542326194" MODIFIED="2013-01-27 12:21:43 +0000" MODIFIED_BY="[Empty name]" ORDER="787" O_E="0.0" SE="0.27326786250001056" STUDY_ID="STD-Neppe-1983" TOTAL_1="3" TOTAL_2="6" VAR="0.07467532467532467" WEIGHT="12.664429887628481"/>
<DICH_DATA CI_END="1.1800480896702055" CI_START="0.5126386601532517" EFFECT_SIZE="0.7777777777777778" ESTIMABLE="YES" EVENTS_1="10" EVENTS_2="12" LOG_CI_END="0.07189970616446736" LOG_CI_START="-0.29018864501460345" LOG_EFFECT_SIZE="-0.10914446942506803" MODIFIED="2013-01-27 12:21:43 +0000" MODIFIED_BY="[Empty name]" ORDER="788" O_E="0.0" SE="0.21269248984883143" STUDY_ID="STD-Simhandl-1996" TOTAL_1="15" TOTAL_2="14" VAR="0.04523809523809526" WEIGHT="39.303403099536666"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="14.309321890535193" CI_END="1.4516457233905864" CI_START="0.5961100356873719" CI_STUDY="95" CI_TOTAL="95" DF="5" EFFECT_MEASURE="RR" EFFECT_SIZE="0.9302368429468827" ESTIMABLE="YES" EVENTS_1="38" EVENTS_2="48" I2="65.0577432092906" I2_Q="0.0" ID="CMP-003.21" LOG_CI_END="0.16186063898807496" LOG_CI_START="-0.22467356663393515" LOG_EFFECT_SIZE="-0.03140646382293008" METHOD="MH" MODIFIED="2013-01-27 13:22:11 +0000" MODIFIED_BY="[Empty name]" NO="21" P_CHI2="0.013759493054902872" P_Q="1.0" P_Z="0.7501058296297883" Q="0.0" RANDOM="YES" SCALE="10.0" SORT_BY="STUDY" STUDIES="6" SUBGROUPS="NO" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.14655511142447195" TOTALS="YES" TOTAL_1="70" TOTAL_2="77" WEIGHT="100.0" Z="0.31849982267751986">
<NAME>Sensitivity analysis: random effects model - less than 50% BPRS reduction</NAME>
<GROUP_LABEL_1>Treatment</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_DATA CI_END="0.6508442277923566" CI_START="0.04459755784973722" EFFECT_SIZE="0.17037037037037037" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="15" LOG_CI_END="-0.1865229424691657" LOG_CI_START="-1.3506889224856609" LOG_EFFECT_SIZE="-0.7686059324774133" MODIFIED="2013-01-27 13:21:22 +0000" MODIFIED_BY="[Empty name]" ORDER="783" O_E="0.0" SE="0.6838368593762301" STUDY_ID="STD-Dose-1987" TOTAL_1="18" TOTAL_2="23" VAR="0.4676328502415459" WEIGHT="8.393628977861445"/>
<DICH_DATA CI_END="45.90114898403462" CI_START="1.0675114040618723" EFFECT_SIZE="7.0" ESTIMABLE="YES" EVENTS_1="7" EVENTS_2="1" LOG_CI_END="1.6618235568048125" LOG_CI_START="0.02837252322370104" LOG_EFFECT_SIZE="0.8450980400142568" MODIFIED="2013-01-27 13:21:22 +0000" MODIFIED_BY="[Empty name]" ORDER="784" O_E="0.0" SE="0.9594972228385659" STUDY_ID="STD-He_x00df_linger-1998" TOTAL_1="9" TOTAL_2="9" VAR="0.9206349206349205" WEIGHT="4.830691552604978"/>
<DICH_DATA CI_END="18.687408406451837" CI_START="0.21404787186108687" EFFECT_SIZE="2.0" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="1" LOG_CI_END="1.2715490770440216" LOG_CI_START="-0.6694890857160593" LOG_EFFECT_SIZE="0.3010299956639812" MODIFIED="2013-01-27 13:21:22 +0000" MODIFIED_BY="[Empty name]" ORDER="785" O_E="0.0" SE="1.1401754250991378" STUDY_ID="STD-Martin_x002d_Munoz-1989" TOTAL_1="10" TOTAL_2="10" VAR="1.2999999999999998" WEIGHT="3.563822651607775"/>
<DICH_DATA CI_END="1.2107898309978289" CI_START="0.8259071677005132" EFFECT_SIZE="1.0" ESTIMABLE="YES" EVENTS_1="14" EVENTS_2="14" LOG_CI_END="0.08306876481172813" LOG_CI_START="-0.08306876481172817" LOG_EFFECT_SIZE="0.0" MODIFIED="2013-01-27 13:21:22 +0000" MODIFIED_BY="[Empty name]" ORDER="786" O_E="0.0" SE="0.09759000729485329" STUDY_ID="STD-Nachshoni-1994" TOTAL_1="15" TOTAL_2="15" VAR="0.009523809523809518" WEIGHT="33.02986618290242"/>
<DICH_DATA CI_END="1.9026084875830005" CI_START="0.6518345516206052" EFFECT_SIZE="1.1136363636363635" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="5" LOG_CI_END="0.27934942981336025" LOG_CI_START="-0.18586262272870785" LOG_EFFECT_SIZE="0.046743403542326194" MODIFIED="2013-01-27 13:21:22 +0000" MODIFIED_BY="[Empty name]" ORDER="787" O_E="0.0" SE="0.27326786250001056" STUDY_ID="STD-Neppe-1983" TOTAL_1="3" TOTAL_2="6" VAR="0.07467532467532467" WEIGHT="23.302697240844434"/>
<DICH_DATA CI_END="1.1800480896702055" CI_START="0.5126386601532517" EFFECT_SIZE="0.7777777777777778" ESTIMABLE="YES" EVENTS_1="10" EVENTS_2="12" LOG_CI_END="0.07189970616446736" LOG_CI_START="-0.29018864501460345" LOG_EFFECT_SIZE="-0.10914446942506803" MODIFIED="2013-01-27 13:21:22 +0000" MODIFIED_BY="[Empty name]" ORDER="788" O_E="0.0" SE="0.21269248984883143" STUDY_ID="STD-Simhandl-1996" TOTAL_1="15" TOTAL_2="14" VAR="0.04523809523809526" WEIGHT="26.87929339417895"/>
</DICH_OUTCOME>
</COMPARISON>
</ANALYSES_AND_DATA>
<FIGURES MODIFIED="2014-03-03 11:55:26 +0000" MODIFIED_BY="[Empty name]">
<FIGURE FILENAME="CARB.jpg" FILE_TYPE="JPG" ID="FIG-01" MODIFIED="2013-05-16 10:50:58 +0100" MODIFIED_BY="[Empty name]" NO="1" SHORT_VERSION_FIGURE="YES" TYPE="OTHER">
<CAPTION>
<P>Carbamazepine</P>
</CAPTION>
<FILE>/9j/4AAQSkZJRgABAgAAAQABAAD/2wBDAAgGBgcGBQgHBwcJCQgKDBQNDAsLDBkSEw8UHRofHh0a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</FILE>
</FIGURE>
<FIGURE FILENAME="Flowchart.png" FILE_TYPE="PNG" ID="FIG-02" MODIFIED="2013-09-16 14:28:12 +0100" MODIFIED_BY="[Empty name]" NO="2" SHORT_VERSION_FIGURE="YES" TYPE="OTHER">
<CAPTION>
<P>Study flow diagram.</P>
</CAPTION>
<FILE>iVBORw0KGgoAAAANSUhEUgAAAZAAAAJ/CAYAAABWRYUGAABBw0lEQVR42u2df4RV2///3yRXkkSS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</FILE>
</FIGURE>
<FIGURE FILENAME="Risk of bias graph.png" FILE_TYPE="PNG" ID="FIG-03" MODIFIED="2014-03-03 11:55:26 +0000" MODIFIED_BY="[Empty name]" NO="3" SHORT_VERSION_FIGURE="YES" TYPE="QUALITY_GRAPH_PLOT">
<CAPTION>
<P>'Risk of bias' graph: review authors' judgements about each risk of bias item presented as percentages across all included studies.</P>
</CAPTION>
<FILE>iVBORw0KGgoAAAANSUhEUgAAAtYAAAEyCAMAAADp82f9AAADAFBMVEUAAADAAAAAwAAAAMDg4ADA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</FILE>
</FIGURE>
<FIGURE FILENAME="Risk of bias summary.png" FILE_TYPE="PNG" ID="FIG-04" MODIFIED="2014-03-03 11:55:26 +0000" MODIFIED_BY="[Empty name]" NO="4" SHORT_VERSION_FIGURE="YES" TYPE="QUALITY_TABLE_PLOT">
<CAPTION>
<P>'Risk of bias' summary: review authors' judgements about each risk of bias item for each included study.</P>
</CAPTION>
<FILE>iVBORw0KGgoAAAANSUhEUgAAAY4AAAL5CAIAAAAoqVTPAAAuqUlEQVR42u3dz24USbbH8ZKQEAsv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</FILE>
</FIGURE>
</FIGURES>
<FEEDBACK/>
<APPENDICES MODIFIED="2014-01-28 12:17:33 +0000" MODIFIED_BY="[Empty name]">
<APPENDIX ID="APP-01" MODIFIED="2014-01-21 11:28:10 +0000" MODIFIED_BY="[Empty name]" NO="1">
<TITLE MODIFIED="2011-02-10 11:04:54 +0000" MODIFIED_BY="[Empty name]">Previous searches</TITLE>
<APPENDIX_BODY MODIFIED="2014-01-21 11:28:10 +0000" MODIFIED_BY="[Empty name]">
<P>1. Update searches in March 2005 and in December 2006</P>
<P>For the update we searched the Cochrane Schizophrenia Group's Register of Trials (March 2005 and November 2006) using the phrase: [((*carbama* or *amizepine* or *carbag* or *carbap* or *carbaz* or *carbymal* or *carpaz* or *cephalon* or *degranol* or *epitol* or *finlepsin* or *fokalepsin* or *hermolepsin* or *neurotol* or *neurotop* or *nordotol* or *sirtal* or *tardotol* or *tegret* or *teril* or *timonil* or *trimonil* or *trialeptal* or *trilpetal*) in Ti, Ab and In fields in References) AND (carbama* in Intervention field in Study)]<BR/>This register is compiled by systematic searches of major databases, hand searches and conference proceedings (see Group Module)</P>
<P>2. Original search<BR/>2.1 Electronic searching<BR/>2.1.1 We searched Biological Abstracts (January 1980 - August 2001) using the Cochrane Schizophrenia Group's phrase for both randomised controlled trials and schizophrenia (see Group search strategy) combined with the phrase:</P>
<P>[and carbamazepine* or tegretol or tardotol or tegretal or carbagamma or carbymal or carpaz or carbapin or degranol or finlepsin or fokalepsin or hermolepsin or neurotol or neurotop or nordotol or oxcarbazepine or sirtal or tardotol or timonil or trimonil or "10,11-dihydro-10-oxo-5H-dobenz[b,f]azepine-5-carboxamide" or "5H-dibenz[b,f]azepine-5-carboxamide" or (GP near1 (49.023 or 10.000 or 47.779 or 47.680)) or trialeptal or trileptal or "trans-10,11-dihydro-10,11-epoxy-5h-dibenz[b,f]azepine-5-carboxamide"]</P>
<P>2.1.2 We searched The Cochrane Library (Issue 3, 2001) using the phrase:</P>
<P>[and carbamazepine* or tegretol or tardotol or tegretal or carbagamma or carbymal or carpaz or carbapin or degranol or finlepsin or fokalepsin or hermolepsin or neurotol or neurotop or nordotol or oxcarbazepine or sirtal or tardotol or timonil or trimonil or "10,11-dihydro-10-oxo-5H-dobenz[b,f]azepine-5-carboxamide" or "5H-dibenz[b,f]azepine-5-carboxamide" or (GP and (49.023 or 10.000 or 47.779 or 47.680)) or trialeptal or trileptal or "trans-10,11-dihydro-10,11-epoxy-5h-dibenz[b,f]azepine-5-carboxamide" or explode CARBAMAZEPINE / all]</P>
<P>2.1.3 We searched the Cochrane Schizophrenia Group's Register of Trials (December 2001) using the phrase:</P>
<P>[and carbamazepine* or tegretol or tardotol or tegretal or carbagamma or carbymal or carpaz or carbapin or degranol or finlepsin or fokalepsin or hermolepsin or neurotol or neurotop or nordotol or oxcarbazepine or sirtal or tardotol or timonil or trimonil or "10,11-dihydro-10-oxo-5H-dobenz[b,f]azepine-5-carboxamide" or "5H-dibenz[b,f]azepine-5-carboxamide" or (GP and (49.023 or 10.000 or 47.779 or 47.680)) or trialeptal or trileptal or "trans-10,11-dihydro-10,11-epoxy-5h-dibenz[b,f]azepine-5-carboxamide"or #42 = 684 or #42 = 20]</P>
<P>#42 is the intervention field within the register and 684 and 20 are the codes for carbamazepine.</P>
<P>2.1.4 We searched EMBASE (January 1980 - August 2001) using the Cochrane Schizophrenia Group's phrase for both randomised controlled trials and schizophrenia (see Group search strategy) combined with the phrase:</P>
<P>[and carbamazepine* or tegretol or tardotol or tegretal or carbagamma or carbymal or carpaz or carbapin or degranol or finlepsin or fokalepsin or hermolepsin or neurotol or neurotop or nordotol or oxcarbazepine or sirtal or tardotol or timonil or trimonil or "10,11-dihydro-10-oxo-5H-dobenz[b,f]azepine-5-carboxamide" or "5H-dibenz[b,f]azepine-5-carboxamide" or (GP near1 (49.023 or 10.000 or 47.779 or 47.680)) or trialeptal or trileptal or "trans-10,11-dihydro-10,11-epoxy-5h-dibenz[b,f]azepine-5-carboxamide"or explode CARBAMAZEPINE / all]</P>
<P>2.1.5 We searched MEDLINE (January 1966 - August 2001) using the Cochrane Schizophrenia Group's phrase for both randomised controlled trials and schizophrenia (see Group search strategy) combined with the phrase:</P>
<P>[and carbamazepine* or tegretol or tardotol or tegretal or carbagamma or carbymal or carpaz or carbapin or degranol or finlepsin or fokalepsin or hermolepsin or neurotol or neurotop or nordotol or oxcarbazepine or sirtal or tardotol or timonil or trimonil or "10,11-dihydro-10-oxo-5H-dobenz[b,f]azepine-5-carboxamide" or "5H-dibenz[b,f]azepine-5-carboxamide" or (GP near1 (49.023 or 10.000 or 47.779 or 47.680)) or trialeptal or trileptal or "trans-10,11-dihydro-10,11-epoxy-5h-dibenz[b,f]azepine-5-carboxamide"or explode CARBAMAZEPINE / all]</P>
<P>2.1.6 We searched PsycLIT (1886 - August 2001) using the Cochrane Schizophrenia Group's phrase for both randomised controlled trials and schizophrenia (see Group search strategy) combined with the phrase:</P>
<P>[and carbamazepine* or tegretol or tardotol or tegretal or carbagamma or carbymal or carpaz or carbapin or degranol or finlepsin or fokalepsin or hermolepsin or neurotol or neurotop or nordotol or oxcarbazepine or sirtal or tardotol or timonil or trimonil or "10,11-dihydro-10-oxo-5H-dobenz[b,f]azepine-5-carboxamide" or "5H-dibenz[b,f]azepine-5-carboxamide" or (GP near1 (49.023 or 10.000 or 47.779 or 47.680)) or trialeptal or trileptal or "trans-10,11-dihydro-10,11-epoxy-5h-dibenz[b,f]azepine-5-carboxamide"or explode "CARBAMAZEPINE" / all]</P>
<P>2.1.7 We searched PSYNDEX (January 1974 - August 2001) using the Cochrane Schizophrenia Group's phrase for both randomised controlled trials and schizophrenia (see Group search strategy) combined with the phrase:</P>
<P>[and carbamazepine* or tegretol or tardotol or tegretal or carbagamma or carbymal or carpaz or carbapin or degranol or finlepsin or fokalepsin or hermolepsin or neurotol or neurotop or nordotol or oxcarbazepine or sirtal or tardotol or timonil or trimonil or "10,11-dihydro-10-oxo-5H-dobenz[b,f]azepine-5-carboxamide" or "5H-dibenz[b,f]azepine-5-carboxamide" or (GP near1 (49.023 or 10.000 or 47.779 or 47.680)) or trialeptal or trileptal or "trans-10,11-dihydro-10,11-epoxy-5h-dibenz[b,f]azepine-5-carboxamide]</P>
<P>2.2 Reference lists<BR/>We searched all references of articles selected for inclusion for further relevant trials.</P>
<P>2.3 Pharmaceutical companies<BR/>We contacted companies performing trials with carbamazepine to obtain data on unpublished trials.</P>
<P>2.4 Personal contact<BR/>We contacted the first author of each included study for more data of their study and any information regarding unpublished trials.</P>
</APPENDIX_BODY>
</APPENDIX>
<APPENDIX ID="APP-02" MODIFIED="2014-01-28 12:17:16 +0000" MODIFIED_BY="[Empty name]" NO="2">
<TITLE MODIFIED="2011-02-10 11:06:00 +0000" MODIFIED_BY="[Empty name]">Previous data collection methods</TITLE>
<APPENDIX_BODY MODIFIED="2014-01-28 12:17:16 +0000" MODIFIED_BY="[Empty name]">
<P>[For definitions of terms used in this, and other sections, please refer to the Glossary.]</P>
<P>1. Selection of trials<BR/>SL independently inspected all reports identified by the search and JM re-inspected these to ensure reliable selection. Where agreement could not be reached, we acquired the full report was for more detailed scrutiny. Once the full reports were obtained we independently inspected them to assess their relevance to this review. Again, if disagreement could not be resolved by discussion or from published information, we added the article to those awaiting assessment and contacted the authors of the study for clarification.</P>
<P>2. Assessment of methodological quality<BR/>We assessed the methodological quality of included trials in this review using the criteria described in the Cochrane Handbook (Higgins 2005) and the Jadad Scale (<LINK REF="REF-Jadad-1996" TYPE="REFERENCE">Jadad 1996</LINK>). The former is based on the evidence of a strong relationship among the potential for bias in the results and the allocation concealment (<LINK REF="REF-Schulz-1995" TYPE="REFERENCE">Schulz 1995</LINK>) and is defined as below:</P>
<P>A. Low risk of bias (adequate allocation concealment)<BR/>B. Moderate risk of bias (some doubt about the results)<BR/>C. High risk of bias (inadequate allocation concealment)</P>
<P>The Jadad Scale measures a wider range of factors that impact on the quality of a trial. The scale includes three items:</P>
<P>1. Was the study described as randomised?<BR/>2. Was the study described as double-blind?<BR/>3. Was there a description of withdrawals and drop outs?</P>
<P>Each item receives one point if the answer is positive. In addition, a point can be deducted if either the randomisation or the blinding/masking procedures described were inadequate or added if random number generation adequate or blinding appropriate. Scores on item 1 and 2 can therefore be 0, 1 or 2.</P>
<P>For the purpose of the analysis in this review, we included trials if they met the criteria A or B of the Cochrane Handbook. We did not use the Jadad scale to exclude trials in this review, but we used it to explore potential heterogeneity as a result of trial quality.</P>
<P>3. Data collection<BR/>We independently extracted the data from included studies. Again, we discussed any disagreement and documented decisions. When this was not possible, we sought further information from authors of the studies and did not enter data from these trials but added them to the list of those awaiting assessment.</P>
<P>4. Data synthesis<BR/>4.1 Data types<BR/>Outcomes are assessed using continuous (for example changes on a behaviour scale), categorical (for example, one of three categories on a behaviour scale, such as 'little change', 'moderate change' or 'much change') or dichotomous measures (for example, either 'no important changes' or 'important changes' in a person's behaviour). Currently RevMan does not support categorical data so they were presented only in the text of the review.</P>
<P>4.2 Incomplete data<BR/>For studies that did not specify the reasons for people leaving the study early (dropped out), we assumed that these people had no change in the clinical outcome variables. If over 50% of people dropped out, and the study did not provide intention-to-treat results for continuous data, we excluded these data.</P>
<P>4.3 Cross-over design<BR/>We expected that some trials would use a cross-over design. In order to exclude the potential additive effect in the second or more stages on these trials, we only analysed data from the first stage.</P>
<P>4.4 Dichotomous - yes/no data<BR/>We carried out an intention-to-treat analysis. On the condition that more than 50% of people completed the study, everyone allocated to the intervention were counted, whether they completed the follow-up or not. We assumed that those who dropped out had the negative outcome, with the exception of death.</P>
<P>Where possible efforts were made to convert outcome measures to dichotomous data. This may be done by identifying cut-off points on rating scales and dividing subjects accordingly into 'clinically improved' or 'not clinically improved'. If the authors of a study had used a designated cut-off point for determining clinical effectiveness we used this where appropriate.</P>
<P>For dichotomous outcomes, a relative risk (RR) with the 95% confidence interval (CI) based on a fixed-effect model was estimated. This is different to previous versions of this review. The reason for the change is that it has been shown that relative risks are more intuitive to clinicians than odds ratios (<LINK REF="REF-Boissel-1999" TYPE="REFERENCE">Boissel 1999</LINK>). Furthermore, clinicians tend to interpret odds ratios as relative risks. This misinterpretation leads to an overestimate of effect (<LINK REF="REF-Deeks-2000" TYPE="REFERENCE">Deeks 2000</LINK>). When overall results were significant we calculated the Number Needed to Treat (NNT) and/or the Number Needed to Harm (NNH) as the inverse of the absolute risk difference.</P>
<P>4.5 Continuous data<BR/>4.5.1 Normally distributed data: Continuous data on outcomes in trials relevant to mental health issues are often not normally distributed. To avoid the pitfall of applying parametric tests to non-parametric data the following standards were applied to data derived from continuous measures of endpoint ('state' data). The criteria were used before inclusion:<BR/>i. standard deviations and means were reported in the paper or were obtainable from the authors and ii. the standard deviation (SD), when multiplied by 2, was less than the mean (as otherwise the mean was unlikely to be an appropriate measure of the centre of the distribution) (<LINK REF="REF-Altman-1996" TYPE="REFERENCE">Altman 1996</LINK>). If a scale starts from a positive value (such as PANSS which can have values from 30 to 210) the calculation described above in ii) should be modified to take the scale starting point into account. In these cases skewness is present if 2SD&gt;(S-Smin), where S is the mean score and Smin is the minimum score. We did not enter data that did not meet the first or second standard into RevMan software for analysis, but reported the data in the text of the results section.</P>
<P>4.5.2 Scale derived data: A wide range of rating scales is available to measure outcomes in mental health trials. These scales vary in quality and many are questionably validated, or even ad hoc. It is generally accepted that measuring instruments should have the properties of reliability (the extent to which a test effectively measures anything at all) and validity (the extent to which a test measures that which it is supposed to measure). Before publication of an instrument, most scientific journals insist that reliability and validity be demonstrated to the satisfaction of referees. We therefore decided, as a minimum standard, not to include any data from a rating scale in this review unless its properties had been published in a peer-reviewed journal. In addition, we set the following minimum standards for rating scales; the rating scale should either be i. a self-report or ii. completed by an independent rater or relative. We may set more stringent standards for instruments in future updates of this review.</P>
<P>Whenever possible we took the opportunity to make direct comparisons between trials that used the same measurement instrument to quantify specific outcomes. Where continuous data were presented from different scales rating the same effect, we presented both sets of data and inspected the general direction of effect.</P>
<P>4.5.3 Endpoint versus change data: For continuous mean change data (endpoint minus baseline) the situation is even more problematic. In the absence of individual patient data it is impossible to know if change data is skewed. The RevMan meta-analyses of continuous data are based on the assumption that the data are, at least to a reasonable degree, normally distributed. It is quite feasible that change data is skewed but, after consulting the ALLSTAT electronic statistics mailing list, it was entered into RevMan in order to summarise the available information. In doing this it is assumed that either data were not skewed or that the analyses within RevMan could cope with the unknown degree of skewness.</P>
<P>4.6 Individual patient data<BR/>For this update we requested the individual patient data from the original authors. Most of these were data derived from the BPRS, a scale measuring mental state. We tried to convert these results to dichotomous data (see 4.3.1). As it seemed impossible to us to predefine which level of reduction of the total score is clinically meaningful, three levels were analysed: a relatively low level (at least 20% BPRS reduction), an intermediate level (at least 35% BPRS reduction) and a relatively high level (at least 50% BPRS reduction).</P>
<P>4.7 Data display<BR/>We entered data into RevMan in such a way that the area to the left of the line of no effect indicated a favourable outcome for carbamazepine alone or carbamazepine augmentation.</P>
<P>4.8 Cluster trials<BR/>Studies increasingly employ "cluster randomisation" (such as randomisation by clinician or practice) but analysis and pooling of clustered data poses problems. Firstly, authors often fail to account for intra class correlation in clustered studies, leading to a "unit of analysis" error (<LINK REF="REF-Divine-1992" TYPE="REFERENCE">Divine 1992</LINK>) whereby P values are spuriously low, confidence intervals unduly narrow and statistical significance overestimated. This causes type 1 errors (<LINK REF="REF-Bland-1997" TYPE="REFERENCE">Bland 1997</LINK>; <LINK REF="REF-Gulliford-1999" TYPE="REFERENCE">Gulliford 1999</LINK>).</P>
<P>Where clustering was not accounted for in primary studies, we presented the data in a table, with a (*) symbol to indicate the presence of a probable unit of analysis error. in subsequent versions of this review we will seek to contact first authors of studies to obtain intra-class correlation co-efficients of their clustered data and to adjust for this using accepted methods (<LINK REF="REF-Gulliford-1999" TYPE="REFERENCE">Gulliford 1999</LINK>). Where clustering was incorporated into the analysis of primary studies, we presented these data as if from a non-cluster randomised study, but adjusted for the clustering effect.</P>
<P>We sought statistical advice and were advised that the binary data as presented in a report should be divided by a "design effect". This is calculated using the mean number of participants per cluster (m) and the intraclass correlation co-efficient (ICC) [Design effect = 1+(m-1)*ICC] (<LINK REF="REF-Donner-2002" TYPE="REFERENCE">Donner 2002</LINK>). If the ICC was not reported, we assumed it to be 0.1 (<LINK REF="REF-Ukoumunne-1999" TYPE="REFERENCE">Ukoumunne 1999</LINK>).<BR/>
<BR/>If cluster studies had been appropriately analysed taking into account intra-class correlation coefficients and relevant data documented in the report, synthesis with other studies would have been possible using the generic inverse variance technique.</P>
<P>5. Investigation for heterogeneity<BR/>Firstly, we visually inspected graphs to investigate the possibility of statistical heterogeneity. This was supplemented using, primarily, the I-squared statistic. This provides an estimate of the percentage of variability due to heterogeneity rather than chance alone. Where the I-squared estimate was greater than or equal to 50% we interpreted this as indicating the presence of considerable levels of heterogeneity (Higgins 2005). The I-squared statistic has been described to be a more appropriate indicator of heterogeneity than the Chi-square test that was used in the previous version of the review (Higgins 2005). If either the I-squared statistic was higher than 50% or the p-value of the Chi-square test, for reasons of consistency we did not deviate from the rule as to when the fixed and when the random-effects model has to be applied, although we would now rather use the random-effects model throughout.</P>
<P>6. Publication bias<BR/>We entered data from all included trials into a funnel graph (trial effect versus trial size or 'precision') in an attempt to investigate the likelihood of overt publication bias. A formal test of funnel plot asymmetry (suggesting potential publication bias) was undertaken, where appropriate (<LINK REF="REF-Egger-1997" TYPE="REFERENCE">Egger 1997</LINK>). Significance levels of P &lt; 0.1 were set a priori to accept the presence of asymmetry. Where only three or four studies reported an outcome or there was little variety in sample size (or precision estimate) between studies tests of asymmetry were not appropriate.</P>
<P>7. Where possible, we entered data in such a way that the area to the left of the line of no effect indicated a favourable outcome for carbamazepine.</P>
</APPENDIX_BODY>
</APPENDIX>
<APPENDIX ID="APP-03" MODIFIED="2014-01-28 12:17:33 +0000" MODIFIED_BY="[Empty name]" NO="3">
<TITLE MODIFIED="2013-02-27 09:54:12 +0000" MODIFIED_BY="[Empty name]">Previous plain language summary</TITLE>
<APPENDIX_BODY MODIFIED="2014-01-28 12:17:33 +0000" MODIFIED_BY="[Empty name]">
<SUBSECTION>
<HEADING LEVEL="3">Carbamazepine for schizophrenia</HEADING>
<P> Schizophrenia is a serious mental illness which can cause people to change the way they sense and understand the world.  It can be very serious and continue to affect some people throughout their life. Although most people with this illness can be helped by taking antipsychotic medication,  5% -15% will continue to suffer from debilitating symptoms. For this group of people a variety of medical options are available to reduce these symptoms, including adjusting the dose of medication, changing to another antipsychotic, or using drugs other than antipsychotics. Carbamazepine is a drug which has been used to treat epilepsy since the 1950s. It is also used as a mood stabiliser when people alternate between very &#8216;high&#8217; and depressed moods (bi-polar affective disorder). This review looks at the effectiveness of carbamazepine when compared to no active medication (placebo), an antipsychotic, or when it is used in addition to an antipsychotic in clinical trials on people who have schizophrenia both with additional mood problems (schizoaffective disorder), and without.Ten trials were found which included a total of 258 people. All except one of these studies were carried out in a hospital setting. One small trial compared carbamazepine treatment with placebo (31 people) and found that there was no significant difference between these in respect to preventing relapse, mental state or development of adverse effects. Another single study of 38 people compared carbamazepine (as a single treatment) with the antipsychotic perphenazine (as a single treatment) and found no significant difference between the people in the two groups except that those on perphenazine were more likely to have movement side effects and be taking medication for them.The remainder of the trials compared antipsychotic plus carbamazepine with antipsychotic plus placebo. Two of these trials (38 people) showed that when carbamazepine was taken with an antipsychotic, there was a general improvement in over half of these people. However, for the majority of the outcomes for which there was acceptable data, there was no significant difference between the two groups. Since all of these trials were small, there is not enough data to clarify whether carbamazepine reduces symptoms without giving too many adverse effects in people with schizophrenia and schizoaffective disorders who are resistant to treatment with antipsychotics alone. A larger well designed trial may provide more robust evidence to support the treatment options for these people.    (Plain language summary prepared for this review by Janey Antoniou of RETHINK, UK <A HREF="http://www.rethink.org">www.rethink.org</A>).</P>
</SUBSECTION>
</APPENDIX_BODY>
</APPENDIX>
</APPENDICES>
<EXTENSIONS>
<EXTENSION ID="FLOW_2" NAME="FIGURE" REVMAN_VERSION="5.1.0" TYPE="FLOWCHART">
<ALIAS ALIAS_ID="2">
<FLOWCHARTBOX TEXT="&lt;p&gt;10 studies met the inclusion criteria and were included in quantitative synthesis (meta-analysis)&lt;/p&gt;" WIDTH="120">
<FLOWCHARTBOX TEXT="&lt;p&gt;10 studies were included into qualitative synthesis&lt;/p&gt;" WIDTH="120">
<FLOWCHARTBOX TEXT="&lt;p&gt;101 of full-text articles assessed for eligibility&lt;/p&gt;" WIDTH="120">
<FLOWCHARTBOX TEXT="&lt;p&gt;The original search strategy identified hundreds of citations&lt;/p&gt;" WIDTH="120"/>
<OUT TEXT="&lt;p&gt;91 full-text articles excluded:&lt;/p&gt;&lt;p&gt; - 64 not appropriately randomised&lt;/p&gt;&lt;p&gt; - 3 wrong participants&lt;/p&gt;&lt;p&gt; - 19 wrong interventions&lt;/p&gt;&lt;p&gt; - 5 no useable outcomes&lt;/p&gt;"/>
</FLOWCHARTBOX>
</FLOWCHARTBOX>
</FLOWCHARTBOX>
</ALIAS>
</EXTENSION>
</EXTENSIONS>
</COCHRANE_REVIEW>